{"items": "704", "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish", "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.", "feed": [{"title": "Continuous Glucose Monitoring Systems Market to Hit US$20.5 Billion by 2030 | Updated Insights Report by Persistence Market Research", "url": "https://www.benzinga.com/pressreleases/24/01/g36683594/continuous-glucose-monitoring-systems-market-to-hit-us-20-5-billion-by-2030-updated-insights-repor", "time_published": "20240118T183000", "authors": ["Globe Newswire"], "summary": "New York, Jan. 19, 2024 ( GLOBE NEWSWIRE ) -- Continuous glucose monitoring ( CGM ) systems have brought significant advancements to the field of diabetes management by providing real-time data on blood glucose levels.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}], "overall_sentiment_score": 0.388487, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "MOOIF", "relevance_score": "0.01706", "ticker_sentiment_score": "0.199568", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABT", "relevance_score": "0.034112", "ticker_sentiment_score": "0.242427", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MDT", "relevance_score": "0.034112", "ticker_sentiment_score": "0.242427", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.034112", "ticker_sentiment_score": "0.198683", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "DexCom  ( DXCM )  Crossed Above the 20-Day Moving Average: What That Means for Investors", "url": "https://www.zacks.com/stock/news/2212075/dexcom-dxcm-crossed-above-the-20-day-moving-average-what-that-means-for-investors", "time_published": "20240118T143503", "authors": ["Zacks Equity Research"], "summary": "Good things could be on the horizon when a stock surpasses the 20-day simple moving average. How should investors react?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default52.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.32065, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.795061", "ticker_sentiment_score": "0.567747", "ticker_sentiment_label": "Bullish"}]}, {"title": "DexCom's  ( DXCM )  G7 Links With Tandem's Insulin Pump in Europe", "url": "https://www.zacks.com/stock/news/2212038/dexcoms-dxcm-g7-links-with-tandems-insulin-pump-in-europe", "time_published": "20240118T140900", "authors": ["Zacks Equity Research"], "summary": "Dexcom's (DXCM) G7 integrates with Tandem's t:slim X2, revolutionizing diabetes care. A perfect combination of accuracy and innovation, this synergy sets a new standard in continuous glucose monitoring.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c0/2297.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.917436"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.344175, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MMSI", "relevance_score": "0.099066", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PODD", "relevance_score": "0.049629", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITGR", "relevance_score": "0.19661", "ticker_sentiment_score": "0.170867", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TNDM", "relevance_score": "0.099066", "ticker_sentiment_score": "0.280691", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DVA", "relevance_score": "0.099066", "ticker_sentiment_score": "0.060078", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.424634", "ticker_sentiment_score": "0.432851", "ticker_sentiment_label": "Bullish"}]}, {"title": "DexCom  ( DXCM )  Advances While Market Declines: Some Information for Investors", "url": "https://www.zacks.com/stock/news/2211752/dexcom-dxcm-advances-while-market-declines-some-information-for-investors", "time_published": "20240117T230021", "authors": ["Zacks Equity Research"], "summary": "DexCom (DXCM) closed the most recent trading day at $125.45, moving +0.8% from the previous trading session.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default221.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.839681"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.141803, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.55992", "ticker_sentiment_score": "0.205339", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Why DexCom  ( DXCM )  Could Beat Earnings Estimates Again", "url": "https://www.zacks.com/stock/news/2211643/why-dexcom-dxcm-could-beat-earnings-estimates-again", "time_published": "20240117T171010", "authors": ["Zacks Equity Research"], "summary": "DexCom (DXCM) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default64.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.99998"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.308829, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.409171", "ticker_sentiment_score": "0.461769", "ticker_sentiment_label": "Bullish"}]}, {"title": "How to Find Strong Medical Stocks Slated for Positive Earnings Surprises", "url": "https://www.zacks.com/stock/news/2211330/how-to-find-strong-medical-stocks-slated-for-positive-earnings-surprises", "time_published": "20240117T135006", "authors": ["Zacks Equity Research"], "summary": "Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default102.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999992"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.367973, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.387875", "ticker_sentiment_score": "0.423278", "ticker_sentiment_label": "Bullish"}, {"ticker": "NVO", "relevance_score": "0.264658", "ticker_sentiment_score": "0.277114", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Penumbra Sees RS Rating Climb To 75", "url": "https://www.investors.com/ibd-data-stories/penumbra-sees-rs-rating-climb-to-75/", "time_published": "20240117T080000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "The Relative Strength ( RS ) Rating for Penumbra ( PEN ) entered a higher percentile Wednesday, as it got a lift from 68 to 75. X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.538269"}], "overall_sentiment_score": 0.458027, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "PEN", "relevance_score": "0.695767", "ticker_sentiment_score": "0.564369", "ticker_sentiment_label": "Bullish"}, {"ticker": "AWON", "relevance_score": "0.162802", "ticker_sentiment_score": "0.177811", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ITGR", "relevance_score": "0.318897", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.318897", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Charts turn bullish on health-care stocks as sector takes early lead in 2024", "url": "https://www.marketwatch.com/story/charts-turn-bullish-on-health-care-stocks-as-sector-takes-early-lead-in-2024-12272495", "time_published": "20240116T162900", "authors": ["Joseph Adinolfi"], "summary": "Health-care stocks are off to a strong start in 2024, and Wall Street analysts are taking notice.", "banner_image": "https://images.mktw.net/im-735118/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.744043"}, {"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.342773, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MCK", "relevance_score": "0.15697", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VTRS", "relevance_score": "0.15697", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.15697", "ticker_sentiment_score": "0.294849", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABBV", "relevance_score": "0.15697", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.15697", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.15697", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DHR", "relevance_score": "0.15697", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick", "url": "https://www.zacks.com/stock/news/2210799/are-you-a-momentum-investor-this-1-stock-could-be-the-perfect-pick", "time_published": "20240116T145007", "authors": ["Zacks Equity Research"], "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default43.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.890401"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.962106"}], "overall_sentiment_score": 0.348095, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.405215", "ticker_sentiment_score": "0.181186", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "3 Top Trends to Invest $1,000 in Right Now", "url": "https://www.fool.com/investing/2024/01/15/3-top-trends-to-invest-1000-in-right-now/", "time_published": "20240115T152300", "authors": ["Ryan Downie"], "summary": "These three trends are reshaping the global economy and rewarding investors.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F761165%2Fgettyimages-1436056497.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.980509"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}], "overall_sentiment_score": 0.280538, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AYX", "relevance_score": "0.041394", "ticker_sentiment_score": "0.135921", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.082677", "ticker_sentiment_score": "0.172244", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVDA", "relevance_score": "0.041394", "ticker_sentiment_score": "0.135921", "ticker_sentiment_label": "Neutral"}, {"ticker": "CSCO", "relevance_score": "0.041394", "ticker_sentiment_score": "0.183908", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NOW", "relevance_score": "0.041394", "ticker_sentiment_score": "0.183908", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMZN", "relevance_score": "0.082677", "ticker_sentiment_score": "0.172244", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.041394", "ticker_sentiment_score": "0.183908", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Dow Jones Falls; Big Banks Struggle After Earnings; Tesla Lags But 3 Stocks Clear Entries", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-falls-big-banks-struggle-after-earnings-tesla-stock-lags-but-3-stocks-clear-entries-apple-stock-unitedhealth-stock/", "time_published": "20240112T211400", "authors": ["MICHAEL LARKIN", "Investor's Business Daily"], "summary": "Dow Jones Falls. Big Banks Struggle After Earnings. Tesla Lags But 3 Stocks Clear Entries Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2022/10/Stock-moneytesla-01-shutt.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.99793"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.983783"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.097469, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.056275", "ticker_sentiment_score": "0.117916", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.167709", "ticker_sentiment_score": "0.132159", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.112269", "ticker_sentiment_score": "0.113642", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.112269", "ticker_sentiment_score": "0.130303", "ticker_sentiment_label": "Neutral"}, {"ticker": "C", "relevance_score": "0.167709", "ticker_sentiment_score": "-0.09191", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.222327", "ticker_sentiment_score": "-0.204876", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JPM", "relevance_score": "0.222327", "ticker_sentiment_score": "0.039807", "ticker_sentiment_label": "Neutral"}, {"ticker": "BK", "relevance_score": "0.112269", "ticker_sentiment_score": "0.179286", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PSN", "relevance_score": "0.167709", "ticker_sentiment_score": "0.018493", "ticker_sentiment_label": "Neutral"}, {"ticker": "ROL", "relevance_score": "0.167709", "ticker_sentiment_score": "-0.101819", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.112269", "ticker_sentiment_score": "-0.071315", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.112269", "ticker_sentiment_score": "0.228371", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MELI", "relevance_score": "0.222327", "ticker_sentiment_score": "0.251215", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TSLA", "relevance_score": "0.167709", "ticker_sentiment_score": "-0.18043", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "WFC", "relevance_score": "0.112269", "ticker_sentiment_score": "-0.168345", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "DXCM", "relevance_score": "0.112269", "ticker_sentiment_score": "-0.028959", "ticker_sentiment_label": "Neutral"}]}, {"title": "Market Rebounds As Nvidia Leads; Bitcoin ETFs, Tesla Fall: Weekly Review", "url": "https://www.investors.com/news/stock-market-rally-rebounds-nvidia-tesla-jpmorgan-bitcoin-etfs-in-focus/", "time_published": "20240112T191300", "authors": ["Investor's Business Daily", "IBD STAFF"], "summary": "Market Rebounds As Nvidia Leads. Bitcoin ETFs, Tesla Fall: Weekly Review Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2019/11/Stock-bounce-05-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Economy - Monetary", "relevance_score": "0.99489"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Earnings", "relevance_score": "0.999999"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": -0.007321, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALK", "relevance_score": "0.045612", "ticker_sentiment_score": "-0.11938", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLK", "relevance_score": "0.068371", "ticker_sentiment_score": "0.028338", "ticker_sentiment_label": "Neutral"}, {"ticker": "UAL", "relevance_score": "0.045612", "ticker_sentiment_score": "-0.11938", "ticker_sentiment_label": "Neutral"}, {"ticker": "C", "relevance_score": "0.091075", "ticker_sentiment_score": "0.060214", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.136242", "ticker_sentiment_score": "0.010052", "ticker_sentiment_label": "Neutral"}, {"ticker": "CROX", "relevance_score": "0.068371", "ticker_sentiment_score": "0.189572", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.045612", "ticker_sentiment_score": "-0.022883", "ticker_sentiment_label": "Neutral"}, {"ticker": "HPQ", "relevance_score": "0.022815", "ticker_sentiment_score": "-0.000921", "ticker_sentiment_label": "Neutral"}, {"ticker": "BK", "relevance_score": "0.068371", "ticker_sentiment_score": "0.028338", "ticker_sentiment_label": "Neutral"}, {"ticker": "COIN", "relevance_score": "0.045612", "ticker_sentiment_score": "0.128458", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.113705", "ticker_sentiment_score": "0.011467", "ticker_sentiment_label": "Neutral"}, {"ticker": "URBN", "relevance_score": "0.068371", "ticker_sentiment_score": "0.131736", "ticker_sentiment_label": "Neutral"}, {"ticker": "KBH", "relevance_score": "0.068371", "ticker_sentiment_score": "-0.140846", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.022815", "ticker_sentiment_score": "0.001816", "ticker_sentiment_label": "Neutral"}, {"ticker": "TGTX", "relevance_score": "0.045612", "ticker_sentiment_score": "-0.022883", "ticker_sentiment_label": "Neutral"}, {"ticker": "EADSF", "relevance_score": "0.022815", "ticker_sentiment_score": "-0.111175", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.136242", "ticker_sentiment_score": "-0.148914", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPR", "relevance_score": "0.045612", "ticker_sentiment_score": "-0.11938", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.045612", "ticker_sentiment_score": "0.027908", "ticker_sentiment_label": "Neutral"}, {"ticker": "HARP", "relevance_score": "0.045612", "ticker_sentiment_score": "-0.022883", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMD", "relevance_score": "0.068371", "ticker_sentiment_score": "0.002016", "ticker_sentiment_label": "Neutral"}, {"ticker": "WT", "relevance_score": "0.022815", "ticker_sentiment_score": "0.120065", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.091075", "ticker_sentiment_score": "0.027513", "ticker_sentiment_label": "Neutral"}, {"ticker": "AXNX", "relevance_score": "0.045612", "ticker_sentiment_score": "-0.022883", "ticker_sentiment_label": "Neutral"}, {"ticker": "MARA", "relevance_score": "0.045612", "ticker_sentiment_score": "0.128458", "ticker_sentiment_label": "Neutral"}, {"ticker": "NFLX", "relevance_score": "0.068371", "ticker_sentiment_score": "0.087256", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.136242", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.045612", "ticker_sentiment_score": "0.027908", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNPR", "relevance_score": "0.068371", "ticker_sentiment_score": "-0.001011", "ticker_sentiment_label": "Neutral"}, {"ticker": "BSX", "relevance_score": "0.045612", "ticker_sentiment_score": "-0.022883", "ticker_sentiment_label": "Neutral"}, {"ticker": "AEO", "relevance_score": "0.045612", "ticker_sentiment_score": "0.185014", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SWN", "relevance_score": "0.068371", "ticker_sentiment_score": "0.150164", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DAL", "relevance_score": "0.136242", "ticker_sentiment_score": "-0.020069", "ticker_sentiment_label": "Neutral"}, {"ticker": "LULU", "relevance_score": "0.045612", "ticker_sentiment_score": "0.185014", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GCO", "relevance_score": "0.045612", "ticker_sentiment_score": "0.185014", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ANF", "relevance_score": "0.068371", "ticker_sentiment_score": "0.131736", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXEL", "relevance_score": "0.045612", "ticker_sentiment_score": "-0.022883", "ticker_sentiment_label": "Neutral"}, {"ticker": "HPE", "relevance_score": "0.180967", "ticker_sentiment_score": "-0.001504", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.045612", "ticker_sentiment_score": "-0.022883", "ticker_sentiment_label": "Neutral"}, {"ticker": "ISRG", "relevance_score": "0.068371", "ticker_sentiment_score": "0.026257", "ticker_sentiment_label": "Neutral"}, {"ticker": "BA", "relevance_score": "0.091075", "ticker_sentiment_score": "-0.023423", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.246923", "ticker_sentiment_score": "0.097548", "ticker_sentiment_label": "Neutral"}]}, {"title": "DexCom  ( DXCM )  Gains As Market Dips: What You Should Know", "url": "https://www.zacks.com/stock/news/2209179/dexcom-dxcm-gains-as-market-dips-what-you-should-know", "time_published": "20240111T230022", "authors": ["Zacks Equity Research"], "summary": "The latest trading day saw DexCom (DXCM) settling at $128.93, representing a +0.73% change from its previous close.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default316.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.95493"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.151127, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.597213", "ticker_sentiment_score": "0.183086", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Stocks With Rising Relative Strength: Teleflex", "url": "https://www.investors.com/ibd-data-stories/stocks-with-rising-relative-strength-teleflex-2/", "time_published": "20240111T080000", "authors": ["INVESTOR'S BUSINESS DAILY", "Investor's Business Daily"], "summary": "On Thursday, Teleflex ( TFX ) got an upgrade to its Relative Strength ( RS ) Rating, from 65 to 75. X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.614606"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.346138, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SYK", "relevance_score": "0.371523", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.371523", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TFX", "relevance_score": "0.853391", "ticker_sentiment_score": "0.415343", "ticker_sentiment_label": "Bullish"}]}, {"title": "Medtronic Getting Closer To Key Technical Benchmark", "url": "https://www.investors.com/ibd-data-stories/medtronic-getting-closer-to-key-technical-benchmark/", "time_published": "20240111T080000", "authors": ["INVESTOR'S BUSINESS DAILY", "Investor's Business Daily"], "summary": "The Relative Strength ( RS ) Rating for Medtronic ( MDT ) climbed into a higher percentile Thursday, as it got a lift from 68 to 73. X As you try to find the best stocks to buy and watch, keep a close on eye on relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.354992, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "MDT", "relevance_score": "0.830573", "ticker_sentiment_score": "0.517117", "ticker_sentiment_label": "Bullish"}, {"ticker": "SYK", "relevance_score": "0.353059", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.353059", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Alphatec Holdings Getting Closer To Key Technical Measure", "url": "https://www.investors.com/ibd-data-stories/alphatec-holdings-getting-closer-to-key-technical-measure/", "time_published": "20240111T080000", "authors": ["INVESTOR'S BUSINESS DAILY", "Investor's Business Daily"], "summary": "Alphatec Holdings ( ATEC ) had its Relative Strength ( RS ) Rating upgraded from 68 to 75 Thursday -- a welcome improvement, but still below the 80 or higher score you prefer to see. When looking for the best stocks to buy and watch, be sure to pay attention to relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.390301, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "ATCN", "relevance_score": "0.174587", "ticker_sentiment_score": "0.447836", "ticker_sentiment_label": "Bullish"}, {"ticker": "SYK", "relevance_score": "0.340915", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.340915", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ATEC", "relevance_score": "0.622414", "ticker_sentiment_score": "0.650283", "ticker_sentiment_label": "Bullish"}]}, {"title": "IBD Rating Upgrades: Merit Medical Systems Flashes Improved Technical Strength", "url": "https://www.investors.com/ibd-data-stories/ibd-rating-upgrades-merit-medical-systems-flashes-improved-technical-strength-2/", "time_published": "20240111T080000", "authors": ["INVESTOR'S BUSINESS DAILY", "Investor's Business Daily"], "summary": "The Relative Strength ( RS ) Rating for Merit Medical Systems ( MMSI ) moved into a higher percentile Thursday, as it got a lift from 62 to 73. X When you're researching the best stocks to buy and watch, keep a close on eye on relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.324517, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SYK", "relevance_score": "0.33628", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.33628", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MMSI", "relevance_score": "0.615462", "ticker_sentiment_score": "0.4939", "ticker_sentiment_label": "Bullish"}]}, {"title": "Cooper Earns Relative Strength Rating Upgrade", "url": "https://www.investors.com/ibd-data-stories/cooper-earns-relative-strength-rating-upgrade/", "time_published": "20240111T080000", "authors": ["INVESTOR'S BUSINESS DAILY", "Investor's Business Daily"], "summary": "The Relative Strength ( RS ) Rating for Cooper ( COO ) moved up into a new percentile Thursday, as it got a lift from 65 to 75. As you try to find the best stocks to buy and watch, keep a close on eye on relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.744043"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.378222, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "SYK", "relevance_score": "0.308891", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.308891", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stryker Sees Relative Strength Rating Climb To 77", "url": "https://www.investors.com/ibd-data-stories/stryker-sees-relative-strength-rating-climb-to-77/", "time_published": "20240111T080000", "authors": ["INVESTOR'S BUSINESS DAILY", "Investor's Business Daily"], "summary": "The Relative Strength ( RS ) Rating for Stryker ( SYK ) jumped into a new percentile Thursday, as it got a lift from 68 to 77. X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.122426, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SYK", "relevance_score": "0.764552", "ticker_sentiment_score": "-0.027931", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.265378", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's How Much $1000 Invested In DexCom 15 Years Ago Would Be Worth Today - DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/news/24/01/36577564/heres-how-much-1000-invested-in-dexcom-15-years-ago-would-be-worth-today", "time_published": "20240110T150030", "authors": ["Benzinga Insights"], "summary": "DexCom DXCM has outperformed the market over the past 15 years by 28.38% on an annualized basis producing an average annual return of 40.59%. Currently, DexCom has a market capitalization of $49.65 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.983605", "ticker_sentiment_score": "0.387251", "ticker_sentiment_label": "Bullish"}]}, {"title": "2 Top Dividend Stocks to Buy in 2024 and Hold Forever", "url": "https://www.fool.com/investing/2024/01/10/2-top-dividend-stocks-to-buy-in-2024-and-hold/", "time_published": "20240110T124500", "authors": ["Prosper Junior Bakiny"], "summary": "It's hard to beat these companies' track records.", "banner_image": "https://media.ycharts.com/charts/361971a021d466f2989532d51c543986.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}], "overall_sentiment_score": 0.226369, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ABT", "relevance_score": "0.055621", "ticker_sentiment_score": "-0.019994", "ticker_sentiment_label": "Neutral"}, {"ticker": "MA", "relevance_score": "0.055621", "ticker_sentiment_score": "0.036001", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDT", "relevance_score": "0.469935", "ticker_sentiment_score": "0.262389", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.055621", "ticker_sentiment_score": "-0.019994", "ticker_sentiment_label": "Neutral"}, {"ticker": "V", "relevance_score": "0.423251", "ticker_sentiment_score": "0.177242", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "DexCom  ( DXCM )  Preliminary Q4 Revenues Ride on Sensor Demand", "url": "https://www.zacks.com/stock/news/2207484/dexcom-dxcm-preliminary-q4-revenues-ride-on-sensor-demand", "time_published": "20240109T144700", "authors": ["Zacks Equity Research"], "summary": "DexCom's (DXCM) revenue growth in the fourth quarter is likely to have been boosted by strong demand for its CGM sensors across the globe. It delivers robust revenue guidance for 2024.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c0/2297.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.928769"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.271669, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MMSI", "relevance_score": "0.129866", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITGR", "relevance_score": "0.256314", "ticker_sentiment_score": "0.20627", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DVA", "relevance_score": "0.193723", "ticker_sentiment_score": "0.140334", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.432818", "ticker_sentiment_score": "0.110692", "ticker_sentiment_label": "Neutral"}]}, {"title": "Tandem Diabetes  ( TNDM )  and Abbott Debut New Integrated Offering", "url": "https://www.zacks.com/stock/news/2207406/tandem-diabetes-tndm-and-abbott-debut-new-integrated-offering", "time_published": "20240109T132900", "authors": ["Zacks Equity Research"], "summary": "Tandem Diabetes' (TNDM) t:slim X2 is the first AID system to be integrated with Abbott's Freestyle Libre 2 Plus sensor.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/58/608.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.838487"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.299495, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "TNDM", "relevance_score": "0.144853", "ticker_sentiment_score": "0.241041", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HAE", "relevance_score": "0.23907", "ticker_sentiment_score": "0.101371", "ticker_sentiment_label": "Neutral"}, {"ticker": "DVA", "relevance_score": "0.144853", "ticker_sentiment_score": "0.064455", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.048523", "ticker_sentiment_score": "0.168902", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "2 Growth Stocks That Could Make You Richer in 2024 and Beyond", "url": "https://www.fool.com/investing/2024/01/09/2-growth-stocks-that-could-make-you-richer-in-2024/", "time_published": "20240109T121500", "authors": ["Prosper Junior Bakiny"], "summary": "Last year wasn't great for either stock, but that's no reason to ignore them.", "banner_image": "https://g.foolcdn.com/editorial/images/760055/physician-giving-a-high-five-to-a-young-patient.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.917436"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.251255, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SRPT", "relevance_score": "0.377958", "ticker_sentiment_score": "0.262341", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.47379", "ticker_sentiment_score": "0.253605", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Futures: Magnificent Seven Stocks Lead Market Rally", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-magnificent-seven-stocks-rally-nvidia-breaks-out-past-buy-point/", "time_published": "20240108T215500", "authors": ["SCOTT LEHTONEN", "Investor's Business Daily"], "summary": "Dow Jones Futures: Magnificent Seven Stocks Rally. Nvidia Breaks Out Past Buy Point Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/02/Stock-Chip-glows-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.2"}], "overall_sentiment_score": 0.208919, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NFLX", "relevance_score": "0.115232", "ticker_sentiment_score": "0.155184", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "META", "relevance_score": "0.076971", "ticker_sentiment_score": "0.086006", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.153226", "ticker_sentiment_score": "0.122934", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.228073", "ticker_sentiment_score": "0.270391", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "C", "relevance_score": "0.076971", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.076971", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.076971", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.153226", "ticker_sentiment_score": "0.202159", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.153226", "ticker_sentiment_score": "0.123387", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.228073", "ticker_sentiment_score": "0.154061", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TSLA", "relevance_score": "0.153226", "ticker_sentiment_score": "0.113992", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.076971", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "V", "relevance_score": "0.153226", "ticker_sentiment_score": "0.155683", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CAT", "relevance_score": "0.115232", "ticker_sentiment_score": "0.220472", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMZN", "relevance_score": "0.190868", "ticker_sentiment_score": "0.251625", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.115232", "ticker_sentiment_score": "0.014102", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dow Jones Up As Nvidia Clears Entry; Cathie Wood Loads Up On This Stock Despite 28% Plunge", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-up-as-nvidia-stock-clears-entry-cathie-wood-loads-up-on-this-stock-despite-28-plunge-apple-stock-palantir-stock/", "time_published": "20240108T201600", "authors": ["MICHAEL LARKIN", "Investor's Business Daily"], "summary": "Dow Jones Up As Nvidia Clears Entry. Cathie Wood Loads Up On This Stock Despite 28% Plunge Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/03/SMT-cathiewoods-05-AP.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Blockchain", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.451494"}], "overall_sentiment_score": 0.28366, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.037681", "ticker_sentiment_score": "0.082612", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.075279", "ticker_sentiment_score": "0.149672", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.112709", "ticker_sentiment_score": "0.221992", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AAPL", "relevance_score": "0.112709", "ticker_sentiment_score": "0.158345", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MS", "relevance_score": "0.037681", "ticker_sentiment_score": "0.153993", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AAL", "relevance_score": "0.112709", "ticker_sentiment_score": "0.177038", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "COIN", "relevance_score": "0.075279", "ticker_sentiment_score": "0.145612", "ticker_sentiment_label": "Neutral"}, {"ticker": "IRDM", "relevance_score": "0.075279", "ticker_sentiment_score": "0.145612", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.075279", "ticker_sentiment_score": "0.149672", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.075279", "ticker_sentiment_score": "0.149672", "ticker_sentiment_label": "Neutral"}, {"ticker": "INTC", "relevance_score": "0.075279", "ticker_sentiment_score": "0.274929", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMD", "relevance_score": "0.075279", "ticker_sentiment_score": "0.223924", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.112709", "ticker_sentiment_score": "0.069892", "ticker_sentiment_label": "Neutral"}, {"ticker": "BA", "relevance_score": "0.112709", "ticker_sentiment_score": "0.004593", "ticker_sentiment_label": "Neutral"}, {"ticker": "PLTR", "relevance_score": "0.112709", "ticker_sentiment_score": "0.081356", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dexcom's 66% Sprint Continues With A Breakout On Bullish Sales", "url": "https://www.investors.com/news/technology/dexcom-stock-continues-its-recent-sprint-with-a-breakout-on-bullish-sales/", "time_published": "20240108T175900", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "Dexcom ( DXCM ) stock popped and broke out Monday after the diabetes devices maker whipped Wall Street's fourth-quarter expectations and announced a new continuous glucose monitor due this summer. Dexcom's devices brought in $1.03 billion in sales, preliminarily, the company said in a news ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/03/Stock-dexcom-one-04-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.962106"}], "overall_sentiment_score": 0.215445, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.778508", "ticker_sentiment_score": "0.409825", "ticker_sentiment_label": "Bullish"}]}, {"title": "A Closer Look at DexCom's Options Market Dynamics - DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/markets/options/24/01/36539678/a-closer-look-at-dexcoms-options-market-dynamics", "time_published": "20240108T173109", "authors": ["Benzinga Insights"], "summary": "Whales with a lot of money to spend have taken a noticeably bullish stance on DexCom. Looking at options history for DexCom DXCM we detected 12 trades. If we consider the specifics of each trade, it is accurate to state that 66% of the investors opened trades with bullish expectations and 33% ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.962106"}, {"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.163889, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "WFC", "relevance_score": "0.105604", "ticker_sentiment_score": "-0.114543", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.888822", "ticker_sentiment_score": "0.306679", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PODD", "relevance_score": "0.105604", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stock Market Mixed To Start New Week; Boeing Sees More Pain, Nvidia Hits A High", "url": "https://www.investors.com/market-trend/stock-market-today/stock-market-starts-week-mostly-higher-boeing-sees-more-pain-as-nvidia-hits-new-high/", "time_published": "20240108T155200", "authors": ["Investor's Business Daily", "KIMBERLEY KOENIG"], "summary": "Stock Market Mixed To Start New Week. Boeing Sees More Pain, Nvidia Hits A High Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2020/12/Stock-AlaskaAir-737-900-company.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.795202"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.089888, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALK", "relevance_score": "0.170075", "ticker_sentiment_score": "-0.171989", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "NVDA", "relevance_score": "0.170075", "ticker_sentiment_score": "-0.00572", "ticker_sentiment_label": "Neutral"}, {"ticker": "C", "relevance_score": "0.113866", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.113866", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BSX", "relevance_score": "0.170075", "ticker_sentiment_score": "0.37368", "ticker_sentiment_label": "Bullish"}, {"ticker": "JPM", "relevance_score": "0.113866", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.057079", "ticker_sentiment_score": "0.218", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "COIN", "relevance_score": "0.170075", "ticker_sentiment_score": "0.019463", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.113866", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPR", "relevance_score": "0.113866", "ticker_sentiment_score": "-0.211623", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "WFC", "relevance_score": "0.113866", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HARP", "relevance_score": "0.113866", "ticker_sentiment_score": "0.08304", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMC", "relevance_score": "0.170075", "ticker_sentiment_score": "0.148555", "ticker_sentiment_label": "Neutral"}, {"ticker": "GCT", "relevance_score": "0.113866", "ticker_sentiment_score": "0.194803", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.170075", "ticker_sentiment_score": "-0.005679", "ticker_sentiment_label": "Neutral"}, {"ticker": "AXNX", "relevance_score": "0.170075", "ticker_sentiment_score": "0.37368", "ticker_sentiment_label": "Bullish"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.170075", "ticker_sentiment_score": "0.019463", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's Why DexCom  ( DXCM )  is a Strong Growth Stock", "url": "https://www.zacks.com/stock/news/2206972/heres-why-dexcom-dxcm-is-a-strong-growth-stock", "time_published": "20240108T144507", "authors": ["Zacks Equity Research"], "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default50.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.769861"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.77141"}], "overall_sentiment_score": 0.419064, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.495015", "ticker_sentiment_score": "0.370776", "ticker_sentiment_label": "Bullish"}]}, {"title": "Glucose Monitor Maker Rallies On Higher 2024 Outlook", "url": "https://www.investors.com/research/dexcom-stock-rallies-on-higher-2024-outlook/", "time_published": "20240108T144200", "authors": ["Investor's Business Daily", "VIDYA RAMAKRISHNAN"], "summary": "Dexcom Stock Rises On Raised 2024 Outlook Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/04/Stock-Dexcom-03-company.jpeg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.990893"}, {"topic": "Earnings", "relevance_score": "0.818451"}], "overall_sentiment_score": 0.286315, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.659096", "ticker_sentiment_score": "0.301002", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Wearable Technology Market Gains Ground, 3 Stocks in Focus", "url": "https://www.zacks.com/stock/news/2206848/wearable-technology-market-gains-ground-3-stocks-in-focus", "time_published": "20240108T134500", "authors": ["Moumi Mondal"], "summary": "In the wearable medical devices industry, investors can keep a keen eye on stocks such as ABT, MDT and DXCM.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/18/20877.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.344721, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GLDAF", "relevance_score": "0.043264", "ticker_sentiment_score": "0.201312", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABT", "relevance_score": "0.2138", "ticker_sentiment_score": "0.303235", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MDT", "relevance_score": "0.295867", "ticker_sentiment_score": "0.377378", "ticker_sentiment_label": "Bullish"}, {"ticker": "DXCM", "relevance_score": "0.374624", "ticker_sentiment_score": "0.423993", "ticker_sentiment_label": "Bullish"}]}, {"title": "DexCom  ( DXCM )  Exceeds Market Returns: Some Facts to Consider", "url": "https://www.zacks.com/stock/news/2206600/dexcom-dxcm-exceeds-market-returns-some-facts-to-consider", "time_published": "20240105T230018", "authors": ["Zacks Equity Research"], "summary": "DexCom (DXCM) closed at $123.98 in the latest trading session, marking a +1.76% move from the prior day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default157.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.891286"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.19441, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.582526", "ticker_sentiment_score": "0.236715", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Alcon  ( ALC )  Business Hurt by Macroeconomic Woes, Competition", "url": "https://www.zacks.com/stock/news/2205673/alcon-alc-business-hurt-by-macroeconomic-woes-competition", "time_published": "20240104T144400", "authors": ["Zacks Equity Research"], "summary": "In the surgical business, Alcon (ALC) faces a mix of competitors, ranging from large manufacturers with multiple business lines to small manufacturers.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972193"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.294853, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALC", "relevance_score": "0.543376", "ticker_sentiment_score": "0.406276", "ticker_sentiment_label": "Bullish"}, {"ticker": "PODD", "relevance_score": "0.176717", "ticker_sentiment_score": "0.060541", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.234119", "ticker_sentiment_score": "0.134635", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.176717", "ticker_sentiment_score": "0.060541", "ticker_sentiment_label": "Neutral"}]}, {"title": "Thermo Fisher  ( TMO )  End Markets Drive Growth Amid Macro Woes", "url": "https://www.zacks.com/stock/news/2205062/thermo-fisher-tmo-end-markets-drive-growth-amid-macro-woes", "time_published": "20240103T150900", "authors": ["Zacks Equity Research"], "summary": "In the academic and government end markets, Thermo Fisher (TMO) is delivering strong growth in the electron microscopy, chromatography and mass spectrometry businesses.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.986413"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.250657, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.146321", "ticker_sentiment_score": "0.057323", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.241444", "ticker_sentiment_score": "0.14158", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.146321", "ticker_sentiment_score": "0.057323", "ticker_sentiment_label": "Neutral"}, {"ticker": "TMO", "relevance_score": "0.333043", "ticker_sentiment_score": "0.166774", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "If You Invested $1000 in DexCom a Decade Ago, This is How Much It'd Be Worth Now", "url": "https://www.zacks.com/stock/news/2204878/if-you-invested-1000-in-dexcom-a-decade-ago-this-is-how-much-itd-be-worth-now", "time_published": "20240103T133004", "authors": ["Zacks Equity Research"], "summary": "Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default199.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.818451"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}], "overall_sentiment_score": 0.305022, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.530849", "ticker_sentiment_score": "0.481481", "ticker_sentiment_label": "Bullish"}]}, {"title": "1 Stock-Split Stock to Buy Hand Over Fist in 2024 and 1 to Avoid", "url": "https://www.fool.com/investing/2024/01/03/1-stock-split-stock-to-buy-in-2024-and-1-to-avoid/", "time_published": "20240103T100600", "authors": ["Sean Williams"], "summary": "Among Nvidia, Amazon, DexCom, Shopify, Alphabet, Tesla, Palo Alto Networks, Monster Beverage, and Novo Nordisk, there's a historically cheap outperformer that's ripe for the picking, as well as an industry leader headed for a breakdown.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F759753%2Fstock-certificate-investment-retire-heirloom-donate-capital-gains-tax-getty.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.875462"}], "overall_sentiment_score": 0.14877, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.233556", "ticker_sentiment_score": "0.222965", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TSLA", "relevance_score": "0.289576", "ticker_sentiment_score": "0.131199", "ticker_sentiment_label": "Neutral"}, {"ticker": "BKNG", "relevance_score": "0.029618", "ticker_sentiment_score": "0.080706", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.029618", "ticker_sentiment_score": "0.185776", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.029618", "ticker_sentiment_score": "0.185776", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "DexCom Unusual Options Activity - DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/markets/options/24/01/36457531/dexcom-unusual-options-activity", "time_published": "20240102T190046", "authors": ["Benzinga Insights"], "summary": "Investors with a lot of money to spend have taken a bullish stance on DexCom DXCM. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.110353, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.085629", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.085629", "ticker_sentiment_score": "-0.119217", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.803061", "ticker_sentiment_score": "0.212283", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MS", "relevance_score": "0.085629", "ticker_sentiment_score": "0.097553", "ticker_sentiment_label": "Neutral"}]}, {"title": "Omnicell  ( OMCL )  Gains From Innovation Amid Cost Pressure", "url": "https://www.zacks.com/stock/news/2204346/omnicell-omcl-gains-from-innovation-amid-cost-pressure", "time_published": "20240102T125800", "authors": ["Zacks Equity Research"], "summary": "Omnicell (OMCL) plans to focus on integrating customer success functions into its broader organizational structure.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.253164, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "OMCL", "relevance_score": "0.504646", "ticker_sentiment_score": "0.366155", "ticker_sentiment_label": "Bullish"}, {"ticker": "PODD", "relevance_score": "0.135347", "ticker_sentiment_score": "0.051322", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.135347", "ticker_sentiment_score": "0.051322", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.135347", "ticker_sentiment_score": "0.051322", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's Why You Should Retain Teleflex  ( TFX )  Stock for Now", "url": "https://www.zacks.com/stock/news/2204317/heres-why-you-should-retain-teleflex-tfx-stock-for-now", "time_published": "20240102T122400", "authors": ["Zacks Equity Research"], "summary": "Investors remain optimistic about Teleflex (TFX), backed by the strong prospects of the Interventional business and stable solvency.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Earnings", "relevance_score": "0.998917"}], "overall_sentiment_score": 0.23315, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.128822", "ticker_sentiment_score": "0.029778", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.171181", "ticker_sentiment_score": "0.097743", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.171181", "ticker_sentiment_score": "0.076601", "ticker_sentiment_label": "Neutral"}, {"ticker": "TFX", "relevance_score": "0.411176", "ticker_sentiment_score": "0.351096", "ticker_sentiment_label": "Bullish"}]}, {"title": "Boston Scientific  ( BSX )  Initiates AVANT GUARD Clinical Trial", "url": "https://www.zacks.com/stock/news/2204314/boston-scientific-bsx-initiates-avant-guard-clinical-trial", "time_published": "20240102T121800", "authors": ["Zacks Equity Research"], "summary": "Boston Scientific's (BSX) AVANT GUARD clinical trial is set to evaluate the FARAPULSE PFA System as the first-line treatment for persistent AF.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/08/595.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972193"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.200097, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.138198", "ticker_sentiment_score": "0.0531", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.228287", "ticker_sentiment_score": "0.087375", "ticker_sentiment_label": "Neutral"}, {"ticker": "BSX", "relevance_score": "0.315397", "ticker_sentiment_score": "0.264255", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.138198", "ticker_sentiment_score": "0.0531", "ticker_sentiment_label": "Neutral"}]}, {"title": "DexCom  ( DXCM )  Stock Moves -0.06%: What You Should Know", "url": "https://www.zacks.com/stock/news/2203929/dexcom-dxcm-stock-moves--006-what-you-should-know", "time_published": "20231229T230019", "authors": ["Zacks Equity Research"], "summary": "The latest trading day saw DexCom (DXCM) settling at $124.09, representing a -0.06% change from its previous close.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default115.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.95493"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.188961, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.580956", "ticker_sentiment_score": "0.253451", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Globus Medical  ( GMED )  Gains From Innovation Amid Macro Issues", "url": "https://www.zacks.com/stock/news/2203657/globus-medical-gmed-gains-from-innovation-amid-macro-issues", "time_published": "20231229T143300", "authors": ["Zacks Equity Research"], "summary": "Globus Medical (GMED) is particularly seeing notable gains in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Earnings", "relevance_score": "0.972193"}], "overall_sentiment_score": 0.30049, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ZBH", "relevance_score": "0.053629", "ticker_sentiment_score": "0.158995", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNN", "relevance_score": "0.053629", "ticker_sentiment_score": "0.158995", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GMED", "relevance_score": "0.498827", "ticker_sentiment_score": "0.421473", "ticker_sentiment_label": "Bullish"}, {"ticker": "DSSMY", "relevance_score": "0.053629", "ticker_sentiment_score": "0.158995", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PODD", "relevance_score": "0.159922", "ticker_sentiment_score": "0.057896", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDT", "relevance_score": "0.053629", "ticker_sentiment_score": "0.158995", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HAE", "relevance_score": "0.263373", "ticker_sentiment_score": "0.231443", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.159922", "ticker_sentiment_score": "0.057896", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's Why Investors Should Retain Labcorp  ( LH )  Stock for Now", "url": "https://www.zacks.com/stock/news/2203637/heres-why-investors-should-retain-labcorp-lh-stock-for-now", "time_published": "20231229T142300", "authors": ["Zacks Equity Research"], "summary": "Investors remain optimistic about Labcorp (LH) due to impressive partnerships and expansion efforts in targeted high-growth areas.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7b/850.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Earnings", "relevance_score": "0.990678"}], "overall_sentiment_score": 0.336243, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "FTRE", "relevance_score": "0.085022", "ticker_sentiment_score": "0.279672", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DGX", "relevance_score": "0.042571", "ticker_sentiment_score": "0.123427", "ticker_sentiment_label": "Neutral"}, {"ticker": "PODD", "relevance_score": "0.127231", "ticker_sentiment_score": "0.080036", "ticker_sentiment_label": "Neutral"}, {"ticker": "LH", "relevance_score": "0.127231", "ticker_sentiment_score": "0.316402", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HAE", "relevance_score": "0.169081", "ticker_sentiment_score": "0.14522", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.169081", "ticker_sentiment_score": "0.132853", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCSG", "relevance_score": "0.042571", "ticker_sentiment_score": "0.221256", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Here's Why You Should Invest in Insulet  ( PODD )  Stock for Now", "url": "https://www.zacks.com/stock/news/2203323/heres-why-you-should-invest-in-insulet-podd-stock-for-now", "time_published": "20231228T181300", "authors": ["Zacks Equity Research"], "summary": "Investors are optimistic about Insulet (PODD), led by the strong adoption of Omnipod 5 and its strong solvency position.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ca/2974.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999476"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.234138, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PEN", "relevance_score": "0.110717", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PODD", "relevance_score": "0.46898", "ticker_sentiment_score": "0.318497", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HAE", "relevance_score": "0.219312", "ticker_sentiment_score": "0.119515", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.110717", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's Why You Should Retain Illumina  ( ILMN )  Stock for Now", "url": "https://www.zacks.com/stock/news/2203319/heres-why-you-should-retain-illumina-ilmn-stock-for-now", "time_published": "20231228T180200", "authors": ["Zacks Equity Research"], "summary": "Investors are optimistic about Illumina's (ILMN) strength in the genomics market and strong solvency position.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Earnings", "relevance_score": "0.99489"}], "overall_sentiment_score": 0.264288, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "A", "relevance_score": "0.046184", "ticker_sentiment_score": "0.233216", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PACB", "relevance_score": "0.046184", "ticker_sentiment_score": "0.233216", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ILMN", "relevance_score": "0.356865", "ticker_sentiment_score": "0.316312", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TMO", "relevance_score": "0.046184", "ticker_sentiment_score": "0.233216", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PODD", "relevance_score": "0.137934", "ticker_sentiment_score": "0.054256", "ticker_sentiment_label": "Neutral"}, {"ticker": "QGEN", "relevance_score": "0.046184", "ticker_sentiment_score": "0.233216", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HAE", "relevance_score": "0.227859", "ticker_sentiment_score": "0.157356", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.137934", "ticker_sentiment_score": "0.054256", "ticker_sentiment_label": "Neutral"}]}, {"title": "National Vision  ( EYE )  Store Openings Aid, Macro Issues Stay", "url": "https://www.zacks.com/stock/news/2203215/national-vision-eye-store-openings-aid-macro-issues-stay", "time_published": "20231228T160700", "authors": ["Zacks Equity Research"], "summary": "In terms of store expansion, National Vision (EYE) continues to see sizable new opportunities for many years to come.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}, {"topic": "Earnings", "relevance_score": "0.972193"}], "overall_sentiment_score": 0.266957, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "EYE", "relevance_score": "0.534664", "ticker_sentiment_score": "0.332499", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PODD", "relevance_score": "0.157827", "ticker_sentiment_score": "0.057409", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.260004", "ticker_sentiment_score": "0.229115", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.157827", "ticker_sentiment_score": "0.057409", "ticker_sentiment_label": "Neutral"}, {"ticker": "WMT", "relevance_score": "0.209365", "ticker_sentiment_score": "0.07035", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's Why You Should Retain QIAGEN  ( QGEN )  Stock for Now", "url": "https://www.zacks.com/stock/news/2203003/heres-why-you-should-retain-qiagen-qgen-stock-for-now", "time_published": "20231228T122500", "authors": ["Zacks Equity Research"], "summary": "Investors remain optimistic about QIAGEN (QGEN), backed by strategic alliances and potential in the Molecular Diagnostics arena.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/08/595.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.9973"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.215934, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.121241", "ticker_sentiment_score": "0.078322", "ticker_sentiment_label": "Neutral"}, {"ticker": "QGEN", "relevance_score": "0.31583", "ticker_sentiment_score": "0.1493", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.16117", "ticker_sentiment_score": "0.1407", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.16117", "ticker_sentiment_score": "0.128708", "ticker_sentiment_label": "Neutral"}, {"ticker": "MYGN", "relevance_score": "0.040553", "ticker_sentiment_score": "-0.048058", "ticker_sentiment_label": "Neutral"}]}, {"title": "Reasons to Buy Prestige Consumer  ( PBH )  Stock for Now", "url": "https://www.zacks.com/stock/news/2203002/reasons-to-buy-prestige-consumer-pbh-stock-for-now", "time_published": "20231228T122000", "authors": ["Zacks Equity Research"], "summary": "Investors remain optimistic about Prestige Consumer (PBH), backed by the robust strength of its consumer brands portfolio.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c0/2563.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Earnings", "relevance_score": "0.9973"}], "overall_sentiment_score": 0.26852, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.129516", "ticker_sentiment_score": "0.079542", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.172097", "ticker_sentiment_score": "0.149755", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.172097", "ticker_sentiment_score": "0.133072", "ticker_sentiment_label": "Neutral"}, {"ticker": "PBH", "relevance_score": "0.129516", "ticker_sentiment_score": "0.323645", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Align Technology  ( ALGN )  Up 30% YTD: Will the Rally Continue?", "url": "https://www.zacks.com/stock/news/2202708/align-technology-algn-up-30-ytd-will-the-rally-continue", "time_published": "20231227T160200", "authors": ["Zacks Equity Research"], "summary": "Investors are optimistic about Align Technology (ALGN), driven by recent strategic alliance and geographic expansion.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/41/899.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.99489"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.319043, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.149656", "ticker_sentiment_score": "0.059357", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALGN", "relevance_score": "0.198628", "ticker_sentiment_score": "0.219406", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HAE", "relevance_score": "0.246832", "ticker_sentiment_score": "0.173139", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.149656", "ticker_sentiment_score": "0.059357", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's Why You Should Retain CVS Health  ( CVS )  Stock for Now", "url": "https://www.zacks.com/stock/news/2202694/heres-why-you-should-retain-cvs-health-cvs-stock-for-now", "time_published": "20231227T153500", "authors": ["Zacks Equity Research"], "summary": "Investors are optimistic about CVS Health (CVS) on its strong segmental performance and impressive restructuring plan.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5a/926.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Earnings", "relevance_score": "0.9973"}], "overall_sentiment_score": 0.308624, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CVS", "relevance_score": "0.37643", "ticker_sentiment_score": "0.367464", "ticker_sentiment_label": "Bullish"}, {"ticker": "PODD", "relevance_score": "0.146025", "ticker_sentiment_score": "0.056006", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.240965", "ticker_sentiment_score": "0.164514", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.146025", "ticker_sentiment_score": "0.056006", "ticker_sentiment_label": "Neutral"}]}, {"title": "Henry Schein  ( HSIC )  Sales Hurt by Cyber Attack, Macro Woes", "url": "https://www.zacks.com/stock/news/2202660/henry-schein-hsic-sales-hurt-by-cyber-attack-macro-woes", "time_published": "20231227T150900", "authors": ["Zacks Equity Research"], "summary": "Henry Schein's (HSIC) financial operations are being affected by the current macroeconomic environment.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Earnings", "relevance_score": "0.99237"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.170424, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HSIC", "relevance_score": "0.523336", "ticker_sentiment_score": "0.205851", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MCK", "relevance_score": "0.043658", "ticker_sentiment_score": "0.08945", "ticker_sentiment_label": "Neutral"}, {"ticker": "PDCO", "relevance_score": "0.087185", "ticker_sentiment_score": "0.062776", "ticker_sentiment_label": "Neutral"}, {"ticker": "IDXX", "relevance_score": "0.043658", "ticker_sentiment_score": "0.08945", "ticker_sentiment_label": "Neutral"}, {"ticker": "PODD", "relevance_score": "0.130453", "ticker_sentiment_score": "0.051554", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.215702", "ticker_sentiment_score": "0.197979", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.130453", "ticker_sentiment_score": "0.051554", "ticker_sentiment_label": "Neutral"}]}, {"title": "Orthofix  ( OFIX )  Releases New Data for Spinal Fusion Procedures", "url": "https://www.zacks.com/stock/news/2202514/orthofix-ofix-releases-new-data-for-spinal-fusion-procedures", "time_published": "20231227T134500", "authors": ["Zacks Equity Research"], "summary": "According to Orthofix (OFIX), this data highlights the noninvasive and cost-effective nature of SpinalStim, enabling patients to continue their healing in the comfort of their homes.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/b3/30471.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972193"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.245319, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "OFIX", "relevance_score": "0.167322", "ticker_sentiment_score": "0.092097", "ticker_sentiment_label": "Neutral"}, {"ticker": "PODD", "relevance_score": "0.167322", "ticker_sentiment_score": "0.061014", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.275246", "ticker_sentiment_score": "0.243439", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.167322", "ticker_sentiment_score": "0.061014", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's Why Investors Should Retain Bruker  ( BRKR )  Stock Now", "url": "https://www.zacks.com/stock/news/2202464/heres-why-investors-should-retain-bruker-brkr-stock-now", "time_published": "20231227T123400", "authors": ["Zacks Equity Research"], "summary": "Investors remain optimistic about Bruker (BRKR) due to the strength of the BSI BioSpin and CALID groups.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e8/547.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}, {"topic": "Earnings", "relevance_score": "0.999938"}], "overall_sentiment_score": 0.222649, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BRKR", "relevance_score": "0.307443", "ticker_sentiment_score": "0.210909", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CURN", "relevance_score": "0.039418", "ticker_sentiment_score": "-0.185304", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PODD", "relevance_score": "0.11787", "ticker_sentiment_score": "0.077406", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.156715", "ticker_sentiment_score": "0.138216", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.156715", "ticker_sentiment_score": "0.12643", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:NANO", "relevance_score": "0.156715", "ticker_sentiment_score": "0.215276", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Meet the Stock-Split Stock Warren Buffett Is Likeliest to Buy in 2024", "url": "https://www.fool.com/investing/2023/12/27/meet-stock-split-stock-warren-buffett-buy-in-2024/", "time_published": "20231227T100600", "authors": ["Sean Williams"], "summary": "Among Nvidia, Amazon, DexCom, Shopify, Alphabet, Tesla, Palo Alto Networks, Monster Beverage, and Novo Nordisk, there's a stock-split stock that checks all the right boxes for the Oracle of Omaha.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F759301%2Fstock-certificate-investment-retire-heirloom-donate-capital-gains-tax-getty.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.838487"}], "overall_sentiment_score": 0.187651, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SHOP", "relevance_score": "0.040553", "ticker_sentiment_score": "-0.038108", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.35278", "ticker_sentiment_score": "0.201355", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TSLA", "relevance_score": "0.040553", "ticker_sentiment_score": "-0.038108", "ticker_sentiment_label": "Neutral"}, {"ticker": "PARA", "relevance_score": "0.040553", "ticker_sentiment_score": "0.137591", "ticker_sentiment_label": "Neutral"}, {"ticker": "BRK-A", "relevance_score": "0.081001", "ticker_sentiment_score": "-0.093549", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.081001", "ticker_sentiment_score": "-0.093549", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.040553", "ticker_sentiment_score": "-0.038108", "ticker_sentiment_label": "Neutral"}]}, {"title": "5 MedTech Stocks Poised to Continue Their Winning Streaks in 2024", "url": "https://www.zacks.com/stock/news/2202263/5-medtech-stocks-poised-to-continue-their-winning-streaks-in-2024", "time_published": "20231226T162600", "authors": ["Zacks Equity Research"], "summary": "Stocks like DexCom Inc. (DXCM), Integer Holdings (ITGR), Penumbra (PEN), Haemonetics (HAE), Health Equity (HAE) and are likely to continue their strong performance in 2024.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/d6/3739.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.999937"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.332638, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PEN", "relevance_score": "0.241684", "ticker_sentiment_score": "0.188309", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HQY", "relevance_score": "0.182506", "ticker_sentiment_score": "0.141618", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITGR", "relevance_score": "0.241684", "ticker_sentiment_score": "0.18675", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HAE", "relevance_score": "0.212248", "ticker_sentiment_score": "0.195618", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.212248", "ticker_sentiment_score": "0.151976", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Three Reasons to Add DaVita  ( DVA )  Stock to Your Portfolio", "url": "https://www.zacks.com/stock/news/2202216/three-reasons-to-add-davita-dva-stock-to-your-portfolio", "time_published": "20231226T145900", "authors": ["Zacks Equity Research"], "summary": "DaVita's (DVA) strength in its DaVita Kidney Care raises optimism about the stock.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/57/1286.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.795202"}], "overall_sentiment_score": 0.382632, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "HQY", "relevance_score": "0.215894", "ticker_sentiment_score": "0.04532", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITGR", "relevance_score": "0.215894", "ticker_sentiment_score": "0.134442", "ticker_sentiment_label": "Neutral"}, {"ticker": "DVA", "relevance_score": "0.41627", "ticker_sentiment_score": "0.583365", "ticker_sentiment_label": "Bullish"}, {"ticker": "DXCM", "relevance_score": "0.215894", "ticker_sentiment_score": "0.088495", "ticker_sentiment_label": "Neutral"}]}, {"title": "Play Potential Earnings Beat With 5 Top-Ranked Stocks", "url": "https://www.zacks.com/stock/news/2202063/play-potential-earnings-beat-with-5-top-ranked-stocks", "time_published": "20231226T124800", "authors": ["Sanghamitra Saha"], "summary": "These top-ranked stocks are likely to beat on the bottom line in their upcoming releases. Tap Amazon.com (AMZN), Deckers Outdoor (DECK), Wingstop (WING), DexCom (DXCM) and NVIDIA (NVDA).", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default271.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.54554"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "1.0"}], "overall_sentiment_score": 0.310234, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NVDA", "relevance_score": "0.189373", "ticker_sentiment_score": "0.135021", "ticker_sentiment_label": "Neutral"}, {"ticker": "WING", "relevance_score": "0.226301", "ticker_sentiment_score": "0.119126", "ticker_sentiment_label": "Neutral"}, {"ticker": "DECK", "relevance_score": "0.189373", "ticker_sentiment_score": "0.169165", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.189373", "ticker_sentiment_score": "0.143936", "ticker_sentiment_label": "Neutral"}]}, {"title": "Thermo Fisher  ( TMO )  Unveils CorEvitas Pharmacovigilance Platform", "url": "https://www.zacks.com/stock/news/2202037/thermo-fisher-tmo-unveils-corevitas-pharmacovigilance-platform", "time_published": "20231226T120800", "authors": ["Zacks Equity Research"], "summary": "Thermo Fisher (TMO) introduces the CorEvitas pharmacovigilance platform for clinical research registries.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7b/850.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972193"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.326489, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.1568", "ticker_sentiment_score": "0.057172", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.258351", "ticker_sentiment_score": "0.229818", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.1568", "ticker_sentiment_score": "0.057172", "ticker_sentiment_label": "Neutral"}, {"ticker": "TMO", "relevance_score": "0.1568", "ticker_sentiment_score": "0.14121", "ticker_sentiment_label": "Neutral"}]}, {"title": "DexCom  ( DXCM )  Stock Falls Amid Market Uptick: What Investors Need to Know", "url": "https://www.zacks.com/stock/news/2201802/dexcom-dxcm-stock-falls-amid-market-uptick-what-investors-need-to-know", "time_published": "20231222T225010", "authors": ["Zacks Equity Research"], "summary": "In the closing of the recent trading day, DexCom (DXCM) stood at $122.17, denoting a -0.51% change from the preceding trading day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default49.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.986564"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.232697, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.398781", "ticker_sentiment_score": "0.222739", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Looking Into DexCom's Recent Short Interest - DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/short-sellers/23/12/36368217/looking-into-dexcoms-recent-short-interest", "time_published": "20231222T190014", "authors": ["Benzinga Insights"], "summary": "DexCom's DXCM short percent of float has risen 7.58% since its last report. The company recently reported that it has 19.12 million shares sold short, which is 5.68% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.85 days to cover their ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.26961, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.224903", "ticker_sentiment_score": "0.158881", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "3 Reasons Why Growth Investors Shouldn't Overlook DexCom  ( DXCM ) ", "url": "https://www.zacks.com/stock/news/2201754/3-reasons-why-growth-investors-shouldnt-overlook-dexcom-dxcm", "time_published": "20231222T174504", "authors": ["Zacks Equity Research"], "summary": "DexCom (DXCM) is well positioned to outperform the market, as it exhibits above-average growth in financials.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default36.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.983783"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.466914, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.492324", "ticker_sentiment_score": "0.421441", "ticker_sentiment_label": "Bullish"}]}, {"title": "Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio", "url": "https://www.zacks.com/stock/news/2201614/why-this-1-momentum-stock-could-be-a-great-addition-to-your-portfolio", "time_published": "20231222T150007", "authors": ["Zacks Equity Research"], "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default85.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.838487"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.929393"}], "overall_sentiment_score": 0.360443, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.385286", "ticker_sentiment_score": "0.218732", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Penumbra  ( PEN )  Stock Up 16.2% YTD: Will the Rally Continue?", "url": "https://www.zacks.com/stock/news/2201524/penumbra-pen-stock-up-162-ytd-will-the-rally-continue", "time_published": "20231222T143700", "authors": ["Zacks Equity Research"], "summary": "Investors are optimistic about Penumbra (PEN), driven by growth in the vascular segments and upbeat guidance.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999816"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.3509, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "PEN", "relevance_score": "0.329551", "ticker_sentiment_score": "0.343749", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PODD", "relevance_score": "0.16849", "ticker_sentiment_score": "0.059936", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.277118", "ticker_sentiment_score": "0.233058", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.16849", "ticker_sentiment_score": "0.059936", "ticker_sentiment_label": "Neutral"}]}, {"title": "Thermo Fisher's  ( TMO )  PPD Business Backs BARDA's Clinical Trial", "url": "https://www.zacks.com/stock/news/2201462/thermo-fishers-tmo-ppd-business-backs-bardas-clinical-trial", "time_published": "20231222T135600", "authors": ["Zacks Equity Research"], "summary": "Thermo Fisher's (TMO) PPD clinical research business is selected by BARDA to support the Phase II platform clinical trial to treat ARDS.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/08/595.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972193"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.213247, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HAE", "relevance_score": "0.22574", "ticker_sentiment_score": "0.206754", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.136629", "ticker_sentiment_score": "0.052779", "ticker_sentiment_label": "Neutral"}, {"ticker": "PODD", "relevance_score": "0.136629", "ticker_sentiment_score": "0.052779", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here are the big health sector themes to watch next year", "url": "https://www.cnbc.com/2023/12/22/health-sector-themes-to-watch-in-2024.html", "time_published": "20231222T134109", "authors": ["Bertha Coombs"], "summary": "The health-care sector has seen a big rebound this month, and analysts say some beaten-down names will continue to have positive momentum in 2024.", "banner_image": "https://image.cnbcfm.com/api/v1/image/106886059-16215272662021-05-20t161326z_1086106208_rc2sjn9cwi51_rtrmadp_0_pharmaceuticals-easteurope.jpeg?v=1621527339&w=1920&h=1080", "source": "CNBC", "category_within_source": "Business", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "IPO", "relevance_score": "0.310843"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.77141"}, {"topic": "Earnings", "relevance_score": "0.614606"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.144638, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CVS", "relevance_score": "0.050679", "ticker_sentiment_score": "0.116952", "ticker_sentiment_label": "Neutral"}, {"ticker": "HUM", "relevance_score": "0.101154", "ticker_sentiment_score": "0.215236", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BAC", "relevance_score": "0.025352", "ticker_sentiment_score": "0.362517", "ticker_sentiment_label": "Bullish"}, {"ticker": "JPM", "relevance_score": "0.025352", "ticker_sentiment_score": "0.033066", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.025352", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.025352", "ticker_sentiment_score": "0.054743", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVTR", "relevance_score": "0.025352", "ticker_sentiment_score": "0.1296", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.025352", "ticker_sentiment_score": "-0.087163", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.025352", "ticker_sentiment_score": "0.110094", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABT", "relevance_score": "0.025352", "ticker_sentiment_score": "0.075078", "ticker_sentiment_label": "Neutral"}, {"ticker": "PODD", "relevance_score": "0.050679", "ticker_sentiment_score": "0.083415", "ticker_sentiment_label": "Neutral"}, {"ticker": "QGEN", "relevance_score": "0.025352", "ticker_sentiment_score": "0.1296", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.025352", "ticker_sentiment_score": "-0.087163", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.050679", "ticker_sentiment_score": "0.083415", "ticker_sentiment_label": "Neutral"}]}, {"title": "CareDx Clears Technical Benchmark, Hitting 90-Plus RS Rating", "url": "https://www.investors.com/ibd-data-stories/caredx-clears-technical-benchmark-hitting-90-plus-rs-rating-2/", "time_published": "20231222T080000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "On Friday, CareDx ( CDNA ) got an upgrade to its Relative Strength ( RS ) Rating, from 88 to 91. X When you're researching the best stocks to buy and watch, be sure to pay attention to relative price strength. IBD's unique rating measures price action with a 1 ( worst ) to 99 ( best ) score.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.408405, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "AWON", "relevance_score": "0.173333", "ticker_sentiment_score": "0.270877", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CDNA", "relevance_score": "0.618922", "ticker_sentiment_score": "0.497793", "ticker_sentiment_label": "Bullish"}, {"ticker": "ITGR", "relevance_score": "0.338582", "ticker_sentiment_score": "0.140977", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.338582", "ticker_sentiment_score": "0.140977", "ticker_sentiment_label": "Neutral"}, {"ticker": "SMLR", "relevance_score": "0.338582", "ticker_sentiment_score": "0.140977", "ticker_sentiment_label": "Neutral"}]}, {"title": "$100 Invested In This Stock 15 Years Ago Would Be Worth $21,000 Today - DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/news/23/12/36351147/100-invested-in-this-stock-15-years-ago-would-be-worth-21-000-today", "time_published": "20231221T200023", "authors": ["Benzinga Insights"], "summary": "DexCom DXCM has outperformed the market over the past 15 years by 30.7% on an annualized basis producing an average annual return of 42.6%. Currently, DexCom has a market capitalization of $46.77 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_4.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.983605", "ticker_sentiment_score": "0.387251", "ticker_sentiment_label": "Bullish"}]}, {"title": "Universal Health  ( UHS )  Up 17% in 3 Months: More Growth Ahead?", "url": "https://www.zacks.com/stock/news/2201204/universal-health-uhs-up-17-in-3-months-more-growth-ahead", "time_published": "20231221T173300", "authors": ["Zacks Equity Research"], "summary": "Universal Health (UHS) is well-poised for growth on the back of the resumption of elective procedures, acquisitions and solid operating cash flows.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7b/2387.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.986413"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.290333, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "UHS", "relevance_score": "0.151858", "ticker_sentiment_score": "0.199929", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PODD", "relevance_score": "0.201523", "ticker_sentiment_score": "0.163044", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.250386", "ticker_sentiment_score": "0.193123", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HCSG", "relevance_score": "0.101582", "ticker_sentiment_score": "0.166345", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVO", "relevance_score": "0.201523", "ticker_sentiment_score": "0.163044", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Henry Schein  ( HSIC )  Enters Orthopedic Market With New Buyout", "url": "https://www.zacks.com/stock/news/2201157/henry-schein-hsic-enters-orthopedic-market-with-new-buyout", "time_published": "20231221T163900", "authors": ["Zacks Equity Research"], "summary": "Henry Schein's (HSIC) recent deals will position it as a prominent producer and supplier in the orthopedic market's Foot and Ankle, Hand and Wrist extremity sectors.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/41/899.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}, {"topic": "Earnings", "relevance_score": "0.996675"}], "overall_sentiment_score": 0.30983, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.158173", "ticker_sentiment_score": "0.0588", "ticker_sentiment_label": "Neutral"}, {"ticker": "HSIC", "relevance_score": "0.49407", "ticker_sentiment_score": "0.44276", "ticker_sentiment_label": "Bullish"}, {"ticker": "HAE", "relevance_score": "0.260559", "ticker_sentiment_score": "0.175131", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.158173", "ticker_sentiment_score": "0.0588", "ticker_sentiment_label": "Neutral"}]}, {"title": "Exact Sciences'  ( EXAS )  Solid Cologuard Sales, Innovation Aid", "url": "https://www.zacks.com/stock/news/2201042/exact-sciences-exas-solid-cologuard-sales-innovation-aid", "time_published": "20231221T144300", "authors": ["Zacks Equity Research"], "summary": "Following the acquisitions of Paradigm and Ashion, Exact Sciences (EXAS) is offering therapy selection tests for patients with advanced cancer.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/08/595.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}, {"topic": "Earnings", "relevance_score": "0.986413"}], "overall_sentiment_score": 0.151267, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.133346", "ticker_sentiment_score": "0.053309", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXAS", "relevance_score": "0.533149", "ticker_sentiment_score": "0.239075", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HAE", "relevance_score": "0.220408", "ticker_sentiment_score": "0.083284", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.133346", "ticker_sentiment_score": "0.053309", "ticker_sentiment_label": "Neutral"}]}, {"title": "Myriad Genetics'  ( MYGN )  New Platform to Advance Cancer Care", "url": "https://www.zacks.com/stock/news/2201001/myriad-genetics-mygn-new-platform-to-advance-cancer-care", "time_published": "20231221T141700", "authors": ["Zacks Equity Research"], "summary": "Myriad Genetics' (MYGN) new MCRR platform advances patient care by combining structured clinical data with genetic and genomic results.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/08/595.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972193"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.211738, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.146618", "ticker_sentiment_score": "0.054886", "ticker_sentiment_label": "Neutral"}, {"ticker": "QGEN", "relevance_score": "0.098054", "ticker_sentiment_score": "0.085347", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.241924", "ticker_sentiment_score": "0.089772", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.146618", "ticker_sentiment_score": "0.054886", "ticker_sentiment_label": "Neutral"}, {"ticker": "MYGN", "relevance_score": "0.377855", "ticker_sentiment_score": "0.260675", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Five S&P 500 Stocks To Buy And Watch In Today's Market", "url": "https://www.investors.com/research/sp-500-stocks-to-buy-and-watch-in-todays-market/", "time_published": "20231221T031100", "authors": ["Investor's Business Daily", "KIMBERLEY KOENIG"], "summary": "The S&P 500's winning stocks were limited to select names and groups this year, but that has started to change. Here, we highlight five leading S&P 500 stocks to buy and watch as the market uptrend continues to broaden.", "banner_image": "https://www.investors.com/wp-content/uploads/2019/05/stock-Buffett-Warren-02-shutter.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.999612"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.17101, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NFLX", "relevance_score": "0.079261", "ticker_sentiment_score": "-0.106661", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.118647", "ticker_sentiment_score": "0.020194", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.157741", "ticker_sentiment_score": "0.046673", "ticker_sentiment_label": "Neutral"}, {"ticker": "BRK-A", "relevance_score": "0.039679", "ticker_sentiment_score": "-0.093338", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAT", "relevance_score": "0.234684", "ticker_sentiment_score": "0.091036", "ticker_sentiment_label": "Neutral"}]}, {"title": "DexCom's Options Frenzy: What You Need to Know - DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/markets/options/23/12/36328765/dexcoms-options-frenzy-what-you-need-to-know", "time_published": "20231220T164547", "authors": ["Benzinga Insights"], "summary": "Whales with a lot of money to spend have taken a noticeably bearish stance on DexCom. Looking at options history for DexCom DXCM we detected 11 trades. If we consider the specifics of each trade, it is accurate to state that 27% of the investors opened trades with bullish expectations and 72% ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.113196, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.098255", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.098255", "ticker_sentiment_score": "-0.143058", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.783009", "ticker_sentiment_score": "0.071681", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.098255", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Bruker  ( BRKR )  Installs First 1.2 GHz NMR at Ohio University", "url": "https://www.zacks.com/stock/news/2200633/bruker-brkr-installs-first-12-ghz-nmr-at-ohio-university", "time_published": "20231220T163200", "authors": ["Zacks Equity Research"], "summary": "Bruker (BRKR) 1.2 GHz AVANCE NMR spectrometer is cutting-edge equipment capable of performing high-resolution liquid and solid-state NMR studies.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2a/1076.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.986413"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.322875, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BRKR", "relevance_score": "0.211652", "ticker_sentiment_score": "0.279157", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PODD", "relevance_score": "0.159569", "ticker_sentiment_score": "0.059133", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.262805", "ticker_sentiment_score": "0.176338", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.159569", "ticker_sentiment_score": "0.059133", "ticker_sentiment_label": "Neutral"}]}, {"title": "Bio-Rad  ( BIO )  Faces Soft Industry-wide Demand, Macro Woes", "url": "https://www.zacks.com/stock/news/2200595/bio-rad-bio-faces-soft-industry-wide-demand-macro-woes", "time_published": "20231220T160300", "authors": ["Zacks Equity Research"], "summary": "Bio-Rad's (BIO) margin performance suffers due to elevated raw material costs, increased logistics costs and higher employee-related expenses.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.996675"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}], "overall_sentiment_score": 0.107778, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BIO", "relevance_score": "0.148121", "ticker_sentiment_score": "-0.258748", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PODD", "relevance_score": "0.148121", "ticker_sentiment_score": "0.055215", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.244354", "ticker_sentiment_score": "0.090504", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.148121", "ticker_sentiment_score": "0.055215", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Reasons to Add HealthEquity  ( HQY )  Stock to Your Portfolio", "url": "https://www.zacks.com/stock/news/2200559/3-reasons-to-add-healthequity-hqy-stock-to-your-portfolio", "time_published": "20231220T150800", "authors": ["Zacks Equity Research"], "summary": "HealthEquity's (HQY) strength in HSA raises optimism about the stock.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2a/3899.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.904684"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.246767, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HQY", "relevance_score": "0.400531", "ticker_sentiment_score": "0.28401", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ITGR", "relevance_score": "0.207127", "ticker_sentiment_score": "0.133349", "ticker_sentiment_label": "Neutral"}, {"ticker": "DVA", "relevance_score": "0.156123", "ticker_sentiment_score": "0.120906", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.207127", "ticker_sentiment_score": "0.103154", "ticker_sentiment_label": "Neutral"}]}, {"title": "Venus Concept  ( VERO )  Expands Global Reach With New Partnerships", "url": "https://www.zacks.com/stock/news/2200464/venus-concept-vero-expands-global-reach-with-new-partnerships", "time_published": "20231220T134900", "authors": ["Zacks Equity Research"], "summary": "Venus Concept (VERO) expects its deals to fetch continued success in both the United Kingdom and India.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972193"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.370128, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.166551", "ticker_sentiment_score": "0.059468", "ticker_sentiment_label": "Neutral"}, {"ticker": "VERO", "relevance_score": "0.376329", "ticker_sentiment_score": "0.5153", "ticker_sentiment_label": "Bullish"}, {"ticker": "HAE", "relevance_score": "0.274012", "ticker_sentiment_score": "0.099354", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.166551", "ticker_sentiment_score": "0.059468", "ticker_sentiment_label": "Neutral"}]}, {"title": "Quest Diagnostics  ( DGX )  Unveils the 88-Compound NPS Test Panel", "url": "https://www.zacks.com/stock/news/2200390/quest-diagnostics-dgx-unveils-the-88-compound-nps-test-panel", "time_published": "20231220T120100", "authors": ["Zacks Equity Research"], "summary": "Quest Diagnostics (DGX) launches the new 88-Compound NPS test panel to address the changing drug epidemic.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/604.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972193"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.019284, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.137148", "ticker_sentiment_score": "0.052885", "ticker_sentiment_label": "Neutral"}, {"ticker": "DGX", "relevance_score": "0.395705", "ticker_sentiment_score": "-0.093476", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.226583", "ticker_sentiment_score": "0.085145", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.137148", "ticker_sentiment_score": "0.052885", "ticker_sentiment_label": "Neutral"}]}, {"title": "DexCom's  ( DXCM )  G7 CGM Connects With Tandem's Insulin Pump", "url": "https://www.zacks.com/stock/news/2200159/dexcoms-dxcm-g7-cgm-connects-with-tandems-insulin-pump", "time_published": "20231219T182700", "authors": ["Zacks Equity Research"], "summary": "Dexcom's (DXCM) G7 integrates with Tandem's t:slim X2, revolutionizing diabetes care. A perfect combination of accuracy and innovation, this synergy sets a new standard in continuous glucose monitoring.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c0/2297.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.917436"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.300773, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BDSX", "relevance_score": "0.154455", "ticker_sentiment_score": "0.045955", "ticker_sentiment_label": "Neutral"}, {"ticker": "HQY", "relevance_score": "0.154455", "ticker_sentiment_score": "0.092867", "ticker_sentiment_label": "Neutral"}, {"ticker": "PODD", "relevance_score": "0.051774", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITGR", "relevance_score": "0.154455", "ticker_sentiment_score": "0.109722", "ticker_sentiment_label": "Neutral"}, {"ticker": "TNDM", "relevance_score": "0.103331", "ticker_sentiment_score": "0.284091", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.483888", "ticker_sentiment_score": "0.490421", "ticker_sentiment_label": "Bullish"}]}, {"title": "Masimo's  ( MASI )  Stork Baby Monitoring System Approved by FDA", "url": "https://www.zacks.com/stock/news/2200083/masimos-masi-stork-baby-monitoring-system-approved-by-fda", "time_published": "20231219T160900", "authors": ["Zacks Equity Research"], "summary": "The latest FDA clearance of Masimo's (MASI) Stork smart home baby monitoring system is likely to provide a continuous and accurate view of babies' health data.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ca/2974.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.20829, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HQY", "relevance_score": "0.108466", "ticker_sentiment_score": "0.046858", "ticker_sentiment_label": "Neutral"}, {"ticker": "MASI", "relevance_score": "0.546745", "ticker_sentiment_score": "0.119965", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITGR", "relevance_score": "0.214937", "ticker_sentiment_score": "0.140507", "ticker_sentiment_label": "Neutral"}, {"ticker": "DVA", "relevance_score": "0.162073", "ticker_sentiment_score": "0.126501", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.108466", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's Why You Should Invest in Penumbra  ( PEN )  Stock Now", "url": "https://www.zacks.com/stock/news/2200052/heres-why-you-should-invest-in-penumbra-pen-stock-now", "time_published": "20231219T153000", "authors": ["Zacks Equity Research"], "summary": "Investors are optimistic about Penumbra (PEN), which is led by growth in vascular and neuro businesses.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.990678"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.77141"}], "overall_sentiment_score": 0.262695, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PEN", "relevance_score": "0.353418", "ticker_sentiment_score": "0.344759", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PODD", "relevance_score": "0.155786", "ticker_sentiment_score": "0.060836", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.256719", "ticker_sentiment_score": "0.099869", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.155786", "ticker_sentiment_score": "0.060836", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:JPY", "relevance_score": "0.052226", "ticker_sentiment_score": "0.036871", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:EUR", "relevance_score": "0.052226", "ticker_sentiment_score": "0.036871", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:USD", "relevance_score": "0.052226", "ticker_sentiment_score": "0.036871", "ticker_sentiment_label": "Neutral"}]}, {"title": "Align's  ( ALGN )  Invisalign Palatal Expander System Gets FDA Nod", "url": "https://www.zacks.com/stock/news/2200045/aligns-algn-invisalign-palatal-expander-system-gets-fda-nod", "time_published": "20231219T152400", "authors": ["Zacks Equity Research"], "summary": "Align's (ALGN) Invisalign Palatal Expander is the company's first direct 3D-printed orthodontic device. It offers a safe, pleasant and clinically effective alternative to traditional palatal expanders.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/41/899.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972193"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.242446, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.155451", "ticker_sentiment_score": "0.058159", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALGN", "relevance_score": "0.256179", "ticker_sentiment_score": "0.1461", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.256179", "ticker_sentiment_score": "0.172771", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.155451", "ticker_sentiment_score": "0.058159", "ticker_sentiment_label": "Neutral"}]}, {"title": "CVS Health  ( CVS )  New Opportunities Drive Growth, Macro Woes Stay", "url": "https://www.zacks.com/stock/news/2199865/cvs-health-cvs-new-opportunities-drive-growth-macro-woes-stay", "time_published": "20231219T132500", "authors": ["Zacks Equity Research"], "summary": "CVS Health's (CVS) restructuring plan poises it well, along with its strategic buyouts.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5a/926.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}, {"topic": "Earnings", "relevance_score": "0.983605"}], "overall_sentiment_score": 0.197385, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CVS", "relevance_score": "0.468687", "ticker_sentiment_score": "0.243696", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PODD", "relevance_score": "0.114865", "ticker_sentiment_score": "0.048774", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.190267", "ticker_sentiment_score": "0.074323", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.114865", "ticker_sentiment_score": "0.048774", "ticker_sentiment_label": "Neutral"}]}, {"title": "SenesTech  ( SNES )  Likely to Expand Into China With New Deal", "url": "https://www.zacks.com/stock/news/2199856/senestech-snes-likely-to-expand-into-china-with-new-deal", "time_published": "20231219T132000", "authors": ["Zacks Equity Research"], "summary": "This partnership provides SenesTech (SNES) with a gateway into one of the largest pest control markets globally, with the support and expertise of Fruit Tree.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972193"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.227861, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.183895", "ticker_sentiment_score": "0.063754", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.301686", "ticker_sentiment_score": "0.107381", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.183895", "ticker_sentiment_score": "0.063754", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNES", "relevance_score": "0.514619", "ticker_sentiment_score": "0.268682", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Charles River's  ( CRL )  Memphis Site Achieves Crucial Approval", "url": "https://www.zacks.com/stock/news/2199833/charles-rivers-crl-memphis-site-achieves-crucial-approval", "time_published": "20231219T130100", "authors": ["Zacks Equity Research"], "summary": "Charles River (CRL) reaches an important milestone in cell therapy manufacturing collaboration with Vertex Pharmaceuticals.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c2/53795.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972193"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.203174, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.143415", "ticker_sentiment_score": "0.072807", "ticker_sentiment_label": "Neutral"}, {"ticker": "PODD", "relevance_score": "0.143415", "ticker_sentiment_score": "0.054195", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRL", "relevance_score": "0.095899", "ticker_sentiment_score": "0.037313", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.236742", "ticker_sentiment_score": "0.08821", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.143415", "ticker_sentiment_score": "0.054195", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's Why You Should Retain Tandem Diabetes  ( TNDM )  Now", "url": "https://www.zacks.com/stock/news/2199822/heres-why-you-should-retain-tandem-diabetes-tndm-now", "time_published": "20231219T125000", "authors": ["Zacks Equity Research"], "summary": "Investors remain optimistic about Tandem Diabetes (TNDM), backed by the impressive spree of product introductions.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c0/2563.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Earnings", "relevance_score": "0.9973"}], "overall_sentiment_score": 0.222292, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.136888", "ticker_sentiment_score": "0.030741", "ticker_sentiment_label": "Neutral"}, {"ticker": "TNDM", "relevance_score": "0.181819", "ticker_sentiment_score": "0.338884", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HAE", "relevance_score": "0.181819", "ticker_sentiment_score": "0.102019", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.22616", "ticker_sentiment_score": "0.198003", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "10x Genomics Clears Key Benchmark, Hitting 80-Plus RS Rating", "url": "https://www.investors.com/ibd-data-stories/10x-genomics-clears-key-benchmark-hitting-80-plus-rs-rating/", "time_published": "20231219T080000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "When considering what names to put on your watch list, look for stocks with an 80 or higher RS Rating. 10x Genomics ( TXG ) now meets that criteria, with an increase from 78 to 83 Tuesday. X When you're researching the best stocks to buy and watch, keep a close on eye on relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.347246, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "TXG", "relevance_score": "0.514619", "ticker_sentiment_score": "0.339702", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AWON", "relevance_score": "0.183895", "ticker_sentiment_score": "0.160697", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ITGR", "relevance_score": "0.358152", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.358152", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Reasons to Add DexCom  ( DXCM )  Stock to Your Portfolio Now", "url": "https://www.zacks.com/stock/news/2199515/reasons-to-add-dexcom-dxcm-stock-to-your-portfolio-now", "time_published": "20231218T165000", "authors": ["Zacks Equity Research"], "summary": "DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c0/2297.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.967321"}], "overall_sentiment_score": 0.290306, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BDSX", "relevance_score": "0.126119", "ticker_sentiment_score": "0.041048", "ticker_sentiment_label": "Neutral"}, {"ticker": "HQY", "relevance_score": "0.126119", "ticker_sentiment_score": "0.083193", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITGR", "relevance_score": "0.126119", "ticker_sentiment_score": "0.098301", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.403264", "ticker_sentiment_score": "0.422698", "ticker_sentiment_label": "Bullish"}]}, {"title": "Abbott  ( ABT )  Gains From Global Expansion Amid Macro Woes", "url": "https://www.zacks.com/stock/news/2199328/abbott-abt-gains-from-global-expansion-amid-macro-woes", "time_published": "20231218T140800", "authors": ["Zacks Equity Research"], "summary": "Abbott's (ABT) EPD business continues to witness low double-digit growth. It has successfully positioned itself as one of the best-positioned large healthcare companies in emerging markets.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3c/1479.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.99237"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.650727"}], "overall_sentiment_score": 0.132602, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.146618", "ticker_sentiment_score": "0.054886", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABT", "relevance_score": "0.146618", "ticker_sentiment_score": "0.144108", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.241924", "ticker_sentiment_score": "0.089772", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.146618", "ticker_sentiment_score": "0.054886", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:EUR", "relevance_score": "0.04912", "ticker_sentiment_score": "0.058925", "ticker_sentiment_label": "Neutral"}]}, {"title": "Thermo Fisher  ( TMO )  to Allocate IFA Testing Kits With New Pact", "url": "https://www.zacks.com/stock/news/2199299/thermo-fisher-tmo-to-allocate-ifa-testing-kits-with-new-pact", "time_published": "20231218T134500", "authors": ["Zacks Equity Research"], "summary": "Thermo Fisher (TMO) will continue to meet the evolving needs of laboratories and healthcare professionals by expanding its immunology product portfolio of EliA autoimmune diagnostics.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972193"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.271982, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.167322", "ticker_sentiment_score": "0.059653", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.275246", "ticker_sentiment_score": "0.099717", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.167322", "ticker_sentiment_score": "0.059653", "ticker_sentiment_label": "Neutral"}, {"ticker": "TMO", "relevance_score": "0.112008", "ticker_sentiment_score": "0.205877", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Quest Diagnostics'  ( DGX )  Haystack Oncology Inks New Deal", "url": "https://www.zacks.com/stock/news/2199231/quest-diagnostics-dgx-haystack-oncology-inks-new-deal", "time_published": "20231218T124700", "authors": ["Zacks Equity Research"], "summary": "Quest Diagnostics' (DGX) wholly owned subsidiary, Haystack Oncology, partners with the Rutgers Cancer Institute of New Jersey.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/604.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972193"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.058416, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "III", "relevance_score": "0.047559", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PODD", "relevance_score": "0.142005", "ticker_sentiment_score": "0.055124", "ticker_sentiment_label": "Neutral"}, {"ticker": "DGX", "relevance_score": "0.449106", "ticker_sentiment_score": "-0.018219", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.234458", "ticker_sentiment_score": "0.1243", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.142005", "ticker_sentiment_score": "0.055124", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's Why You Should Invest in IDEXX  ( IDXX )  Stock Right Now", "url": "https://www.zacks.com/stock/news/2199228/heres-why-you-should-invest-in-idexx-idxx-stock-right-now", "time_published": "20231218T124000", "authors": ["Zacks Equity Research"], "summary": "Investors continue to be optimistic about IDEXX (IDXX), backed by the strength of the CAG Diagnostics business.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e0/1871.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999974"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.280081, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "IDXX", "relevance_score": "0.081001", "ticker_sentiment_score": "0.178681", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PODD", "relevance_score": "0.121241", "ticker_sentiment_score": "0.02893", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.16117", "ticker_sentiment_score": "0.093877", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.16117", "ticker_sentiment_score": "0.138035", "ticker_sentiment_label": "Neutral"}, {"ticker": "IDGXF", "relevance_score": "0.040553", "ticker_sentiment_score": "0.210163", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Here's Why You Should Retain Hologic  ( HOLX )  Stock for Now", "url": "https://www.zacks.com/stock/news/2199227/heres-why-you-should-retain-hologic-holx-stock-for-now", "time_published": "20231218T123900", "authors": ["Zacks Equity Research"], "summary": "Investors are optimistic about Hologic (HOLX), which is led by growth with recovery in procedural volumes and acceleration from new business lines.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ca/2974.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}, {"topic": "Earnings", "relevance_score": "0.99915"}], "overall_sentiment_score": 0.198188, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HOLX", "relevance_score": "0.272788", "ticker_sentiment_score": "0.210232", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PODD", "relevance_score": "0.138464", "ticker_sentiment_score": "0.054367", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.228717", "ticker_sentiment_score": "0.087507", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.138464", "ticker_sentiment_score": "0.054367", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stocks To Watch: Glaukos Sees RS Rating Jump To 94", "url": "https://www.investors.com/ibd-data-stories/stocks-to-watch-glaukos-sees-rs-rating-jump-to-94/", "time_published": "20231218T080000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "On Monday, Glaukos ( GKOS ) earned an upgrade to its Relative Strength ( RS ) Rating, from 90 to 94. When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.158535, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GKOS", "relevance_score": "0.585687", "ticker_sentiment_score": "-0.151398", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "LNTH", "relevance_score": "0.316846", "ticker_sentiment_score": "0.129444", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.316846", "ticker_sentiment_score": "0.129444", "ticker_sentiment_label": "Neutral"}, {"ticker": "SMLR", "relevance_score": "0.316846", "ticker_sentiment_score": "0.129444", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why DexCom  ( DXCM )  Dipped More Than Broader Market Today", "url": "https://www.zacks.com/stock/news/2199032/why-dexcom-dxcm-dipped-more-than-broader-market-today", "time_published": "20231215T225011", "authors": ["Zacks Equity Research"], "summary": "DexCom (DXCM) reachead $122.59 at the closing of the latest trading day, reflecting a -0.41% change compared to its last close.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default47.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.95493"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.209838, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.598621", "ticker_sentiment_score": "0.286127", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Here's Why You Should Retain Globus Medical  ( GMED )  Stock Now", "url": "https://www.zacks.com/stock/news/2198889/heres-why-you-should-retain-globus-medical-gmed-stock-now", "time_published": "20231215T171400", "authors": ["Zacks Equity Research"], "summary": "Investors are optimistic about Globus Medical (GMED) on growing demand for musculoskeletal devices and its strong solvency position.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ca/2974.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999756"}, {"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.211945, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.147516", "ticker_sentiment_score": "0.056339", "ticker_sentiment_label": "Neutral"}, {"ticker": "GMED", "relevance_score": "0.464633", "ticker_sentiment_score": "0.258215", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HAE", "relevance_score": "0.243376", "ticker_sentiment_score": "0.165828", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.147516", "ticker_sentiment_score": "0.056339", "ticker_sentiment_label": "Neutral"}]}, {"title": "Neogen  ( NEOG )  to Advance Feline DNA Testing With New Pact", "url": "https://www.zacks.com/stock/news/2198888/neogen-neog-to-advance-feline-dna-testing-with-new-pact", "time_published": "20231215T171300", "authors": ["Zacks Equity Research"], "summary": "Neogen's (NEOG) strategic alliance will expand feline DNA testing and strengthen its relationship with the kitty community.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972193"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.312754, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.163909", "ticker_sentiment_score": "0.064206", "ticker_sentiment_label": "Neutral"}, {"ticker": "NEOG", "relevance_score": "0.465196", "ticker_sentiment_score": "0.48332", "ticker_sentiment_label": "Bullish"}, {"ticker": "HAE", "relevance_score": "0.269776", "ticker_sentiment_score": "0.103985", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.163909", "ticker_sentiment_score": "0.064206", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's Why You Should Retain Catalent  ( CTLT )  Stock for Now", "url": "https://www.zacks.com/stock/news/2198761/heres-why-you-should-retain-catalent-ctlt-stock-for-now", "time_published": "20231215T151700", "authors": ["Zacks Equity Research"], "summary": "Catalent's (CTLT) products and services portfolio and technology foundation raise optimism about the stock.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2a/3899.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.838487"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.276353, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ITGR", "relevance_score": "0.204936", "ticker_sentiment_score": "0.135412", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTLT", "relevance_score": "0.350564", "ticker_sentiment_score": "0.270521", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DVA", "relevance_score": "0.154455", "ticker_sentiment_score": "0.122696", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.154455", "ticker_sentiment_score": "0.051468", "ticker_sentiment_label": "Neutral"}]}, {"title": "Align's  ( ALGN )  New Launches Aid, Macroeconomic Woes Linger", "url": "https://www.zacks.com/stock/news/2198721/aligns-algn-new-launches-aid-macroeconomic-woes-linger", "time_published": "20231215T145200", "authors": ["Zacks Equity Research"], "summary": "Align Technology (ALGN) performs digital treatment planning and interpretation for restorative cases worldwide, including Costa Rica, China, Germany, Spain, Poland and Japan, among others.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}, {"topic": "Earnings", "relevance_score": "0.986413"}], "overall_sentiment_score": 0.109741, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.127908", "ticker_sentiment_score": "0.051068", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALGN", "relevance_score": "0.370908", "ticker_sentiment_score": "0.107363", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.21156", "ticker_sentiment_score": "0.080626", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.127908", "ticker_sentiment_score": "0.051068", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:USD", "relevance_score": "0.0428", "ticker_sentiment_score": "-0.090404", "ticker_sentiment_label": "Neutral"}]}, {"title": "Align Technologies  ( ALGN )  Secures Updated Medical Device License", "url": "https://www.zacks.com/stock/news/2198549/align-technologies-algn-secures-updated-medical-device-license", "time_published": "20231215T140200", "authors": ["Zacks Equity Research"], "summary": "Align Technologies' (ALGN) Invisalign Palatal Expander system receives an updated medical device license from Health Canada.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/41/899.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972193"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.18987, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HAE", "relevance_score": "0.224903", "ticker_sentiment_score": "0.127005", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.136113", "ticker_sentiment_score": "0.052674", "ticker_sentiment_label": "Neutral"}, {"ticker": "PODD", "relevance_score": "0.136113", "ticker_sentiment_score": "0.052674", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's Why You Should Buy Neogen  ( NEOG )  Stock Now", "url": "https://www.zacks.com/stock/news/2198536/heres-why-you-should-buy-neogen-neog-stock-now", "time_published": "20231215T135500", "authors": ["Zacks Equity Research"], "summary": "Investors are optimistic about Neogen (NEOG), owing to product launches and the performance of segments.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2a/3899.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.9973"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.301907, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.134841", "ticker_sentiment_score": "-0.008645", "ticker_sentiment_label": "Neutral"}, {"ticker": "NEOG", "relevance_score": "0.349329", "ticker_sentiment_score": "0.362332", "ticker_sentiment_label": "Bullish"}, {"ticker": "HAE", "relevance_score": "0.179121", "ticker_sentiment_score": "0.134197", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.179121", "ticker_sentiment_score": "-0.010378", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's Why You Should Retain CONMED  ( CNMD )  Stock for Now", "url": "https://www.zacks.com/stock/news/2198436/heres-why-you-should-retain-conmed-cnmd-stock-for-now", "time_published": "20231215T122500", "authors": ["Zacks Equity Research"], "summary": "CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default277.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.857896"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.744043"}], "overall_sentiment_score": 0.162802, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BDSX", "relevance_score": "0.132611", "ticker_sentiment_score": "0.043307", "ticker_sentiment_label": "Neutral"}, {"ticker": "HQY", "relevance_score": "0.132611", "ticker_sentiment_score": "0.086422", "ticker_sentiment_label": "Neutral"}, {"ticker": "CNMD", "relevance_score": "0.459624", "ticker_sentiment_score": "0.215424", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.132611", "ticker_sentiment_score": "0.098327", "ticker_sentiment_label": "Neutral"}]}, {"title": "Reasons to Retain Inari Medical  ( NARI )  in Your Portfolio Now", "url": "https://www.zacks.com/stock/news/2198434/reasons-to-retain-inari-medical-nari-in-your-portfolio-now", "time_published": "20231215T122400", "authors": ["Zacks Equity Research"], "summary": "Inari Medical (NARI) continues to benefit from its commitment to understand the venous system. However, its dependency on the adoption of products is a concern.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c0/2297.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.769861"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.221558, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BDSX", "relevance_score": "0.125025", "ticker_sentiment_score": "0.042061", "ticker_sentiment_label": "Neutral"}, {"ticker": "HQY", "relevance_score": "0.125025", "ticker_sentiment_score": "0.084019", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.125025", "ticker_sentiment_score": "0.095593", "ticker_sentiment_label": "Neutral"}, {"ticker": "NARI", "relevance_score": "0.470894", "ticker_sentiment_score": "0.248794", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "DexCom Gets Relative Strength Rating Upgrade", "url": "https://www.investors.com/ibd-data-stories/dexcom-gets-relative-strength-rating-upgrade-2/", "time_published": "20231215T080000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "DexCom ( DXCM ) had its Relative Strength ( RS ) Rating upgraded from 66 to 71 Friday -- a welcome improvement, but still short of the 80 or better score you prefer to see. X As you try to find the best stocks to buy and watch, be sure to pay attention to relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.424359, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "LNTH", "relevance_score": "0.348103", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.885652", "ticker_sentiment_score": "0.619559", "ticker_sentiment_label": "Bullish"}]}, {"title": "CONMED Sees IBD RS Rating Improve To 73", "url": "https://www.investors.com/ibd-data-stories/conmed-sees-ibd-rs-rating-improve-to-73/", "time_published": "20231215T080000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "On Friday, CONMED ( CNMD ) received an upgrade to its Relative Strength ( RS ) Rating, from 63 to 73. X As you try to find the best stocks to buy and watch, be sure to pay attention to relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.351403, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "CNMD", "relevance_score": "0.655281", "ticker_sentiment_score": "0.6901", "ticker_sentiment_label": "Bullish"}, {"ticker": "LNTH", "relevance_score": "0.363388", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.363388", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stocks Showing Improved Relative Strength: Teleflex", "url": "https://www.investors.com/ibd-data-stories/stocks-showing-improved-relative-strength-teleflex-2/", "time_published": "20231215T080000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "The Relative Strength ( RS ) Rating for Teleflex ( TFX ) jumped into a higher percentile Friday, as it got a lift from 63 to 73. When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.38899, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "AWON", "relevance_score": "0.158519", "ticker_sentiment_score": "0.231359", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LNTH", "relevance_score": "0.310843", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.310843", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TFX", "relevance_score": "0.576289", "ticker_sentiment_score": "0.421924", "ticker_sentiment_label": "Bullish"}]}, {"title": "Tandem Diabetes  ( TNDM )  Avails Tandem Source in the United States", "url": "https://www.zacks.com/stock/news/2198106/tandem-diabetes-tndm-avails-tandem-source-in-the-united-states", "time_published": "20231214T162300", "authors": ["Zacks Equity Research"], "summary": "Tandem Diabetes (TNDM) announces the full U.S. launch of Tandem Source, a new diabetes management platform for customers and healthcare providers.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/6e/37920.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972193"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.252445, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.152499", "ticker_sentiment_score": "0.057473", "ticker_sentiment_label": "Neutral"}, {"ticker": "TNDM", "relevance_score": "0.202366", "ticker_sentiment_score": "0.151263", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HAE", "relevance_score": "0.152499", "ticker_sentiment_score": "0.057473", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.202366", "ticker_sentiment_score": "0.101317", "ticker_sentiment_label": "Neutral"}]}, {"title": "Integra  ( IART )  to Advance ENT Division With New Buyout Deal", "url": "https://www.zacks.com/stock/news/2198095/integra-iart-to-advance-ent-division-with-new-buyout-deal", "time_published": "20231214T161400", "authors": ["Zacks Equity Research"], "summary": "Integra (IART) will be among the top suppliers of ENT products and technologies following the Acclarent acquisition.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.993781"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.28448, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "IART", "relevance_score": "0.10607", "ticker_sentiment_score": "0.070167", "ticker_sentiment_label": "Neutral"}, {"ticker": "PODD", "relevance_score": "0.158519", "ticker_sentiment_score": "0.057569", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.261117", "ticker_sentiment_score": "0.09553", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.158519", "ticker_sentiment_score": "0.057569", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.053153", "ticker_sentiment_score": "0.064716", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is DexCom  ( DXCM )  Stock Outpacing Its Medical Peers This Year?", "url": "https://www.zacks.com/stock/news/2198011/is-dexcom-dxcm-stock-outpacing-its-medical-peers-this-year", "time_published": "20231214T144006", "authors": ["Zacks Equity Research"], "summary": "Here is how DexCom (DXCM) and Exscientia PLC Sponsored ADR (EXAI) have performed compared to their sector so far this year.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default348.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Earnings", "relevance_score": "0.614606"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.257247, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.75957", "ticker_sentiment_score": "0.426356", "ticker_sentiment_label": "Bullish"}, {"ticker": "EXAI", "relevance_score": "0.485711", "ticker_sentiment_score": "0.306284", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Boston Scientific  ( BSX )  Hits 52-Week High: What's Aiding It?", "url": "https://www.zacks.com/stock/news/2197938/boston-scientific-bsx-hits-52-week-high-whats-aiding-it", "time_published": "20231214T141600", "authors": ["Zacks Equity Research"], "summary": "Investors are optimistic about Boston Scientific's (BSX) impressive market share gain in the MedSurg segment.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2a/3899.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.838487"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.364232, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "HQY", "relevance_score": "0.21686", "ticker_sentiment_score": "0.045481", "ticker_sentiment_label": "Neutral"}, {"ticker": "BSX", "relevance_score": "0.269181", "ticker_sentiment_score": "0.297479", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DVA", "relevance_score": "0.163539", "ticker_sentiment_score": "0.127247", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.163539", "ticker_sentiment_score": "0.056069", "ticker_sentiment_label": "Neutral"}]}, {"title": "Myriad Genetics'  ( MYGN )  New Partnerships Aid Amid FX Woes", "url": "https://www.zacks.com/stock/news/2197835/myriad-genetics-mygn-new-partnerships-aid-amid-fx-woes", "time_published": "20231214T132200", "authors": ["Zacks Equity Research"], "summary": "Myriad Genetics (MYGN) continues to record strong revenue growth from companion diagnostics, including significant revenue share from its proprietary myChoiceCDx test.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7b/850.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Earnings", "relevance_score": "0.998287"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.089132, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.142005", "ticker_sentiment_score": "0.053895", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.234458", "ticker_sentiment_score": "0.087521", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.142005", "ticker_sentiment_score": "0.053895", "ticker_sentiment_label": "Neutral"}, {"ticker": "ILMN", "relevance_score": "0.047559", "ticker_sentiment_score": "0.032908", "ticker_sentiment_label": "Neutral"}, {"ticker": "MYGN", "relevance_score": "0.525827", "ticker_sentiment_score": "0.070115", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:USD", "relevance_score": "0.142005", "ticker_sentiment_score": "0.020589", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's Why You Should Retain Glaukos  ( GKOS )  Stock for Now", "url": "https://www.zacks.com/stock/news/2197789/heres-why-you-should-retain-glaukos-gkos-stock-for-now", "time_published": "20231214T124500", "authors": ["Zacks Equity Research"], "summary": "Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c0/2297.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.938238"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.241531, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BDSX", "relevance_score": "0.159218", "ticker_sentiment_score": "0.048218", "ticker_sentiment_label": "Neutral"}, {"ticker": "GKOS", "relevance_score": "0.578355", "ticker_sentiment_score": "0.433041", "ticker_sentiment_label": "Bullish"}, {"ticker": "HQY", "relevance_score": "0.159218", "ticker_sentiment_score": "0.095984", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.159218", "ticker_sentiment_score": "0.109196", "ticker_sentiment_label": "Neutral"}]}, {"title": "Reasons to Retain Baxter International  ( BAX )  in Your Portfolio", "url": "https://www.zacks.com/stock/news/2197783/reasons-to-retain-baxter-international-bax-in-your-portfolio", "time_published": "20231214T124200", "authors": ["Zacks Equity Research"], "summary": "Baxter International's (BAX) robust growth across all geographies, along with transformational initiatives, boosts confidence. However, pandemic-related disruption continues to hurt sales.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c0/2297.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972476"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.124673, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BDSX", "relevance_score": "0.151222", "ticker_sentiment_score": "0.046667", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAX", "relevance_score": "0.515543", "ticker_sentiment_score": "0.33413", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HQY", "relevance_score": "0.151222", "ticker_sentiment_score": "0.092952", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.151222", "ticker_sentiment_score": "0.105751", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stocks With Rising Relative Strength: 10x Genomics", "url": "https://www.investors.com/ibd-data-stories/stocks-with-rising-relative-strength-10x-genomics/", "time_published": "20231214T080000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "10x Genomics ( TXG ) had its Relative Strength ( RS ) Rating upgraded from 65 to 74 Thursday -- a welcome improvement, but still short of the 80 or better score you look for. When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.379866, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "LNTH", "relevance_score": "0.31282", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.31282", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TXG", "relevance_score": "0.772973", "ticker_sentiment_score": "0.551915", "ticker_sentiment_label": "Bullish"}]}, {"title": "Medtronic  ( MDT )  Expands AI-Driven Care With New Partnership", "url": "https://www.zacks.com/stock/news/2197563/medtronic-mdt-expands-ai-driven-care-with-new-partnership", "time_published": "20231213T175200", "authors": ["Zacks Equity Research"], "summary": "Medtronic's (MDT) expanded collaboration with Cosmo Pharmaceuticals is a strategic step forward in its quest to use AI to improve patient care.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ca/2974.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972193"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.345579, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.149346", "ticker_sentiment_score": "0.055486", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDT", "relevance_score": "0.384397", "ticker_sentiment_score": "0.518618", "ticker_sentiment_label": "Bullish"}, {"ticker": "HAE", "relevance_score": "0.246333", "ticker_sentiment_score": "0.0911", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.149346", "ticker_sentiment_score": "0.055486", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's Why You Should Retain Exact Sciences  ( EXAS )  Stock Now", "url": "https://www.zacks.com/stock/news/2197564/heres-why-you-should-retain-exact-sciences-exas-stock-now", "time_published": "20231213T175200", "authors": ["Zacks Equity Research"], "summary": "Investors are optimistic about Exact Sciences (EXAS) on strong Cologuard adoption and raised guidance.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.998917"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}], "overall_sentiment_score": 0.120452, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.144853", "ticker_sentiment_score": "0.054504", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXAS", "relevance_score": "0.41608", "ticker_sentiment_score": "0.138392", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.23907", "ticker_sentiment_score": "0.088912", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.144853", "ticker_sentiment_score": "0.054504", "ticker_sentiment_label": "Neutral"}]}, {"title": "QIAGEN's  ( QGEN )  Strategic Alliances Aid Amid Macro Woes", "url": "https://www.zacks.com/stock/news/2197534/qiagens-qgen-strategic-alliances-aid-amid-macro-woes", "time_published": "20231213T171900", "authors": ["Zacks Equity Research"], "summary": "QIAGEN (QGEN) aims to expand the NGS platform by rapidly scaling up the new Enterprise Genomics Services.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/08/595.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.995869"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.112227, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.138464", "ticker_sentiment_score": "0.053155", "ticker_sentiment_label": "Neutral"}, {"ticker": "QGEN", "relevance_score": "0.399204", "ticker_sentiment_score": "0.072332", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.228717", "ticker_sentiment_score": "0.085789", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.138464", "ticker_sentiment_score": "0.053155", "ticker_sentiment_label": "Neutral"}, {"ticker": "MYGN", "relevance_score": "0.046363", "ticker_sentiment_score": "-0.123545", "ticker_sentiment_label": "Neutral"}]}, {"title": "Terumo  ( TRUMY )  Launches AZUR HydroPack in Embolotherapy Space", "url": "https://www.zacks.com/stock/news/2197507/terumo-trumy-launches-azur-hydropack-in-embolotherapy-space", "time_published": "20231213T171100", "authors": ["Zacks Equity Research"], "summary": "Terumo's (TRUMY) coil system boasts a soft, universal-shaped platinum and hydrogel composition, which sets it apart in the peripheral coil market.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ca/2974.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972193"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.276241, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.211191", "ticker_sentiment_score": "0.070831", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.344712", "ticker_sentiment_score": "0.119233", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.211191", "ticker_sentiment_score": "0.070831", "ticker_sentiment_label": "Neutral"}, {"ticker": "TRUMF", "relevance_score": "0.211191", "ticker_sentiment_score": "0.397643", "ticker_sentiment_label": "Bullish"}]}, {"title": "Integer Holdings  ( ITGR )  Hits 52-Week High: What's Aiding It?", "url": "https://www.zacks.com/stock/news/2197435/integer-holdings-itgr-hits-52-week-high-whats-aiding-it", "time_published": "20231213T155700", "authors": ["Zacks Equity Research"], "summary": "Investors are optimistic about Integer Holdings' (ITGR) solid foothold in the broader MedTech space.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2a/3899.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.769861"}], "overall_sentiment_score": 0.218087, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HQY", "relevance_score": "0.21258", "ticker_sentiment_score": "0.043082", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITGR", "relevance_score": "0.499789", "ticker_sentiment_score": "0.322914", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DVA", "relevance_score": "0.160277", "ticker_sentiment_score": "0.080485", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.160277", "ticker_sentiment_score": "0.052691", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pet Parents Keep Spending", "url": "https://www.fool.com/investing/2023/12/13/pet-parents-keep-spending/", "time_published": "20231213T145600", "authors": ["Motley Fool Staff"], "summary": "We also talk with Dexcom CEO Kevin Sayer about the impact of weight loss drugs on diabetes care.", "banner_image": "https://g.foolcdn.com/editorial/images/757751/mfm_07.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999982"}, {"topic": "Earnings", "relevance_score": "0.875462"}], "overall_sentiment_score": 0.171816, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DG", "relevance_score": "0.078494", "ticker_sentiment_score": "0.035883", "ticker_sentiment_label": "Neutral"}, {"ticker": "DLTR", "relevance_score": "0.02144", "ticker_sentiment_score": "0.058124", "ticker_sentiment_label": "Neutral"}, {"ticker": "CHWY", "relevance_score": "0.05713", "ticker_sentiment_score": "0.018016", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDT", "relevance_score": "0.014294", "ticker_sentiment_score": "0.08141", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.02144", "ticker_sentiment_score": "0.065329", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.121037", "ticker_sentiment_score": "0.10913", "ticker_sentiment_label": "Neutral"}, {"ticker": "WMT", "relevance_score": "0.007147", "ticker_sentiment_score": "0.064686", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:USD", "relevance_score": "0.028583", "ticker_sentiment_score": "0.050845", "ticker_sentiment_label": "Neutral"}]}, {"title": "Integer Holdings Corporation  ( ITGR )  Hit a 52 Week High, Can the Run Continue?", "url": "https://www.zacks.com/stock/news/2197283/integer-holdings-corporation-itgr-hit-a-52-week-high-can-the-run-continue", "time_published": "20231213T141506", "authors": ["Zacks Equity Research"], "summary": "Integer (ITGR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default343.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.99246"}], "overall_sentiment_score": 0.307161, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ITGR", "relevance_score": "0.746902", "ticker_sentiment_score": "0.50806", "ticker_sentiment_label": "Bullish"}, {"ticker": "DXCM", "relevance_score": "0.432291", "ticker_sentiment_score": "0.449174", "ticker_sentiment_label": "Bullish"}]}, {"title": "Charles River  ( CRL )  Expands 3D In Vitro Services Via New Deal", "url": "https://www.zacks.com/stock/news/2197217/charles-river-crl-expands-3d-in-vitro-services-via-new-deal", "time_published": "20231213T132900", "authors": ["Zacks Equity Research"], "summary": "Charles River (CRL) finalizes agreement with service-based biotechnology company, CELLphenomics.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/08/595.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972193"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.083775, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.14573", "ticker_sentiment_score": "0.054693", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRL", "relevance_score": "0.14573", "ticker_sentiment_score": "0.099466", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.240489", "ticker_sentiment_score": "0.134001", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.14573", "ticker_sentiment_score": "0.054693", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's Why You Should Retain McKesson  ( MCK )  Stock for Now", "url": "https://www.zacks.com/stock/news/2197165/heres-why-you-should-retain-mckesson-mck-stock-for-now", "time_published": "20231213T120900", "authors": ["Zacks Equity Research"], "summary": "McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/6e/37920.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Earnings", "relevance_score": "0.928139"}], "overall_sentiment_score": 0.238892, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HQY", "relevance_score": "0.159569", "ticker_sentiment_score": "0.09612", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCK", "relevance_score": "0.497869", "ticker_sentiment_score": "0.169161", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.053509", "ticker_sentiment_score": "0.267896", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BDSX", "relevance_score": "0.159569", "ticker_sentiment_score": "0.048288", "ticker_sentiment_label": "Neutral"}, {"ticker": "SKXJF", "relevance_score": "0.053509", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSGR", "relevance_score": "0.211652", "ticker_sentiment_score": "-0.017259", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSKYF", "relevance_score": "0.053509", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.159569", "ticker_sentiment_score": "0.109351", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCSG", "relevance_score": "0.053509", "ticker_sentiment_score": "0.099702", "ticker_sentiment_label": "Neutral"}, {"ticker": "SWTX", "relevance_score": "0.053509", "ticker_sentiment_score": "0.267896", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Lantheus Holdings Clears Technical Benchmark, Hitting 80-Plus RS Rating", "url": "https://www.investors.com/ibd-data-stories/lantheus-holdings-clears-technical-benchmark-hitting-80-plus-rs-rating/", "time_published": "20231213T080000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "On Wednesday, Lantheus Holdings ( LNTH ) hit a noteworthy performance benchmark, with its Relative Strength ( RS ) Rating rising into the 80-plus percentile with an upgrade to 83, a rise from 74 the day before. X When looking for the best stocks to buy and watch, one factor to watch closely ...", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.538269"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.367116, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "LNTH", "relevance_score": "0.84035", "ticker_sentiment_score": "0.290688", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.360752", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Boston Scientific Clears Technical Benchmark, Hitting 80-Plus RS Rating", "url": "https://www.investors.com/ibd-data-stories/boston-scientific-clears-technical-benchmark-hitting-80-plus-rs-rating-2/", "time_published": "20231213T080000", "authors": ["INVESTOR'S BUSINESS DAILY", "Investor's Business Daily"], "summary": "When looking for the best stocks to buy and watch, focus on those with rising relative price strength. One stock that fits that bill is Boston Scientific ( BSX ) , which had its Relative Strength ( RS ) Rating upgraded from 76 to 81 Wednesday.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.46504, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "LNTH", "relevance_score": "0.320974", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BSX", "relevance_score": "0.592095", "ticker_sentiment_score": "0.572743", "ticker_sentiment_label": "Bullish"}, {"ticker": "DXCM", "relevance_score": "0.320974", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Masimo's  ( MASI )  ORi Favored by Study for PaO2 Information", "url": "https://www.zacks.com/stock/news/2196904/masimos-masi-ori-favored-by-study-for-pao2-information", "time_published": "20231212T164200", "authors": ["Zacks Equity Research"], "summary": "Masimo's (MASI) latest study indicates that ORi can be a valuable tool to provide information on arterial oxygenation even during OLV.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ca/2974.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.178138, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MASI", "relevance_score": "0.592095", "ticker_sentiment_score": "0.118542", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITGR", "relevance_score": "0.217346", "ticker_sentiment_score": "0.081126", "ticker_sentiment_label": "Neutral"}, {"ticker": "DVA", "relevance_score": "0.163909", "ticker_sentiment_score": "0.127436", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.163909", "ticker_sentiment_score": "0.05347", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's Why You Should Retain Surmodics  ( SRDX )  Stock for Now", "url": "https://www.zacks.com/stock/news/2196894/heres-why-you-should-retain-surmodics-srdx-stock-for-now", "time_published": "20231212T163100", "authors": ["Zacks Equity Research"], "summary": "Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/45/26891.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.838487"}], "overall_sentiment_score": 0.220485, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ITGR", "relevance_score": "0.213517", "ticker_sentiment_score": "0.079999", "ticker_sentiment_label": "Neutral"}, {"ticker": "SRDX", "relevance_score": "0.721423", "ticker_sentiment_score": "0.395373", "ticker_sentiment_label": "Bullish"}, {"ticker": "DVA", "relevance_score": "0.16099", "ticker_sentiment_score": "0.125952", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.16099", "ticker_sentiment_score": "0.052843", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's Why Investors Should Retain ResMed  ( RMD )  Stock for Now", "url": "https://www.zacks.com/stock/news/2196711/heres-why-investors-should-retain-resmed-rmd-stock-for-now", "time_published": "20231212T141900", "authors": ["Zacks Equity Research"], "summary": "Investors continue to be optimistic about ResMed (RMD) due to the sustained growth in the SaaS business.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c0/2563.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999476"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.173929, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "RMD", "relevance_score": "0.196451", "ticker_sentiment_score": "0.159024", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CURN", "relevance_score": "0.039679", "ticker_sentiment_score": "-0.192819", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PODD", "relevance_score": "0.118647", "ticker_sentiment_score": "-0.008117", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.157741", "ticker_sentiment_score": "0.05641", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.157741", "ticker_sentiment_score": "-0.009512", "ticker_sentiment_label": "Neutral"}, {"ticker": "FSPKF", "relevance_score": "0.039679", "ticker_sentiment_score": "0.115761", "ticker_sentiment_label": "Neutral"}]}, {"title": "Thermo Fisher  ( TMO )  Launches New Solutions for Clinical Labs", "url": "https://www.zacks.com/stock/news/2196649/thermo-fisher-tmo-launches-new-solutions-for-clinical-labs", "time_published": "20231212T135200", "authors": ["Zacks Equity Research"], "summary": "Thermo Fisher (TMO) introduces the KingFisher Apex Dx system and Applied Biosystems MagMAX Dx Isolation Kit to improve preanalytical workflows for clinical laboratories.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/67/1932.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972193"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.182493, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.152499", "ticker_sentiment_score": "0.056191", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.25142", "ticker_sentiment_score": "0.138888", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.152499", "ticker_sentiment_score": "0.056191", "ticker_sentiment_label": "Neutral"}, {"ticker": "TMO", "relevance_score": "0.152499", "ticker_sentiment_score": "-0.065059", "ticker_sentiment_label": "Neutral"}]}, {"title": "Reasons to Add Cardinal Health  ( CAH )  to Your Portfolio Now", "url": "https://www.zacks.com/stock/news/2196582/reasons-to-add-cardinal-health-cah-to-your-portfolio-now", "time_published": "20231212T121300", "authors": ["Zacks Equity Research"], "summary": "Cardinal Health (CAH) continues to gain traction from a solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/6e/37920.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Earnings", "relevance_score": "0.875462"}], "overall_sentiment_score": 0.252304, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BDSX", "relevance_score": "0.131164", "ticker_sentiment_score": "0.041852", "ticker_sentiment_label": "Neutral"}, {"ticker": "HQY", "relevance_score": "0.131164", "ticker_sentiment_score": "0.084767", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAH", "relevance_score": "0.379691", "ticker_sentiment_score": "0.339252", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.131164", "ticker_sentiment_score": "0.100161", "ticker_sentiment_label": "Neutral"}]}, {"title": "Edwards Lifesciences  ( EW )  Forwards Growth Strategy and Outlook", "url": "https://www.zacks.com/stock/news/2196357/edwards-lifesciences-ew-forwards-growth-strategy-and-outlook", "time_published": "20231211T172700", "authors": ["Zacks Equity Research"], "summary": "Edwards Lifesciences' (EW) TAVR remains strong, driven by greater awareness, patient activation and advances in new technologies such as RESILIA.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.993781"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}], "overall_sentiment_score": 0.325035, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "EW", "relevance_score": "0.374312", "ticker_sentiment_score": "0.340144", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PODD", "relevance_score": "0.145145", "ticker_sentiment_score": "0.118155", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.192694", "ticker_sentiment_score": "0.143058", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.145145", "ticker_sentiment_score": "0.118155", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why You Should Retain Merit Medical  ( MMSI )  Stock for Now", "url": "https://www.zacks.com/stock/news/2196236/why-you-should-retain-merit-medical-mmsi-stock-for-now", "time_published": "20231211T152500", "authors": ["Zacks Equity Research"], "summary": "Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2a/3899.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.857896"}], "overall_sentiment_score": 0.367702, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "MMSI", "relevance_score": "0.108712", "ticker_sentiment_score": "0.218864", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ITGR", "relevance_score": "0.215415", "ticker_sentiment_score": "0.080557", "ticker_sentiment_label": "Neutral"}, {"ticker": "DVA", "relevance_score": "0.162437", "ticker_sentiment_score": "0.126685", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.162437", "ticker_sentiment_score": "0.053153", "ticker_sentiment_label": "Neutral"}]}, {"title": "McKesson  ( MCK )  Announces Availability of FDA-Approved Drug", "url": "https://www.zacks.com/stock/news/2196237/mckesson-mck-announces-availability-of-fda-approved-drug", "time_published": "20231211T152400", "authors": ["Zacks Equity Research"], "summary": "The availability of the FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for desmoid tumors.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/08/595.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.614606"}], "overall_sentiment_score": 0.192248, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ITGR", "relevance_score": "0.262522", "ticker_sentiment_score": "0.094382", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCK", "relevance_score": "0.597963", "ticker_sentiment_score": "0.059973", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.066784", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DVA", "relevance_score": "0.198493", "ticker_sentiment_score": "0.145992", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.198493", "ticker_sentiment_score": "0.06135", "ticker_sentiment_label": "Neutral"}, {"ticker": "SWTX", "relevance_score": "0.066784", "ticker_sentiment_score": "-0.05709", "ticker_sentiment_label": "Neutral"}]}, {"title": "Illumina  ( ILMN )  Expands Globally Despite Macroeconomic Woes", "url": "https://www.zacks.com/stock/news/2196086/illumina-ilmn-expands-globally-despite-macroeconomic-woes", "time_published": "20231211T141300", "authors": ["Zacks Equity Research"], "summary": "The NovaSeq X launch strengthens Illumina's (ILMN) competitive position in high-throughput sequencing.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/08/595.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Earnings", "relevance_score": "0.972193"}], "overall_sentiment_score": 0.187342, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.120834", "ticker_sentiment_score": "0.049781", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.200024", "ticker_sentiment_score": "0.07719", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.120834", "ticker_sentiment_score": "0.049781", "ticker_sentiment_label": "Neutral"}, {"ticker": "ILMN", "relevance_score": "0.387674", "ticker_sentiment_score": "0.167359", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Walgreens'  ( WBA )  AllianceRx Pharmacy Will Now Distribute XDEMVY", "url": "https://www.zacks.com/stock/news/2196004/walgreens-wba-alliancerx-pharmacy-will-now-distribute-xdemvy", "time_published": "20231211T130200", "authors": ["Zacks Equity Research"], "summary": "Walgreens' (WBA) subsidiary, AllianceRx Walgreens Pharmacy, is one of the four specialty pharmacies selected to distribute XDEMVY.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/1b/461.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972193"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.133055, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "TARS", "relevance_score": "0.086713", "ticker_sentiment_score": "0.091392", "ticker_sentiment_label": "Neutral"}, {"ticker": "PODD", "relevance_score": "0.129749", "ticker_sentiment_score": "0.051418", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARGX", "relevance_score": "0.043421", "ticker_sentiment_score": "-0.102889", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.214557", "ticker_sentiment_score": "0.122367", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.129749", "ticker_sentiment_score": "0.051418", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCSG", "relevance_score": "0.043421", "ticker_sentiment_score": "0.03972", "ticker_sentiment_label": "Neutral"}]}, {"title": "AMN Healthcare's  ( AMN )  New Tie-Up to Boost Patient Outcome", "url": "https://www.zacks.com/stock/news/2195558/amn-healthcares-amn-new-tie-up-to-boost-patient-outcome", "time_published": "20231208T161900", "authors": ["Zacks Equity Research"], "summary": "AMN Healthcare's (AMN) collaboration is likely to bolster its portfolio of products and simplify the language procurement process for customers.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.355937, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "AMN", "relevance_score": "0.516656", "ticker_sentiment_score": "0.516715", "ticker_sentiment_label": "Bullish"}, {"ticker": "ITGR", "relevance_score": "0.220809", "ticker_sentiment_score": "0.082146", "ticker_sentiment_label": "Neutral"}, {"ticker": "DVA", "relevance_score": "0.166551", "ticker_sentiment_score": "0.128793", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.166551", "ticker_sentiment_score": "0.054044", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCSG", "relevance_score": "0.111488", "ticker_sentiment_score": "0.203674", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "BrainsWay  ( BWAY )  Strengthens South Korean Foothold With Deep TMS", "url": "https://www.zacks.com/stock/news/2195323/brainsway-bway-strengthens-south-korean-foothold-with-deep-tms", "time_published": "20231208T131600", "authors": ["Zacks Equity Research"], "summary": "BrainsWay's (BWAY) Deep TMS targets affected brain structures with a magnetic field, stimulating crucial neural networks.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972193"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.219507, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BRSYF", "relevance_score": "0.379051", "ticker_sentiment_score": "0.301317", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PODD", "relevance_score": "0.195287", "ticker_sentiment_score": "0.069712", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.319725", "ticker_sentiment_score": "0.16381", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.195287", "ticker_sentiment_score": "0.069712", "ticker_sentiment_label": "Neutral"}]}, {"title": "Quest Diagnostics  ( DGX )  & CDC to Assess Hepatitis C Burden", "url": "https://www.zacks.com/stock/news/2195277/quest-diagnostics-dgx-cdc-to-assess-hepatitis-c-burden", "time_published": "20231208T122500", "authors": ["Zacks Equity Research"], "summary": "Quest Diagnostics (DGX) and CDC expand research collaboration to better understand the Hepatitis C burden in the United States.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c3/648.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972193"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.150184, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.139804", "ticker_sentiment_score": "0.053433", "ticker_sentiment_label": "Neutral"}, {"ticker": "DGX", "relevance_score": "0.62148", "ticker_sentiment_score": "0.255827", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HAE", "relevance_score": "0.230892", "ticker_sentiment_score": "0.121054", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.139804", "ticker_sentiment_score": "0.053433", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's Why You Should Retain Boston Scientific  ( BSX )  Now", "url": "https://www.zacks.com/stock/news/2195111/heres-why-you-should-retain-boston-scientific-bsx-now", "time_published": "20231207T201400", "authors": ["Zacks Equity Research"], "summary": "Investors are optimistic about Boston Scientific (BSX) on strong worldwide demand for its GI and pulmonary treatment options and traction in Europe for its next-generation WATCHMAN FLX.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.990678"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.918141"}], "overall_sentiment_score": 0.325653, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "EW", "relevance_score": "0.049835", "ticker_sentiment_score": "0.090277", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNN", "relevance_score": "0.049835", "ticker_sentiment_score": "0.090277", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSSMY", "relevance_score": "0.049835", "ticker_sentiment_score": "0.090277", "ticker_sentiment_label": "Neutral"}, {"ticker": "BSX", "relevance_score": "0.426225", "ticker_sentiment_score": "0.484124", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.049835", "ticker_sentiment_score": "0.090277", "ticker_sentiment_label": "Neutral"}, {"ticker": "PODD", "relevance_score": "0.148731", "ticker_sentiment_score": "0.05535", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDT", "relevance_score": "0.049835", "ticker_sentiment_score": "0.090277", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.245339", "ticker_sentiment_score": "0.090801", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.148731", "ticker_sentiment_score": "0.05535", "ticker_sentiment_label": "Neutral"}, {"ticker": "PXXXF", "relevance_score": "0.049835", "ticker_sentiment_score": "0.147548", "ticker_sentiment_label": "Neutral"}]}, {"title": "If You Invested $1000 In This Stock 5 Years Ago, You Would Have $3,800 Today - DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/news/23/12/36136854/if-you-invested-1000-in-this-stock-5-years-ago-you-would-have-3-800-today", "time_published": "20231207T160015", "authors": ["Benzinga Insights"], "summary": "DexCom DXCM has outperformed the market over the past 5 years by 19.36% on an annualized basis producing an average annual return of 30.98%. Currently, DexCom has a market capitalization of $45.26 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_3.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.983605", "ticker_sentiment_score": "0.387251", "ticker_sentiment_label": "Bullish"}]}, {"title": "Here's Why You Should Retain OPKO Health  ( OPK )  Stock for Now", "url": "https://www.zacks.com/stock/news/2194846/heres-why-you-should-retain-opko-health-opk-stock-for-now", "time_published": "20231207T152000", "authors": ["Zacks Equity Research"], "summary": "OPKO Health's (OPK) potential in Rayaldee raises optimism about the stock.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2a/3899.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.769861"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.245139, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "OPK", "relevance_score": "0.330286", "ticker_sentiment_score": "0.317164", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ITGR", "relevance_score": "0.223866", "ticker_sentiment_score": "0.083048", "ticker_sentiment_label": "Neutral"}, {"ticker": "DVA", "relevance_score": "0.168884", "ticker_sentiment_score": "0.130001", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.168884", "ticker_sentiment_score": "0.054556", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.056674", "ticker_sentiment_score": "0.303021", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Veeva Systems  ( VEEV )  Beats on Q3 Earnings, Revises FY24 Outlook", "url": "https://www.zacks.com/stock/news/2194810/veeva-systems-veev-beats-on-q3-earnings-revises-fy24-outlook", "time_published": "20231207T144800", "authors": ["Zacks Equity Research"], "summary": "Veeva Systems' (VEEV) fiscal Q3 results reflect impressive performances by both segments.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/01/36484.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.999986"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.140967, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VEEV", "relevance_score": "0.515345", "ticker_sentiment_score": "0.278247", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ITGR", "relevance_score": "0.158259", "ticker_sentiment_score": "0.02397", "ticker_sentiment_label": "Neutral"}, {"ticker": "DVA", "relevance_score": "0.158259", "ticker_sentiment_score": "0.054548", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.158259", "ticker_sentiment_score": "0.022618", "ticker_sentiment_label": "Neutral"}]}, {"title": "Globus Medical  ( GMED )  Gains From NuVasive Deal, Macro Woes Stay", "url": "https://www.zacks.com/stock/news/2194719/globus-medical-gmed-gains-from-nuvasive-deal-macro-woes-stay", "time_published": "20231207T142000", "authors": ["Zacks Equity Research"], "summary": "Globus Medical (GMED) witnesses notable gains across its product portfolio in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/b3/30471.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Earnings", "relevance_score": "0.972193"}], "overall_sentiment_score": 0.263119, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ZBH", "relevance_score": "0.050254", "ticker_sentiment_score": "0.163833", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNN", "relevance_score": "0.050254", "ticker_sentiment_score": "0.163833", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GMED", "relevance_score": "0.622414", "ticker_sentiment_score": "0.431204", "ticker_sentiment_label": "Bullish"}, {"ticker": "DSSMY", "relevance_score": "0.050254", "ticker_sentiment_score": "0.163833", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PODD", "relevance_score": "0.149966", "ticker_sentiment_score": "0.055624", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDT", "relevance_score": "0.050254", "ticker_sentiment_score": "0.163833", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HAE", "relevance_score": "0.247334", "ticker_sentiment_score": "0.091401", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.149966", "ticker_sentiment_score": "0.055624", "ticker_sentiment_label": "Neutral"}]}, {"title": "OrthoPediatrics  ( KIDS )  Introduces Unit for Non-Surgical Bracing", "url": "https://www.zacks.com/stock/news/2194705/orthopediatrics-kids-introduces-unit-for-non-surgical-bracing", "time_published": "20231207T141000", "authors": ["Zacks Equity Research"], "summary": "OrthoPediatrics (KIDS) continues to diversify its non-surgical offerings with the introduction of the DF2 Brace.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972193"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.214381, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.194242", "ticker_sentiment_score": "0.066402", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.318074", "ticker_sentiment_score": "0.111994", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.194242", "ticker_sentiment_score": "0.066402", "ticker_sentiment_label": "Neutral"}, {"ticker": "KIDS", "relevance_score": "0.433877", "ticker_sentiment_score": "0.144484", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's Why You Should Retain National Vision  ( EYE )  Stock Now", "url": "https://www.zacks.com/stock/news/2194602/heres-why-you-should-retain-national-vision-eye-stock-now", "time_published": "20231207T115900", "authors": ["Zacks Equity Research"], "summary": "Investors are optimistic about National Vision's (EYE) stock, banking on comparable store sales growth and a favorable liquidity structure.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e0/1871.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}, {"topic": "Earnings", "relevance_score": "0.999917"}], "overall_sentiment_score": 0.258912, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "EYE", "relevance_score": "0.397517", "ticker_sentiment_score": "0.361977", "ticker_sentiment_label": "Bullish"}, {"ticker": "PODD", "relevance_score": "0.124164", "ticker_sentiment_score": "0.02925", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.165031", "ticker_sentiment_score": "0.095342", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.165031", "ticker_sentiment_score": "0.034503", "ticker_sentiment_label": "Neutral"}]}, {"title": "Tandem Diabetes  ( TNDM )  Launches Dexcom G7 Integrated t:slim X2", "url": "https://www.zacks.com/stock/news/2194597/tandem-diabetes-tndm-launches-dexcom-g7-integrated-tslim-x2", "time_published": "20231207T115500", "authors": ["Zacks Equity Research"], "summary": "Tandem Diabetes' (TNDM) t:slim X2 is the first AID system in the world to feature Dexcom's most advanced CGM technology.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2a/3899.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972193"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.275014, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.135602", "ticker_sentiment_score": "0.052571", "ticker_sentiment_label": "Neutral"}, {"ticker": "TNDM", "relevance_score": "0.180124", "ticker_sentiment_score": "0.078444", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.224072", "ticker_sentiment_score": "0.084388", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.574528", "ticker_sentiment_score": "0.410596", "ticker_sentiment_label": "Bullish"}]}, {"title": "Is DexCom  ( DXCM )  a Solid Growth Stock? 3 Reasons to Think \"Yes\"", "url": "https://www.zacks.com/stock/news/2194412/is-dexcom-dxcm-a-solid-growth-stock-3-reasons-to-think-yes", "time_published": "20231206T174504", "authors": ["Zacks Equity Research"], "summary": "DexCom (DXCM) possesses solid growth attributes, which could help it handily outperform the market.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default118.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.983783"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.461883, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.50605", "ticker_sentiment_score": "0.395547", "ticker_sentiment_label": "Bullish"}]}, {"title": " ( DXCM )  - Analyzing DexCom's Short Interest - DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/short-sellers/23/12/36116498/dxcm-analyzing-dexcoms-short-interest", "time_published": "20231206T163029", "authors": ["Benzinga Insights"], "summary": "DexCom's DXCM short percent of float has fallen 15.65% since its last report. The company recently reported that it has 17.75 million shares sold short, which is 5.28% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.86 days to cover their ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.24389, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.224903", "ticker_sentiment_score": "0.085754", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Reasons to Retain AMN Healthcare  ( AMN )  Stock in Your Portfolio", "url": "https://www.zacks.com/stock/news/2194242/3-reasons-to-retain-amn-healthcare-amn-stock-in-your-portfolio", "time_published": "20231206T152200", "authors": ["Zacks Equity Research"], "summary": "Investors remain optimistic about AMN Healthcare's (AMN) broad array of services.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2a/3899.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.838487"}], "overall_sentiment_score": 0.294182, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMN", "relevance_score": "0.550879", "ticker_sentiment_score": "0.525445", "ticker_sentiment_label": "Bullish"}, {"ticker": "ITGR", "relevance_score": "0.21686", "ticker_sentiment_score": "0.080983", "ticker_sentiment_label": "Neutral"}, {"ticker": "DVA", "relevance_score": "0.163539", "ticker_sentiment_score": "0.127247", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.163539", "ticker_sentiment_score": "0.05339", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCSG", "relevance_score": "0.054857", "ticker_sentiment_score": "0.164003", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Omnicell's  ( OMCL )  Global Expansion Strong, Macro Issues Ail", "url": "https://www.zacks.com/stock/news/2194093/omnicells-omcl-global-expansion-strong-macro-issues-ail", "time_published": "20231206T142500", "authors": ["Zacks Equity Research"], "summary": "Omnicell (OMCL) accelerates a shift to cloud-based solutions and tech-enabled services through the launches of Inventory Optimization Service and Central Pharmacy Dispensing Services.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}, {"topic": "Earnings", "relevance_score": "0.999858"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.185512, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "OMCL", "relevance_score": "0.50287", "ticker_sentiment_score": "0.219751", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PODD", "relevance_score": "0.146916", "ticker_sentiment_score": "0.054951", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.242406", "ticker_sentiment_score": "0.089918", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.146916", "ticker_sentiment_score": "0.054951", "ticker_sentiment_label": "Neutral"}]}, {"title": "HealthEquity  ( HQY )  Q3 Earnings Surpass Estimates, Margins Up", "url": "https://www.zacks.com/stock/news/2194092/healthequity-hqy-q3-earnings-surpass-estimates-margins-up", "time_published": "20231206T142400", "authors": ["Zacks Equity Research"], "summary": "HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust performances in the majority of its segments, in the third quarter of fiscal 2024.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/01/36484.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.999997"}], "overall_sentiment_score": 0.092017, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "HQY", "relevance_score": "0.398148", "ticker_sentiment_score": "0.364949", "ticker_sentiment_label": "Bullish"}, {"ticker": "ITGR", "relevance_score": "0.165314", "ticker_sentiment_score": "0.023292", "ticker_sentiment_label": "Neutral"}, {"ticker": "DVA", "relevance_score": "0.165314", "ticker_sentiment_score": "0.020505", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.165314", "ticker_sentiment_score": "0.023272", "ticker_sentiment_label": "Neutral"}]}, {"title": "Neogen  ( NEOG )  to Offer Biosecurity Products With New Pact", "url": "https://www.zacks.com/stock/news/2194003/neogen-neog-to-offer-biosecurity-products-with-new-pact", "time_published": "20231206T131600", "authors": ["Zacks Equity Research"], "summary": "Neogen will be able to highlight its biosecurity and horse health products, like the COMPANION range of cleansers and disinfection solutions, through the latest collaboration.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.980509"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.265854, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.207571", "ticker_sentiment_score": "0.071471", "ticker_sentiment_label": "Neutral"}, {"ticker": "NEOG", "relevance_score": "0.570165", "ticker_sentiment_score": "0.358335", "ticker_sentiment_label": "Bullish"}, {"ticker": "HAE", "relevance_score": "0.339046", "ticker_sentiment_score": "0.120066", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.207571", "ticker_sentiment_score": "0.071471", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's Why You Should Retain Align Technology  ( ALGN )  Stock Now", "url": "https://www.zacks.com/stock/news/2193991/heres-why-you-should-retain-align-technology-algn-stock-now", "time_published": "20231206T130800", "authors": ["Zacks Equity Research"], "summary": "Investors are optimistic about Align Technology (ALGN) on global expansion and strategic alliance.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ca/2974.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}, {"topic": "Earnings", "relevance_score": "0.998287"}], "overall_sentiment_score": 0.231901, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.145437", "ticker_sentiment_score": "0.055876", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALGN", "relevance_score": "0.331129", "ticker_sentiment_score": "0.25506", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HAE", "relevance_score": "0.240014", "ticker_sentiment_score": "0.090982", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.145437", "ticker_sentiment_score": "0.055876", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:USD", "relevance_score": "0.04872", "ticker_sentiment_score": "0.011995", "ticker_sentiment_label": "Neutral"}]}, {"title": "Market Whales and Their Recent Bets on DXCM Options - DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/markets/options/23/12/36100418/market-whales-and-their-recent-bets-on-dxcm-options", "time_published": "20231205T201557", "authors": ["Benzinga Insights"], "summary": "High-rolling investors have positioned themselves bearish on DexCom DXCM, and it's important for retail traders to take note. \\This activity came to our attention today through Benzinga's tracking of publicly available options data.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.122618, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.760593", "ticker_sentiment_score": "0.174073", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MS", "relevance_score": "0.093653", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PODD", "relevance_score": "0.093653", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "West Pharmaceutical's  ( WST )  New Launch to Expand Portfolio", "url": "https://www.zacks.com/stock/news/2193729/west-pharmaceuticals-wst-new-launch-to-expand-portfolio", "time_published": "20231205T165900", "authors": ["Zacks Equity Research"], "summary": "West Pharmaceutical's (WST) latest addition to its portfolio is likely to address the critical need for more drug preparation and delivery options at the point of care.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/08/595.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.21814, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "WST", "relevance_score": "0.131643", "ticker_sentiment_score": "0.057693", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITGR", "relevance_score": "0.259727", "ticker_sentiment_score": "0.093571", "ticker_sentiment_label": "Neutral"}, {"ticker": "DVA", "relevance_score": "0.196344", "ticker_sentiment_score": "0.144802", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.196344", "ticker_sentiment_score": "0.060843", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why You Should Retain UnitedHealth Group  ( UNH )  Stock Now", "url": "https://www.zacks.com/stock/news/2193656/why-you-should-retain-unitedhealth-group-unh-stock-now", "time_published": "20231205T151200", "authors": ["Zacks Equity Research"], "summary": "Growing membership, expanding government business, strategic acquisitions, improving operating margin and solid growth outlook poise UnitedHealth Group (UNH) well for growth.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/16/2258.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Earnings", "relevance_score": "0.996675"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.338086, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MEDP", "relevance_score": "0.160633", "ticker_sentiment_score": "0.155024", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMPH", "relevance_score": "0.200024", "ticker_sentiment_score": "0.154568", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMED", "relevance_score": "0.040416", "ticker_sentiment_score": "0.239098", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.200024", "ticker_sentiment_score": "0.131379", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.552826", "ticker_sentiment_score": "0.490478", "ticker_sentiment_label": "Bullish"}]}, {"title": "Integra Gains From New Product Launches, Mounting Costs Ail", "url": "https://www.zacks.com/stock/news/2193456/integra-gains-from-new-product-launches-mounting-costs-ail", "time_published": "20231205T133500", "authors": ["Zacks Equity Research"], "summary": "Integra expands the international reach of the CUSA platform and registers DuraGen, DuraSeal, Mayfield and Duo LED lighting in the EMEA and Latin America.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Earnings", "relevance_score": "0.99237"}], "overall_sentiment_score": 0.175398, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "IART", "relevance_score": "0.280294", "ticker_sentiment_score": "0.057252", "ticker_sentiment_label": "Neutral"}, {"ticker": "PODD", "relevance_score": "0.170475", "ticker_sentiment_score": "0.060418", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.280294", "ticker_sentiment_score": "0.101199", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.170475", "ticker_sentiment_score": "0.060418", "ticker_sentiment_label": "Neutral"}]}, {"title": "Boston Scientific  ( BSX )  Gains From Global Expansion, FX Woe Ails", "url": "https://www.zacks.com/stock/news/2193448/boston-scientific-bsx-gains-from-global-expansion-fx-woe-ails", "time_published": "20231205T133000", "authors": ["Zacks Equity Research"], "summary": "Boston Scientific's (BSX) Endoscopy business within MedSurg benefits from strong worldwide demand for its broad range of GI and pulmonary treatment options.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/39/612.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.650727"}, {"topic": "Earnings", "relevance_score": "0.983605"}], "overall_sentiment_score": 0.219449, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "EW", "relevance_score": "0.045139", "ticker_sentiment_score": "0.061782", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNN", "relevance_score": "0.045139", "ticker_sentiment_score": "0.061782", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSSMY", "relevance_score": "0.045139", "ticker_sentiment_score": "0.061782", "ticker_sentiment_label": "Neutral"}, {"ticker": "BSX", "relevance_score": "0.538177", "ticker_sentiment_score": "0.476395", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.045139", "ticker_sentiment_score": "0.061782", "ticker_sentiment_label": "Neutral"}, {"ticker": "PODD", "relevance_score": "0.134841", "ticker_sentiment_score": "0.052418", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDT", "relevance_score": "0.045139", "ticker_sentiment_score": "0.061782", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.222838", "ticker_sentiment_score": "0.084016", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.134841", "ticker_sentiment_score": "0.052418", "ticker_sentiment_label": "Neutral"}, {"ticker": "PXXXF", "relevance_score": "0.045139", "ticker_sentiment_score": "0.197268", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Henry Schein's  ( HSIC )  Zahn Dental and Myerson Enter New Deal", "url": "https://www.zacks.com/stock/news/2193401/henry-scheins-hsic-zahn-dental-and-myerson-enter-new-deal", "time_published": "20231205T123700", "authors": ["Zacks Equity Research"], "summary": "Henry Schein's (HSIC) dental laboratory business, Zahn Dental, is set to exclusively distribute Myerson's New Trusana 3D Premium Denture System.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/58/608.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Earnings", "relevance_score": "0.972193"}], "overall_sentiment_score": 0.356187, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.146321", "ticker_sentiment_score": "0.054821", "ticker_sentiment_label": "Neutral"}, {"ticker": "HSIC", "relevance_score": "0.287762", "ticker_sentiment_score": "0.301113", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HAE", "relevance_score": "0.241444", "ticker_sentiment_score": "0.089628", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.146321", "ticker_sentiment_score": "0.054821", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's Why You Should Retain Charles River  ( CRL )  Stock Now", "url": "https://www.zacks.com/stock/news/2193393/heres-why-you-should-retain-charles-river-crl-stock-now", "time_published": "20231205T122900", "authors": ["Zacks Equity Research"], "summary": "Charles River's (CRL) share price is likely to grow, backed by the strength of the DSA segment.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/08/595.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999813"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.194418, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.125025", "ticker_sentiment_score": "0.029346", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRL", "relevance_score": "0.206862", "ticker_sentiment_score": "0.207409", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HAE", "relevance_score": "0.166169", "ticker_sentiment_score": "0.095782", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.166169", "ticker_sentiment_score": "0.075051", "ticker_sentiment_label": "Neutral"}]}, {"title": "DexCom Earns Relative Strength Rating Upgrade", "url": "https://www.investors.com/ibd-data-stories/dexcom-earns-relative-strength-rating-upgrade/", "time_published": "20231205T080000", "authors": ["INVESTOR'S BUSINESS DAILY", "Investor's Business Daily"], "summary": "In a welcome move, DexCom ( DXCM ) saw its Relative Strength Rating rise from 70 to 77 on Tuesday. X As you try to find the best stocks to buy and watch, keep a close on eye on relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.32972, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LNTH", "relevance_score": "0.368773", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.850133", "ticker_sentiment_score": "0.390955", "ticker_sentiment_label": "Bullish"}]}, {"title": "CONMED Sees RS Rating Improve To 74", "url": "https://www.investors.com/ibd-data-stories/conmed-sees-rs-rating-improve-to-74/", "time_published": "20231205T080000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "The Relative Strength ( RS ) Rating for CONMED ( CNMD ) headed into a higher percentile Tuesday, as it got a lift from 67 to 74. X When you're researching the best stocks to buy and watch, be sure to pay attention to relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.297354, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CNMD", "relevance_score": "0.625937", "ticker_sentiment_score": "0.396899", "ticker_sentiment_label": "Bullish"}, {"ticker": "LNTH", "relevance_score": "0.343279", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.343279", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Merit Medical Systems Sees RS Rating Improve To 74", "url": "https://www.investors.com/ibd-data-stories/merit-medical-systems-sees-rs-rating-improve-to-74/", "time_published": "20231205T080000", "authors": ["INVESTOR'S BUSINESS DAILY", "Investor's Business Daily"], "summary": "Merit Medical Systems ( MMSI ) had its Relative Strength ( RS ) Rating upgraded from 62 to 74 Tuesday -- a welcome improvement, but still shy of the 80 or higher score you look for. X As you try to find the best stocks to buy and watch, be sure to pay attention to relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.336513, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LNTH", "relevance_score": "0.323078", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.323078", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MMSI", "relevance_score": "0.702434", "ticker_sentiment_score": "0.400788", "ticker_sentiment_label": "Bullish"}]}, {"title": "Community Health  ( CYH )  Sells Three Florida Facilities for $294M", "url": "https://www.zacks.com/stock/news/2193200/community-health-cyh-sells-three-florida-facilities-for-294m", "time_published": "20231204T180500", "authors": ["Zacks Equity Research"], "summary": "Community Health (CYH) divests three hospitals in Florida to Tampa General Hospital, substantiating its endeavor to intensify its focus on high-growth business areas.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/d9/3163.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.928139"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.269236, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MEDP", "relevance_score": "0.214462", "ticker_sentiment_score": "0.132112", "ticker_sentiment_label": "Neutral"}, {"ticker": "CYH", "relevance_score": "0.316846", "ticker_sentiment_score": "0.110309", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITGR", "relevance_score": "0.214462", "ticker_sentiment_score": "0.132112", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.214462", "ticker_sentiment_score": "0.089664", "ticker_sentiment_label": "Neutral"}]}, {"title": "Exact Sciences  ( EXAS )  Up 35.4% YTD: Will the Rally Continue?", "url": "https://www.zacks.com/stock/news/2193144/exact-sciences-exas-up-354-ytd-will-the-rally-continue", "time_published": "20231204T171300", "authors": ["Zacks Equity Research"], "summary": "Investors are optimistic about Exact Sciences (EXAS), driven by growth in Screening and Precision Oncology segments.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.993781"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.112745, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.160633", "ticker_sentiment_score": "0.059387", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXAS", "relevance_score": "0.264515", "ticker_sentiment_score": "0.106219", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.264515", "ticker_sentiment_score": "0.137011", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.160633", "ticker_sentiment_score": "0.059387", "ticker_sentiment_label": "Neutral"}]}, {"title": "Thermo Fisher  ( TMO )  Advances Health Equity via New Partnership", "url": "https://www.zacks.com/stock/news/2192709/thermo-fisher-tmo-advances-health-equity-via-new-partnership", "time_published": "20231204T111500", "authors": ["Zacks Equity Research"], "summary": "Thermo Fisher (TMO) announces a collaboration with Project HOPE to improve health outcomes by enabling expanded access to HIV testing and support services in Nigeria.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/58/36600.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972193"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.224286, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.135857", "ticker_sentiment_score": "0.052622", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.224487", "ticker_sentiment_score": "0.084513", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.135857", "ticker_sentiment_score": "0.052622", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.045482", "ticker_sentiment_score": "-0.117717", "ticker_sentiment_label": "Neutral"}, {"ticker": "TMO", "relevance_score": "0.135857", "ticker_sentiment_score": "0.140317", "ticker_sentiment_label": "Neutral"}]}, {"title": "BiomX  ( PHGE )  Reports Positive Pulmonary Infection Treatment Data", "url": "https://www.zacks.com/stock/news/2192692/biomx-phge-reports-positive-pulmonary-infection-treatment-data", "time_published": "20231204T103800", "authors": ["Zacks Equity Research"], "summary": "BiomX's (PHGE) BX004 showcases an impressive 14% conversion to a negative P. aeruginosa sputum culture at the end of treatment.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ca/2974.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972193"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.166398, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HAE", "relevance_score": "0.288893", "ticker_sentiment_score": "0.103705", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.175859", "ticker_sentiment_score": "0.061741", "ticker_sentiment_label": "Neutral"}, {"ticker": "PODD", "relevance_score": "0.175859", "ticker_sentiment_score": "0.061741", "ticker_sentiment_label": "Neutral"}]}, {"title": "Nevro  ( NVRO )  Up 15.7% Since Last Earnings Report: Can It Continue?", "url": "https://www.zacks.com/stock/news/2192439/nevro-nvro-up-157-since-last-earnings-report-can-it-continue", "time_published": "20231201T163144", "authors": ["Zacks Equity Research"], "summary": "Nevro (NVRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default357.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.980922"}, {"topic": "Earnings", "relevance_score": "0.986413"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.096512, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVRO", "relevance_score": "0.479385", "ticker_sentiment_score": "0.153791", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.20279", "ticker_sentiment_score": "0.023676", "ticker_sentiment_label": "Neutral"}]}, {"title": "Neogen  ( NEOG )  Unveils New Assay for Walnut Allergens Detection", "url": "https://www.zacks.com/stock/news/2192294/neogen-neog-unveils-new-assay-for-walnut-allergens-detection", "time_published": "20231201T160100", "authors": ["Zacks Equity Research"], "summary": "Neogen's (NEOG) Veratox VIP for Walnut allergy test displays robust performance across sample types while keeping the Veratox product line's simple testing approach.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972193"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.313124, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.182967", "ticker_sentiment_score": "0.063519", "ticker_sentiment_label": "Neutral"}, {"ticker": "NEOG", "relevance_score": "0.30021", "ticker_sentiment_score": "0.426115", "ticker_sentiment_label": "Bullish"}, {"ticker": "HAE", "relevance_score": "0.30021", "ticker_sentiment_score": "0.10696", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.182967", "ticker_sentiment_score": "0.063519", "ticker_sentiment_label": "Neutral"}]}, {"title": "CVS Health's  ( CVS )  Digital Focus Aids Growth, Macro Issues Ail", "url": "https://www.zacks.com/stock/news/2192251/cvs-healths-cvs-digital-focus-aids-growth-macro-issues-ail", "time_published": "20231201T145400", "authors": ["Zacks Equity Research"], "summary": "CVS Health's (CVS) Health Care Benefits segment demonstrates value to consumers and clients by successfully managing drug cost trends and bringing innovative clinical solutions to the market.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/56/2031.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.650727"}, {"topic": "Earnings", "relevance_score": "0.972193"}], "overall_sentiment_score": 0.280482, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CVS", "relevance_score": "0.504646", "ticker_sentiment_score": "0.440376", "ticker_sentiment_label": "Bullish"}, {"ticker": "PODD", "relevance_score": "0.162073", "ticker_sentiment_score": "0.058402", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.266828", "ticker_sentiment_score": "0.097229", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.162073", "ticker_sentiment_score": "0.058402", "ticker_sentiment_label": "Neutral"}]}, {"title": "Philips  ( PHG )  Adds Smart Fit Coils to Boost Diagnostic Imaging", "url": "https://www.zacks.com/stock/news/2192064/philips-phg-adds-smart-fit-coils-to-boost-diagnostic-imaging", "time_published": "20231201T132500", "authors": ["Zacks Equity Research"], "summary": "Philips (PHG) launches three MR Smart Fit coils, namely TorsoCardiac 1.5T, 1.5T shoulder and Knee 3.0T, enhancing flexibility, reducing patient setup time and improving image quality resolution.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/67/1932.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.769861"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.47019, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "FATE", "relevance_score": "0.287537", "ticker_sentiment_score": "0.123771", "ticker_sentiment_label": "Neutral"}, {"ticker": "DVA", "relevance_score": "0.287537", "ticker_sentiment_score": "0.227833", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.231884", "ticker_sentiment_score": "0.19743", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PHG", "relevance_score": "0.175009", "ticker_sentiment_score": "0.42377", "ticker_sentiment_label": "Bullish"}]}, {"title": "Walgreens  ( WBA )  Launches Rx Savings Finder Digital Tool", "url": "https://www.zacks.com/stock/news/2191998/walgreens-wba-launches-rx-savings-finder-digital-tool", "time_published": "20231201T120400", "authors": ["Zacks Equity Research"], "summary": "Walgreens (WBA) introduces Rx Savings Finder to help patients save on prescription medications.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/6e/37920.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.972193"}], "overall_sentiment_score": 0.252537, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.131643", "ticker_sentiment_score": "0.051785", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.217639", "ticker_sentiment_score": "0.08245", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.131643", "ticker_sentiment_score": "0.051785", "ticker_sentiment_label": "Neutral"}, {"ticker": "WBA", "relevance_score": "0.174903", "ticker_sentiment_score": "0.25281", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "2 Strong Stocks Trading 30% Below Their Highs to Buy in December", "url": "https://www.zacks.com/stock/news/2191986/2-strong-stocks-trading-30-below-their-highs-to-buy-in-december", "time_published": "20231201T120000", "authors": ["Benjamin Rains"], "summary": "Why investors might want to buy Global Payments (GPN) and DexCom (DXCM) stock right now for long-term growth, with both trading at least 30% below their record highs.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fb/27696.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.988787"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.990999"}], "overall_sentiment_score": 0.184111, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.583495", "ticker_sentiment_score": "0.392716", "ticker_sentiment_label": "Bullish"}]}, {"title": "TransMedics Group Clears Key Benchmark, Hitting 80-Plus RS Rating", "url": "https://www.investors.com/ibd-data-stories/transmedics-group-clears-key-benchmark-hitting-80-plus-rs-rating/", "time_published": "20231201T080000", "authors": ["INVESTOR'S BUSINESS DAILY", "Investor's Business Daily"], "summary": "When putting together your watch list, focus on stocks with an 80 or higher RS Rating. TransMedics Group ( TMDX ) is one stock that just reached the mark, now earning a score of 85. When you're researching the best stocks to buy and watch, be sure to pay attention to relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.302164, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SYK", "relevance_score": "0.348103", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.348103", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TMDX", "relevance_score": "0.633079", "ticker_sentiment_score": "0.297833", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Thermo Fisher  ( TMO )  Extends Partnership With Flagship Pioneering", "url": "https://www.zacks.com/stock/news/2191700/thermo-fisher-tmo-extends-partnership-with-flagship-pioneering", "time_published": "20231130T165100", "authors": ["Zacks Equity Research"], "summary": "Thermo Fisher's (TMO) in-depth knowledge of the life sciences sector will be combined with Flagship Pioneering to create revolutionary capabilities for the ecosystem.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ca/2974.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.986413"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.280104, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.158173", "ticker_sentiment_score": "0.0588", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.260559", "ticker_sentiment_score": "0.097271", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.158173", "ticker_sentiment_score": "0.0588", "ticker_sentiment_label": "Neutral"}, {"ticker": "TMO", "relevance_score": "0.158173", "ticker_sentiment_score": "0.0292", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's Why Investors Should Hold Humana  ( HUM )  Stock for Now", "url": "https://www.zacks.com/stock/news/2191651/heres-why-investors-should-hold-humana-hum-stock-for-now", "time_published": "20231130T162900", "authors": ["Zacks Equity Research"], "summary": "Humana (HUM) is expected to benefit from a strong growth outlook, upgraded health plan offering suite, expanding Medicare Advantage membership, and solid cash reserves.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c0/2563.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.9545"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.392514, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "CNC", "relevance_score": "0.210731", "ticker_sentiment_score": "0.117445", "ticker_sentiment_label": "Neutral"}, {"ticker": "HUM", "relevance_score": "0.495963", "ticker_sentiment_score": "0.515469", "ticker_sentiment_label": "Bullish"}, {"ticker": "ITGR", "relevance_score": "0.210731", "ticker_sentiment_score": "0.149613", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.158868", "ticker_sentiment_score": "0.060281", "ticker_sentiment_label": "Neutral"}]}, {"title": "Charles River  ( CRL )  Gains on Price & Volume Growth Amid FX Woe", "url": "https://www.zacks.com/stock/news/2191596/charles-river-crl-gains-on-price-volume-growth-amid-fx-woe", "time_published": "20231130T161700", "authors": ["Zacks Equity Research"], "summary": "At present, Charles River (CRL) is the largest provider of outsourced drug discovery, non-clinical development and regulated safety testing services worldwide.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999953"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.744043"}], "overall_sentiment_score": 0.255462, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.144275", "ticker_sentiment_score": "0.054379", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRL", "relevance_score": "0.144275", "ticker_sentiment_score": "0.251319", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HAE", "relevance_score": "0.238133", "ticker_sentiment_score": "0.08863", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.144275", "ticker_sentiment_score": "0.054379", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:EUR", "relevance_score": "0.048327", "ticker_sentiment_score": "0.076733", "ticker_sentiment_label": "Neutral"}]}, {"title": "Inspira  ( IINN )  Expands in Life Support Space With New Deal", "url": "https://www.zacks.com/stock/news/2191591/inspira-iinn-expands-in-life-support-space-with-new-deal", "time_published": "20231130T160400", "authors": ["Zacks Equity Research"], "summary": "According to Inspira (IINN), the integration of its technology to oxygenate blood combined with Ennocure's infection prevention solutions is likely to help improve patient outcomes in ICUs.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/15/2078.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972193"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.192422, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HAE", "relevance_score": "0.384102", "ticker_sentiment_score": "0.129307", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.236588", "ticker_sentiment_score": "0.07757", "ticker_sentiment_label": "Neutral"}, {"ticker": "PODD", "relevance_score": "0.236588", "ticker_sentiment_score": "0.07757", "ticker_sentiment_label": "Neutral"}]}, {"title": "11 Stocks Turn $10,000 Into $230,769 In 11 Months", "url": "https://www.investors.com/etfs-and-funds/sectors/sp500-stocks-turn-10000-into-in-11-months/", "time_published": "20231130T130000", "authors": ["Investor's Business Daily", "MATT KRANTZ"], "summary": "Hope you didn't bail out of S&P 500 stocks after three straight months of losses. November turned into a big moneymaker for patient investors.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/10/stock-money-12-adobe.jpeg.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.325071, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GEN", "relevance_score": "0.099683", "ticker_sentiment_score": "0.160428", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ANET", "relevance_score": "0.099683", "ticker_sentiment_score": "0.108654", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTLT", "relevance_score": "0.099683", "ticker_sentiment_score": "0.108654", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXPE", "relevance_score": "0.197816", "ticker_sentiment_score": "0.227095", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CNC", "relevance_score": "0.049939", "ticker_sentiment_score": "0.099", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPGI", "relevance_score": "0.049939", "ticker_sentiment_score": "0.103251", "ticker_sentiment_label": "Neutral"}, {"ticker": "PODD", "relevance_score": "0.099683", "ticker_sentiment_score": "0.160428", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DVA", "relevance_score": "0.099683", "ticker_sentiment_score": "0.160428", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.099683", "ticker_sentiment_score": "0.160428", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Penumbra  ( PEN )  Enrolls First Patient in Landmark STORM-PE Trial", "url": "https://www.zacks.com/stock/news/2191307/penumbra-pen-enrolls-first-patient-in-landmark-storm-pe-trial", "time_published": "20231130T123700", "authors": ["Zacks Equity Research"], "summary": "Penumbra (PEN) achieves an important milestone by enrolling the first patient in STORM-PE RCT.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e7/2307.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972193"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.225037, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PEN", "relevance_score": "0.325208", "ticker_sentiment_score": "0.224383", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PODD", "relevance_score": "0.166169", "ticker_sentiment_score": "0.062085", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.273399", "ticker_sentiment_score": "0.103137", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.166169", "ticker_sentiment_score": "0.062085", "ticker_sentiment_label": "Neutral"}]}, {"title": "Reasons to Retain Quest Diagnostics  ( DGX )  Stock for Now", "url": "https://www.zacks.com/stock/news/2191302/reasons-to-retain-quest-diagnostics-dgx-stock-for-now", "time_published": "20231130T122800", "authors": ["Zacks Equity Research"], "summary": "Investors are optimistic about Quest Diagnostics (DGX) on the strength of the base business.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/57/40404.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999813"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.320748, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "III", "relevance_score": "0.039483", "ticker_sentiment_score": "0.104679", "ticker_sentiment_label": "Neutral"}, {"ticker": "PODD", "relevance_score": "0.118064", "ticker_sentiment_score": "0.028592", "ticker_sentiment_label": "Neutral"}, {"ticker": "DGX", "relevance_score": "0.379435", "ticker_sentiment_score": "0.455406", "ticker_sentiment_label": "Bullish"}, {"ticker": "HAE", "relevance_score": "0.15697", "ticker_sentiment_score": "0.092274", "ticker_sentiment_label": "Neutral"}, {"ticker": "SRPT", "relevance_score": "0.039483", "ticker_sentiment_score": "0.098765", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.15697", "ticker_sentiment_score": "0.033379", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's Why You Should Retain Zimmer Biomet  ( ZBH )  for Now", "url": "https://www.zacks.com/stock/news/2190999/heres-why-you-should-retain-zimmer-biomet-zbh-for-now", "time_published": "20231129T163400", "authors": ["Zacks Equity Research"], "summary": "Investors are optimistic about Zimmer Biomet (ZBH), driven by a recovery in business and an expanding global footprint.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999813"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}], "overall_sentiment_score": 0.321779, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ZBH", "relevance_score": "0.282777", "ticker_sentiment_score": "0.289991", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNN", "relevance_score": "0.048133", "ticker_sentiment_score": "0.161812", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DSSMY", "relevance_score": "0.048133", "ticker_sentiment_score": "0.161812", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PODD", "relevance_score": "0.1437", "ticker_sentiment_score": "0.055494", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDT", "relevance_score": "0.048133", "ticker_sentiment_score": "0.161812", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HAE", "relevance_score": "0.237204", "ticker_sentiment_score": "0.090118", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.1437", "ticker_sentiment_score": "0.055494", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:CHF", "relevance_score": "0.048133", "ticker_sentiment_score": "0.042963", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:JPY", "relevance_score": "0.048133", "ticker_sentiment_score": "0.042963", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:EUR", "relevance_score": "0.048133", "ticker_sentiment_score": "0.042963", "ticker_sentiment_label": "Neutral"}]}, {"title": "Quest Diagnostics'  ( DGX )  New Pact to Scale Precision Medicine", "url": "https://www.zacks.com/stock/news/2191001/quest-diagnostics-dgx-new-pact-to-scale-precision-medicine", "time_published": "20231129T163300", "authors": ["Zacks Equity Research"], "summary": "Quest Diagnostics' (DGX) will supply next-generation sequencing and enhanced RNA extraction services for Scipher's PrismRA test through a new collaboration.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ca/2974.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972193"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.217732, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.147516", "ticker_sentiment_score": "0.056339", "ticker_sentiment_label": "Neutral"}, {"ticker": "DGX", "relevance_score": "0.614479", "ticker_sentiment_score": "0.317989", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HAE", "relevance_score": "0.243376", "ticker_sentiment_score": "0.129893", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.147516", "ticker_sentiment_score": "0.056339", "ticker_sentiment_label": "Neutral"}]}, {"title": "Accelerate Diagnostics  ( AXDX )  Expands in In Vitro Diagnostics", "url": "https://www.zacks.com/stock/news/2190753/accelerate-diagnostics-axdx-expands-in-in-vitro-diagnostics", "time_published": "20231129T134300", "authors": ["Zacks Equity Research"], "summary": "Accelerate Diagnostics' (AXDX) Arc system eliminates the need for overnight culture incubation, drastically reducing the wait time for identification results.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/12/31139.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.890401"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.170534, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BRKR", "relevance_score": "0.160633", "ticker_sentiment_score": "0.217403", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PODD", "relevance_score": "0.238913", "ticker_sentiment_score": "0.095981", "ticker_sentiment_label": "Neutral"}, {"ticker": "AXDX", "relevance_score": "0.582526", "ticker_sentiment_score": "0.217627", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.238913", "ticker_sentiment_score": "0.095981", "ticker_sentiment_label": "Neutral"}]}, {"title": "Charles River  ( CRL )  Backs the Quest to Cure SPG56 via New Deal", "url": "https://www.zacks.com/stock/news/2190717/charles-river-crl-backs-the-quest-to-cure-spg56-via-new-deal", "time_published": "20231129T125700", "authors": ["Zacks Equity Research"], "summary": "Charles River (CRL) and GC4K announce a gene therapy manufacturing collaboration.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/57/40404.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972193"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.206191, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.148121", "ticker_sentiment_score": "0.055215", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRL", "relevance_score": "0.099066", "ticker_sentiment_score": "0.056042", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.244354", "ticker_sentiment_score": "0.090504", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.148121", "ticker_sentiment_score": "0.055215", "ticker_sentiment_label": "Neutral"}]}, {"title": "Should Vanguard Mid-Cap Growth ETF  ( VOT )  Be on Your Investing Radar?", "url": "https://www.zacks.com/stock/news/2190653/should-vanguard-mid-cap-growth-etf-vot-be-on-your-investing-radar", "time_published": "20231129T112005", "authors": ["Zacks Equity Research"], "summary": "Style Box ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default161.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.313192, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "APH", "relevance_score": "0.118064", "ticker_sentiment_score": "0.067312", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.118064", "ticker_sentiment_score": "0.067312", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCHP", "relevance_score": "0.118064", "ticker_sentiment_score": "0.067312", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's Why Investors Should Retain Molina Healthcare  ( MOH )  Now", "url": "https://www.zacks.com/stock/news/2190493/heres-why-investors-should-retain-molina-healthcare-moh-now", "time_published": "20231128T172000", "authors": ["Zacks Equity Research"], "summary": "Molina Healthcare (MOH) is well-poised for improvement on the back of membership growth in the Medicaid and Medicare businesses. Acquisitions and a solid cash balance act as added tailwinds.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e0/1871.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Earnings", "relevance_score": "0.997845"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.323388, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MEDP", "relevance_score": "0.20279", "ticker_sentiment_score": "0.182665", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMPH", "relevance_score": "0.251941", "ticker_sentiment_score": "0.185175", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.251941", "ticker_sentiment_score": "0.157586", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MOH", "relevance_score": "0.436843", "ticker_sentiment_score": "0.519237", "ticker_sentiment_label": "Bullish"}]}, {"title": "Smith & Nephew  ( SNN )  New Buyout Expands Sports Medicine Suite", "url": "https://www.zacks.com/stock/news/2190443/smith-nephew-snn-new-buyout-expands-sports-medicine-suite", "time_published": "20231128T163100", "authors": ["Zacks Equity Research"], "summary": "Smith & Nephew (SNN) will pay an initial cash consideration of $180 million at closure, with an additional $150 million based on financial performance to acquire CartiHeal.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ca/2974.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972193"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}], "overall_sentiment_score": 0.278564, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.158868", "ticker_sentiment_score": "0.05765", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNN", "relevance_score": "0.452384", "ticker_sentiment_score": "0.327824", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DSSMY", "relevance_score": "0.407019", "ticker_sentiment_score": "0.361586", "ticker_sentiment_label": "Bullish"}, {"ticker": "HAE", "relevance_score": "0.261678", "ticker_sentiment_score": "0.095697", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.158868", "ticker_sentiment_score": "0.05765", "ticker_sentiment_label": "Neutral"}]}, {"title": "Penumbra's  ( PEN )  Expansion Moves, New Launches Aid Growth", "url": "https://www.zacks.com/stock/news/2190374/penumbras-pen-expansion-moves-new-launches-aid-growth", "time_published": "20231128T145400", "authors": ["Zacks Equity Research"], "summary": "Penumbra (PEN) expects to materially increase both revenues and profitability of the international business in the next three years and beyond.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/39/612.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}, {"topic": "Earnings", "relevance_score": "0.997845"}], "overall_sentiment_score": 0.253674, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PEN", "relevance_score": "0.467176", "ticker_sentiment_score": "0.401871", "ticker_sentiment_label": "Bullish"}, {"ticker": "PODD", "relevance_score": "0.148426", "ticker_sentiment_score": "0.055282", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.244846", "ticker_sentiment_score": "0.090652", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.148426", "ticker_sentiment_score": "0.055282", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:JPY", "relevance_score": "0.049732", "ticker_sentiment_score": "0.036756", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:EUR", "relevance_score": "0.049732", "ticker_sentiment_score": "0.036756", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:USD", "relevance_score": "0.049732", "ticker_sentiment_score": "0.036756", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why DexCom  ( DXCM )  is a Top Growth Stock for the Long-Term", "url": "https://www.zacks.com/stock/news/2190346/why-dexcom-dxcm-is-a-top-growth-stock-for-the-long-term", "time_published": "20231128T144507", "authors": ["Zacks Equity Research"], "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default113.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.838487"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.274454, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.737032", "ticker_sentiment_score": "0.446196", "ticker_sentiment_label": "Bullish"}]}, {"title": "Is Connect Biopharma Holdings  ( CNTB )  Stock Outpacing Its Medical Peers This Year?", "url": "https://www.zacks.com/stock/news/2190330/is-connect-biopharma-holdings-cntb-stock-outpacing-its-medical-peers-this-year", "time_published": "20231128T144007", "authors": ["Zacks Equity Research"], "summary": "Here is how Connect Biopharma Holdings Limited Sponsored ADR (CNTB) and DexCom (DXCM) have performed compared to their sector so far this year.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default215.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Earnings", "relevance_score": "0.714479"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.13658, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CNTB", "relevance_score": "0.712214", "ticker_sentiment_score": "0.178883", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.363388", "ticker_sentiment_score": "0.200003", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Philips  ( PHG )  Bolsters Diagnostic Imaging With New Launches", "url": "https://www.zacks.com/stock/news/2190198/philips-phg-bolsters-diagnostic-imaging-with-new-launches", "time_published": "20231128T133800", "authors": ["Zacks Equity Research"], "summary": "Philips (PHG) unveils an array of AI-enabled innovations at RSNA23 to enhance diagnostic imaging capabilities across healthcare providers.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.769861"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.450175, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "FATE", "relevance_score": "0.287537", "ticker_sentiment_score": "0.123771", "ticker_sentiment_label": "Neutral"}, {"ticker": "DVA", "relevance_score": "0.287537", "ticker_sentiment_score": "0.227833", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.231884", "ticker_sentiment_score": "0.19743", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PHG", "relevance_score": "0.175009", "ticker_sentiment_score": "0.462561", "ticker_sentiment_label": "Bullish"}]}, {"title": "Bruker's  ( BRKR )  New Collaboration to Use MALDI Biotyper System", "url": "https://www.zacks.com/stock/news/2190142/brukers-brkr-new-collaboration-to-use-maldi-biotyper-system", "time_published": "20231128T125000", "authors": ["Zacks Equity Research"], "summary": "Bruker (BRKR) and Accelerate Diagnostics are set to work together to bring rapid, automated microbial identification directly from positive blood culture samples.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/57/40404.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.838487"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.288375, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BRKR", "relevance_score": "0.548805", "ticker_sentiment_score": "0.326407", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AXDX", "relevance_score": "0.268", "ticker_sentiment_score": "0.372092", "ticker_sentiment_label": "Bullish"}, {"ticker": "HAE", "relevance_score": "0.215894", "ticker_sentiment_score": "0.099989", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.108958", "ticker_sentiment_score": "0.065325", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's Why You Should Retain Teleflex  ( TFX )  Stock for Now", "url": "https://www.zacks.com/stock/news/2190140/heres-why-you-should-retain-teleflex-tfx-stock-for-now", "time_published": "20231128T124100", "authors": ["Zacks Equity Research"], "summary": "Investors remain optimistic about Teleflex (TFX) on the strength of the Vascular and Interventional businesses.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/13/54831.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}, {"topic": "Earnings", "relevance_score": "0.999813"}], "overall_sentiment_score": 0.205263, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.1331", "ticker_sentiment_score": "0.030282", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.176825", "ticker_sentiment_score": "0.099987", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.176825", "ticker_sentiment_score": "0.078373", "ticker_sentiment_label": "Neutral"}, {"ticker": "TFX", "relevance_score": "0.345073", "ticker_sentiment_score": "0.22025", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Philips  ( PHG )  Adds BlueSeal to its Diagnostic Imaging Portfolio", "url": "https://www.zacks.com/stock/news/2189803/philips-phg-adds-blueseal-to-its-diagnostic-imaging-portfolio", "time_published": "20231127T152700", "authors": ["Zacks Equity Research"], "summary": "Philips (PHG) showcases BlueSeal MR Mobile to enhance diagnostic imaging capabilities across remote and rural communities.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c2/53795.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.769861"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.374988, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "FATE", "relevance_score": "0.317254", "ticker_sentiment_score": "0.133757", "ticker_sentiment_label": "Neutral"}, {"ticker": "DVA", "relevance_score": "0.317254", "ticker_sentiment_score": "0.245773", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.256314", "ticker_sentiment_score": "0.116716", "ticker_sentiment_label": "Neutral"}, {"ticker": "PHG", "relevance_score": "0.193723", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's Why Investors Should Retain Labcorp  ( LH )  Stock for Now", "url": "https://www.zacks.com/stock/news/2189584/heres-why-investors-should-retain-labcorp-lh-stock-for-now", "time_published": "20231127T133500", "authors": ["Zacks Equity Research"], "summary": "Investors are increasingly optimistic about Labcorp (LH) due to development in targeted high-growth areas.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2a/3899.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}, {"topic": "Earnings", "relevance_score": "0.99489"}], "overall_sentiment_score": 0.238273, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.126119", "ticker_sentiment_score": "0.029469", "ticker_sentiment_label": "Neutral"}, {"ticker": "DGX", "relevance_score": "0.042196", "ticker_sentiment_score": "0.123309", "ticker_sentiment_label": "Neutral"}, {"ticker": "LH", "relevance_score": "0.126119", "ticker_sentiment_score": "0.245332", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HAE", "relevance_score": "0.167612", "ticker_sentiment_score": "0.096344", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.167612", "ticker_sentiment_score": "0.075495", "ticker_sentiment_label": "Neutral"}]}, {"title": "Investing $5,000 in These 3 Stocks Could Make You Rich", "url": "https://www.fool.com/investing/2023/11/27/investing-5000-in-these-3-stocks-could-make-you-ri/", "time_published": "20231127T105000", "authors": ["Keith Speights"], "summary": "Artificial intelligence should be a huge tailwind for all three of these stocks.", "banner_image": "https://g.foolcdn.com/editorial/images/755969/ai-icons-hand.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}, {"topic": "Earnings", "relevance_score": "0.108179"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.214828, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PATH", "relevance_score": "0.347754", "ticker_sentiment_score": "0.29224", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GOOG", "relevance_score": "0.393462", "ticker_sentiment_score": "-0.016784", "ticker_sentiment_label": "Neutral"}, {"ticker": "EG", "relevance_score": "0.05133", "ticker_sentiment_score": "0.072527", "ticker_sentiment_label": "Neutral"}, {"ticker": "IT", "relevance_score": "0.05133", "ticker_sentiment_score": "0.072527", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBER", "relevance_score": "0.05133", "ticker_sentiment_score": "0.121431", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.3007", "ticker_sentiment_score": "0.244601", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.05133", "ticker_sentiment_score": "0.121431", "ticker_sentiment_label": "Neutral"}]}, {"title": "Orthofix  ( OFIX )  Q3 Earnings Top Estimates, 2023 Sales View Cut", "url": "https://www.zacks.com/stock/news/2189267/orthofix-ofix-q3-earnings-top-estimates-2023-sales-view-cut", "time_published": "20231124T172800", "authors": ["Zacks Equity Research"], "summary": "Orthofix (OFIX) saw very strong growth across multiple business segments and product lines in Q3.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c0/53200.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}, {"topic": "Earnings", "relevance_score": "0.999999"}, {"topic": "Economy - Macro", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.096979, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CURN", "relevance_score": "0.049939", "ticker_sentiment_score": "0.120215", "ticker_sentiment_label": "Neutral"}, {"ticker": "OFIX", "relevance_score": "0.245835", "ticker_sentiment_score": "-0.05059", "ticker_sentiment_label": "Neutral"}, {"ticker": "PODD", "relevance_score": "0.149038", "ticker_sentiment_score": "0.059211", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.245835", "ticker_sentiment_score": "0.138208", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.197816", "ticker_sentiment_score": "0.034323", "ticker_sentiment_label": "Neutral"}]}, {"title": "Labcorp  ( LH )  Closes the Legacy Health Asset Acquisition Deal", "url": "https://www.zacks.com/stock/news/2188867/labcorp-lh-closes-the-legacy-health-asset-acquisition-deal", "time_published": "20231124T122100", "authors": ["Zacks Equity Research"], "summary": "Labcorp (LH) finalizes the comprehensive laboratory relationship with Legacy Health.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2a/3899.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972193"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.322853, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.170878", "ticker_sentiment_score": "0.060516", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.280938", "ticker_sentiment_score": "0.101388", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.170878", "ticker_sentiment_score": "0.060516", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCSG", "relevance_score": "0.057352", "ticker_sentiment_score": "0.184996", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Cardinal Health  ( CAH )  Hits 52-Week High: What's Aiding It?", "url": "https://www.zacks.com/stock/news/2188324/cardinal-health-cah-hits-52-week-high-whats-aiding-it", "time_published": "20231123T135100", "authors": ["Zacks Equity Research"], "summary": "Investors are optimistic about Cardinal Health's (CAH) diversified product portfolio.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/45/26891.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.769861"}], "overall_sentiment_score": 0.213753, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CVS", "relevance_score": "0.105836", "ticker_sentiment_score": "-0.168711", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CAH", "relevance_score": "0.405378", "ticker_sentiment_score": "0.033715", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITGR", "relevance_score": "0.209819", "ticker_sentiment_score": "0.045983", "ticker_sentiment_label": "Neutral"}, {"ticker": "DVA", "relevance_score": "0.158173", "ticker_sentiment_score": "0.121904", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.209819", "ticker_sentiment_score": "-0.013299", "ticker_sentiment_label": "Neutral"}]}, {"title": "EssilorLuxottica  ( ESLOY ) , Moncler Ink Luxury Eyewear Deal", "url": "https://www.zacks.com/stock/news/2188322/essilorluxottica-esloy-moncler-ink-luxury-eyewear-deal", "time_published": "20231123T134900", "authors": ["Zacks Equity Research"], "summary": "The first Moncler Lunettes collection produced with EssilorLuxottica (ESLOY) is called Fall-Winter 2024.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972193"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.353523, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.237358", "ticker_sentiment_score": "0.077774", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.385286", "ticker_sentiment_score": "0.129598", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.237358", "ticker_sentiment_score": "0.077774", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESLOF", "relevance_score": "0.385286", "ticker_sentiment_score": "0.511494", "ticker_sentiment_label": "Bullish"}]}, {"title": "Here's Why You Should Retain Edward Lifesciences  ( EW )  Stock Now", "url": "https://www.zacks.com/stock/news/2188215/heres-why-you-should-retain-edward-lifesciences-ew-stock-now", "time_published": "20231123T110600", "authors": ["Zacks Equity Research"], "summary": "Investors remain optimistic about Edward Lifesciences (EW) due to Surgical's differentiated portfolio and TMTT franchise.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/57/40404.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.998917"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.20021, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "EW", "relevance_score": "0.307511", "ticker_sentiment_score": "0.277083", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PODD", "relevance_score": "0.13459", "ticker_sentiment_score": "0.030461", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.17879", "ticker_sentiment_score": "0.100776", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.17879", "ticker_sentiment_score": "-0.014819", "ticker_sentiment_label": "Neutral"}]}, {"title": "Smart Medical Devices Market Accelerates to Hit USD 70.1 billion by 2028, with a CAGR of 7.5 %: Transparency Market Research Inc.", "url": "https://www.benzinga.com/pressreleases/23/11/g35921256/smart-medical-devices-market-accelerates-to-hit-usd-70-1-billion-by-2028-with-a-cagr-of-7-5-transp", "time_published": "20231122T173000", "authors": ["Globe Newswire"], "summary": "Wilmington, Delaware, United States, Nov. 22, 2023 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global smart medical devices market stood at US$ 48.6 billion in 2020 and the global market is projected to reach US$ 70.1 billion in 2028.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.363939, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.083687", "ticker_sentiment_score": "0.135235", "ticker_sentiment_label": "Neutral"}]}, {"title": "Quest Diagnostics'  ( DGX )  New Pact to Advance Cancer Screening", "url": "https://www.zacks.com/stock/news/2187944/quest-diagnostics-dgx-new-pact-to-advance-cancer-screening", "time_published": "20231122T153800", "authors": ["Zacks Equity Research"], "summary": "Quest Diagnostics' (DGX) latest partnership will increase the likelihood that Americans will eventually have an easy, reliable and accessible way to check for colorectal cancer.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972193"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.088469, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.149966", "ticker_sentiment_score": "0.055624", "ticker_sentiment_label": "Neutral"}, {"ticker": "DGX", "relevance_score": "0.511864", "ticker_sentiment_score": "0.210453", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HAE", "relevance_score": "0.247334", "ticker_sentiment_score": "0.091401", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.149966", "ticker_sentiment_score": "0.055624", "ticker_sentiment_label": "Neutral"}]}, {"title": "Abbott  ( ABT )  Benefits From Innovation Amid FX Headwinds", "url": "https://www.zacks.com/stock/news/2187790/abbott-abt-benefits-from-innovation-amid-fx-headwinds", "time_published": "20231122T141000", "authors": ["Zacks Equity Research"], "summary": "Abbott's (ABT) mAbxience collaboration is likely to help introduce cutting-edge medicines in the areas of oncology, women's health and respiratory diseases.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/db/2802.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972193"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.650727"}], "overall_sentiment_score": 0.133291, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.190667", "ticker_sentiment_score": "0.065481", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABT", "relevance_score": "0.190667", "ticker_sentiment_score": "-0.104297", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.312423", "ticker_sentiment_score": "0.110416", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.190667", "ticker_sentiment_score": "0.065481", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:EUR", "relevance_score": "0.064104", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Teleflex  ( TFX )  Enrolls First Patient in ACCESS-MANTA Registry", "url": "https://www.zacks.com/stock/news/2187672/teleflex-tfx-enrolls-first-patient-in-access-manta-registry", "time_published": "20231122T122500", "authors": ["Zacks Equity Research"], "summary": "Teleflex's (TFX) ACCESS-MANTA Registry is likely to examine the contemporary on-label use of the MANTA VCD.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/13/54831.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972193"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.288712, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.148426", "ticker_sentiment_score": "0.055282", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.244846", "ticker_sentiment_score": "0.090652", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.148426", "ticker_sentiment_score": "0.055282", "ticker_sentiment_label": "Neutral"}, {"ticker": "TFX", "relevance_score": "0.337592", "ticker_sentiment_score": "0.326735", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Medtronic  ( MDT )  Q2 Earnings Beat Estimates, 2024 View Up", "url": "https://www.zacks.com/stock/news/2187364/medtronic-mdt-q2-earnings-beat-estimates-2024-view-up", "time_published": "20231121T160200", "authors": ["Zacks Equity Research"], "summary": "Medtronic (MDT) Q2 results reflect broad strength across businesses and geographies, benefiting from durable fundamentals.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/dd/52606.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}, {"topic": "Earnings", "relevance_score": "1.0"}], "overall_sentiment_score": 0.195456, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CURN", "relevance_score": "0.043499", "ticker_sentiment_score": "0.196403", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PODD", "relevance_score": "0.129983", "ticker_sentiment_score": "0.047943", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDT", "relevance_score": "0.256538", "ticker_sentiment_score": "0.248711", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HAE", "relevance_score": "0.214937", "ticker_sentiment_score": "0.078366", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.129983", "ticker_sentiment_score": "0.047943", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's Why You Should Retain Myriad Genetics  ( MYGN )  Stock Now", "url": "https://www.zacks.com/stock/news/2187353/heres-why-you-should-retain-myriad-genetics-mygn-stock-now", "time_published": "20231121T155400", "authors": ["Zacks Equity Research"], "summary": "Investors are optimistic about Myriad Genetics (MYGN) on recent partnerships and growth in testing volumes.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ca/2974.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.77141"}, {"topic": "Earnings", "relevance_score": "0.990678"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.115078, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.142284", "ticker_sentiment_score": "0.055185", "ticker_sentiment_label": "Neutral"}, {"ticker": "QGEN", "relevance_score": "0.095138", "ticker_sentiment_score": "0.13494", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.234911", "ticker_sentiment_score": "0.089413", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.142284", "ticker_sentiment_score": "0.055185", "ticker_sentiment_label": "Neutral"}, {"ticker": "MYGN", "relevance_score": "0.489057", "ticker_sentiment_score": "0.130147", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:USD", "relevance_score": "0.047654", "ticker_sentiment_score": "-0.051259", "ticker_sentiment_label": "Neutral"}]}, {"title": "Zimmer Biomet's  ( ZBH )  Knee Sales Robust, Macro Woes Hurt", "url": "https://www.zacks.com/stock/news/2187140/zimmer-biomets-zbh-knee-sales-robust-macro-woes-hurt", "time_published": "20231121T135200", "authors": ["Zacks Equity Research"], "summary": "Zimmer Biomet (ZBH) is working to strengthen its foothold in emerging markets that provide long-term opportunities for growth.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/39/612.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Earnings", "relevance_score": "0.99237"}], "overall_sentiment_score": 0.238375, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ZBH", "relevance_score": "0.471615", "ticker_sentiment_score": "0.305177", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNN", "relevance_score": "0.041901", "ticker_sentiment_score": "0.112542", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSSMY", "relevance_score": "0.041901", "ticker_sentiment_score": "0.112542", "ticker_sentiment_label": "Neutral"}, {"ticker": "PODD", "relevance_score": "0.125242", "ticker_sentiment_score": "0.050572", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDT", "relevance_score": "0.041901", "ticker_sentiment_score": "0.112542", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.207216", "ticker_sentiment_score": "0.079327", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.125242", "ticker_sentiment_score": "0.050572", "ticker_sentiment_label": "Neutral"}]}, {"title": "Boston Scientific  ( BSX )  Closes the Relievant Medsystems Buyout", "url": "https://www.zacks.com/stock/news/2187043/boston-scientific-bsx-closes-the-relievant-medsystems-buyout", "time_published": "20231121T115600", "authors": ["Zacks Equity Research"], "summary": "Boston Scientific (BSX) expands the neuromodulation portfolio with the acquisition of Relievant Medsystems.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c0/2563.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.997845"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": -0.029505, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "HUM", "relevance_score": "0.049019", "ticker_sentiment_score": "0.05593", "ticker_sentiment_label": "Neutral"}, {"ticker": "PODD", "relevance_score": "0.146321", "ticker_sentiment_score": "0.054821", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.241444", "ticker_sentiment_score": "0.089628", "ticker_sentiment_label": "Neutral"}, {"ticker": "BSX", "relevance_score": "0.287762", "ticker_sentiment_score": "-0.215979", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "DXCM", "relevance_score": "0.146321", "ticker_sentiment_score": "0.054821", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's Why Investors Should Retain STERIS  ( STE )  Stock for Now", "url": "https://www.zacks.com/stock/news/2187041/heres-why-investors-should-retain-steris-ste-stock-for-now", "time_published": "20231121T115200", "authors": ["Zacks Equity Research"], "summary": "STERIS' (STE) Healthcare segment continues to benefit from procedure volume recovery.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/eb/4111.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.99489"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.222121, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CURN", "relevance_score": "0.088635", "ticker_sentiment_score": "0.003195", "ticker_sentiment_label": "Neutral"}, {"ticker": "PODD", "relevance_score": "0.132611", "ticker_sentiment_score": "0.030223", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.17618", "ticker_sentiment_score": "0.125481", "ticker_sentiment_label": "Neutral"}, {"ticker": "STE", "relevance_score": "0.383578", "ticker_sentiment_score": "0.222091", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.17618", "ticker_sentiment_score": "-0.014663", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDX", "relevance_score": "0.088635", "ticker_sentiment_score": "0.265021", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "3 Growth Stocks to Buy With $1,000 Right Now", "url": "https://www.fool.com/investing/2023/11/21/3-growth-stocks-to-buy-with-1000-right-now/", "time_published": "20231121T113000", "authors": ["James Brumley"], "summary": "If you're having trouble finding your portfolio's next growth holding, here are three great options to choose from -- or you can choose all three.", "banner_image": "https://media.ycharts.com/charts/14716920df75938eb365bc9dc55d7f2e.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Earnings", "relevance_score": "0.650727"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.129694, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.142777", "ticker_sentiment_score": "0.092151", "ticker_sentiment_label": "Neutral"}, {"ticker": "HUBS", "relevance_score": "0.212736", "ticker_sentiment_score": "0.145354", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.107335", "ticker_sentiment_score": "0.052371", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.035875", "ticker_sentiment_score": "0.087515", "ticker_sentiment_label": "Neutral"}]}, {"title": "DexCom  ( DXCM )  is an Incredible Growth Stock: 3 Reasons Why", "url": "https://www.zacks.com/stock/news/2186846/dexcom-dxcm-is-an-incredible-growth-stock-3-reasons-why", "time_published": "20231120T174506", "authors": ["Zacks Equity Research"], "summary": "DexCom (DXCM) is well positioned to outperform the market, as it exhibits above-average growth in financials.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default113.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.983783"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.476293, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.495015", "ticker_sentiment_score": "0.420054", "ticker_sentiment_label": "Bullish"}]}, {"title": "National Vision's  ( EYE )  Market Expansion Aids, Inflation Ails", "url": "https://www.zacks.com/stock/news/2186766/national-visions-eye-market-expansion-aids-inflation-ails", "time_published": "20231120T163200", "authors": ["Zacks Equity Research"], "summary": "National Vision (EYE) is expanding sales by the continued rollout of its remote medicine technology.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Earnings", "relevance_score": "0.972193"}], "overall_sentiment_score": 0.29741, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "EYE", "relevance_score": "0.536492", "ticker_sentiment_score": "0.429491", "ticker_sentiment_label": "Bullish"}, {"ticker": "PODD", "relevance_score": "0.134339", "ticker_sentiment_score": "0.052317", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.222022", "ticker_sentiment_score": "0.08377", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.134339", "ticker_sentiment_score": "0.052317", "ticker_sentiment_label": "Neutral"}, {"ticker": "WMT", "relevance_score": "0.04497", "ticker_sentiment_score": "0.000992", "ticker_sentiment_label": "Neutral"}]}, {"title": "Myriad Genetics  ( MYGN )  Expands Pharma Services With New Pact", "url": "https://www.zacks.com/stock/news/2186741/myriad-genetics-mygn-expands-pharma-services-with-new-pact", "time_published": "20231120T161800", "authors": ["Zacks Equity Research"], "summary": "Myriad Genetics (MYGN) will market the Personalis ImmunoID NeXT ultra-comprehensive biomarker discovery platform to its pharmaceutical partners with a new collaboration.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.983605"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.098602, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.191675", "ticker_sentiment_score": "0.067239", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.314017", "ticker_sentiment_score": "0.113074", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.191675", "ticker_sentiment_score": "0.067239", "ticker_sentiment_label": "Neutral"}, {"ticker": "ILMN", "relevance_score": "0.064449", "ticker_sentiment_score": "0.031156", "ticker_sentiment_label": "Neutral"}, {"ticker": "MYGN", "relevance_score": "0.428632", "ticker_sentiment_score": "0.288083", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Medtronic's  ( MDT )  Symplicity Spyral RDN System Gets FDA Boost", "url": "https://www.zacks.com/stock/news/2186720/medtronics-mdt-symplicity-spyral-rdn-system-gets-fda-boost", "time_published": "20231120T154700", "authors": ["Zacks Equity Research"], "summary": "Medtronic (MDT) receives the FDA approval for Symplicity blood pressure procedure for the treatment of hypertension.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/57/40404.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972193"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.172682, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.153145", "ticker_sentiment_score": "0.056337", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDT", "relevance_score": "0.48028", "ticker_sentiment_score": "0.224768", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HAE", "relevance_score": "0.252463", "ticker_sentiment_score": "0.092941", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.153145", "ticker_sentiment_score": "0.056337", "ticker_sentiment_label": "Neutral"}]}, {"title": "Paragon 28  ( FNA )  BEAST Cortical Fibers Launch Boosts Biologics", "url": "https://www.zacks.com/stock/news/2186709/paragon-28-fna-beast-cortical-fibers-launch-boosts-biologics", "time_published": "20231120T153400", "authors": ["Zacks Equity Research"], "summary": "Paragon 28's (FNA) BEAST Cortical Fibers' advanced processing capability ensures the preservation of native bone morphogenic proteins and other growth factors crucial for bone formation.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/39/612.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}, {"topic": "Earnings", "relevance_score": "0.972193"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.207976, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "FNA", "relevance_score": "0.387875", "ticker_sentiment_score": "0.368535", "ticker_sentiment_label": "Bullish"}, {"ticker": "PODD", "relevance_score": "0.200134", "ticker_sentiment_score": "0.069479", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.327366", "ticker_sentiment_score": "0.114557", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.200134", "ticker_sentiment_score": "0.069479", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's How Much $100 Invested In DexCom 15 Years Ago Would Be Worth Today - DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/news/23/11/35872735/heres-how-much-100-invested-in-dexcom-15-years-ago-would-be-worth-today", "time_published": "20231120T140016", "authors": ["Benzinga Insights"], "summary": "DexCom DXCM has outperformed the market over the past 15 years by 31.26% on an annualized basis producing an average annual return of 42.97%. Currently, DexCom has a market capitalization of $40.06 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_3.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.983605", "ticker_sentiment_score": "0.387251", "ticker_sentiment_label": "Bullish"}]}, {"title": "Ozempic Might Be Helping Abbott Laboratories and DexCom Stock. Here's How.", "url": "https://www.fool.com/investing/2023/11/20/ozempic-helping-abbott-laboratories-dexcom-stock/", "time_published": "20231120T110300", "authors": ["Alex Carchidi"], "summary": "New medicines for weight loss and diabetes stand to disrupt the competitive scene.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.796627"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.098238, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.309539", "ticker_sentiment_score": "0.092734", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.105604", "ticker_sentiment_score": "-0.027037", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABT", "relevance_score": "0.105604", "ticker_sentiment_score": "0.210518", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "2 Stock Split Growth Stocks to Buy and Hold", "url": "https://www.fool.com/investing/2023/11/19/2-stock-split-growth-stocks-to-buy-and-hold/", "time_published": "20231119T140000", "authors": ["Prosper Junior Bakiny"], "summary": "These companies could continue delivering excellent results long after their most recent stock splits are forgotten.", "banner_image": "https://media.ycharts.com/charts/97dec6401261b8125ab86b1449e770f2.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}, {"topic": "Earnings", "relevance_score": "0.928769"}], "overall_sentiment_score": 0.272374, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMZN", "relevance_score": "0.511864", "ticker_sentiment_score": "0.413186", "ticker_sentiment_label": "Bullish"}, {"ticker": "DXCM", "relevance_score": "0.47147", "ticker_sentiment_score": "0.359958", "ticker_sentiment_label": "Bullish"}, {"ticker": "ABT", "relevance_score": "0.050254", "ticker_sentiment_score": "0.050993", "ticker_sentiment_label": "Neutral"}]}, {"title": "Investing Lesson: Value Drivers", "url": "https://www.fool.com/investing/2023/11/18/investing-lesson-value-drivers/", "time_published": "20231118T131400", "authors": ["Motley Fool Staff"], "summary": "Trends come, trends go. So, how can investors spot the difference between another passing fad and something with real, sustainable value?", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.839681"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Technology", "relevance_score": "0.25"}], "overall_sentiment_score": 0.210346, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "TGT", "relevance_score": "0.006558", "ticker_sentiment_score": "0.057985", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.006558", "ticker_sentiment_score": "0.024028", "ticker_sentiment_label": "Neutral"}, {"ticker": "COST", "relevance_score": "0.130571", "ticker_sentiment_score": "0.128562", "ticker_sentiment_label": "Neutral"}, {"ticker": "SG", "relevance_score": "0.032781", "ticker_sentiment_score": "0.088079", "ticker_sentiment_label": "Neutral"}, {"ticker": "CHGG", "relevance_score": "0.039332", "ticker_sentiment_score": "0.111831", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMG", "relevance_score": "0.006558", "ticker_sentiment_score": "0.075288", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.006558", "ticker_sentiment_score": "0.024028", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIRK", "relevance_score": "0.026227", "ticker_sentiment_score": "0.135627", "ticker_sentiment_label": "Neutral"}, {"ticker": "RENT", "relevance_score": "0.006558", "ticker_sentiment_score": "0.079309", "ticker_sentiment_label": "Neutral"}, {"ticker": "WMT", "relevance_score": "0.019672", "ticker_sentiment_score": "0.123354", "ticker_sentiment_label": "Neutral"}]}, {"title": "Nemaura  ( NMRD )  to Expand in UK With Metabolic Health Program", "url": "https://www.zacks.com/stock/news/2186133/nemaura-nmrd-to-expand-in-uk-with-metabolic-health-program", "time_published": "20231117T164100", "authors": ["Zacks Equity Research"], "summary": "The latest program leverages Nemaura's (NMRD) world-first daily wear non-invasive CGM technology, providing individuals with real-time insights into their body's glucose dynamics.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/15/2078.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.9545"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.247389, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.195814", "ticker_sentiment_score": "0.066808", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.259037", "ticker_sentiment_score": "0.130929", "ticker_sentiment_label": "Neutral"}, {"ticker": "NMRD", "relevance_score": "0.195814", "ticker_sentiment_score": "0.103616", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.195814", "ticker_sentiment_score": "0.066808", "ticker_sentiment_label": "Neutral"}]}, {"title": "What's in the Cards for Medtronic  ( MDT )  in Q2 Earnings?", "url": "https://www.zacks.com/stock/news/2186123/whats-in-the-cards-for-medtronic-mdt-in-q2-earnings", "time_published": "20231117T162700", "authors": ["Zacks Equity Research"], "summary": "Strength in all four businesses is likely to drive Medtronic's (MDT) fiscal second-quarter performance.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5e/1093.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999892"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.305415, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ABT", "relevance_score": "0.084275", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITGR", "relevance_score": "0.167612", "ticker_sentiment_score": "0.024901", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDT", "relevance_score": "0.508441", "ticker_sentiment_score": "0.496656", "ticker_sentiment_label": "Bullish"}, {"ticker": "DXCM", "relevance_score": "0.167612", "ticker_sentiment_score": "0.023512", "ticker_sentiment_label": "Neutral"}]}, {"title": "Neogen's  ( NEOG )  Innovation Aids, Currency Headwind Stays", "url": "https://www.zacks.com/stock/news/2186126/neogens-neog-innovation-aids-currency-headwind-stays", "time_published": "20231117T162300", "authors": ["Zacks Equity Research"], "summary": "Neogen (NEOG) is progressing well in terms of picking the right growth markets and gaining a bigger share of those markets.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972193"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.281675, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.175009", "ticker_sentiment_score": "0.06153", "ticker_sentiment_label": "Neutral"}, {"ticker": "NEOG", "relevance_score": "0.6979", "ticker_sentiment_score": "0.518133", "ticker_sentiment_label": "Bullish"}, {"ticker": "HAE", "relevance_score": "0.287537", "ticker_sentiment_score": "0.140375", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.175009", "ticker_sentiment_score": "0.06153", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:USD", "relevance_score": "0.058759", "ticker_sentiment_score": "0.059983", "ticker_sentiment_label": "Neutral"}]}, {"title": "Looking Into DexCom's Recent Short Interest - DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/short-sellers/23/11/35850439/looking-into-dexcoms-recent-short-interest", "time_published": "20231117T153019", "authors": ["Benzinga Insights"], "summary": "DexCom's DXCM short percent of float has risen 32.63% since its last report. The company recently reported that it has 21.06 million shares sold short, which is 6.26% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.33 days to cover their ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.26961, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.224903", "ticker_sentiment_score": "0.158881", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Is DexCom the Next Big Growth Stock?", "url": "https://www.fool.com/investing/2023/11/17/is-dexcom-the-next-big-growth-stock/", "time_published": "20231117T150700", "authors": ["Alex Carchidi"], "summary": "It has significant growth drivers in play, but competitors are making inroads too.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.980716"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.19795, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.54572", "ticker_sentiment_score": "0.278789", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABT", "relevance_score": "0.054236", "ticker_sentiment_score": "-0.01101", "ticker_sentiment_label": "Neutral"}]}, {"title": "Reasons to Add DexCom  ( DXCM )  Stock to Your Portfolio Now", "url": "https://www.zacks.com/stock/news/2185917/reasons-to-add-dexcom-dxcm-stock-to-your-portfolio-now", "time_published": "20231117T141500", "authors": ["Zacks Equity Research"], "summary": "DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e0/2272.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}, {"topic": "Earnings", "relevance_score": "0.990786"}], "overall_sentiment_score": 0.30078, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BDSX", "relevance_score": "0.126784", "ticker_sentiment_score": "0.097376", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAH", "relevance_score": "0.126784", "ticker_sentiment_score": "0.104372", "ticker_sentiment_label": "Neutral"}, {"ticker": "PDCO", "relevance_score": "0.126784", "ticker_sentiment_score": "0.098541", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.367865", "ticker_sentiment_score": "0.422002", "ticker_sentiment_label": "Bullish"}]}, {"title": "Charles River  ( CRL )  Widens CliniPrime GMP Suite With New Launch", "url": "https://www.zacks.com/stock/news/2185867/charles-river-crl-widens-cliniprime-gmp-suite-with-new-launch", "time_published": "20231117T134000", "authors": ["Zacks Equity Research"], "summary": "Charles River (CRL) brings CliniPrime Cryopreserved Leukopaks for cell therapy development and manufacturing.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/57/40404.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.99237"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.241214, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.165031", "ticker_sentiment_score": "0.059104", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRL", "relevance_score": "0.165031", "ticker_sentiment_score": "0.060244", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.271576", "ticker_sentiment_score": "0.098635", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.165031", "ticker_sentiment_score": "0.059104", "ticker_sentiment_label": "Neutral"}]}, {"title": "4 Best Stocks Exhibiting Solid Earnings Growth", "url": "https://www.zacks.com/stock/news/2185786/4-best-stocks-exhibiting-solid-earnings-growth", "time_published": "20231117T113700", "authors": ["Tirthankar Chakraborty"], "summary": "Invest in stocks such as DexCom (DXCM), Arthur J. Gallagher (AJG), Limbach (LMB) and Hartford Financial Services (HIG) for superb earnings growth.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e7/2427.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Real Estate & Construction", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.306769, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LMB", "relevance_score": "0.161349", "ticker_sentiment_score": "0.124801", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.161349", "ticker_sentiment_score": "0.147468", "ticker_sentiment_label": "Neutral"}, {"ticker": "HIG", "relevance_score": "0.161349", "ticker_sentiment_score": "0.182116", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Paragon 28  ( FNA )  New Staple System Expands Ankle Device Line", "url": "https://www.zacks.com/stock/news/2185482/paragon-28-fna-new-staple-system-expands-ankle-device-line", "time_published": "20231116T163100", "authors": ["Zacks Equity Research"], "summary": "Paragon 28's (FNA) JAWS Great White Staple System is claimed to have 400 times greater fatigue life compared to competitors under similar load conditions.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/39/612.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972193"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.291929, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "FNA", "relevance_score": "0.396052", "ticker_sentiment_score": "0.343346", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PODD", "relevance_score": "0.204647", "ticker_sentiment_score": "0.069111", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.270523", "ticker_sentiment_score": "0.133646", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.204647", "ticker_sentiment_score": "0.069111", "ticker_sentiment_label": "Neutral"}]}, {"title": "Omnicell's  ( OMCL )  Portfolio Expansion Aids Amid Macro Woes", "url": "https://www.zacks.com/stock/news/2185461/omnicells-omcl-portfolio-expansion-aids-amid-macro-woes", "time_published": "20231116T161900", "authors": ["Zacks Equity Research"], "summary": "Omnicell (OMCL) accelerates its shift to cloud-based solutions and tech-enabled services through the launch of Inventory Optimization Service and Central Pharmacy Dispensing Services.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}, {"topic": "Earnings", "relevance_score": "0.972193"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.191409, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "OMCL", "relevance_score": "0.55931", "ticker_sentiment_score": "0.425203", "ticker_sentiment_label": "Bullish"}, {"ticker": "PODD", "relevance_score": "0.166551", "ticker_sentiment_score": "0.059468", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.220809", "ticker_sentiment_score": "0.113481", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.166551", "ticker_sentiment_score": "0.059468", "ticker_sentiment_label": "Neutral"}]}, {"title": "Industry Comparison: Evaluating DexCom Against Competitors In Health Care Equipment & Supplies Industry - DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/news/23/11/35831044/industry-comparison-evaluating-dexcom-against-competitors-in-health-care-equipment-amp-supplies-indu", "time_published": "20231116T160047", "authors": ["Benzinga Insights"], "summary": "In today's rapidly changing and fiercely competitive business landscape, it is vital for investors and industry enthusiasts to carefully evaluate companies. In this article, we will perform a comprehensive industry comparison, evaluating DexCom DXCM against its key competitors in the Health Care ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.928769"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.5855"}], "overall_sentiment_score": 0.250015, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.571516", "ticker_sentiment_score": "0.466045", "ticker_sentiment_label": "Bullish"}, {"ticker": "PODD", "relevance_score": "0.070105", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Could DexCom Stock Help You Become a Millionaire?", "url": "https://www.fool.com/investing/2023/11/16/could-dexcom-stock-help-you-become-a-millionaire/", "time_published": "20231116T150000", "authors": ["David Jagielski"], "summary": "DexCom has achieved strong growth over the years, but there's a big question mark over how strong it will be in the future.", "banner_image": "https://media.ycharts.com/charts/500b7f1f0bda72b79c250f3ac706736c.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.614606"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.998962"}], "overall_sentiment_score": 0.182078, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.397098", "ticker_sentiment_score": "0.212781", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "QIAGEN  ( QGEN )  Expands Sample Technologies Line With New Launch", "url": "https://www.zacks.com/stock/news/2185396/qiagen-qgen-expands-sample-technologies-line-with-new-launch", "time_published": "20231116T145800", "authors": ["Zacks Equity Research"], "summary": "QIAGEN's (QGEN) latest launches will better address the special needs of researchers working with challenging samples, allowing them to work more efficiently.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.95493"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.27567, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "QGEN", "relevance_score": "0.286082", "ticker_sentiment_score": "0.252355", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABT", "relevance_score": "0.097259", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITGR", "relevance_score": "0.193078", "ticker_sentiment_score": "0.027615", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.193078", "ticker_sentiment_score": "0.027615", "ticker_sentiment_label": "Neutral"}, {"ticker": "ILMN", "relevance_score": "0.04872", "ticker_sentiment_score": "0.167946", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Digital Health Market is Expected to Reach $549.7 billion | MarketsandMarkets.", "url": "https://www.benzinga.com/pressreleases/23/11/g35824455/digital-health-market-is-expected-to-reach-549-7-billion-marketsandmarkets", "time_published": "20231116T123000", "authors": ["Globe Newswire"], "summary": "Chicago, Nov. 16, 2023 ( GLOBE NEWSWIRE ) -- Digital Health market in terms of revenue was estimated to be worth $180.2 billion in 2023 and is poised to reach $549.7 billion by 2028, growing at a CAGR of 25.0% from 2023 to 2028 according to a latest report published by MarketsandMarkets\u2122.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.249454, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.040484", "ticker_sentiment_score": "-0.0347", "ticker_sentiment_label": "Neutral"}, {"ticker": "OMRNF", "relevance_score": "0.040484", "ticker_sentiment_score": "-0.0347", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.040484", "ticker_sentiment_score": "-0.0347", "ticker_sentiment_label": "Neutral"}, {"ticker": "TDOC", "relevance_score": "0.040484", "ticker_sentiment_score": "-0.0347", "ticker_sentiment_label": "Neutral"}, {"ticker": "BTCY", "relevance_score": "0.040484", "ticker_sentiment_score": "-0.0347", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.040484", "ticker_sentiment_score": "-0.0347", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDRX", "relevance_score": "0.040484", "ticker_sentiment_score": "-0.0347", "ticker_sentiment_label": "Neutral"}, {"ticker": "SEMHF", "relevance_score": "0.040484", "ticker_sentiment_score": "-0.0347", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDT", "relevance_score": "0.080865", "ticker_sentiment_score": "0.026583", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.040484", "ticker_sentiment_score": "-0.0347", "ticker_sentiment_label": "Neutral"}, {"ticker": "PHG", "relevance_score": "0.040484", "ticker_sentiment_score": "-0.0347", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's Why You Should Retain Omnicell  ( OMCL )  Stock Now", "url": "https://www.zacks.com/stock/news/2185113/heres-why-you-should-retain-omnicell-omcl-stock-now", "time_published": "20231116T115300", "authors": ["Zacks Equity Research"], "summary": "Investors are optimistic about Omnicell (OMCL) due to its technology and innovative solutions.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/57/40404.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Earnings", "relevance_score": "0.998917"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.149385, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "OMCL", "relevance_score": "0.405651", "ticker_sentiment_score": "0.312102", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PODD", "relevance_score": "0.140896", "ticker_sentiment_score": "0.031241", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.1871", "ticker_sentiment_score": "0.104172", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.1871", "ticker_sentiment_score": "-0.015321", "ticker_sentiment_label": "Neutral"}]}, {"title": "Illumina  ( ILMN )  Launches Initiative on Pathogen Sequencing", "url": "https://www.zacks.com/stock/news/2185110/illumina-ilmn-launches-initiative-on-pathogen-sequencing", "time_published": "20231116T114900", "authors": ["Zacks Equity Research"], "summary": "Illumina (ILMN) introduces a new initiative to drive more equitable access to genomics globally.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/13/54831.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972193"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.132554, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.140896", "ticker_sentiment_score": "0.053661", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.232661", "ticker_sentiment_score": "0.086979", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.140896", "ticker_sentiment_score": "0.053661", "ticker_sentiment_label": "Neutral"}, {"ticker": "ILMN", "relevance_score": "0.364053", "ticker_sentiment_score": "0.1515", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Alcon  ( ALC )  Q3 Earnings Miss Estimates, Margins Increase", "url": "https://www.zacks.com/stock/news/2184719/alcon-alc-q3-earnings-miss-estimates-margins-increase", "time_published": "20231115T160700", "authors": ["Zacks Equity Research"], "summary": "Alcon (ALC) Q3 revenues increase year over year, driven by strength in Surgical and Vision Care segments.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/49/44858.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.999491"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.189199, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALC", "relevance_score": "0.291842", "ticker_sentiment_score": "0.313121", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABT", "relevance_score": "0.085173", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITGR", "relevance_score": "0.169378", "ticker_sentiment_score": "0.023682", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.169378", "ticker_sentiment_score": "0.025068", "ticker_sentiment_label": "Neutral"}]}, {"title": "Prestige Consumer's  ( PBH )  Brand Building, Innovation Aid Growth", "url": "https://www.zacks.com/stock/news/2184695/prestige-consumers-pbh-brand-building-innovation-aid-growth", "time_published": "20231115T152000", "authors": ["Zacks Equity Research"], "summary": "Prestige Consumer's (PBH) long-term brand-building efforts, efficient marketing, channel development and innovation help the company to continually hold a leading market share position.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}, {"topic": "Earnings", "relevance_score": "0.983605"}], "overall_sentiment_score": 0.290667, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.172507", "ticker_sentiment_score": "0.065083", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.283542", "ticker_sentiment_score": "0.102148", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.172507", "ticker_sentiment_score": "0.065083", "ticker_sentiment_label": "Neutral"}, {"ticker": "PBH", "relevance_score": "0.172507", "ticker_sentiment_score": "0.330817", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "QIAGEN  ( QGEN )  Launches QIAcuity Kits and Software Update", "url": "https://www.zacks.com/stock/news/2184368/qiagen-qgen-launches-qiacuity-kits-and-software-update", "time_published": "20231115T113200", "authors": ["Zacks Equity Research"], "summary": "QIAGEN's (QGEN) new QIAcuity kits are likely to expand application areas and foster digital PCR adoption.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/57/40404.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972193"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.222876, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.159569", "ticker_sentiment_score": "0.057814", "ticker_sentiment_label": "Neutral"}, {"ticker": "QGEN", "relevance_score": "0.31282", "ticker_sentiment_score": "0.127218", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.262805", "ticker_sentiment_score": "0.096033", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.159569", "ticker_sentiment_score": "0.057814", "ticker_sentiment_label": "Neutral"}]}, {"title": "Behind the Scenes of DexCom's Latest Options Trends - DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/markets/options/23/11/35780189/behind-the-scenes-of-dexcoms-latest-options-trends", "time_published": "20231114T154553", "authors": ["Benzinga Insights"], "summary": "Deep-pocketed investors have adopted a bullish approach towards DexCom DXCM, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.962106"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.152059, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.087824", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.814341", "ticker_sentiment_score": "0.28988", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JPM", "relevance_score": "0.087824", "ticker_sentiment_score": "-0.119755", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.087824", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's Why You Should Retain Penumbra  ( PEN )  Stock for Now", "url": "https://www.zacks.com/stock/news/2184063/heres-why-you-should-retain-penumbra-pen-stock-for-now", "time_published": "20231114T151900", "authors": ["Zacks Equity Research"], "summary": "Investors are optimistic about Penumbra (PEN) on strong vascular and neuro businesses growth and upbeat guidance.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.995921"}], "overall_sentiment_score": 0.284794, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ABT", "relevance_score": "0.096477", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITGR", "relevance_score": "0.191549", "ticker_sentiment_score": "0.027415", "ticker_sentiment_label": "Neutral"}, {"ticker": "BSX", "relevance_score": "0.048327", "ticker_sentiment_score": "0.061822", "ticker_sentiment_label": "Neutral"}, {"ticker": "TRUMF", "relevance_score": "0.048327", "ticker_sentiment_score": "0.061822", "ticker_sentiment_label": "Neutral"}, {"ticker": "PEN", "relevance_score": "0.28387", "ticker_sentiment_score": "0.387119", "ticker_sentiment_label": "Bullish"}, {"ticker": "MDT", "relevance_score": "0.048327", "ticker_sentiment_score": "0.061822", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.191549", "ticker_sentiment_score": "0.027415", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:JPY", "relevance_score": "0.048327", "ticker_sentiment_score": "0.03766", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:EUR", "relevance_score": "0.048327", "ticker_sentiment_score": "0.03766", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:USD", "relevance_score": "0.048327", "ticker_sentiment_score": "0.03766", "ticker_sentiment_label": "Neutral"}]}, {"title": "Bio-Rad  ( BIO )  Hurt by Macroeconomic Woes, Margin Pressure", "url": "https://www.zacks.com/stock/news/2183916/bio-rad-bio-hurt-by-macroeconomic-woes-margin-pressure", "time_published": "20231114T141500", "authors": ["Zacks Equity Research"], "summary": "Bio-Rad's (BIO) margin performance is affected by the inflationary trend of elevated raw material costs, increased logistics costs and higher employee-related expenses.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f5/284.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.967645"}], "overall_sentiment_score": 0.103356, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BIO", "relevance_score": "0.171485", "ticker_sentiment_score": "-0.135665", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABT", "relevance_score": "0.086245", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITGR", "relevance_score": "0.171485", "ticker_sentiment_score": "0.025329", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.171485", "ticker_sentiment_score": "0.025329", "ticker_sentiment_label": "Neutral"}]}, {"title": "Charles River  ( CRL )  to Advance AI Drug Discovery With New Pact", "url": "https://www.zacks.com/stock/news/2183914/charles-river-crl-to-advance-ai-drug-discovery-with-new-pact", "time_published": "20231114T141200", "authors": ["Zacks Equity Research"], "summary": "Charles River's (CRL) recent partnership will enable the optimization of the discovery and early development of multiple therapeutic programs for neurodegenerative disease and oncology.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ca/2974.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.839681"}], "overall_sentiment_score": 0.20567, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ITGR", "relevance_score": "0.18967", "ticker_sentiment_score": "0.027213", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.18967", "ticker_sentiment_score": "0.025695", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABT", "relevance_score": "0.095517", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's Why Investors Should Buy Alcon  ( ALC )  Stock Right Now", "url": "https://www.zacks.com/stock/news/2183772/heres-why-investors-should-buy-alcon-alc-stock-right-now", "time_published": "20231114T122500", "authors": ["Zacks Equity Research"], "summary": "Investors continue to be optimistic about Alcon (ALC), backed by a competitive product portfolio and strong commercial execution.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/57/40404.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.998626"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.744043"}], "overall_sentiment_score": 0.292325, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALC", "relevance_score": "0.458799", "ticker_sentiment_score": "0.443565", "ticker_sentiment_label": "Bullish"}, {"ticker": "PODD", "relevance_score": "0.145437", "ticker_sentiment_score": "0.030539", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.193078", "ticker_sentiment_score": "0.109705", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.193078", "ticker_sentiment_score": "-0.014109", "ticker_sentiment_label": "Neutral"}]}, {"title": "Henry Schein  ( HSIC )  Q3 Revenues Miss, 2023 Guidance Cut", "url": "https://www.zacks.com/stock/news/2183765/henry-schein-hsic-q3-revenues-miss-2023-guidance-cut", "time_published": "20231114T122000", "authors": ["Zacks Equity Research"], "summary": "Henry Schein's (HSIC) third-quarter 2023 performance demonstrates remarkable sales growth in the Technology and Value-Added Service businesses.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/6e/54381.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.650727"}, {"topic": "Earnings", "relevance_score": "0.999763"}], "overall_sentiment_score": 0.122111, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MEDP", "relevance_score": "0.15697", "ticker_sentiment_score": "0.022491", "ticker_sentiment_label": "Neutral"}, {"ticker": "CURN", "relevance_score": "0.07887", "ticker_sentiment_score": "0.164756", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HSIC", "relevance_score": "0.447528", "ticker_sentiment_score": "0.132782", "ticker_sentiment_label": "Neutral"}, {"ticker": "ENSG", "relevance_score": "0.15697", "ticker_sentiment_score": "0.022499", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.15697", "ticker_sentiment_score": "0.052878", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 High-Yield Dividend Stocks You Can Buy Now and Hold for a Decade", "url": "https://www.fool.com/investing/2023/11/14/2-high-yield-dividend-stocks-you-can-buy-now-and-h/", "time_published": "20231114T103600", "authors": ["Cory Renauer"], "summary": "These stocks could be great investments to bump up your passive income stream.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F754880%2Finvestment-presentation-getty.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.682689"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.130805, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ABBV", "relevance_score": "0.282234", "ticker_sentiment_score": "0.106675", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABT", "relevance_score": "0.057628", "ticker_sentiment_score": "-0.048151", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDT", "relevance_score": "0.227538", "ticker_sentiment_score": "0.150408", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.057628", "ticker_sentiment_score": "-0.048151", "ticker_sentiment_label": "Neutral"}]}, {"title": "Humana's  ( HUM )  CenterWell Unit Plans Expansion in Indiana", "url": "https://www.zacks.com/stock/news/2183514/humanas-hum-centerwell-unit-plans-expansion-in-indiana", "time_published": "20231113T173100", "authors": ["Zacks Equity Research"], "summary": "Humana's (HUM) CenterWell brand will open four senior-focused primary care centers across Indianapolis in order to address the unique needs of the area's senior population.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/55/1345.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.890401"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.321951, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "EHC", "relevance_score": "0.214462", "ticker_sentiment_score": "0.119891", "ticker_sentiment_label": "Neutral"}, {"ticker": "HUM", "relevance_score": "0.316846", "ticker_sentiment_score": "0.387156", "ticker_sentiment_label": "Bullish"}, {"ticker": "LGND", "relevance_score": "0.214462", "ticker_sentiment_score": "0.119891", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.266246", "ticker_sentiment_score": "0.143253", "ticker_sentiment_label": "Neutral"}]}, {"title": "Novo, Lilly Skid - But These Weight-Loss Results Are 'Hard To Ignore'", "url": "https://www.investors.com/news/technology/novo-nordisk-stock-can-weight-loss-drugs-prevent-diabetes/", "time_published": "20231113T162500", "authors": ["ALLISON GATLIN", "Investor's Business Daily"], "summary": "Novo Nordisk Stock: Can Weight-Loss Drugs Prevent Diabetes? Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2020/10/Stock-EliLilly-Lab01-company.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.995077"}], "overall_sentiment_score": 0.03874, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.295867", "ticker_sentiment_score": "-0.057783", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABT", "relevance_score": "0.120733", "ticker_sentiment_score": "0.171906", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BAC", "relevance_score": "0.120733", "ticker_sentiment_score": "0.162739", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MDT", "relevance_score": "0.180236", "ticker_sentiment_score": "0.26716", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.238718", "ticker_sentiment_score": "0.327328", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVO", "relevance_score": "0.295867", "ticker_sentiment_score": "0.008872", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's Why You Should Retain CVS Health  ( CVS )  Stock for Now", "url": "https://www.zacks.com/stock/news/2183413/heres-why-you-should-retain-cvs-health-cvs-stock-for-now", "time_published": "20231113T154100", "authors": ["Zacks Equity Research"], "summary": "Investors are optimistic about CVS Health's (CVS) strength in Health Care Benefits business arm and stable solvency position.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.994953"}], "overall_sentiment_score": 0.199823, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CVS", "relevance_score": "0.392264", "ticker_sentiment_score": "0.357068", "ticker_sentiment_label": "Bullish"}, {"ticker": "ABT", "relevance_score": "0.090816", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITGR", "relevance_score": "0.18046", "ticker_sentiment_score": "0.026233", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.18046", "ticker_sentiment_score": "0.026233", "ticker_sentiment_label": "Neutral"}]}, {"title": "Quest Diagnostics  ( DGX )  Introduces Mobile Phlebotomy Service", "url": "https://www.zacks.com/stock/news/2183411/quest-diagnostics-dgx-introduces-mobile-phlebotomy-service", "time_published": "20231113T153400", "authors": ["Zacks Equity Research"], "summary": "Quest Diagnostics (DGX) can offer patients and physicians a seamless connection to Quest Diagnostic's laboratory testing with the launch of Quest Mobile.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.839681"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.216723, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ABT", "relevance_score": "0.101582", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DGX", "relevance_score": "0.5174", "ticker_sentiment_score": "0.40802", "ticker_sentiment_label": "Bullish"}, {"ticker": "ITGR", "relevance_score": "0.201523", "ticker_sentiment_score": "0.028497", "ticker_sentiment_label": "Neutral"}, {"ticker": "SRPT", "relevance_score": "0.050894", "ticker_sentiment_score": "0.174892", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.201523", "ticker_sentiment_score": "0.028497", "ticker_sentiment_label": "Neutral"}]}, {"title": "Medical device makers rise on relief after Wegovy obesity trial data", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/medical-device-makers-rise-relief-after-wegovy-obesity-trial-data-2023-11-13/", "time_published": "20231113T152100", "authors": ["Reuters"], "summary": "A 0.25 mg injection pen of Novo Nordisk's weight-loss drug Wegovy is shown in this photo illustration in Oslo, Norway, September 1, 2023. REUTERS/Victoria Klesty/Illustration/File Photo Acquire Licensing Rights", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/TVXSNFD64BNWPDVJYHK3ZLYCTM.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.107828, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.147818", "ticker_sentiment_score": "0.317247", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABT", "relevance_score": "0.147818", "ticker_sentiment_score": "0.317247", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MDT", "relevance_score": "0.147818", "ticker_sentiment_score": "0.317247", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.147818", "ticker_sentiment_score": "0.317247", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NARI", "relevance_score": "0.147818", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "IDEXX's  ( IDXX )  Upcoming Launch to Detect Canine Leishmaniosis", "url": "https://www.zacks.com/stock/news/2183048/idexxs-idxx-upcoming-launch-to-detect-canine-leishmaniosis", "time_published": "20231113T111000", "authors": ["Zacks Equity Research"], "summary": "IDEXX (IDXX) expands the SNAP franchise with a comprehensive solution for detecting canine leishmaniosis.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c2/53795.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.99237"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.309072, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "IDXX", "relevance_score": "0.097259", "ticker_sentiment_score": "0.100203", "ticker_sentiment_label": "Neutral"}, {"ticker": "PODD", "relevance_score": "0.145437", "ticker_sentiment_score": "0.05463", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.240014", "ticker_sentiment_score": "0.089197", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.145437", "ticker_sentiment_score": "0.05463", "ticker_sentiment_label": "Neutral"}]}, {"title": "Smart Wearable Healthcare Devices Market to grow by USD 24.22 billion from 2023 to 2028; North America to account ... - PR Newswire", "url": "https://www.prnewswire.com/news-releases/smart-wearable-healthcare-devices-market-to-grow-by-usd-24-22-billion-from-2023-to-2028-north-america-to-account-for-34-of-market-growth--technavio-301984301.html", "time_published": "20231110T194500", "authors": [], "summary": "Smart Wearable Healthcare Devices Market to grow by USD 24.22 billion from 2023 to 2028. North America to account ... PR ...", "banner_image": null, "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.364792, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "SSNLF", "relevance_score": "0.065506", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.130571", "ticker_sentiment_score": "0.056284", "ticker_sentiment_label": "Neutral"}, {"ticker": "OMRNF", "relevance_score": "0.065506", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.065506", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BSX", "relevance_score": "0.065506", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BTCY", "relevance_score": "0.065506", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MASI", "relevance_score": "0.065506", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "IRTC", "relevance_score": "0.065506", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NOK", "relevance_score": "0.065506", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GRMN", "relevance_score": "0.065506", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.065506", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PHG", "relevance_score": "0.065506", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Hologic's  ( HOLX )  Q4 Earnings Beat Estimates, Gross Margin Down", "url": "https://www.zacks.com/stock/news/2182249/hologics-holx-q4-earnings-beat-estimates-gross-margin-down", "time_published": "20231110T140200", "authors": ["Zacks Equity Research"], "summary": "Solid year-over-year growth in the Breast Health segment drives Hologic's (HOLX) Q4 performance.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/b1/41955.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.042807, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "HOLX", "relevance_score": "0.303644", "ticker_sentiment_score": "0.326171", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABT", "relevance_score": "0.077719", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITGR", "relevance_score": "0.154703", "ticker_sentiment_score": "0.02362", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.154703", "ticker_sentiment_score": "0.02362", "ticker_sentiment_label": "Neutral"}]}, {"title": "National Vision  ( EYE )  Q3 Earnings Top Estimates, Margins Fall", "url": "https://www.zacks.com/stock/news/2182197/national-vision-eye-q3-earnings-top-estimates-margins-fall", "time_published": "20231110T130800", "authors": ["Zacks Equity Research"], "summary": "National Vision's (EYE) higher SG&A expenses in the third quarter reflect increases in performance-based incentives and stock-based compensations.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/66/49902.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}, {"topic": "Earnings", "relevance_score": "0.999894"}], "overall_sentiment_score": 0.186322, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "EYE", "relevance_score": "0.498479", "ticker_sentiment_score": "0.468747", "ticker_sentiment_label": "Bullish"}, {"ticker": "MEDP", "relevance_score": "0.193078", "ticker_sentiment_score": "0.026021", "ticker_sentiment_label": "Neutral"}, {"ticker": "ENSG", "relevance_score": "0.193078", "ticker_sentiment_score": "0.027565", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.193078", "ticker_sentiment_score": "0.061163", "ticker_sentiment_label": "Neutral"}, {"ticker": "WMT", "relevance_score": "0.097259", "ticker_sentiment_score": "0.136297", "ticker_sentiment_label": "Neutral"}]}, {"title": "Illumina  ( ILMN )  Q3 Earnings Surpass Estimates, '23 View Cut", "url": "https://www.zacks.com/stock/news/2182172/illumina-ilmn-q3-earnings-surpass-estimates-23-view-cut", "time_published": "20231110T125200", "authors": ["Zacks Equity Research"], "summary": "Illumina (ILMN) reports solid earnings in the third quarter of 2023 amid a challenging macro environment.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c0/53200.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.650727"}], "overall_sentiment_score": 0.106773, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MEDP", "relevance_score": "0.147818", "ticker_sentiment_score": "0.021667", "ticker_sentiment_label": "Neutral"}, {"ticker": "ENSG", "relevance_score": "0.147818", "ticker_sentiment_score": "0.021675", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.147818", "ticker_sentiment_score": "0.050945", "ticker_sentiment_label": "Neutral"}, {"ticker": "ILMN", "relevance_score": "0.571596", "ticker_sentiment_score": "0.259398", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "This Is What Whales Are Betting On DexCom - DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/markets/options/23/11/35709498/this-is-what-whales-are-betting-on-dexcom", "time_published": "20231109T191710", "authors": ["Benzinga Insights"], "summary": "Investors with a lot of money to spend have taken a bearish stance on DexCom DXCM. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.10809, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.08687", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.769861", "ticker_sentiment_score": "0.04331", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.08687", "ticker_sentiment_score": "-0.119516", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.08687", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "BD  ( BDX )  Q4 Earnings In-Line With Estimates, Margins Contract", "url": "https://www.zacks.com/stock/news/2181912/bd-bdx-q4-earnings-in-line-with-estimates-margins-contract", "time_published": "20231109T190500", "authors": ["Zacks Equity Research"], "summary": "BD's (BDX) overall top line benefits from revenue growth in all its segments and both geographic regions in the fiscal fourth quarter.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default86.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.127102, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ABT", "relevance_score": "0.07031", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITGR", "relevance_score": "0.140076", "ticker_sentiment_score": "0.022263", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.140076", "ticker_sentiment_score": "0.02226", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDX", "relevance_score": "0.140076", "ticker_sentiment_score": "0.119591", "ticker_sentiment_label": "Neutral"}]}, {"title": "Surmodics  ( SRDX )  Q4 Earnings Top Estimates, Revenues Up Y/Y", "url": "https://www.zacks.com/stock/news/2181864/surmodics-srdx-q4-earnings-top-estimates-revenues-up-yy", "time_published": "20231109T174400", "authors": ["Zacks Equity Research"], "summary": "Surmodics (SRDX) reports a solid fiscal fourth quarter top line on the back of robust segmental revenues.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/01/36484.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "1.0"}], "overall_sentiment_score": 0.095171, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ABT", "relevance_score": "0.071251", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITGR", "relevance_score": "0.141935", "ticker_sentiment_score": "0.021176", "ticker_sentiment_label": "Neutral"}, {"ticker": "SRDX", "relevance_score": "0.497551", "ticker_sentiment_score": "0.265339", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.141935", "ticker_sentiment_score": "0.022416", "ticker_sentiment_label": "Neutral"}]}, {"title": "Inspire Medical  ( INSP )  Q3 Earnings Top Estimates, Revenues Lag", "url": "https://www.zacks.com/stock/news/2181854/inspire-medical-insp-q3-earnings-top-estimates-revenues-lag", "time_published": "20231109T174100", "authors": ["Zacks Equity Research"], "summary": "Inspire Medical's (INSP) both geographic regions witness strong revenue growth in the third quarter.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/6e/54381.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.996718"}], "overall_sentiment_score": 0.216646, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "INSP", "relevance_score": "0.244109", "ticker_sentiment_score": "-0.090158", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABT", "relevance_score": "0.082535", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITGR", "relevance_score": "0.164188", "ticker_sentiment_score": "0.024559", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.164188", "ticker_sentiment_score": "0.024555", "ticker_sentiment_label": "Neutral"}]}, {"title": "Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick", "url": "https://www.zacks.com/stock/news/2181662/are-you-a-growth-investor-this-1-stock-could-be-the-perfect-pick", "time_published": "20231109T144508", "authors": ["Zacks Equity Research"], "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default75.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.838487"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}], "overall_sentiment_score": 0.370808, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.508593", "ticker_sentiment_score": "0.376404", "ticker_sentiment_label": "Bullish"}]}, {"title": "Here's Why You Should Invest in IDEXX  ( IDXX )  Stock Right Now", "url": "https://www.zacks.com/stock/news/2181457/heres-why-you-should-invest-in-idexx-idxx-stock-right-now", "time_published": "20231109T124800", "authors": ["Zacks Equity Research"], "summary": "Investors continue to be optimistic about IDEXX (IDXX), backed by the strength of the CAG Diagnostics business and momentum in ProCyte One expansion.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/13/54831.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999917"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.295409, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "IDXX", "relevance_score": "0.091162", "ticker_sentiment_score": "0.30775", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PODD", "relevance_score": "0.13637", "ticker_sentiment_score": "0.030678", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.181137", "ticker_sentiment_score": "0.101743", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.181137", "ticker_sentiment_score": "-0.01496", "ticker_sentiment_label": "Neutral"}]}, {"title": "Phibro  ( PAHC )  Q1 Earnings and Revenues Miss, Margins Down", "url": "https://www.zacks.com/stock/news/2181451/phibro-pahc-q1-earnings-and-revenues-miss-margins-down", "time_published": "20231109T124200", "authors": ["Zacks Equity Research"], "summary": "Phibro's (PAHC) fiscal 2024 first-quarter performance reflects reduced sales in Mineral Nutrition and Performance Products.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/60/43413.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999966"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}], "overall_sentiment_score": 0.026217, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MEDP", "relevance_score": "0.17879", "ticker_sentiment_score": "0.024581", "ticker_sentiment_label": "Neutral"}, {"ticker": "PAHC", "relevance_score": "0.17879", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ENSG", "relevance_score": "0.17879", "ticker_sentiment_score": "0.024591", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.17879", "ticker_sentiment_score": "0.057781", "ticker_sentiment_label": "Neutral"}]}, {"title": "Corporate America weighs business impact of new weight-loss drugs", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/corporate-america-weighs-business-impact-new-weight-loss-drugs-2023-11-08/", "time_published": "20231108T181900", "authors": ["Reuters"], "summary": "[1/3] A 0.25 mg injection pen of Novo Nordisk's weight-loss drug Wegovy is shown in this photo illustration in Oslo, Norway, September 1, 2023. REUTERS/Victoria Klesty/Illustration/File Photo Acquire Licensing Rights", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/BDRWR7ZSR5JSXIAJL2GP24IQY4.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}], "overall_sentiment_score": 0.110954, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "KO", "relevance_score": "0.054114", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BSX", "relevance_score": "0.054114", "ticker_sentiment_score": "-0.009037", "ticker_sentiment_label": "Neutral"}, {"ticker": "COR", "relevance_score": "0.054114", "ticker_sentiment_score": "0.033123", "ticker_sentiment_label": "Neutral"}, {"ticker": "RMD", "relevance_score": "0.054114", "ticker_sentiment_score": "0.004", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAH", "relevance_score": "0.054114", "ticker_sentiment_score": "0.033123", "ticker_sentiment_label": "Neutral"}, {"ticker": "DVA", "relevance_score": "0.054114", "ticker_sentiment_score": "0.036002", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABT", "relevance_score": "0.054114", "ticker_sentiment_score": "0.178815", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FSNUF", "relevance_score": "0.054114", "ticker_sentiment_score": "0.083764", "ticker_sentiment_label": "Neutral"}, {"ticker": "KDP", "relevance_score": "0.054114", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PEP", "relevance_score": "0.054114", "ticker_sentiment_score": "0.128764", "ticker_sentiment_label": "Neutral"}, {"ticker": "PODD", "relevance_score": "0.054114", "ticker_sentiment_score": "-0.048816", "ticker_sentiment_label": "Neutral"}, {"ticker": "ISRG", "relevance_score": "0.054114", "ticker_sentiment_score": "0.025012", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.054114", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "WMT", "relevance_score": "0.054114", "ticker_sentiment_score": "0.264935", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Inogen  ( INGN )  Q3 Earnings Miss Estimates, Revenues Down Y/Y", "url": "https://www.zacks.com/stock/news/2180988/inogen-ingn-q3-earnings-miss-estimates-revenues-down-yy", "time_published": "20231108T160900", "authors": ["Zacks Equity Research"], "summary": "Despite higher international business-to-business sales and rental revenues, Inogen's (INGN) overall third-quarter results reflect soft performances.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/66/49902.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.999939"}], "overall_sentiment_score": 0.05735, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ABT", "relevance_score": "0.088635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITGR", "relevance_score": "0.17618", "ticker_sentiment_score": "0.025788", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.17618", "ticker_sentiment_score": "0.025784", "ticker_sentiment_label": "Neutral"}, {"ticker": "INGN", "relevance_score": "0.530665", "ticker_sentiment_score": "0.143625", "ticker_sentiment_label": "Neutral"}]}, {"title": "Accuray  ( ARAY )  Q1 Earnings In-Line With Estimates, Revenues Top", "url": "https://www.zacks.com/stock/news/2180978/accuray-aray-q1-earnings-in-line-with-estimates-revenues-top", "time_published": "20231108T160400", "authors": ["Zacks Equity Research"], "summary": "Accuray (ARAY) reports a solid fiscal first quarter top line on the back of robust Product revenues.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/dd/52606.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.995921"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.024188, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ABT", "relevance_score": "0.090474", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITGR", "relevance_score": "0.179788", "ticker_sentiment_score": "0.026166", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.179788", "ticker_sentiment_score": "0.026162", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARAY", "relevance_score": "0.468029", "ticker_sentiment_score": "0.244842", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "DaVita  ( DVA )  Q3 Earnings & Revenues Top Estimates, Margins Up", "url": "https://www.zacks.com/stock/news/2180975/davita-dva-q3-earnings-revenues-top-estimates-margins-up", "time_published": "20231108T155600", "authors": ["Zacks Equity Research"], "summary": "DaVita's (DVA) robust segmental revenues drive its third-quarter performance.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/01/36484.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.999896"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.099113, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ABT", "relevance_score": "0.098255", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITGR", "relevance_score": "0.195025", "ticker_sentiment_score": "0.02624", "ticker_sentiment_label": "Neutral"}, {"ticker": "DVA", "relevance_score": "0.462953", "ticker_sentiment_score": "0.379448", "ticker_sentiment_label": "Bullish"}, {"ticker": "DXCM", "relevance_score": "0.195025", "ticker_sentiment_score": "0.027776", "ticker_sentiment_label": "Neutral"}]}, {"title": "Chemed's  ( CHE )  VITAS Performance Aids, Macro Issues Linger", "url": "https://www.zacks.com/stock/news/2180967/chemeds-che-vitas-performance-aids-macro-issues-linger", "time_published": "20231108T153300", "authors": ["Zacks Equity Research"], "summary": "Chemed (CHE) believes Roto-Rooter is well-positioned for growth and anticipates continued expansion of the segment's market share.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}, {"topic": "Earnings", "relevance_score": "0.99998"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.27411, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CHE", "relevance_score": "0.245959", "ticker_sentiment_score": "0.239596", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GOOG", "relevance_score": "0.062434", "ticker_sentiment_score": "0.190171", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "META", "relevance_score": "0.062434", "ticker_sentiment_score": "0.190171", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PODD", "relevance_score": "0.245959", "ticker_sentiment_score": "0.181664", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HAE", "relevance_score": "0.361626", "ticker_sentiment_score": "0.153093", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.245959", "ticker_sentiment_score": "0.149142", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Medical Device Companies Experiencing Strong Demand Even as Weight-Loss Drugs Rise in Popularity", "url": "https://www.fool.com/investing/2023/11/08/2-medical-device-companies-experiencing-strong/", "time_published": "20231108T143700", "authors": ["David Jagielski"], "summary": "Investors could be making a mistake by selling off these stocks this year.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.891286"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.962106"}], "overall_sentiment_score": 0.310882, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.566543", "ticker_sentiment_score": "0.482679", "ticker_sentiment_label": "Bullish"}, {"ticker": "ABT", "relevance_score": "0.185781", "ticker_sentiment_score": "0.198329", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Masimo  ( MASI )  Q3 Earnings Beat Estimates, Margins Fall", "url": "https://www.zacks.com/stock/news/2180756/masimo-masi-q3-earnings-beat-estimates-margins-fall", "time_published": "20231108T140800", "authors": ["Zacks Equity Research"], "summary": "Masimo's (MASI) overall third-quarter results reflect soft performance despite strength in the Hearables category.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/66/49902.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.999696"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.009458, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MASI", "relevance_score": "0.453905", "ticker_sentiment_score": "0.161488", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABT", "relevance_score": "0.096091", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITGR", "relevance_score": "0.190793", "ticker_sentiment_score": "0.117831", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.190793", "ticker_sentiment_score": "0.071488", "ticker_sentiment_label": "Neutral"}]}, {"title": "STERIS  ( STE )  Q2 Revenues Surpass Estimates, Margins Down", "url": "https://www.zacks.com/stock/news/2180621/steris-ste-q2-revenues-surpass-estimates-margins-down", "time_published": "20231108T114900", "authors": ["Zacks Equity Research"], "summary": "STERIS' (STE) fiscal 2024 second-quarter results reflect continued momentum in the Healthcare business.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/66/49902.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}, {"topic": "Earnings", "relevance_score": "0.999998"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.087059, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MEDP", "relevance_score": "0.173022", "ticker_sentiment_score": "0.024014", "ticker_sentiment_label": "Neutral"}, {"ticker": "ENSG", "relevance_score": "0.173022", "ticker_sentiment_score": "0.024023", "ticker_sentiment_label": "Neutral"}, {"ticker": "STE", "relevance_score": "0.415242", "ticker_sentiment_score": "0.136444", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.173022", "ticker_sentiment_score": "0.056451", "ticker_sentiment_label": "Neutral"}]}, {"title": "MannKind  ( MNKD )  Q3 2023 Earnings Call Transcript", "url": "https://www.fool.com/earnings/call-transcripts/2023/11/07/mannkind-mnkd-q3-2023-earnings-call-transcript/", "time_published": "20231108T021520", "authors": ["Motley Fool Transcribing"], "summary": "MNKD earnings call for the period ending September 30, 2023.", "banner_image": "https://g.foolcdn.com/misc-assets/fool-transcripts-logo.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.995973"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.276589, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.006831", "ticker_sentiment_score": "0.067905", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.006831", "ticker_sentiment_score": "0.234282", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MNKD", "relevance_score": "0.115722", "ticker_sentiment_score": "0.142931", "ticker_sentiment_label": "Neutral"}, {"ticker": "UTHR", "relevance_score": "0.034146", "ticker_sentiment_score": "0.051932", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:EUR", "relevance_score": "0.006831", "ticker_sentiment_score": "0.047735", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:USD", "relevance_score": "0.006831", "ticker_sentiment_score": "0.047735", "ticker_sentiment_label": "Neutral"}]}, {"title": "OPKO Health  ( OPK )  Q3 Earnings Lag Estimates, Revenues Top", "url": "https://www.zacks.com/stock/news/2180185/opko-health-opk-q3-earnings-lag-estimates-revenues-top", "time_published": "20231107T152900", "authors": ["Zacks Equity Research"], "summary": "Despite OPKO Health's (OPK) robust RAYALDEE sales and strength in the Pharmaceuticals segment, its overall third-quarter results reflect soft performances.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/01/36484.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.986564"}], "overall_sentiment_score": 0.06911, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ABT", "relevance_score": "0.076358", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "OPK", "relevance_score": "0.497733", "ticker_sentiment_score": "0.076968", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITGR", "relevance_score": "0.152018", "ticker_sentiment_score": "0.023366", "ticker_sentiment_label": "Neutral"}, {"ticker": "ENTX", "relevance_score": "0.038223", "ticker_sentiment_score": "0.043833", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.152018", "ticker_sentiment_score": "0.023362", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.076358", "ticker_sentiment_score": "0.122029", "ticker_sentiment_label": "Neutral"}]}, {"title": "Shockwave Medical  ( SWAV )  Q3 Earnings Beat, Revenues Rise Y/Y", "url": "https://www.zacks.com/stock/news/2179942/shockwave-medical-swav-q3-earnings-beat-revenues-rise-yy", "time_published": "20231107T134700", "authors": ["Zacks Equity Research"], "summary": "Shockwave Medical's (SWAV) third-quarter results reflect robust revenue growth and gross margin expansion on the back of strong demand and new launches.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/62/54862.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.999763"}], "overall_sentiment_score": 0.274802, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ABT", "relevance_score": "0.092036", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITGR", "relevance_score": "0.182851", "ticker_sentiment_score": "0.112768", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.182851", "ticker_sentiment_score": "0.067834", "ticker_sentiment_label": "Neutral"}, {"ticker": "SWAV", "relevance_score": "0.397098", "ticker_sentiment_score": "0.385689", "ticker_sentiment_label": "Bullish"}]}, {"title": "Insulet  ( PODD )  Banks on Omnipod for Consistent Market Share Gain", "url": "https://www.zacks.com/stock/news/2179888/insulet-podd-banks-on-omnipod-for-consistent-market-share-gain", "time_published": "20231107T130000", "authors": ["Zacks Equity Research"], "summary": "Insulet's (PODD) Omnipod 5 continues to be a driving force behind U.S. and international growth.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.990678"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.145038, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "HQY", "relevance_score": "0.210274", "ticker_sentiment_score": "0.054512", "ticker_sentiment_label": "Neutral"}, {"ticker": "PODD", "relevance_score": "0.682689", "ticker_sentiment_score": "0.188292", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HAE", "relevance_score": "0.310843", "ticker_sentiment_score": "0.094603", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.210274", "ticker_sentiment_score": "0.096329", "ticker_sentiment_label": "Neutral"}]}, {"title": "QIAGEN  ( QGEN )  Launches Workflow to Boost Microbiome Research", "url": "https://www.zacks.com/stock/news/2179834/qiagen-qgen-launches-workflow-to-boost-microbiome-research", "time_published": "20231107T120100", "authors": ["Zacks Equity Research"], "summary": "QIAGEN (QGEN) expands the Microbiome solutions portfolio with the launch of Microbiome WGS SeqSets.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/12/31139.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972193"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.241379, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.143415", "ticker_sentiment_score": "0.054195", "ticker_sentiment_label": "Neutral"}, {"ticker": "QGEN", "relevance_score": "0.326746", "ticker_sentiment_score": "0.302778", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HAE", "relevance_score": "0.236742", "ticker_sentiment_score": "0.08821", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.143415", "ticker_sentiment_score": "0.054195", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's Why You Should Retain Tandem Diabetes  ( TNDM )  Now", "url": "https://www.zacks.com/stock/news/2179816/heres-why-you-should-retain-tandem-diabetes-tndm-now", "time_published": "20231107T115300", "authors": ["Zacks Equity Research"], "summary": "Investors remain optimistic about Tandem Diabetes (TNDM), backed by upcoming innovative launches, including Mobi and the new integrated CGM offering.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/d6/3739.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.9973"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.220594, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.137934", "ticker_sentiment_score": "0.03087", "ticker_sentiment_label": "Neutral"}, {"ticker": "TNDM", "relevance_score": "0.227859", "ticker_sentiment_score": "0.351277", "ticker_sentiment_label": "Bullish"}, {"ticker": "HAE", "relevance_score": "0.183198", "ticker_sentiment_score": "0.102579", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.227859", "ticker_sentiment_score": "0.187388", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Mobile health solutions market to grow at a USD 256.69 billion from 2022 to 2027 | Abbott Laboratories, AirStrip ... - PR Newswire", "url": "https://www.prnewswire.com/news-releases/mobile-health-solutions-market-to-grow-at-a-usd-256-69-billion-from-2022-to-2027--abbott-laboratories-airstrip-technologies-inc-apple-inc-and-more-among-the-key-companies-in-the-market---technavio-301978707.html", "time_published": "20231107T011500", "authors": [], "summary": "Mobile health solutions market to grow at a USD 256.69 billion from 2022 to 2027 | Abbott Laboratories, AirStrip ... PR ...", "banner_image": null, "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.324869, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AAPL", "relevance_score": "0.058047", "ticker_sentiment_score": "0.143994", "ticker_sentiment_label": "Neutral"}, {"ticker": "CSCO", "relevance_score": "0.058047", "ticker_sentiment_score": "0.143994", "ticker_sentiment_label": "Neutral"}, {"ticker": "BSX", "relevance_score": "0.058047", "ticker_sentiment_score": "0.143994", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.058047", "ticker_sentiment_score": "0.143994", "ticker_sentiment_label": "Neutral"}, {"ticker": "MASI", "relevance_score": "0.115787", "ticker_sentiment_score": "0.275034", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ORCL", "relevance_score": "0.058047", "ticker_sentiment_score": "0.143994", "ticker_sentiment_label": "Neutral"}, {"ticker": "NOK", "relevance_score": "0.058047", "ticker_sentiment_score": "0.143994", "ticker_sentiment_label": "Neutral"}, {"ticker": "SSNLF", "relevance_score": "0.058047", "ticker_sentiment_score": "0.143994", "ticker_sentiment_label": "Neutral"}, {"ticker": "OMRNF", "relevance_score": "0.058047", "ticker_sentiment_score": "0.143994", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABT", "relevance_score": "0.058047", "ticker_sentiment_score": "0.143994", "ticker_sentiment_label": "Neutral"}, {"ticker": "QCOM", "relevance_score": "0.058047", "ticker_sentiment_score": "0.143994", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDRX", "relevance_score": "0.058047", "ticker_sentiment_score": "0.143994", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDT", "relevance_score": "0.058047", "ticker_sentiment_score": "0.143994", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.058047", "ticker_sentiment_score": "0.143994", "ticker_sentiment_label": "Neutral"}]}, {"title": "Check Out What Whales Are Doing With DXCM - DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/markets/options/23/11/35628761/check-out-what-whales-are-doing-with-dxcm", "time_published": "20231106T201600", "authors": ["Benzinga Insights"], "summary": "Someone with a lot of money to spend has taken a bullish stance on DexCom DXCM. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.185138, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.771727", "ticker_sentiment_score": "0.208654", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JPM", "relevance_score": "0.095899", "ticker_sentiment_score": "-0.128401", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.095899", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "QIAGEN's  ( QGEN )  Molecular Diagnostics Gains Share, FX Woe Stays", "url": "https://www.zacks.com/stock/news/2179016/qiagens-qgen-molecular-diagnostics-gains-share-fx-woe-stays", "time_published": "20231106T133500", "authors": ["Zacks Equity Research"], "summary": "QIAGEN (QGEN) continues to see a very healthy conversion trend from the tuberculin skin test.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/12/31139.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.99998"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.131156, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.133593", "ticker_sentiment_score": "0.132213", "ticker_sentiment_label": "Neutral"}, {"ticker": "QGEN", "relevance_score": "0.42503", "ticker_sentiment_score": "-0.00586", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.220809", "ticker_sentiment_score": "0.111811", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.133593", "ticker_sentiment_score": "0.108264", "ticker_sentiment_label": "Neutral"}, {"ticker": "MYGN", "relevance_score": "0.044718", "ticker_sentiment_score": "-0.123304", "ticker_sentiment_label": "Neutral"}]}, {"title": "Bruker  ( BRKR )  Q3 Earnings and Revenues Top, '23 Sales View Up", "url": "https://www.zacks.com/stock/news/2178941/bruker-brkr-q3-earnings-and-revenues-top-23-sales-view-up", "time_published": "20231106T121800", "authors": ["Zacks Equity Research"], "summary": "Bruker (BRKR) delivers better-than-expected earnings and revenues in the third quarter of 2023.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/66/49902.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.18371, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BRKR", "relevance_score": "0.506754", "ticker_sentiment_score": "0.318338", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MEDP", "relevance_score": "0.155201", "ticker_sentiment_score": "0.022328", "ticker_sentiment_label": "Neutral"}, {"ticker": "ENSG", "relevance_score": "0.155201", "ticker_sentiment_score": "0.022337", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.155201", "ticker_sentiment_score": "0.052497", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:NANO", "relevance_score": "0.077972", "ticker_sentiment_score": "0.106455", "ticker_sentiment_label": "Neutral"}]}, {"title": "Inari Medical  ( NARI )  Q3 Earnings and Revenues Beat Estimates", "url": "https://www.zacks.com/stock/news/2178311/inari-medical-nari-q3-earnings-and-revenues-beat-estimates", "time_published": "20231103T162700", "authors": ["Zacks Equity Research"], "summary": "Inari Medical's (NARI) third-quarter results benefit from strong product adoption and geographical performances.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/29/44156.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.999174"}], "overall_sentiment_score": 0.165028, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ABT", "relevance_score": "0.097062", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITGR", "relevance_score": "0.192694", "ticker_sentiment_score": "0.026002", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.192694", "ticker_sentiment_score": "0.027524", "ticker_sentiment_label": "Neutral"}, {"ticker": "NARI", "relevance_score": "0.497609", "ticker_sentiment_score": "0.461452", "ticker_sentiment_label": "Bullish"}]}, {"title": "AMN Healthcare  ( AMN )  Q3 Earnings and Revenues Beat Estimates", "url": "https://www.zacks.com/stock/news/2178304/amn-healthcare-amn-q3-earnings-and-revenues-beat-estimates", "time_published": "20231103T162200", "authors": ["Zacks Equity Research"], "summary": "AMN Healthcare's (AMN) dismal results in all its segments led to a soft overall third-quarter performance.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/01/36484.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.999862"}], "overall_sentiment_score": 0.01923, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMN", "relevance_score": "0.542261", "ticker_sentiment_score": "0.081216", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABT", "relevance_score": "0.07887", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITGR", "relevance_score": "0.15697", "ticker_sentiment_score": "0.023844", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.15697", "ticker_sentiment_score": "0.02384", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCSG", "relevance_score": "0.118064", "ticker_sentiment_score": "-0.0195", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Insulet Corp  ( PODD )  Stock Is Soaring Today - Insulet  ( NASDAQ:PODD ) ", "url": "https://www.benzinga.com/news/earnings/23/11/35587621/omnipod-insulin-pump-working-well-for-insulet-lifts-annual-forecast", "time_published": "20231103T135729", "authors": ["Vandana Singh"], "summary": "Insulet Corporation PODD reported Q3 sales of $432.7 million, up 27.0%, or 25.1% in constant currency, beating the consensus of $414.383 million. Total Omnipod revenue of $422 million marked a year-over-year increase of 29.4%.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/03/podd.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.905476"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.194856, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.12165", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PODD", "relevance_score": "0.779232", "ticker_sentiment_score": "0.146484", "ticker_sentiment_label": "Neutral"}]}, {"title": "Cardinal Health  ( CAH )  Beats on Q1 Earnings, Ups '24 EPS View", "url": "https://www.zacks.com/stock/news/2178192/cardinal-health-cah-beats-on-q1-earnings-ups-24-eps-view", "time_published": "20231103T133500", "authors": ["Zacks Equity Research"], "summary": "Cardinal Health's (CAH) first-quarter fiscal 2024 results benefit from the Pharmaceutical segment's solid performance.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5d/41051.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.99999"}], "overall_sentiment_score": 0.211913, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ABT", "relevance_score": "0.113329", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAH", "relevance_score": "0.431371", "ticker_sentiment_score": "0.502662", "ticker_sentiment_label": "Bullish"}, {"ticker": "ITGR", "relevance_score": "0.224383", "ticker_sentiment_score": "0.133528", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.224383", "ticker_sentiment_score": "0.081096", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stryker  ( SYK )  Q3 Earnings Beat on Strong Segmental Result", "url": "https://www.zacks.com/stock/news/2178190/stryker-syk-q3-earnings-beat-on-strong-segmental-result", "time_published": "20231103T133400", "authors": ["Zacks Equity Research"], "summary": "Stryker's (SYK) third-quarter earnings reflect strong performance across its segments and geographies. However, unfavorable currency movement hurts sales growth, and rising costs affect margins.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/66/49902.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.999981"}], "overall_sentiment_score": 0.234452, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ABT", "relevance_score": "0.104683", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITGR", "relevance_score": "0.207571", "ticker_sentiment_score": "0.124024", "ticker_sentiment_label": "Neutral"}, {"ticker": "SYK", "relevance_score": "0.489394", "ticker_sentiment_score": "0.483734", "ticker_sentiment_label": "Bullish"}, {"ticker": "DXCM", "relevance_score": "0.207571", "ticker_sentiment_score": "0.074655", "ticker_sentiment_label": "Neutral"}]}, {"title": "Fresenius Medical  ( FMS )  Q3 Earnings Miss, Operating Margin Up", "url": "https://www.zacks.com/stock/news/2178191/fresenius-medical-fms-q3-earnings-miss-operating-margin-up", "time_published": "20231103T133400", "authors": ["Zacks Equity Research"], "summary": "Fresenius Medical's (FMS) third-quarter revenues suffer due to unfavorable currency movement. However, the company's transformational plans continue to benefit its operating income.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3a/51481.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.999691"}, {"topic": "Economy - Macro", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.219941, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ABT", "relevance_score": "0.083541", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "FSNUF", "relevance_score": "0.246999", "ticker_sentiment_score": "0.205537", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ITGR", "relevance_score": "0.166169", "ticker_sentiment_score": "0.106858", "ticker_sentiment_label": "Neutral"}, {"ticker": "FMS", "relevance_score": "0.325208", "ticker_sentiment_score": "0.24026", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.166169", "ticker_sentiment_score": "0.064795", "ticker_sentiment_label": "Neutral"}]}, {"title": "Prestige Consumer  ( PBH )  Q2 Revenues Top, Margins Expand", "url": "https://www.zacks.com/stock/news/2177869/prestige-consumer-pbh-q2-revenues-top-margins-expand", "time_published": "20231103T115700", "authors": ["Zacks Equity Research"], "summary": "Prestige Consumer's (PBH) second-quarter fiscal 2024 results benefit from a diverse brand portfolio and broad distribution.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/dd/52606.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999999"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.838487"}], "overall_sentiment_score": 0.106138, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MEDP", "relevance_score": "0.16171", "ticker_sentiment_score": "0.022931", "ticker_sentiment_label": "Neutral"}, {"ticker": "ENSG", "relevance_score": "0.16171", "ticker_sentiment_score": "0.022934", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.16171", "ticker_sentiment_score": "0.053911", "ticker_sentiment_label": "Neutral"}, {"ticker": "PBH", "relevance_score": "0.279015", "ticker_sentiment_score": "0.11817", "ticker_sentiment_label": "Neutral"}]}, {"title": "Omnicell  ( OMCL )  Q3 Earnings and Revenues Beat, Margins Down", "url": "https://www.zacks.com/stock/news/2177863/omnicell-omcl-q3-earnings-and-revenues-beat-margins-down", "time_published": "20231103T115200", "authors": ["Zacks Equity Research"], "summary": "Omnicell's (OMCL) third-quarter 2023 results reflect operational discipline in a weak demand environment.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/66/49902.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}, {"topic": "Earnings", "relevance_score": "0.999996"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.061091, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MEDP", "relevance_score": "0.184246", "ticker_sentiment_score": "0.025118", "ticker_sentiment_label": "Neutral"}, {"ticker": "OMCL", "relevance_score": "0.439786", "ticker_sentiment_score": "0.119273", "ticker_sentiment_label": "Neutral"}, {"ticker": "ENSG", "relevance_score": "0.184246", "ticker_sentiment_score": "0.025128", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.184246", "ticker_sentiment_score": "0.022111", "ticker_sentiment_label": "Neutral"}]}, {"title": "If You Invested $100 In This Stock 10 Years Ago, You Would Have $1,300 Today - DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/news/23/11/35572255/if-you-invested-100-in-this-stock-10-years-ago-you-would-have-1-300-today", "time_published": "20231102T180020", "authors": ["Benzinga Insights"], "summary": "DexCom DXCM has outperformed the market over the past 10 years by 20.9% on an annualized basis producing an average annual return of 30.18%. Currently, DexCom has a market capitalization of $36.77 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.983605", "ticker_sentiment_score": "0.387251", "ticker_sentiment_label": "Bullish"}]}, {"title": "Avanos  ( AVNS )  Q3 Earnings Top Estimates, Margins Contract", "url": "https://www.zacks.com/stock/news/2177569/avanos-avns-q3-earnings-top-estimates-margins-contract", "time_published": "20231102T162500", "authors": ["Zacks Equity Research"], "summary": "Despite strength in Avanos' (AVNS) Digestive Health segment, its overall third-quarter results reflect soft performances.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/dd/52606.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.650727"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.999966"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.050678, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ABT", "relevance_score": "0.081691", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVNS", "relevance_score": "0.162528", "ticker_sentiment_score": "0.067855", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITGR", "relevance_score": "0.162528", "ticker_sentiment_score": "0.024393", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.162528", "ticker_sentiment_score": "0.024389", "ticker_sentiment_label": "Neutral"}]}, {"title": "QuidelOrtho  ( QDEL )  Q3 Earnings Top Estimates, Margins Down", "url": "https://www.zacks.com/stock/news/2177567/quidelortho-qdel-q3-earnings-top-estimates-margins-down", "time_published": "20231102T162200", "authors": ["Zacks Equity Research"], "summary": "Despite solid performances by the Labs and TM segments and China and Other regions, QuidelOrtho (QDEL) reports soft overall top-line results in third-quarter 2023.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/01/36484.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.999981"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": -0.004765, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ABT", "relevance_score": "0.072217", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITGR", "relevance_score": "0.143843", "ticker_sentiment_score": "0.022603", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.143843", "ticker_sentiment_score": "0.0226", "ticker_sentiment_label": "Neutral"}, {"ticker": "QDEL", "relevance_score": "0.474207", "ticker_sentiment_score": "0.157009", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Why DexCom  ( DXCM )  Might be Well Poised for a Surge", "url": "https://www.zacks.com/stock/news/2177564/why-dexcom-dxcm-might-be-well-poised-for-a-surge", "time_published": "20231102T162006", "authors": ["Zacks Equity Research"], "summary": "DexCom (DXCM) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default73.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.9545"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.444127, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.612521", "ticker_sentiment_score": "0.696121", "ticker_sentiment_label": "Bullish"}]}, {"title": "Nevro  ( NVRO )  Q3 Earnings Top Estimates, FY23 Revenue View Up", "url": "https://www.zacks.com/stock/news/2177558/nevro-nvro-q3-earnings-top-estimates-fy23-revenue-view-up", "time_published": "20231102T161600", "authors": ["Zacks Equity Research"], "summary": "Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in the third quarter, owing to robust domestic performance.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/29/44156.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.996718"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.078684, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVRO", "relevance_score": "0.480429", "ticker_sentiment_score": "0.034716", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABT", "relevance_score": "0.085476", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITGR", "relevance_score": "0.169975", "ticker_sentiment_score": "0.025146", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.169975", "ticker_sentiment_score": "0.025142", "ticker_sentiment_label": "Neutral"}]}, {"title": "Cencora  ( COR )  Q4 Earnings Top, GLP-1 Drugs Boost Sales", "url": "https://www.zacks.com/stock/news/2177583/cencora-cor-q4-earnings-top-glp-1-drugs-boost-sales", "time_published": "20231102T154300", "authors": ["Zacks Equity Research"], "summary": "Cencora's (COR) fourth-quarter fiscal 2023 results benefit from overall market growth, including rising demand for GLP-1 drugs approved for diabetes and weight loss. Inflationary pressure remains.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5d/41051.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.99994"}, {"topic": "Real Estate & Construction", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.258815, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ABT", "relevance_score": "0.088147", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITGR", "relevance_score": "0.175221", "ticker_sentiment_score": "0.1094", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.175221", "ticker_sentiment_score": "0.065797", "ticker_sentiment_label": "Neutral"}, {"ticker": "COR", "relevance_score": "0.561606", "ticker_sentiment_score": "0.417419", "ticker_sentiment_label": "Bullish"}]}, {"title": "Baxter  ( BAX )  Beats on Q3 Earnings, Divests BioPharma Business", "url": "https://www.zacks.com/stock/news/2177513/baxter-bax-beats-on-q3-earnings-divests-biopharma-business", "time_published": "20231102T145600", "authors": ["Zacks Equity Research"], "summary": "Baxter (BAX) reports better-than-expected third-quarter earnings and sales. The company completes the divestment of its BioPharma Solution business. It starts reporting under a new operating model.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/95/42646.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.999995"}], "overall_sentiment_score": 0.109982, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BAX", "relevance_score": "0.393462", "ticker_sentiment_score": "0.064856", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABT", "relevance_score": "0.068404", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITGR", "relevance_score": "0.136306", "ticker_sentiment_score": "0.093687", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.136306", "ticker_sentiment_score": "0.056321", "ticker_sentiment_label": "Neutral"}]}, {"title": "DENTSPLY SIRONA  ( XRAY )  Beats on Q3 Earnings, Lowers '23 Guidance", "url": "https://www.zacks.com/stock/news/2177511/dentsply-sirona-xray-beats-on-q3-earnings-lowers-23-guidance", "time_published": "20231102T145400", "authors": ["Zacks Equity Research"], "summary": "DENTSPLY SIRONA's (XRAY) Q3 revenues are driven by a rise in demand for aligners and CAD/CAM in the United States and a recovery in demand in China. Challenging macro headwinds linger.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3a/51481.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.999986"}], "overall_sentiment_score": 0.112424, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ABT", "relevance_score": "0.073209", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "XRAY", "relevance_score": "0.320742", "ticker_sentiment_score": "0.146308", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITGR", "relevance_score": "0.145804", "ticker_sentiment_score": "0.098484", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.145804", "ticker_sentiment_score": "0.059702", "ticker_sentiment_label": "Neutral"}]}, {"title": "Glaukos  ( GKOS )  Q3 Earnings Beat Estimates, Revenues Rise Y/Y", "url": "https://www.zacks.com/stock/news/2177492/glaukos-gkos-q3-earnings-beat-estimates-revenues-rise-yy", "time_published": "20231102T143400", "authors": ["Zacks Equity Research"], "summary": "Glaukos' (GKOS) third-quarter revenues beat estimates but fall year over year. Sales and gross margin improve, while higher operating expenses lead to a wider operating loss.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/69/45495.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.995015"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.095122, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GKOS", "relevance_score": "0.570165", "ticker_sentiment_score": "0.155094", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABT", "relevance_score": "0.114137", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITGR", "relevance_score": "0.22595", "ticker_sentiment_score": "0.134268", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.22595", "ticker_sentiment_score": "0.08155", "ticker_sentiment_label": "Neutral"}]}, {"title": "McKesson  ( MCK )  Beats on Q2 Earnings, Raises '23 EPS View", "url": "https://www.zacks.com/stock/news/2177488/mckesson-mck-beats-on-q2-earnings-raises-23-eps-view", "time_published": "20231102T143200", "authors": ["Zacks Equity Research"], "summary": "McKesson's (MCK) second-quarter fiscal 2024 results benefit from growth in the United States. Divestment hurts the International segment.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3a/51481.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.999986"}], "overall_sentiment_score": 0.178091, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "RADCQ", "relevance_score": "0.045396", "ticker_sentiment_score": "-0.227409", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ABT", "relevance_score": "0.090645", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITGR", "relevance_score": "0.180124", "ticker_sentiment_score": "0.111557", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCK", "relevance_score": "0.309725", "ticker_sentiment_score": "0.338279", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.180124", "ticker_sentiment_score": "0.067101", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Growth Stocks That Could Help Set You Up for Life", "url": "https://www.fool.com/investing/2023/11/02/2-growth-stocks-that-could-help-set-you-up-for-lif/", "time_published": "20231102T135734", "authors": ["Rachel Warren"], "summary": "These businesses have more beneath the surface than what their share prices might indicate.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.77141"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.977154"}], "overall_sentiment_score": 0.124534, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ETSY", "relevance_score": "0.457794", "ticker_sentiment_score": "0.015124", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.16099", "ticker_sentiment_score": "0.101993", "ticker_sentiment_label": "Neutral"}]}, {"title": "Wall Street Analysts Think DexCom  ( DXCM )  Could Surge 36.81%: Read This Before Placing a Bet", "url": "https://www.zacks.com/stock/news/2177300/wall-street-analysts-think-dexcom-dxcm-could-surge-3681-read-this-before-placing-a-bet", "time_published": "20231102T135515", "authors": ["Zacks Equity Research"], "summary": "The average of price targets set by Wall Street analysts indicates a potential upside of 36.8% in DexCom (DXCM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default201.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.795202"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.5855"}], "overall_sentiment_score": 0.258337, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.290952", "ticker_sentiment_score": "0.363113", "ticker_sentiment_label": "Bullish"}]}, {"title": "DexCom  ( DXCM )  Just Reclaimed the 50-Day Moving Average", "url": "https://www.zacks.com/stock/news/2177214/dexcom-dxcm-just-reclaimed-the-50-day-moving-average", "time_published": "20231102T133004", "authors": ["Zacks Equity Research"], "summary": "Good things could be on the horizon when a stock surpasses the 50-Day simple moving average. How should investors react?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default167.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.296671, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.885652", "ticker_sentiment_score": "0.565341", "ticker_sentiment_label": "Bullish"}]}, {"title": "Tandem Diabetes  ( TNDM )  Posts Wider Q3 Loss, Trims '23 Sales View", "url": "https://www.zacks.com/stock/news/2177038/tandem-diabetes-tndm-posts-wider-q3-loss-trims-23-sales-view", "time_published": "20231102T115900", "authors": ["Zacks Equity Research"], "summary": "Tandem Diabetes (TNDM) reports a higher-than-anticipated loss in the third quarter of 2023.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/6e/54381.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.021432, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MEDP", "relevance_score": "0.193078", "ticker_sentiment_score": "0.026017", "ticker_sentiment_label": "Neutral"}, {"ticker": "TNDM", "relevance_score": "0.240014", "ticker_sentiment_score": "-0.121923", "ticker_sentiment_label": "Neutral"}, {"ticker": "ENSG", "relevance_score": "0.193078", "ticker_sentiment_score": "0.026021", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.193078", "ticker_sentiment_score": "0.061149", "ticker_sentiment_label": "Neutral"}]}, {"title": "DexCom Unusual Options Activity - DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/markets/options/23/11/35542110/dexcom-unusual-options-activity", "time_published": "20231101T160107", "authors": ["Benzinga Insights"], "summary": "Someone with a lot of money to spend has taken a bullish stance on DexCom DXCM. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.185058, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.764287", "ticker_sentiment_score": "0.207851", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JPM", "relevance_score": "0.09439", "ticker_sentiment_score": "-0.12791", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.09439", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Analyzing DexCom In Comparison To Competitors In Health Care Equipment & Supplies Industry - DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/news/23/11/35542089/analyzing-dexcom-in-comparison-to-competitors-in-health-care-equipment-amp-supplies-industry", "time_published": "20231101T160059", "authors": ["Benzinga Insights"], "summary": "In today's fast-paced and highly competitive business world, it is crucial for investors and industry followers to conduct comprehensive company evaluations. In this article, we will delve into an extensive industry comparison, evaluating DexCom DXCM in relation to its major competitors in the ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.928769"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.623304"}], "overall_sentiment_score": 0.259324, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.598255", "ticker_sentiment_score": "0.460926", "ticker_sentiment_label": "Bullish"}, {"ticker": "PODD", "relevance_score": "0.07423", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Reasons Growth Investors Will Love DexCom  ( DXCM ) ", "url": "https://www.zacks.com/stock/news/2175776/3-reasons-growth-investors-will-love-dexcom-dxcm", "time_published": "20231031T164507", "authors": ["Zacks Equity Research"], "summary": "DexCom (DXCM) is well positioned to outperform the market, as it exhibits above-average growth in financials.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default128.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.983783"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.466898, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.510302", "ticker_sentiment_score": "0.442766", "ticker_sentiment_label": "Bullish"}]}, {"title": "What Makes DexCom  ( DXCM )  a New Buy Stock", "url": "https://www.zacks.com/stock/news/2175733/what-makes-dexcom-dxcm-a-new-buy-stock", "time_published": "20231031T160005", "authors": ["Zacks Equity Research"], "summary": "DexCom (DXCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default67.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.997845"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.692272"}], "overall_sentiment_score": 0.299262, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.366061", "ticker_sentiment_score": "0.310197", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Ensign Group  ( ENSG )  Q3 Earnings Beat on Occupancy, Stock Up 2.4%", "url": "https://www.zacks.com/stock/news/2174775/ensign-group-ensg-q3-earnings-beat-on-occupancy-stock-up-24", "time_published": "20231030T155200", "authors": ["Zacks Equity Research"], "summary": "Ensign Group's (ENSG) third-quarter results benefit on solid segmental contribution and occupancy strength. Management currently expects adjusted EPS to be within $4.73-$4.79 for 2023.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}, {"topic": "Earnings", "relevance_score": "0.999819"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.193797, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "EHC", "relevance_score": "0.203729", "ticker_sentiment_score": "0.152039", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MMSI", "relevance_score": "0.123104", "ticker_sentiment_score": "0.057053", "ticker_sentiment_label": "Neutral"}, {"ticker": "ENSG", "relevance_score": "0.357865", "ticker_sentiment_score": "0.267607", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.163631", "ticker_sentiment_score": "0.078896", "ticker_sentiment_label": "Neutral"}]}, {"title": "Barron's Weekend Stock Picks: Verizon, VF Corp And Altria's Dividend Yield - First Citizens BancShares  ( NASDAQ:FCNCA ) , DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/news/23/10/35479457/barrons-weekend-stock-picks-verizon-vf-corp-and-altrias-dividend-yield", "time_published": "20231029T000425", "authors": ["Justin Chan"], "summary": "Benzinga reviews this weekend's top stories covered by Barron's. Here are the articles investors need to read. In \"Verizon Stock Is Having Its Best Week Since January.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/28/shutterstock_1761572375.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.999922"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.576289"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.14951, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SSTK", "relevance_score": "0.11983", "ticker_sentiment_score": "0.140534", "ticker_sentiment_label": "Neutral"}, {"ticker": "MO", "relevance_score": "0.348919", "ticker_sentiment_score": "-0.388346", "ticker_sentiment_label": "Bearish"}, {"ticker": "VFC", "relevance_score": "0.348919", "ticker_sentiment_score": "-0.29794", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "VZ", "relevance_score": "0.348919", "ticker_sentiment_score": "0.532294", "ticker_sentiment_label": "Bullish"}, {"ticker": "CZBS", "relevance_score": "0.11983", "ticker_sentiment_score": "0.19524", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FIZN", "relevance_score": "0.11983", "ticker_sentiment_score": "0.19524", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.348919", "ticker_sentiment_score": "0.394673", "ticker_sentiment_label": "Bullish"}]}, {"title": "Stock Market Mixed With The Nasdaq Slightly Ahead; Indexes Have A Rough October", "url": "https://www.investors.com/market-trend/stock-market-today/stock-market-mixed-with-the-nasdaq-slightly-ahead-indexes-have-rough-october/", "time_published": "20231027T191900", "authors": ["Investor's Business Daily", "KIMBERLEY KOENIG"], "summary": "Stock Market Mixed With The Nasdaq Slightly Ahead. Indexes Have ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2019/05/AdobeStock_89594175.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.95493"}], "overall_sentiment_score": -0.002423, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CVX", "relevance_score": "0.216215", "ticker_sentiment_score": "-0.226338", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "INTC", "relevance_score": "0.216215", "ticker_sentiment_score": "0.151418", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "XOM", "relevance_score": "0.145145", "ticker_sentiment_score": "-0.305874", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CMG", "relevance_score": "0.216215", "ticker_sentiment_score": "0.343223", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IVZ", "relevance_score": "0.072876", "ticker_sentiment_score": "0.048951", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.216215", "ticker_sentiment_score": "-0.010244", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.285526", "ticker_sentiment_score": "0.124345", "ticker_sentiment_label": "Neutral"}]}, {"title": "MedTech Giant DexCom Spotlight Is On G7 US Launch, Analyst Forecasts 22% Revenue Gain In 2024 - DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/analyst-ratings/analyst-color/23/10/35468867/medtech-giant-dexcom-spotlight-is-on-g7-us-launch-analyst-forecasts-22-revenue-gain", "time_published": "20231027T181550", "authors": ["Nabaparna Bhattacharya"], "summary": "Oppenheimer analyst Steven Lichtman reiterated the Outperform rating on DexCom, Inc. DXCM, with a reduced price target of $122 from $150. With an underpenetrated patient population and robust pipeline, Lichtman forecasts strong sales growth over the next several years for DexCom.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/27/dxcm.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.290151, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.685386", "ticker_sentiment_score": "0.645423", "ticker_sentiment_label": "Bullish"}, {"ticker": "ABT", "relevance_score": "0.262522", "ticker_sentiment_score": "0.063564", "ticker_sentiment_label": "Neutral"}]}, {"title": "Chipotle, Amazon, Deckers Outdoor, Capital One And Other Stocks Move Higher On Friday - AppFolio  ( NASDAQ:APPF ) , Amazon.com  ( NASDAQ:AMZN ) ", "url": "https://www.benzinga.com/news/23/10/35465271/chipotle-amazon-deckers-outdoor-capital-one-and-other-stocks-move-higher-on-friday", "time_published": "20231027T155700", "authors": ["Lisa Levin"], "summary": "U.S. stocks traded mixed, with the Nasdaq Composite gaining more than 100 points on Friday. Here are some big stocks recording gains in today's session. NerdWallet, Inc. NRDS shares rose 27.7% to $8.48 following strong quarterly results. ImmunityBio, Inc.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/27/chipotle_mexican_grill_-_logo.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Earnings", "relevance_score": "0.997335"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": 0.496684, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "MDXG", "relevance_score": "0.175221", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SWK", "relevance_score": "0.175221", "ticker_sentiment_score": "0.285617", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SWKH", "relevance_score": "0.088147", "ticker_sentiment_score": "0.211476", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "EGO", "relevance_score": "0.175221", "ticker_sentiment_score": "0.592808", "ticker_sentiment_label": "Bullish"}, {"ticker": "ARCB", "relevance_score": "0.175221", "ticker_sentiment_score": "0.592808", "ticker_sentiment_label": "Bullish"}, {"ticker": "ATGE", "relevance_score": "0.175221", "ticker_sentiment_score": "0.5696", "ticker_sentiment_label": "Bullish"}, {"ticker": "SKYW", "relevance_score": "0.175221", "ticker_sentiment_score": "0.372622", "ticker_sentiment_label": "Bullish"}, {"ticker": "TBBK", "relevance_score": "0.175221", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCM", "relevance_score": "0.175221", "ticker_sentiment_score": "-0.269043", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "FIX", "relevance_score": "0.175221", "ticker_sentiment_score": "0.34166", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DECK", "relevance_score": "0.175221", "ticker_sentiment_score": "0.377967", "ticker_sentiment_label": "Bullish"}, {"ticker": "INTC", "relevance_score": "0.175221", "ticker_sentiment_score": "0.424172", "ticker_sentiment_label": "Bullish"}, {"ticker": "PMT", "relevance_score": "0.175221", "ticker_sentiment_score": "0.607604", "ticker_sentiment_label": "Bullish"}, {"ticker": "NRDS", "relevance_score": "0.175221", "ticker_sentiment_score": "0.515512", "ticker_sentiment_label": "Bullish"}, {"ticker": "OIS", "relevance_score": "0.175221", "ticker_sentiment_score": "0.555424", "ticker_sentiment_label": "Bullish"}, {"ticker": "APPF", "relevance_score": "0.175221", "ticker_sentiment_score": "0.425477", "ticker_sentiment_label": "Bullish"}, {"ticker": "COF", "relevance_score": "0.175221", "ticker_sentiment_score": "0.328084", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CMG", "relevance_score": "0.175221", "ticker_sentiment_score": "0.328084", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IBRX", "relevance_score": "0.175221", "ticker_sentiment_score": "0.107992", "ticker_sentiment_label": "Neutral"}, {"ticker": "TXRH", "relevance_score": "0.175221", "ticker_sentiment_score": "0.607604", "ticker_sentiment_label": "Bullish"}, {"ticker": "DXCM", "relevance_score": "0.175221", "ticker_sentiment_score": "0.217563", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MBIN", "relevance_score": "0.175221", "ticker_sentiment_score": "0.469252", "ticker_sentiment_label": "Bullish"}]}, {"title": "Why DexCom Inc Stock Is Trading Higher After Earnings - DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/news/23/10/35466724/why-dexcom-inc-stock-is-trading-higher-after-earnings", "time_published": "20231027T153258", "authors": ["Erica Kollmann"], "summary": "DexCom, Inc. DXCM shares are trading higher Friday after the company reported strong third-quarter results and announced a $500 million buyback. DexCom reported its third-quarter financial results after the market close on Thursday.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/27/dexcom_inc_shares_dxcm_stock_higher_earnings_.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Earnings", "relevance_score": "0.818451"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.345564, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.967875", "ticker_sentiment_score": "0.618961", "ticker_sentiment_label": "Bullish"}, {"ticker": "MS", "relevance_score": "0.169676", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dow Dives But Magnificent Seven Reverse Higher; Buffett's Berkshire Slammed With Lawsuit", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-rises-after-chip-giants-beat-and-raise-report-warren-buffetts-berkshire-slammed-amid-haslams-law-suit/", "time_published": "20231027T150800", "authors": ["Investor's Business Daily", "VIDYA RAMAKRISHNAN"], "summary": "Indexes Mixed After Intel's Beat And Raise Report. Buffett's ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/10/Stock-Intel-NoyceBldg-company.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Economy - Fiscal", "relevance_score": "0.310843"}, {"topic": "Financial Markets", "relevance_score": "0.999995"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.999594"}], "overall_sentiment_score": 0.031452, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AON", "relevance_score": "0.095327", "ticker_sentiment_score": "0.038497", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.047749", "ticker_sentiment_score": "0.042999", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.142565", "ticker_sentiment_score": "0.006601", "ticker_sentiment_label": "Neutral"}, {"ticker": "CVX", "relevance_score": "0.095327", "ticker_sentiment_score": "-0.308215", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "INTC", "relevance_score": "0.235366", "ticker_sentiment_score": "0.030773", "ticker_sentiment_label": "Neutral"}, {"ticker": "BRK-A", "relevance_score": "0.047749", "ticker_sentiment_score": "-0.225793", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "DXCM", "relevance_score": "0.189298", "ticker_sentiment_score": "0.073029", "ticker_sentiment_label": "Neutral"}, {"ticker": "KNSL", "relevance_score": "0.095327", "ticker_sentiment_score": "0.038497", "ticker_sentiment_label": "Neutral"}]}, {"title": "Diabetes stocks jump as obesity-drug recovery comes ahead of schedule, analysts say", "url": "https://www.marketwatch.com/story/diabetes-stocks-jump-as-obesity-drug-recovery-comes-ahead-of-schedule-analysts-say-11e9d470", "time_published": "20231027T130000", "authors": ["Eleanor Laise"], "summary": "DexCom's strong quarterly results give device makers a boost.", "banner_image": "https://images.mktw.net/im-852331/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}], "overall_sentiment_score": 0.197242, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "TNDM", "relevance_score": "0.202366", "ticker_sentiment_score": "0.355536", "ticker_sentiment_label": "Bullish"}, {"ticker": "DXCM", "relevance_score": "0.800175", "ticker_sentiment_score": "0.407799", "ticker_sentiment_label": "Bullish"}, {"ticker": "PODD", "relevance_score": "0.391923", "ticker_sentiment_score": "0.213962", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "3 Revolutionary Stocks I'd Buy Right Now Without Hesitation", "url": "https://www.fool.com/investing/2023/10/27/3-revolutionary-stocks-id-buy-without-hesitation/", "time_published": "20231027T130000", "authors": ["Rachel Warren"], "summary": "These businesses are in widely disparate industries, but each has a growth story poised for long-term investor gains.", "banner_image": "https://g.foolcdn.com/editorial/images/752114/happy-young-man-with-smart-phone-at-night.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}, {"topic": "Earnings", "relevance_score": "0.918141"}], "overall_sentiment_score": 0.217587, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMZN", "relevance_score": "0.285526", "ticker_sentiment_score": "0.211824", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.285526", "ticker_sentiment_score": "0.245704", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABNB", "relevance_score": "0.180866", "ticker_sentiment_score": "0.112756", "ticker_sentiment_label": "Neutral"}]}, {"title": "Weight-Loss Beating Continues For Devices Makers; Why It's Overdone", "url": "https://www.investors.com/news/technology/weight-loss-drugs-spook-medical-device-stocks-an-overreaction/", "time_published": "20231027T130000", "authors": ["ALLISON GATLIN", "Investor's Business Daily"], "summary": "Weight-Loss Drugs Spooked Medical Device Stocks. Did Investors ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/10/IT2c103023-300x171.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.997405"}, {"topic": "Earnings", "relevance_score": "0.538269"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.093424, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "INSP", "relevance_score": "0.034907", "ticker_sentiment_score": "-0.017925", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZBH", "relevance_score": "0.034907", "ticker_sentiment_score": "0.125221", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.017458", "ticker_sentiment_score": "-0.108231", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.087122", "ticker_sentiment_score": "0.080517", "ticker_sentiment_label": "Neutral"}, {"ticker": "RMD", "relevance_score": "0.034907", "ticker_sentiment_score": "0.125221", "ticker_sentiment_label": "Neutral"}, {"ticker": "MASI", "relevance_score": "0.034907", "ticker_sentiment_score": "0.23697", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.034907", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DVA", "relevance_score": "0.087122", "ticker_sentiment_score": "0.002112", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.034907", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "EW", "relevance_score": "0.034907", "ticker_sentiment_score": "0.23697", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FSNUF", "relevance_score": "0.017458", "ticker_sentiment_score": "0.047327", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.069748", "ticker_sentiment_score": "0.111489", "ticker_sentiment_label": "Neutral"}, {"ticker": "PODD", "relevance_score": "0.034907", "ticker_sentiment_score": "0.099119", "ticker_sentiment_label": "Neutral"}, {"ticker": "SLNO", "relevance_score": "0.017458", "ticker_sentiment_score": "0.014131", "ticker_sentiment_label": "Neutral"}, {"ticker": "ISRG", "relevance_score": "0.05234", "ticker_sentiment_score": "0.026937", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.121738", "ticker_sentiment_score": "0.072049", "ticker_sentiment_label": "Neutral"}]}, {"title": "Futures Mixed Ahead Of Key Inflation Data", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-key-inflation-data-amazon-stock-surges-on-earnings/", "time_published": "20231027T115700", "authors": ["SCOTT LEHTONEN", "Investor's Business Daily"], "summary": "Dow Jones Futures Fall Ahead Of Key Inflation Data. Amazon Stock ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2017/04/stock-wallstreet-shutter.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Economy - Fiscal", "relevance_score": "0.310843"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.857896"}], "overall_sentiment_score": 0.186426, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NVDA", "relevance_score": "0.074115", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.147592", "ticker_sentiment_score": "0.125642", "ticker_sentiment_label": "Neutral"}, {"ticker": "INSW", "relevance_score": "0.183895", "ticker_sentiment_score": "0.171419", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IVZ", "relevance_score": "0.037098", "ticker_sentiment_score": "0.185545", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "UNH", "relevance_score": "0.147592", "ticker_sentiment_score": "0.088679", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.147592", "ticker_sentiment_score": "0.125642", "ticker_sentiment_label": "Neutral"}, {"ticker": "LULU", "relevance_score": "0.110973", "ticker_sentiment_score": "0.096597", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.110973", "ticker_sentiment_score": "0.109025", "ticker_sentiment_label": "Neutral"}, {"ticker": "LNW", "relevance_score": "0.183895", "ticker_sentiment_score": "0.168515", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DECK", "relevance_score": "0.074115", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "INTC", "relevance_score": "0.110973", "ticker_sentiment_score": "0.110954", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMG", "relevance_score": "0.110973", "ticker_sentiment_score": "0.110954", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.110973", "ticker_sentiment_score": "0.058524", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.110973", "ticker_sentiment_score": "0.110954", "ticker_sentiment_label": "Neutral"}, {"ticker": "WMT", "relevance_score": "0.147592", "ticker_sentiment_score": "0.088691", "ticker_sentiment_label": "Neutral"}]}, {"title": "DexCom  ( DXCM )  Beats on Q3 Earnings, Raises Sales Outlook", "url": "https://www.zacks.com/stock/news/2173560/dexcom-dxcm-beats-on-q3-earnings-raises-sales-outlook", "time_published": "20231027T113000", "authors": ["Zacks Equity Research"], "summary": "DexCom's (DXCM) third-quarter 2023 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/dd/52606.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}], "overall_sentiment_score": 0.209083, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "EW", "relevance_score": "0.182162", "ticker_sentiment_score": "0.078976", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABT", "relevance_score": "0.091684", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.579839", "ticker_sentiment_score": "0.292694", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ELV", "relevance_score": "0.182162", "ticker_sentiment_score": "0.069092", "ticker_sentiment_label": "Neutral"}]}, {"title": "Nasdaq, S&P 500 Eye Rebound While Bitcoin Edges Down: Amazon's Q3 Lifts Tech Stocks As Traders Eye Fed's Favorite Inflation Gauge - Enphase Energy  ( NASDAQ:ENPH ) , Meta Platforms  ( NASDAQ:META ) , Ford Motor  ( NYSE:F ) , Colgate-Palmolive  ( NYSE:CL ) ", "url": "https://www.benzinga.com/news/earnings/23/10/35460910/nasdaq-s-p-500-eye-rebound-while-bitcoin-edges-down-amazons-q3-lifts-tech-stocks-as-traders-eye-fed", "time_published": "20231027T112017", "authors": ["Shanthi Rexaline"], "summary": "As Amazon, Inc. AMZN hawked good tidings, the negative sentiment in the equity market appears to have reversed. The recovery could be in part due to traders looking for bargains following a two-day slump seen in the market.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/Stock_Market_Broker_Analyzing_Graphs_On_Multiple_Computer_Screens._Photo_by_Andrey_Popov_on_Shutterstock_24.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Blockchain", "relevance_score": "0.158519"}, {"topic": "Economy - Monetary", "relevance_score": "0.576289"}, {"topic": "Economy - Fiscal", "relevance_score": "0.576289"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "0.99676"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.158519"}], "overall_sentiment_score": -0.041094, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ENPH", "relevance_score": "0.088147", "ticker_sentiment_score": "-0.434418", "ticker_sentiment_label": "Bearish"}, {"ticker": "META", "relevance_score": "0.088147", "ticker_sentiment_score": "-0.036583", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.088147", "ticker_sentiment_score": "-0.111535", "ticker_sentiment_label": "Neutral"}, {"ticker": "CL", "relevance_score": "0.088147", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MASI", "relevance_score": "0.088147", "ticker_sentiment_score": "-0.111535", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.044141", "ticker_sentiment_score": "0.217647", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AN", "relevance_score": "0.044141", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMA", "relevance_score": "0.044141", "ticker_sentiment_score": "-0.011862", "ticker_sentiment_label": "Neutral"}, {"ticker": "INTC", "relevance_score": "0.088147", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "XOM", "relevance_score": "0.088147", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CHTR", "relevance_score": "0.088147", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.131884", "ticker_sentiment_score": "-0.067182", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.088147", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.088147", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:JPY", "relevance_score": "0.044141", "ticker_sentiment_score": "0.025892", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:EUR", "relevance_score": "0.044141", "ticker_sentiment_score": "0.025892", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:USD", "relevance_score": "0.088147", "ticker_sentiment_score": "0.027484", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.088147", "ticker_sentiment_score": "0.027484", "ticker_sentiment_label": "Neutral"}]}, {"title": "Shares of Amazon, Intel climb after earnings beats, as NatWest and Sanofi tumble on warnings, and other stocks on the move", "url": "https://www.marketwatch.com/story/shares-of-amazon-intel-climb-after-earnings-beats-as-natwest-and-sanofi-tumble-on-warnings-and-other-stocks-on-the-move-0451fbda", "time_published": "20231027T093300", "authors": ["MarketWatch"], "summary": "Shares in Amazon, NatWest, Intel, Sanofi, Decker, Ford, DexCom, and Enphase were all active in pre-market trading ...", "banner_image": "https://images.mktw.net/im-876690/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.744043"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.131108, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ENPH", "relevance_score": "0.31282", "ticker_sentiment_score": "-0.149197", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.31282", "ticker_sentiment_score": "0.484795", "ticker_sentiment_label": "Bullish"}, {"ticker": "F", "relevance_score": "0.31282", "ticker_sentiment_score": "0.458568", "ticker_sentiment_label": "Bullish"}, {"ticker": "INTC", "relevance_score": "0.31282", "ticker_sentiment_score": "0.262262", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NWG", "relevance_score": "0.31282", "ticker_sentiment_score": "-0.420607", "ticker_sentiment_label": "Bearish"}, {"ticker": "SNY", "relevance_score": "0.31282", "ticker_sentiment_score": "-0.06078", "ticker_sentiment_label": "Neutral"}]}, {"title": "DexCom  ( DXCM )  Q3 2023 Earnings Call Transcript", "url": "https://www.fool.com/earnings/call-transcripts/2023/10/26/dexcom-dxcm-q3-2023-earnings-call-transcript/", "time_published": "20231027T020020", "authors": ["Motley Fool Transcribing"], "summary": "DXCM earnings call for the period ending September 30, 2023.", "banner_image": "https://g.foolcdn.com/misc-assets/fool-transcripts-logo.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.961735"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.360215"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.288092, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BCS", "relevance_score": "0.004725", "ticker_sentiment_score": "0.14035", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.004725", "ticker_sentiment_score": "0.14035", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.004725", "ticker_sentiment_score": "0.14035", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.136353", "ticker_sentiment_score": "0.183303", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JPM", "relevance_score": "0.004725", "ticker_sentiment_score": "0.14035", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:UZS", "relevance_score": "0.004725", "ticker_sentiment_score": "0.178951", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "DexCom  ( DXCM )  Q3 Earnings and Revenues Surpass Estimates", "url": "https://www.zacks.com/stock/news/2173147/dexcom-dxcm-q3-earnings-and-revenues-surpass-estimates", "time_published": "20231026T213014", "authors": ["Zacks Equity Research"], "summary": "DexCom (DXCM) delivered earnings and revenue surprises of 47.06% and 4.02%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default90.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999992"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.15305, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NMRD", "relevance_score": "0.210579", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.406745", "ticker_sentiment_score": "0.147248", "ticker_sentiment_label": "Neutral"}]}, {"title": "Medical Device Maker DexCom Stock Rises On Q3 Performance - Raises FY23 Outlook, Announces Stock Buyback - DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/news/earnings/23/10/35452909/medical-device-maker-dexcom-stock-rises-on-q3-performance-raises-fy23-outlook-announces-stock-buyba", "time_published": "20231026T211857", "authors": ["Ryan Gustafson"], "summary": "DexCom, Inc. DXCM shares are trading higher in Thursday's after-hours session on the heels of the company's third-quarter earnings. Here's what happened. What To Know: DexCom reported earnings of 50 cents per share, which beat the estimate of 34 cents.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/26/medical-563427_12802.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.938793"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.425083, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.948969", "ticker_sentiment_score": "0.680674", "ticker_sentiment_label": "Bullish"}]}, {"title": "Dexcom Shrugs Off Pressure From Weight-Loss Drugs, Boosts 2023 Outlook", "url": "https://www.investors.com/news/technology/dxcm-stock-dexcom-earnings-q3-2023/", "time_published": "20231026T201800", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "DXCM Stock Pops 10% After Besting Forecasts And Boosting Its ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/03/Stock-dexcom-one-04-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.962106"}], "overall_sentiment_score": 0.184809, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BSX", "relevance_score": "0.233556", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.962402", "ticker_sentiment_score": "0.321872", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "EW", "relevance_score": "0.233556", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "This Is What Whales Are Betting On DexCom - DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/markets/options/23/10/35449619/this-is-what-whales-are-betting-on-dexcom", "time_published": "20231026T193149", "authors": ["Benzinga Insights"], "summary": "A whale with a lot of money to spend has taken a noticeably bullish stance on DexCom. Looking at options history for DexCom DXCM we detected 25 strange trades. If we consider the specifics of each trade, it is accurate to state that 64% of the investors opened trades with bullish expectations ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.129343, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.874135", "ticker_sentiment_score": "0.254236", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JPM", "relevance_score": "0.12165", "ticker_sentiment_score": "-0.139143", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.12165", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Best Healthcare Stocks to Buy Right Now", "url": "https://www.fool.com/investing/2023/10/26/2-best-healthcare-stocks-to-buy-right-now/", "time_published": "20231026T131500", "authors": ["Rachel Warren"], "summary": "The healthcare industry is an explosive space full of promising, profitable companies.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.538269"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.192651, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.113329", "ticker_sentiment_score": "0.194721", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.169279", "ticker_sentiment_score": "0.224401", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "MedTech Stocks to Watch for Earnings on Oct 26: WST, DXCM & More", "url": "https://www.zacks.com/stock/news/2171804/medtech-stocks-to-watch-for-earnings-on-oct-26-wst-dxcm-more", "time_published": "20231025T142100", "authors": ["Debanjana Dey"], "summary": "MedTech companies' Q3 results are likely to reflect strength in customer demand. Let's see how WST, DXCM, MMSI and ITGR are placed ahead of their earnings releases.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/dd/52606.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.21033, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CURN", "relevance_score": "0.0362", "ticker_sentiment_score": "0.074987", "ticker_sentiment_label": "Neutral"}, {"ticker": "WST", "relevance_score": "0.21462", "ticker_sentiment_score": "0.141298", "ticker_sentiment_label": "Neutral"}, {"ticker": "MMSI", "relevance_score": "0.179521", "ticker_sentiment_score": "0.134193", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITGR", "relevance_score": "0.249288", "ticker_sentiment_score": "0.227718", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.249288", "ticker_sentiment_score": "0.306885", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings", "url": "https://www.zacks.com/stock/news/2171383/want-better-returns-dont-ignore-these-2-medical-stocks-set-to-beat-earnings", "time_published": "20231025T125011", "authors": ["Zacks Equity Research"], "summary": "Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default288.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999682"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}], "overall_sentiment_score": 0.362652, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.335367", "ticker_sentiment_score": "0.320379", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LGND", "relevance_score": "0.271274", "ticker_sentiment_score": "0.304867", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AWON", "relevance_score": "0.069094", "ticker_sentiment_score": "0.196045", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "DexCom  ( DXCM )  to Report Q3 Earnings: Is a Beat in Store?", "url": "https://www.zacks.com/stock/news/2171438/dexcom-dxcm-to-report-q3-earnings-is-a-beat-in-store", "time_published": "20231025T121700", "authors": ["Zacks Equity Research"], "summary": "DexCom's (DXCM) third-quarter 2023 results are likely to reflect rising volumes across all channels.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c0/2297.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999999"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.239913, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "COO", "relevance_score": "0.112269", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "XRAY", "relevance_score": "0.112269", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVNS", "relevance_score": "0.167709", "ticker_sentiment_score": "-0.156702", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "DXCM", "relevance_score": "0.378777", "ticker_sentiment_score": "0.270118", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Stocks to own ahead of a rally that this $15 billion fund house says is coming soon", "url": "https://www.marketwatch.com/story/stocks-to-own-ahead-of-a-rally-that-this-15-billion-fund-house-says-is-coming-soon-adffe026", "time_published": "20231025T120700", "authors": ["Barbara Kollmeyer"], "summary": "Sit Investment Associates, Roger Sit, says a short sharp recession is coming, along with a stock rally and lots of opportunities to own names across the board.", "banner_image": "https://images.mktw.net/im-874884?width=700&height=302", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "0.972756"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Earnings", "relevance_score": "0.650727"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": 0.086559, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALK", "relevance_score": "0.071784", "ticker_sentiment_score": "0.016336", "ticker_sentiment_label": "Neutral"}, {"ticker": "J", "relevance_score": "0.071784", "ticker_sentiment_score": "0.016336", "ticker_sentiment_label": "Neutral"}, {"ticker": "TXN", "relevance_score": "0.071784", "ticker_sentiment_score": "-0.199451", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MSFT", "relevance_score": "0.107495", "ticker_sentiment_score": "0.029475", "ticker_sentiment_label": "Neutral"}, {"ticker": "HLT", "relevance_score": "0.071784", "ticker_sentiment_score": "-0.052264", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABT", "relevance_score": "0.071784", "ticker_sentiment_score": "0.136927", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.035929", "ticker_sentiment_score": "0.16218", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "KNX", "relevance_score": "0.071784", "ticker_sentiment_score": "0.016336", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTRYF", "relevance_score": "0.035929", "ticker_sentiment_score": "-0.161194", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "FDX", "relevance_score": "0.071784", "ticker_sentiment_score": "0.016336", "ticker_sentiment_label": "Neutral"}, {"ticker": "BKNG", "relevance_score": "0.071784", "ticker_sentiment_score": "0.138737", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.071784", "ticker_sentiment_score": "0.136927", "ticker_sentiment_label": "Neutral"}, {"ticker": "PANW", "relevance_score": "0.071784", "ticker_sentiment_score": "0.138737", "ticker_sentiment_label": "Neutral"}, {"ticker": "NFLX", "relevance_score": "0.035929", "ticker_sentiment_score": "0.16218", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WHR", "relevance_score": "0.071784", "ticker_sentiment_score": "-0.052264", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.035929", "ticker_sentiment_score": "0.16218", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "META", "relevance_score": "0.071784", "ticker_sentiment_score": "-0.052264", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.107495", "ticker_sentiment_score": "0.165941", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MP", "relevance_score": "0.071784", "ticker_sentiment_score": "0.136927", "ticker_sentiment_label": "Neutral"}, {"ticker": "HON", "relevance_score": "0.071784", "ticker_sentiment_score": "0.016336", "ticker_sentiment_label": "Neutral"}, {"ticker": "MOH", "relevance_score": "0.071784", "ticker_sentiment_score": "0.136927", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACN", "relevance_score": "0.071784", "ticker_sentiment_score": "0.138737", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADBE", "relevance_score": "0.071784", "ticker_sentiment_score": "0.138737", "ticker_sentiment_label": "Neutral"}, {"ticker": "PH", "relevance_score": "0.071784", "ticker_sentiment_score": "0.016336", "ticker_sentiment_label": "Neutral"}, {"ticker": "CNC", "relevance_score": "0.071784", "ticker_sentiment_score": "0.136927", "ticker_sentiment_label": "Neutral"}, {"ticker": "ATRC", "relevance_score": "0.071784", "ticker_sentiment_score": "0.136927", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.142989", "ticker_sentiment_score": "0.158804", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BA", "relevance_score": "0.071784", "ticker_sentiment_score": "-0.052264", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.071784", "ticker_sentiment_score": "-0.052264", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Coke, others, may be spared, as a $100 billion opportunity in weight loss drugs unfolds says JPMorgan", "url": "https://www.marketwatch.com/story/the-weight-loss-drugs-are-coming-for-these-companies-but-heres-why-coke-others-may-be-spared-says-jpmorgan-c6c24538", "time_published": "20231024T104200", "authors": ["Barbara Kollmeyer"], "summary": "JPMorgan says the weight-loss drug industry is now a \"$100 billion plus opportunity.\" Coke is one of the stocks they say is likely to get hit less hard.", "banner_image": "https://images.mktw.net/im-874075?width=700&height=763", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.929393"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.451494"}], "overall_sentiment_score": 0.129162, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "KO", "relevance_score": "0.126784", "ticker_sentiment_score": "0.038342", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTLT", "relevance_score": "0.084722", "ticker_sentiment_score": "0.067688", "ticker_sentiment_label": "Neutral"}, {"ticker": "GM", "relevance_score": "0.084722", "ticker_sentiment_score": "0.116945", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.126784", "ticker_sentiment_score": "0.019258", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.084722", "ticker_sentiment_score": "-0.045214", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.126784", "ticker_sentiment_score": "0.095915", "ticker_sentiment_label": "Neutral"}, {"ticker": "HPNN", "relevance_score": "0.042421", "ticker_sentiment_score": "0.243126", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TXN", "relevance_score": "0.084722", "ticker_sentiment_score": "0.116945", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVTR", "relevance_score": "0.084722", "ticker_sentiment_score": "0.067688", "ticker_sentiment_label": "Neutral"}, {"ticker": "DASH", "relevance_score": "0.084722", "ticker_sentiment_score": "0.140662", "ticker_sentiment_label": "Neutral"}, {"ticker": "DHR", "relevance_score": "0.084722", "ticker_sentiment_score": "0.067688", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.126784", "ticker_sentiment_score": "0.182706", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TSLA", "relevance_score": "0.042421", "ticker_sentiment_score": "0.243126", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "KDP", "relevance_score": "0.084722", "ticker_sentiment_score": "0.142685", "ticker_sentiment_label": "Neutral"}, {"ticker": "V", "relevance_score": "0.084722", "ticker_sentiment_score": "0.116945", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.084722", "ticker_sentiment_score": "0.083395", "ticker_sentiment_label": "Neutral"}, {"ticker": "RGEN", "relevance_score": "0.084722", "ticker_sentiment_score": "0.067688", "ticker_sentiment_label": "Neutral"}, {"ticker": "PEP", "relevance_score": "0.084722", "ticker_sentiment_score": "-0.10898", "ticker_sentiment_label": "Neutral"}, {"ticker": "PODD", "relevance_score": "0.084722", "ticker_sentiment_score": "0.211781", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SFM", "relevance_score": "0.084722", "ticker_sentiment_score": "0.142685", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBER", "relevance_score": "0.084722", "ticker_sentiment_score": "0.140662", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.084722", "ticker_sentiment_score": "0.211781", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WMT", "relevance_score": "0.084722", "ticker_sentiment_score": "-0.10898", "ticker_sentiment_label": "Neutral"}]}, {"title": "mHealth Market Size to Hit $410.39 Billion, Globally, by 2028 - Exclusive Report by The Insight Partners", "url": "https://www.benzinga.com/pressreleases/23/10/g35389192/mhealth-market-size-to-hit-410-39-billion-globally-by-2028-exclusive-report-by-the-insight-partner", "time_published": "20231024T102348", "authors": ["Globe Newswire"], "summary": "Pune, India, Oct. 24, 2023 ( GLOBE NEWSWIRE ) -- Mobile health ( mHealth ) is a technique that includes the use of mobile commination devices, such as mobile phones, tablets, PDAs ( personal digital assistants ) and other wireless devices for distributing health services and information. mHealth ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.277922, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.032164", "ticker_sentiment_score": "0.137616", "ticker_sentiment_label": "Neutral"}, {"ticker": "QEBR", "relevance_score": "0.032164", "ticker_sentiment_score": "0.103473", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.032164", "ticker_sentiment_score": "0.137616", "ticker_sentiment_label": "Neutral"}, {"ticker": "CSCO", "relevance_score": "0.032164", "ticker_sentiment_score": "0.137616", "ticker_sentiment_label": "Neutral"}, {"ticker": "BSX", "relevance_score": "0.064276", "ticker_sentiment_score": "0.140473", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCSG", "relevance_score": "0.032164", "ticker_sentiment_score": "0.103473", "ticker_sentiment_label": "Neutral"}, {"ticker": "PHG", "relevance_score": "0.032164", "ticker_sentiment_score": "0.137616", "ticker_sentiment_label": "Neutral"}, {"ticker": "SSNLF", "relevance_score": "0.032164", "ticker_sentiment_score": "0.137616", "ticker_sentiment_label": "Neutral"}, {"ticker": "QCOM", "relevance_score": "0.032164", "ticker_sentiment_score": "0.137616", "ticker_sentiment_label": "Neutral"}, {"ticker": "TMO", "relevance_score": "0.032164", "ticker_sentiment_score": "0.108912", "ticker_sentiment_label": "Neutral"}, {"ticker": "PODD", "relevance_score": "0.032164", "ticker_sentiment_score": "0.16299", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MDT", "relevance_score": "0.032164", "ticker_sentiment_score": "0.137616", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.064276", "ticker_sentiment_score": "0.171264", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "As Ozempic and Wegovy take off, this tech startup just raised $20 million to tackle weight loss with data", "url": "https://www.cnbc.com/2023/10/24/signos-raised-20-million-to-tackle-weight-loss-with-cgms-and-data.html", "time_published": "20231024T100001", "authors": ["Ashley Capoot"], "summary": "Signos, a Silicon Valley startup that's trying to help consumers lose weight, raised $20 million in a funding round led by Cheyenne Ventures and GV.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107315308-16970398441697039842-31555766578-1080pnbcnews.jpg?v=1697040673&w=750&h=422&vtcrop=y", "source": "CNBC", "category_within_source": "Top News", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.165461, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.039944", "ticker_sentiment_score": "0.109745", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABT", "relevance_score": "0.039944", "ticker_sentiment_score": "0.135374", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.158781", "ticker_sentiment_score": "0.147437", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.039944", "ticker_sentiment_score": "-0.217865", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "NVO", "relevance_score": "0.039944", "ticker_sentiment_score": "0.239868", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Here's How Much You Would Have Made Owning DexCom Stock In The Last 15 Years - DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/news/23/10/35353005/heres-how-much-you-would-have-made-owning-dexcom-stock-in-the-last-15-years", "time_published": "20231020T153033", "authors": ["Benzinga Insights"], "summary": "DexCom DXCM has outperformed the market over the past 15 years by 23.25% on an annualized basis producing an average annual return of 34.63%. Currently, DexCom has a market capitalization of $33.37 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.983605", "ticker_sentiment_score": "0.387251", "ticker_sentiment_label": "Bullish"}]}, {"title": "Will Patient Volumes Aid Community Health's  ( CYH )  Q3 Earnings?", "url": "https://www.zacks.com/stock/news/2169727/will-patient-volumes-aid-community-healths-cyh-q3-earnings", "time_published": "20231020T135100", "authors": ["Zacks Equity Research"], "summary": "Community Health's (CYH) third-quarter results are likely to benefit from improved payer mix and growing surgery volumes, partly offset by a decline in patient days.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/49005.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.182984, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.114137", "ticker_sentiment_score": "0.050875", "ticker_sentiment_label": "Neutral"}, {"ticker": "CYH", "relevance_score": "0.333257", "ticker_sentiment_score": "0.287386", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "XRAY", "relevance_score": "0.114137", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "What's in Store for West Pharmaceutical  ( WST )  in Q3 Earnings?", "url": "https://www.zacks.com/stock/news/2169450/whats-in-store-for-west-pharmaceutical-wst-in-q3-earnings", "time_published": "20231020T113900", "authors": ["Zacks Equity Research"], "summary": "West Pharmaceutical's (WST) third-quarter 2023 results are likely to reflect strength in the Proprietary Products business. However, unfavorable currency movements might have hurt the top and bottom lines.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c0/2297.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.999973"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.189966, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CURN", "relevance_score": "0.074692", "ticker_sentiment_score": "-0.020465", "ticker_sentiment_label": "Neutral"}, {"ticker": "WST", "relevance_score": "0.360752", "ticker_sentiment_score": "0.137447", "ticker_sentiment_label": "Neutral"}, {"ticker": "PODD", "relevance_score": "0.148731", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.221481", "ticker_sentiment_score": "-0.008599", "ticker_sentiment_label": "Neutral"}, {"ticker": "IQV", "relevance_score": "0.221481", "ticker_sentiment_score": "-0.008594", "ticker_sentiment_label": "Neutral"}]}, {"title": "DexCom  ( DXCM )  Earnings Expected to Grow: Should You Buy?", "url": "https://www.zacks.com/stock/news/2168855/dexcom-dxcm-earnings-expected-to-grow-should-you-buy", "time_published": "20231019T140158", "authors": ["Zacks Equity Research"], "summary": "DexCom (DXCM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default272.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.172297, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.258808", "ticker_sentiment_score": "0.220115", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TMO", "relevance_score": "0.087663", "ticker_sentiment_score": "0.039084", "ticker_sentiment_label": "Neutral"}]}, {"title": "4 Medical Product Stocks Set to Outpace Q3 Earnings Estimates", "url": "https://www.zacks.com/stock/news/2168593/4-medical-product-stocks-set-to-outpace-q3-earnings-estimates", "time_published": "20231019T105400", "authors": ["Indrajit Bandyopadhyay"], "summary": "Medical Product companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how EW, PODD, DXCM and IQV are poised ahead of their earnings release.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c2/53795.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.18297, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "EW", "relevance_score": "0.365294", "ticker_sentiment_score": "0.037789", "ticker_sentiment_label": "Neutral"}, {"ticker": "PODD", "relevance_score": "0.265666", "ticker_sentiment_score": "0.048412", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.265666", "ticker_sentiment_score": "0.091071", "ticker_sentiment_label": "Neutral"}, {"ticker": "IQV", "relevance_score": "0.316168", "ticker_sentiment_score": "0.138088", "ticker_sentiment_label": "Neutral"}]}, {"title": "Can DexCom  ( DXCM )  Keep the Earnings Surprise Streak Alive?", "url": "https://www.zacks.com/stock/news/2168277/can-dexcom-dxcm-keep-the-earnings-surprise-streak-alive", "time_published": "20231018T161010", "authors": ["Zacks Equity Research"], "summary": "DexCom (DXCM) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default209.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.99989"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.327938, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.415927", "ticker_sentiment_score": "0.475313", "ticker_sentiment_label": "Bullish"}]}, {"title": "Comparing DexCom With Industry Competitors In Health Care Equipment & Supplies Industry - DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/news/23/10/35312875/comparing-dexcom-with-industry-competitors-in-health-care-equipment-amp-supplies-industry", "time_published": "20231018T160043", "authors": ["Benzinga Insights"], "summary": "In today's rapidly changing and fiercely competitive business landscape, it is essential for investors and industry enthusiasts to thoroughly analyze companies. In this article, we will conduct a comprehensive industry comparison, evaluating DexCom DXCM against its key competitors in the Health ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.928769"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.623304"}], "overall_sentiment_score": 0.25035, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.466811", "ticker_sentiment_score": "0.376554", "ticker_sentiment_label": "Bullish"}, {"ticker": "PODD", "relevance_score": "0.070935", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Abbott Laboratories, Nasdaq, Spirit AeroSystems And Other Big Stocks Moving Higher On Wednesday - Abbott Laboratories  ( NYSE:ABT ) , Ardelyx  ( NASDAQ:ARDX ) ", "url": "https://www.benzinga.com/news/23/10/35310235/abbott-laboratories-nasdaq-spirit-aerosystems-and-other-big-stocks-moving-higher-on-wednesday", "time_published": "20231018T150405", "authors": ["Lisa Levin"], "summary": "U.S. stocks traded lower, with the Dow Jones falling around 50 points on Wednesday. Here are some big stocks recording gains in today's session. Spirit AeroSystems Holdings, Inc. SPR jumped 24.6% to $21.42 after the company announced it reached an agreement with Boeing to support production ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/18/abbott_laboratories_-_logo.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.769861"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}], "overall_sentiment_score": 0.461724, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "ABT", "relevance_score": "0.327366", "ticker_sentiment_score": "0.529605", "ticker_sentiment_label": "Bullish"}, {"ticker": "SPR", "relevance_score": "0.327366", "ticker_sentiment_score": "0.699192", "ticker_sentiment_label": "Bullish"}, {"ticker": "FDMT", "relevance_score": "0.47379", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NATR", "relevance_score": "0.327366", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "FWRG", "relevance_score": "0.47379", "ticker_sentiment_score": "0.662669", "ticker_sentiment_label": "Bullish"}, {"ticker": "PG", "relevance_score": "0.327366", "ticker_sentiment_score": "0.62155", "ticker_sentiment_label": "Bullish"}, {"ticker": "RSTGF", "relevance_score": "0.167322", "ticker_sentiment_score": "0.354868", "ticker_sentiment_label": "Bullish"}, {"ticker": "ARDX", "relevance_score": "0.327366", "ticker_sentiment_score": "0.709446", "ticker_sentiment_label": "Bullish"}, {"ticker": "GDHG", "relevance_score": "0.327366", "ticker_sentiment_score": "0.673788", "ticker_sentiment_label": "Bullish"}, {"ticker": "DHC", "relevance_score": "0.327366", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.327366", "ticker_sentiment_score": "0.673788", "ticker_sentiment_label": "Bullish"}, {"ticker": "BA", "relevance_score": "0.167322", "ticker_sentiment_score": "0.480657", "ticker_sentiment_label": "Bullish"}]}, {"title": "Price Over Earnings Overview: DexCom - DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/news/23/10/35310073/price-over-earnings-overview-dexcom", "time_published": "20231018T141515", "authors": ["Benzinga Insights"], "summary": "In the current market session, DexCom Inc. DXCM price is at $84.54, after a 5.03% spike. However, over the past month, the stock decreased by 8.78%, and in the past year, by 10.45%. Shareholders might be interested in knowing whether the stock is undervalued, even if the company is performing up ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.218753, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.445569", "ticker_sentiment_score": "0.230478", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "2 Healthcare Stocks Near Their 52-Week Lows That Could Double in Value", "url": "https://www.fool.com/investing/2023/10/18/2-healthcare-stocks-near-their-52-week-lows-that/", "time_published": "20231018T135300", "authors": ["David Jagielski"], "summary": "These can be excellent investments to buy and hold for years.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.225318, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.265089", "ticker_sentiment_score": "0.232728", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "INMD", "relevance_score": "0.457794", "ticker_sentiment_score": "0.302777", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "3 Stock-Split Stocks With 110% to 696% Upside, According to Select Wall Street Analysts and Pundits", "url": "https://www.fool.com/investing/2023/10/18/3-stock-split-stocks-110-to-696-upside-wall-street/", "time_published": "20231018T090600", "authors": ["Sean Williams"], "summary": "Among Nvidia, Amazon, DexCom, Shopify, Alphabet, Tesla, Palo Alto Networks, Monster Beverage, and Novo Nordisk, there are three stock-split stocks select people on Wall Street believe offer mouthwatering upside.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F751081%2Fstock-certificate-investment-retire-heirloom-donate-capital-gains-tax-getty.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999999"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.684621"}], "overall_sentiment_score": 0.116237, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMD", "relevance_score": "0.028422", "ticker_sentiment_score": "0.050316", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.27838", "ticker_sentiment_score": "0.072516", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.304886", "ticker_sentiment_score": "0.119687", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.196953", "ticker_sentiment_score": "0.030427", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSM", "relevance_score": "0.028422", "ticker_sentiment_score": "-0.103739", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why the Market Dipped But DexCom  ( DXCM )  Gained Today", "url": "https://www.zacks.com/stock/news/2167569/why-the-market-dipped-but-dexcom-dxcm-gained-today", "time_published": "20231017T220016", "authors": ["Zacks Equity Research"], "summary": "The latest trading day saw DexCom (DXCM) settling at $80.49, representing a +1.95% change from its previous close.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default333.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.976913"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.129216, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.523451", "ticker_sentiment_score": "0.239459", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Looking Into DexCom's Recent Short Interest - DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/short-sellers/23/10/35286767/looking-into-dexcoms-recent-short-interest", "time_published": "20231017T130028", "authors": ["Benzinga Insights"], "summary": "DexCom's DXCM short percent of float has fallen 5.26% since its last report. The company recently reported that it has 16.03 million shares sold short, which is 4.68% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.4 days to cover their ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.24389, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.224903", "ticker_sentiment_score": "0.085754", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why DexCom Stock Rallied on Monday", "url": "https://www.fool.com/investing/2023/10/16/why-dexcom-stock-rallied-on-monday/", "time_published": "20231016T191504", "authors": ["Danny Vena"], "summary": "The medical device maker got a little love from Wall Street.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.043819, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.769861", "ticker_sentiment_score": "0.14796", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why DexCom Stock Is Rising During Monday's Session - DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/news/23/10/35273764/why-dexcom-stock-is-rising-during-mondays-session", "time_published": "20231016T183652", "authors": ["Henry Khederian"], "summary": "DexCom, Inc. DXCM shares are trading higher by 3.75% to $79.05 Thursday afternoon. Leerink Partners initiated coverage on the stock with an Outperform rating and a $110 price target. DexCom is otherwise trading lower in recent sessions following the FDA's announcement of the establishment of a ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/16/business-3560916.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.260964, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.512093", "ticker_sentiment_score": "-0.003297", "ticker_sentiment_label": "Neutral"}]}, {"title": "DexCom Unusual Options Activity - DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/markets/options/23/10/35246698/dexcom-unusual-options-activity", "time_published": "20231013T181749", "authors": ["Benzinga Insights"], "summary": "A whale with a lot of money to spend has taken a noticeably bullish stance on DexCom. Looking at options history for DexCom DXCM we detected 15 strange trades. If we consider the specifics of each trade, it is accurate to state that 60% of the investors opened trades with bullish expectations ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.149884, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.887556", "ticker_sentiment_score": "0.36663", "ticker_sentiment_label": "Bullish"}, {"ticker": "MS", "relevance_score": "0.126119", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Shares of Insulet Dropped This Week", "url": "https://www.fool.com/investing/2023/10/12/why-shares-of-insulet-dropped-this-week/", "time_published": "20231012T214053", "authors": ["James Halley"], "summary": "Positive news regarding diabetes therapy Ozempic worried investors.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.961735"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.095949, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SPGI", "relevance_score": "0.130926", "ticker_sentiment_score": "0.061375", "ticker_sentiment_label": "Neutral"}, {"ticker": "PODD", "relevance_score": "0.59016", "ticker_sentiment_score": "0.151349", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TNDM", "relevance_score": "0.130926", "ticker_sentiment_score": "-0.043105", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.130926", "ticker_sentiment_score": "-0.043105", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.258351", "ticker_sentiment_score": "-0.092374", "ticker_sentiment_label": "Neutral"}]}, {"title": "Novo drugs Ozempic and Wegovy are shaking up stock markets again", "url": "https://www.financialexpress.com/healthcare/pharma-healthcare/novo-drugs-ozempic-and-wegovy-are-shaking-up-stock-markets-again/3270796/", "time_published": "20231012T105154", "authors": ["Bloomberg"], "summary": "Novo Nordisk, the Danish company, now Europe's largest by market value, said late Tuesday it was halting a study that looked at the impact of its blockbuster Ozempic drug on kidney failure after it showed effectiveness surprisingly early. The news hit shares of the world's biggest kidney dialysis ...", "banner_image": "https://www.financialexpress.com/wp-content/uploads/2023/10/pills-g5a602a81d_1920-1.jpg", "source": "The Financial Express", "category_within_source": "n/a", "source_domain": "www.financialexpress.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.133369, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "WW", "relevance_score": "0.206685", "ticker_sentiment_score": "0.268136", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "C", "relevance_score": "0.104228", "ticker_sentiment_score": "0.012125", "ticker_sentiment_label": "Neutral"}, {"ticker": "FSNUF", "relevance_score": "0.104228", "ticker_sentiment_score": "-0.118925", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.104228", "ticker_sentiment_score": "0.175207", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BAX", "relevance_score": "0.104228", "ticker_sentiment_score": "-0.118925", "ticker_sentiment_label": "Neutral"}, {"ticker": "PODD", "relevance_score": "0.104228", "ticker_sentiment_score": "0.107321", "ticker_sentiment_label": "Neutral"}, {"ticker": "FMS", "relevance_score": "0.104228", "ticker_sentiment_score": "-0.118925", "ticker_sentiment_label": "Neutral"}, {"ticker": "DVA", "relevance_score": "0.104228", "ticker_sentiment_score": "-0.118925", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.104228", "ticker_sentiment_score": "0.107321", "ticker_sentiment_label": "Neutral"}, {"ticker": "OM", "relevance_score": "0.104228", "ticker_sentiment_score": "-0.118925", "ticker_sentiment_label": "Neutral"}, {"ticker": "WMT", "relevance_score": "0.104228", "ticker_sentiment_score": "0.012974", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dow Jones Rises After Fed Minutes As House Vote On New Speaker Looms; Meta Breaks Out", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-rises-after-fed-minutes-as-house-vote-on-new-speaker-looms-meta-breaks-out/", "time_published": "20231011T195200", "authors": ["VIDYA RAMAKRISHNAN", "Investor's Business Daily"], "summary": "Dow Jones Rises After Fed Minutes As House Vote On New ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2019/01/stock-FederalReserve-snow-11-shutter.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.769861"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.999981"}, {"topic": "Earnings", "relevance_score": "0.451494"}], "overall_sentiment_score": 0.062531, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "META", "relevance_score": "0.100308", "ticker_sentiment_score": "0.04817", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAVA", "relevance_score": "0.100308", "ticker_sentiment_score": "-0.081807", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.050254", "ticker_sentiment_score": "0.236385", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JPM", "relevance_score": "0.100308", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.050254", "ticker_sentiment_score": "-0.076389", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADBE", "relevance_score": "0.100308", "ticker_sentiment_score": "0.197599", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LLY", "relevance_score": "0.149966", "ticker_sentiment_score": "0.235216", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FAST", "relevance_score": "0.100308", "ticker_sentiment_score": "0.032902", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.199037", "ticker_sentiment_score": "0.209207", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.100308", "ticker_sentiment_score": "0.04772", "ticker_sentiment_label": "Neutral"}]}, {"title": "DexCom  ( DXCM )  Stock Sinks As Market Gains: What You Should Know", "url": "https://www.zacks.com/stock/news/2162995/dexcom-dxcm-stock-sinks-as-market-gains-what-you-should-know", "time_published": "20231009T220017", "authors": ["Zacks Equity Research"], "summary": "DexCom (DXCM) closed the most recent trading day at $83.09, moving -0.16% from the previous trading session.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default147.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.99246"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.172432, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.651499", "ticker_sentiment_score": "0.343213", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Here's Why DexCom  ( DXCM )  is a Strong Growth Stock", "url": "https://www.zacks.com/stock/news/2162633/heres-why-dexcom-dxcm-is-a-strong-growth-stock", "time_published": "20231009T134507", "authors": ["Zacks Equity Research"], "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default25.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.682689"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.384987, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.595343", "ticker_sentiment_score": "0.407965", "ticker_sentiment_label": "Bullish"}]}, {"title": "DexCom  ( DXCM )  to Launch Latest CGM System G7 in Canada", "url": "https://www.zacks.com/stock/news/2162674/dexcom-dxcm-to-launch-latest-cgm-system-g7-in-canada", "time_published": "20231009T130200", "authors": ["Zacks Equity Research"], "summary": "DexCom's (DXCM) G7 CGM System (launched in Canada) is expected to combine simplicity and power, thereby providing a better way to manage diabetes.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c0/2297.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}], "overall_sentiment_score": 0.260121, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MEDP", "relevance_score": "0.165409", "ticker_sentiment_score": "0.097054", "ticker_sentiment_label": "Neutral"}, {"ticker": "PODD", "relevance_score": "0.055492", "ticker_sentiment_score": "0.022931", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALGN", "relevance_score": "0.165409", "ticker_sentiment_score": "0.111949", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCK", "relevance_score": "0.165409", "ticker_sentiment_score": "0.049471", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.634467", "ticker_sentiment_score": "0.328837", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Best Buy to offer a continuous glucose-monitoring system as its first prescription-based medical device", "url": "https://www.marketwatch.com/story/best-buy-to-start-offering-a-continuous-glucose-monitoring-system-for-diabetics-its-first-prescription-based-medical-device-cbc6d341", "time_published": "20231009T124100", "authors": ["Ciara Linnane"], "summary": "Best Buy Co. Inc. has become the latest retailer to enter the healthcare space with the news that it will soon start offering a CGM system.", "banner_image": "https://images.mktw.net/im-864874/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}], "overall_sentiment_score": 0.143112, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BBY", "relevance_score": "0.165031", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CVS", "relevance_score": "0.165031", "ticker_sentiment_score": "0.213106", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "COST", "relevance_score": "0.323078", "ticker_sentiment_score": "0.236072", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMZN", "relevance_score": "0.245339", "ticker_sentiment_score": "0.07444", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.165031", "ticker_sentiment_score": "0.064029", "ticker_sentiment_label": "Neutral"}, {"ticker": "WMT", "relevance_score": "0.323078", "ticker_sentiment_score": "0.246262", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Here's Why You Should Retain Tandem Diabetes  ( TNDM )  Now", "url": "https://www.zacks.com/stock/news/2162463/heres-why-you-should-retain-tandem-diabetes-tndm-now", "time_published": "20231009T123500", "authors": ["Zacks Equity Research"], "summary": "Investors remain optimistic about Tandem Diabetes (TNDM), backed by strategic developments and innovative new launches.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c0/2563.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Earnings", "relevance_score": "0.990678"}], "overall_sentiment_score": 0.234201, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALGN", "relevance_score": "0.136113", "ticker_sentiment_score": "0.155275", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TNDM", "relevance_score": "0.136113", "ticker_sentiment_score": "0.235155", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HAE", "relevance_score": "0.180798", "ticker_sentiment_score": "0.101606", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.090989", "ticker_sentiment_score": "0.118989", "ticker_sentiment_label": "Neutral"}, {"ticker": "QTRX", "relevance_score": "0.180798", "ticker_sentiment_score": "0.035286", "ticker_sentiment_label": "Neutral"}]}, {"title": "Best Buy To Offer Continuous Glucose Monitoring Systems, Marking Debut Of Prescription Based Medical Devices Sale - Best Buy Co  ( NYSE:BBY ) ", "url": "https://www.benzinga.com/markets/equities/23/10/35142254/best-buy-to-offer-continuous-glucose-monitoring-systems-marking-debut-of-prescription-based-medi", "time_published": "20231009T115452", "authors": ["Shivani Kumaresan"], "summary": "Specialty consumer electronics retailer Best Buy Co Inc BBY will soon sell the Dexcom G7 Continuous Glucose Monitoring System ( CGM ) to eligible customers through BestBuy.com. This marks the first time Best Buy will offer prescription-based medical devices.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/09/bby.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}], "overall_sentiment_score": 0.262601, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BBY", "relevance_score": "0.827318", "ticker_sentiment_score": "0.385207", "ticker_sentiment_label": "Bullish"}, {"ticker": "DXCM", "relevance_score": "0.414559", "ticker_sentiment_score": "0.146253", "ticker_sentiment_label": "Neutral"}]}, {"title": "Best Buy's Latest Health Business: Glucose Monitoring Systems", "url": "https://www.forbes.com/sites/brucejapsen/2023/10/09/best-buys-latest-health-business-glucose-monitoring-systems/", "time_published": "20231009T100000", "authors": ["Bruce Japsen"], "summary": "Best Buy will soon begin carrying continuous glucose monitoring devices that require a prescription, opening the door to broader future healthcare product offerings.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/651f88bee3242cf2ed10c783/0x0.jpg?format=jpg&width=1200", "source": "Forbes", "category_within_source": "Business", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}], "overall_sentiment_score": 0.23066, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BBY", "relevance_score": "0.822984", "ticker_sentiment_score": "0.38453", "ticker_sentiment_label": "Bullish"}, {"ticker": "DXCM", "relevance_score": "0.34729", "ticker_sentiment_score": "0.16509", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HCSG", "relevance_score": "0.119235", "ticker_sentiment_score": "0.061931", "ticker_sentiment_label": "Neutral"}]}, {"title": "A Bull Market Is Coming: 2 Magnificent Stock-Split Growth Stocks That Could Soar 40% and 51%, According to Wall Street", "url": "https://www.fool.com/investing/2023/10/08/a-bull-market-is-coming-2-magnificent-stock-split/", "time_published": "20231008T110000", "authors": ["Danny Vena"], "summary": "Two investor-favorite stock-split stocks still have plenty of room to run.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F749703%2Fa-businesspeson-standing-near-the-display-with-various-graphs.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.658903"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.99676"}], "overall_sentiment_score": 0.114583, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVDA", "relevance_score": "0.215319", "ticker_sentiment_score": "0.142409", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.338004", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stocks That Hit 52-Week Lows On Thursday - PRA Group  ( NASDAQ:PRAA ) , Perimeter Solutions  ( NYSE:PRM ) ", "url": "https://www.benzinga.com/news/23/10/35111787/stocks-that-hit-52-week-lows-on-thursday", "time_published": "20231005T172202", "authors": ["Benzinga Insights"], "summary": "On Thursday, 369 companies hit new 52-week lows. The largest company in terms of market cap to set a new 52-week low was Coca-Cola KO. The smallest company by market cap to hit a new 52-week low was Neptune Wellness Solns NEPT.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": -0.11524, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VIAV", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.079402", "ticker_sentiment_label": "Neutral"}, {"ticker": "FLGC", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.079402", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZIVO", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.113741", "ticker_sentiment_label": "Neutral"}, {"ticker": "FSEA", "relevance_score": "0.013047", "ticker_sentiment_score": "0.005387", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNDX", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.083761", "ticker_sentiment_label": "Neutral"}, {"ticker": "ASST", "relevance_score": "0.013047", "ticker_sentiment_score": "0.005387", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVST", "relevance_score": "0.013047", "ticker_sentiment_score": "0.065807", "ticker_sentiment_label": "Neutral"}, {"ticker": "EYE", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.110266", "ticker_sentiment_label": "Neutral"}, {"ticker": "JOAN", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.110266", "ticker_sentiment_label": "Neutral"}, {"ticker": "VIRX", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.097823", "ticker_sentiment_label": "Neutral"}, {"ticker": "BALY", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.103839", "ticker_sentiment_label": "Neutral"}, {"ticker": "CDT", "relevance_score": "0.013047", "ticker_sentiment_score": "0.004444", "ticker_sentiment_label": "Neutral"}, {"ticker": "NGVT", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.103839", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVCR", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.083761", "ticker_sentiment_label": "Neutral"}, {"ticker": "INBS", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.101353", "ticker_sentiment_label": "Neutral"}, {"ticker": "PTAIF", "relevance_score": "0.006524", "ticker_sentiment_score": "-0.082676", "ticker_sentiment_label": "Neutral"}, {"ticker": "DOCN", "relevance_score": "0.013047", "ticker_sentiment_score": "0.005387", "ticker_sentiment_label": "Neutral"}, {"ticker": "MGYR", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.097823", "ticker_sentiment_label": "Neutral"}, {"ticker": "HOG", "relevance_score": "0.013047", "ticker_sentiment_score": "0.003524", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVRO", "relevance_score": "0.013047", "ticker_sentiment_score": "0.004444", "ticker_sentiment_label": "Neutral"}, {"ticker": "RBT", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.087261", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMBM", "relevance_score": "0.013047", "ticker_sentiment_score": "0.003524", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNGO", "relevance_score": "0.013047", "ticker_sentiment_score": "0.00439", "ticker_sentiment_label": "Neutral"}, {"ticker": "ASTR", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.087261", "ticker_sentiment_label": "Neutral"}, {"ticker": "SUP", "relevance_score": "0.013047", "ticker_sentiment_score": "0.00439", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAP", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.097823", "ticker_sentiment_label": "Neutral"}, {"ticker": "HESG", "relevance_score": "0.006524", "ticker_sentiment_score": "0.004253", "ticker_sentiment_label": "Neutral"}, {"ticker": "SEE", "relevance_score": "0.013047", "ticker_sentiment_score": "0.00436", "ticker_sentiment_label": "Neutral"}, {"ticker": "RBOT", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.097823", "ticker_sentiment_label": "Neutral"}, {"ticker": "TGL", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.087261", "ticker_sentiment_label": "Neutral"}, {"ticker": "ASTC", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.09253", "ticker_sentiment_label": "Neutral"}, {"ticker": "RTC", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.09253", "ticker_sentiment_label": "Neutral"}, {"ticker": "A", "relevance_score": "0.006524", "ticker_sentiment_score": "0.004169", "ticker_sentiment_label": "Neutral"}, {"ticker": "MTTR", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.101353", "ticker_sentiment_label": "Neutral"}, {"ticker": "AEZS", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.110266", "ticker_sentiment_label": "Neutral"}, {"ticker": "BE", "relevance_score": "0.006524", "ticker_sentiment_score": "-0.087721", "ticker_sentiment_label": "Neutral"}, {"ticker": "D", "relevance_score": "0.006524", "ticker_sentiment_score": "0.004253", "ticker_sentiment_label": "Neutral"}, {"ticker": "GNL", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.101353", "ticker_sentiment_label": "Neutral"}, {"ticker": "CFG", "relevance_score": "0.006524", "ticker_sentiment_score": "0.003297", "ticker_sentiment_label": "Neutral"}, {"ticker": "G", "relevance_score": "0.01957", "ticker_sentiment_score": "-0.013723", "ticker_sentiment_label": "Neutral"}, {"ticker": "EGRX", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.103839", "ticker_sentiment_label": "Neutral"}, {"ticker": "INDI", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.087261", "ticker_sentiment_label": "Neutral"}, {"ticker": "BTTX", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.087261", "ticker_sentiment_label": "Neutral"}, {"ticker": "JAGX", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.101353", "ticker_sentiment_label": "Neutral"}, {"ticker": "FATE", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.110266", "ticker_sentiment_label": "Neutral"}, {"ticker": "KIDS", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.087261", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACET", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.113741", "ticker_sentiment_label": "Neutral"}, {"ticker": "PENN", "relevance_score": "0.013047", "ticker_sentiment_score": "0.004465", "ticker_sentiment_label": "Neutral"}, {"ticker": "RKDA", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.09253", "ticker_sentiment_label": "Neutral"}, {"ticker": "BYND", "relevance_score": "0.013047", "ticker_sentiment_score": "0.00439", "ticker_sentiment_label": "Neutral"}, {"ticker": "SVV", "relevance_score": "0.013047", "ticker_sentiment_score": "0.004424", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLDE", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.097823", "ticker_sentiment_label": "Neutral"}, {"ticker": "CWH", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.087261", "ticker_sentiment_label": "Neutral"}, {"ticker": "ASH", "relevance_score": "0.013047", "ticker_sentiment_score": "0.004424", "ticker_sentiment_label": "Neutral"}, {"ticker": "LHX", "relevance_score": "0.013047", "ticker_sentiment_score": "0.003524", "ticker_sentiment_label": "Neutral"}, {"ticker": "SQ", "relevance_score": "0.013047", "ticker_sentiment_score": "0.004444", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCRB", "relevance_score": "0.013047", "ticker_sentiment_score": "0.00439", "ticker_sentiment_label": "Neutral"}, {"ticker": "NMG", "relevance_score": "0.013047", "ticker_sentiment_score": "0.004444", "ticker_sentiment_label": "Neutral"}, {"ticker": "LSDI", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.097823", "ticker_sentiment_label": "Neutral"}, {"ticker": "IOVA", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.110266", "ticker_sentiment_label": "Neutral"}, {"ticker": "SEDG", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.110266", "ticker_sentiment_label": "Neutral"}, {"ticker": "FNA", "relevance_score": "0.013047", "ticker_sentiment_score": "0.00436", "ticker_sentiment_label": "Neutral"}, {"ticker": "WOLF", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.113741", "ticker_sentiment_label": "Neutral"}, {"ticker": "AONC", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.113741", "ticker_sentiment_label": "Neutral"}, {"ticker": "SLDP", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.097823", "ticker_sentiment_label": "Neutral"}, {"ticker": "DH", "relevance_score": "0.013047", "ticker_sentiment_score": "0.004424", "ticker_sentiment_label": "Neutral"}, {"ticker": "WOOF", "relevance_score": "0.013047", "ticker_sentiment_score": "0.004424", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALIT", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.087261", "ticker_sentiment_label": "Neutral"}, {"ticker": "CZOO", "relevance_score": "0.013047", "ticker_sentiment_score": "0.00439", "ticker_sentiment_label": "Neutral"}, {"ticker": "EVRI", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.08953", "ticker_sentiment_label": "Neutral"}, {"ticker": "PRM", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.087261", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADN", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.104029", "ticker_sentiment_label": "Neutral"}, {"ticker": "LITE", "relevance_score": "0.013047", "ticker_sentiment_score": "0.00436", "ticker_sentiment_label": "Neutral"}, {"ticker": "LICY", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.09253", "ticker_sentiment_label": "Neutral"}, {"ticker": "SQFTP", "relevance_score": "0.006524", "ticker_sentiment_score": "-0.082676", "ticker_sentiment_label": "Neutral"}, {"ticker": "PZZA", "relevance_score": "0.013047", "ticker_sentiment_score": "0.004444", "ticker_sentiment_label": "Neutral"}, {"ticker": "UI", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.087261", "ticker_sentiment_label": "Neutral"}, {"ticker": "ENSC", "relevance_score": "0.013047", "ticker_sentiment_score": "0.073742", "ticker_sentiment_label": "Neutral"}, {"ticker": "RGNX", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.113741", "ticker_sentiment_label": "Neutral"}, {"ticker": "PODD", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.110266", "ticker_sentiment_label": "Neutral"}, {"ticker": "EE", "relevance_score": "0.013047", "ticker_sentiment_score": "0.004465", "ticker_sentiment_label": "Neutral"}, {"ticker": "FREY", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.087261", "ticker_sentiment_label": "Neutral"}, {"ticker": "SAND", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.097823", "ticker_sentiment_label": "Neutral"}, {"ticker": "GSUN", "relevance_score": "0.013047", "ticker_sentiment_score": "0.004444", "ticker_sentiment_label": "Neutral"}, {"ticker": "AEMD", "relevance_score": "0.01957", "ticker_sentiment_score": "-0.084192", "ticker_sentiment_label": "Neutral"}, {"ticker": "DCPH", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.087261", "ticker_sentiment_label": "Neutral"}, {"ticker": "RCUS", "relevance_score": "0.013047", "ticker_sentiment_score": "0.00439", "ticker_sentiment_label": "Neutral"}, {"ticker": "NOK", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.097823", "ticker_sentiment_label": "Neutral"}, {"ticker": "AKYA", "relevance_score": "0.013047", "ticker_sentiment_score": "0.004424", "ticker_sentiment_label": "Neutral"}, {"ticker": "BGS", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.087261", "ticker_sentiment_label": "Neutral"}, {"ticker": "IMCR", "relevance_score": "0.013047", "ticker_sentiment_score": "0.003477", "ticker_sentiment_label": "Neutral"}, {"ticker": "SLDB", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.101353", "ticker_sentiment_label": "Neutral"}, {"ticker": "SII", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.103839", "ticker_sentiment_label": "Neutral"}, {"ticker": "SYY", "relevance_score": "0.013047", "ticker_sentiment_score": "0.005387", "ticker_sentiment_label": "Neutral"}, {"ticker": "BTWN", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.097823", "ticker_sentiment_label": "Neutral"}, {"ticker": "TMCI", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.103839", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARVL", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.101353", "ticker_sentiment_label": "Neutral"}, {"ticker": "RGP", "relevance_score": "0.013047", "ticker_sentiment_score": "0.004465", "ticker_sentiment_label": "Neutral"}, {"ticker": "SHLS", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.087261", "ticker_sentiment_label": "Neutral"}, {"ticker": "LAES", "relevance_score": "0.013047", "ticker_sentiment_score": "0.00436", "ticker_sentiment_label": "Neutral"}, {"ticker": "KZR", "relevance_score": "0.013047", "ticker_sentiment_score": "0.004465", "ticker_sentiment_label": "Neutral"}, {"ticker": "VZIO", "relevance_score": "0.013047", "ticker_sentiment_score": "0.003524", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOSL", "relevance_score": "0.013047", "ticker_sentiment_score": "0.004465", "ticker_sentiment_label": "Neutral"}, {"ticker": "VAXX", "relevance_score": "0.013047", "ticker_sentiment_score": "0.005387", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVR", "relevance_score": "0.013047", "ticker_sentiment_score": "0.004465", "ticker_sentiment_label": "Neutral"}, {"ticker": "GPRO", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.103839", "ticker_sentiment_label": "Neutral"}, {"ticker": "HLGN", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.110266", "ticker_sentiment_label": "Neutral"}, {"ticker": "BRDG", "relevance_score": "0.013047", "ticker_sentiment_score": "0.003524", "ticker_sentiment_label": "Neutral"}, {"ticker": "ENV", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.087261", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.01957", "ticker_sentiment_score": "0.048269", "ticker_sentiment_label": "Neutral"}, {"ticker": "NEXI", "relevance_score": "0.013047", "ticker_sentiment_score": "0.005387", "ticker_sentiment_label": "Neutral"}, {"ticker": "HTZ", "relevance_score": "0.013047", "ticker_sentiment_score": "0.004465", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGMO", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.110266", "ticker_sentiment_label": "Neutral"}, {"ticker": "MGOL", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.087261", "ticker_sentiment_label": "Neutral"}, {"ticker": "SBSW", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.113741", "ticker_sentiment_label": "Neutral"}, {"ticker": "SLGL", "relevance_score": "0.013047", "ticker_sentiment_score": "0.004465", "ticker_sentiment_label": "Neutral"}, {"ticker": "NSTG", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.097823", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGMT", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.097823", "ticker_sentiment_label": "Neutral"}, {"ticker": "HUN", "relevance_score": "0.013047", "ticker_sentiment_score": "0.004444", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIG", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.087261", "ticker_sentiment_label": "Neutral"}, {"ticker": "HIPO", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.083761", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXFY", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.079402", "ticker_sentiment_label": "Neutral"}, {"ticker": "GM", "relevance_score": "0.013047", "ticker_sentiment_score": "0.003524", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALLT", "relevance_score": "0.013047", "ticker_sentiment_score": "0.073742", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALLR", "relevance_score": "0.013047", "ticker_sentiment_score": "0.003524", "ticker_sentiment_label": "Neutral"}, {"ticker": "NUWE", "relevance_score": "0.013047", "ticker_sentiment_score": "0.004465", "ticker_sentiment_label": "Neutral"}, {"ticker": "VBIV", "relevance_score": "0.013047", "ticker_sentiment_score": "0.005387", "ticker_sentiment_label": "Neutral"}, {"ticker": "ONEW", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.087261", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLFD", "relevance_score": "0.013047", "ticker_sentiment_score": "0.004424", "ticker_sentiment_label": "Neutral"}, {"ticker": "HA", "relevance_score": "0.013047", "ticker_sentiment_score": "0.00439", "ticker_sentiment_label": "Neutral"}, {"ticker": "RICK", "relevance_score": "0.013047", "ticker_sentiment_score": "0.003477", "ticker_sentiment_label": "Neutral"}, {"ticker": "OTRK", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.087261", "ticker_sentiment_label": "Neutral"}, {"ticker": "DGII", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.09896", "ticker_sentiment_label": "Neutral"}, {"ticker": "GTN", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.083761", "ticker_sentiment_label": "Neutral"}, {"ticker": "HL", "relevance_score": "0.013047", "ticker_sentiment_score": "0.004465", "ticker_sentiment_label": "Neutral"}, {"ticker": "AGTI", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.09253", "ticker_sentiment_label": "Neutral"}, {"ticker": "EDBL", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.101353", "ticker_sentiment_label": "Neutral"}, {"ticker": "COMS", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.113741", "ticker_sentiment_label": "Neutral"}, {"ticker": "CARE", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.097823", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLX", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.097823", "ticker_sentiment_label": "Neutral"}, {"ticker": "HLIT", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.087261", "ticker_sentiment_label": "Neutral"}, {"ticker": "VERI", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.087261", "ticker_sentiment_label": "Neutral"}, {"ticker": "ELBM", "relevance_score": "0.013047", "ticker_sentiment_score": "0.003524", "ticker_sentiment_label": "Neutral"}, {"ticker": "WTO", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.097823", "ticker_sentiment_label": "Neutral"}, {"ticker": "NUZE", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.097823", "ticker_sentiment_label": "Neutral"}, {"ticker": "HNNA", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.097823", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNVR", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.097823", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMP", "relevance_score": "0.013047", "ticker_sentiment_score": "0.003499", "ticker_sentiment_label": "Neutral"}, {"ticker": "VTNR", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.087261", "ticker_sentiment_label": "Neutral"}, {"ticker": "OUT", "relevance_score": "0.006524", "ticker_sentiment_score": "0.005137", "ticker_sentiment_label": "Neutral"}, {"ticker": "CHPT", "relevance_score": "0.013047", "ticker_sentiment_score": "0.004444", "ticker_sentiment_label": "Neutral"}, {"ticker": "KNTE", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.097823", "ticker_sentiment_label": "Neutral"}, {"ticker": "SONN", "relevance_score": "0.013047", "ticker_sentiment_score": "0.00439", "ticker_sentiment_label": "Neutral"}, {"ticker": "SONO", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.09253", "ticker_sentiment_label": "Neutral"}, {"ticker": "CARV", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.110266", "ticker_sentiment_label": "Neutral"}, {"ticker": "ETAO", "relevance_score": "0.013047", "ticker_sentiment_score": "0.00436", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLK", "relevance_score": "0.01957", "ticker_sentiment_score": "0.049358", "ticker_sentiment_label": "Neutral"}, {"ticker": "NKGN", "relevance_score": "0.013047", "ticker_sentiment_score": "0.004465", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMRC", "relevance_score": "0.013047", "ticker_sentiment_score": "0.004424", "ticker_sentiment_label": "Neutral"}, {"ticker": "CNS", "relevance_score": "0.006524", "ticker_sentiment_score": "-0.099512", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZAPP", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.097823", "ticker_sentiment_label": "Neutral"}, {"ticker": "HKIT", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.093428", "ticker_sentiment_label": "Neutral"}, {"ticker": "LOVE", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.110266", "ticker_sentiment_label": "Neutral"}, {"ticker": "EBS", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.110266", "ticker_sentiment_label": "Neutral"}, {"ticker": "NEXPF", "relevance_score": "0.006524", "ticker_sentiment_score": "0.005137", "ticker_sentiment_label": "Neutral"}, {"ticker": "PCRX", "relevance_score": "0.013047", "ticker_sentiment_score": "0.004424", "ticker_sentiment_label": "Neutral"}, {"ticker": "OFIX", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.087261", "ticker_sentiment_label": "Neutral"}, {"ticker": "KO", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.097823", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOSS", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.097823", "ticker_sentiment_label": "Neutral"}, {"ticker": "SATS", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.101353", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.013047", "ticker_sentiment_score": "0.004444", "ticker_sentiment_label": "Neutral"}, {"ticker": "LGVNR", "relevance_score": "0.006524", "ticker_sentiment_score": "-0.10474", "ticker_sentiment_label": "Neutral"}, {"ticker": "NEE", "relevance_score": "0.01957", "ticker_sentiment_score": "0.004589", "ticker_sentiment_label": "Neutral"}, {"ticker": "OGI", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.09253", "ticker_sentiment_label": "Neutral"}, {"ticker": "KXIN", "relevance_score": "0.013047", "ticker_sentiment_score": "0.068827", "ticker_sentiment_label": "Neutral"}, {"ticker": "SOL", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.087261", "ticker_sentiment_label": "Neutral"}, {"ticker": "DAR", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.097823", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMRN", "relevance_score": "0.013047", "ticker_sentiment_score": "0.073742", "ticker_sentiment_label": "Neutral"}, {"ticker": "PLBY", "relevance_score": "0.013047", "ticker_sentiment_score": "0.003524", "ticker_sentiment_label": "Neutral"}, {"ticker": "SLFPF", "relevance_score": "0.006524", "ticker_sentiment_score": "0.003297", "ticker_sentiment_label": "Neutral"}, {"ticker": "MXCT", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.101353", "ticker_sentiment_label": "Neutral"}, {"ticker": "NEP", "relevance_score": "0.013047", "ticker_sentiment_score": "0.003524", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADPT", "relevance_score": "0.013047", "ticker_sentiment_score": "0.073742", "ticker_sentiment_label": "Neutral"}, {"ticker": "CHRS", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.087261", "ticker_sentiment_label": "Neutral"}, {"ticker": "EVGO", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.079402", "ticker_sentiment_label": "Neutral"}, {"ticker": "KBNT", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.079402", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZBRA", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.079402", "ticker_sentiment_label": "Neutral"}, {"ticker": "DRUG", "relevance_score": "0.013047", "ticker_sentiment_score": "0.003524", "ticker_sentiment_label": "Neutral"}, {"ticker": "CSIQ", "relevance_score": "0.013047", "ticker_sentiment_score": "0.073742", "ticker_sentiment_label": "Neutral"}, {"ticker": "PRAA", "relevance_score": "0.013047", "ticker_sentiment_score": "0.004424", "ticker_sentiment_label": "Neutral"}, {"ticker": "MODN", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.087261", "ticker_sentiment_label": "Neutral"}, {"ticker": "MODV", "relevance_score": "0.013047", "ticker_sentiment_score": "0.065807", "ticker_sentiment_label": "Neutral"}, {"ticker": "FTCI", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.09253", "ticker_sentiment_label": "Neutral"}, {"ticker": "WHG", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.087261", "ticker_sentiment_label": "Neutral"}, {"ticker": "ME", "relevance_score": "0.006524", "ticker_sentiment_score": "0.004169", "ticker_sentiment_label": "Neutral"}, {"ticker": "PYPD", "relevance_score": "0.013047", "ticker_sentiment_score": "0.004444", "ticker_sentiment_label": "Neutral"}, {"ticker": "VSAT", "relevance_score": "0.013047", "ticker_sentiment_score": "0.00439", "ticker_sentiment_label": "Neutral"}, {"ticker": "HOTH", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.097823", "ticker_sentiment_label": "Neutral"}, {"ticker": "UTZ", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.097823", "ticker_sentiment_label": "Neutral"}, {"ticker": "NWL", "relevance_score": "0.013047", "ticker_sentiment_score": "0.00439", "ticker_sentiment_label": "Neutral"}, {"ticker": "MP", "relevance_score": "0.013047", "ticker_sentiment_score": "0.00439", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMRA", "relevance_score": "0.013047", "ticker_sentiment_score": "0.004444", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMT", "relevance_score": "0.01957", "ticker_sentiment_score": "-0.004616", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAG", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.09253", "ticker_sentiment_label": "Neutral"}, {"ticker": "MAXN", "relevance_score": "0.013047", "ticker_sentiment_score": "0.004465", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRNT", "relevance_score": "0.013047", "ticker_sentiment_score": "0.004424", "ticker_sentiment_label": "Neutral"}, {"ticker": "SAFE", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.079402", "ticker_sentiment_label": "Neutral"}, {"ticker": "MED", "relevance_score": "0.013047", "ticker_sentiment_score": "0.065807", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOEV", "relevance_score": "0.013047", "ticker_sentiment_score": "0.004444", "ticker_sentiment_label": "Neutral"}, {"ticker": "PXMD", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.097823", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESTA", "relevance_score": "0.013047", "ticker_sentiment_score": "0.004424", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANL", "relevance_score": "0.013047", "ticker_sentiment_score": "0.004424", "ticker_sentiment_label": "Neutral"}, {"ticker": "SKLZ", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.101353", "ticker_sentiment_label": "Neutral"}, {"ticker": "PARA", "relevance_score": "0.01957", "ticker_sentiment_score": "-0.030206", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRIS", "relevance_score": "0.013047", "ticker_sentiment_score": "0.005387", "ticker_sentiment_label": "Neutral"}, {"ticker": "PRTA", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.083761", "ticker_sentiment_label": "Neutral"}, {"ticker": "INO", "relevance_score": "0.013047", "ticker_sentiment_score": "0.004465", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNSE", "relevance_score": "0.013047", "ticker_sentiment_score": "0.00439", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANGI", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.087261", "ticker_sentiment_label": "Neutral"}, {"ticker": "PLL", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.09253", "ticker_sentiment_label": "Neutral"}, {"ticker": "CHEF", "relevance_score": "0.013047", "ticker_sentiment_score": "0.004465", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.013047", "ticker_sentiment_score": "0.004465", "ticker_sentiment_label": "Neutral"}, {"ticker": "RMBL", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.097823", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.013047", "ticker_sentiment_score": "0.004444", "ticker_sentiment_label": "Neutral"}, {"ticker": "DRVN", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.075927", "ticker_sentiment_label": "Neutral"}, {"ticker": "CSLR", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.09253", "ticker_sentiment_label": "Neutral"}, {"ticker": "RVTY", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.097823", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMPS", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.113741", "ticker_sentiment_label": "Neutral"}, {"ticker": "LMDX", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.087261", "ticker_sentiment_label": "Neutral"}, {"ticker": "SCI", "relevance_score": "0.013047", "ticker_sentiment_score": "0.003467", "ticker_sentiment_label": "Neutral"}, {"ticker": "DVN", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.113741", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXR", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.087261", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLNE", "relevance_score": "0.013047", "ticker_sentiment_score": "-0.09253", "ticker_sentiment_label": "Neutral"}]}, {"title": "These diabetes stocks, pummeled by the Ozempic craze, now look like bargains, analysts say", "url": "https://www.marketwatch.com/story/these-diabetes-stocks-pummeled-by-the-ozempic-craze-now-look-like-bargains-analysts-say-30906b51", "time_published": "20231005T133100", "authors": ["Eleanor Laise"], "summary": "DexCom could be the first stock to break out of 'GLP jail,' analysts say, as market continues to punish device makers ...", "banner_image": "https://images.mktw.net/im-852331/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.133373, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "INSP", "relevance_score": "0.105836", "ticker_sentiment_score": "0.104689", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.105836", "ticker_sentiment_score": "-0.013472", "ticker_sentiment_label": "Neutral"}, {"ticker": "PODD", "relevance_score": "0.260559", "ticker_sentiment_score": "0.154043", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABT", "relevance_score": "0.105836", "ticker_sentiment_score": "0.023242", "ticker_sentiment_label": "Neutral"}, {"ticker": "TNDM", "relevance_score": "0.105836", "ticker_sentiment_score": "0.138579", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.405378", "ticker_sentiment_score": "0.22407", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Stocks making the biggest moves midday: Sunnova Energy, Cal-Maine Foods, Marathon Petroleum and more", "url": "https://www.cnbc.com/2023/10/04/stocks-making-the-biggest-moves-midday-sunnova-energy-cal-maine-foods-marathon-petroleum-and-more.html", "time_published": "20231004T172048", "authors": ["Sarah Min"], "summary": "These are the stocks posting the largest moves in midday trading.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107311223-1696415314649-gettyimages-1075912616-GC183128.jpeg?v=1696440048&w=1920&h=1080", "source": "CNBC", "category_within_source": "Market Insider", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.576289"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}], "overall_sentiment_score": 0.202802, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CALM", "relevance_score": "0.121037", "ticker_sentiment_score": "0.096135", "ticker_sentiment_label": "Neutral"}, {"ticker": "MPC", "relevance_score": "0.121037", "ticker_sentiment_score": "0.160091", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PSX", "relevance_score": "0.121037", "ticker_sentiment_score": "0.160091", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NCLH", "relevance_score": "0.121037", "ticker_sentiment_score": "-0.006037", "ticker_sentiment_label": "Neutral"}, {"ticker": "NOVA", "relevance_score": "0.239305", "ticker_sentiment_score": "0.079917", "ticker_sentiment_label": "Neutral"}, {"ticker": "PODD", "relevance_score": "0.352223", "ticker_sentiment_score": "-0.005119", "ticker_sentiment_label": "Neutral"}, {"ticker": "RCL", "relevance_score": "0.121037", "ticker_sentiment_score": "-0.006037", "ticker_sentiment_label": "Neutral"}, {"ticker": "RUN", "relevance_score": "0.239305", "ticker_sentiment_score": "0.079917", "ticker_sentiment_label": "Neutral"}, {"ticker": "FLR", "relevance_score": "0.352223", "ticker_sentiment_score": "0.763831", "ticker_sentiment_label": "Bullish"}, {"ticker": "DXCM", "relevance_score": "0.239305", "ticker_sentiment_score": "-0.003786", "ticker_sentiment_label": "Neutral"}]}, {"title": "DexCom  ( DXCM )  Outpaces Stock Market Gains: What You Should Know", "url": "https://www.zacks.com/stock/news/2158890/dexcom-dxcm-outpaces-stock-market-gains-what-you-should-know", "time_published": "20231002T220019", "authors": ["Zacks Equity Research"], "summary": "In the latest trading session, DexCom (DXCM) closed at $94.55, marking a +1.34% move from the previous day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default195.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.95493"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.136318, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.618922", "ticker_sentiment_score": "0.274619", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Here's How Much You Would Have Made Owning DexCom Stock In The Last 15 Years - DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/news/earnings/23/10/35039555/heres-how-much-you-would-have-made-owning-dexcom-stock-in-the-last-15-years", "time_published": "20231002T193019", "authors": ["Benzinga Insights"], "summary": "DexCom DXCM has outperformed the market over the past 15 years by 22.87% on an annualized basis producing an average annual return of 33.0%. Currently, DexCom has a market capitalization of $36.07 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.983605", "ticker_sentiment_score": "0.387251", "ticker_sentiment_label": "Bullish"}]}, {"title": "3 Revolutionary Stocks I'd Buy Right Now Without Hesitation", "url": "https://www.fool.com/investing/2023/10/01/3-revolutionary-stocks-id-buy-right-now-without-he/", "time_published": "20231002T020700", "authors": ["Prosper Junior Bakiny"], "summary": "These companies are helping change medicine. they could make boatloads of money along the way.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.325233, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.09239", "ticker_sentiment_score": "0.086438", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABT", "relevance_score": "0.228287", "ticker_sentiment_score": "0.373606", "ticker_sentiment_label": "Bullish"}, {"ticker": "MRNA", "relevance_score": "0.272282", "ticker_sentiment_score": "0.123322", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.046273", "ticker_sentiment_score": "0.292442", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Buy this Tech Stock on the Dip in October for 50% Upside?", "url": "https://www.zacks.com/stock/news/2158109/buy-this-tech-stock-on-the-dip-in-october-for-50-upside", "time_published": "20230929T204900", "authors": ["Benjamin Rains"], "summary": "DXCM stock is currently down over 40% from its 2021 highs and trading 51% below its average Zacks price target even though it stands out in the connected health world that's likely to become standard medical practice.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default136.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.503496"}, {"topic": "Earnings", "relevance_score": "0.682689"}], "overall_sentiment_score": 0.224853, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.802526", "ticker_sentiment_score": "0.294208", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": " ( DXCM )  - Analyzing DexCom's Short Interest - DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/short-sellers/23/09/35010744/dxcm-analyzing-dexcoms-short-interest", "time_published": "20230929T193016", "authors": ["Benzinga Insights"], "summary": "DexCom's DXCM short percent of float has fallen 5.26% since its last report. The company recently reported that it has 16.03 million shares sold short, which is 4.68% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.4 days to cover their ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.24389, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.224903", "ticker_sentiment_score": "0.085754", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Abbott Says It Won't Be A Casualty Of The Weight-Loss Battle", "url": "https://www.investors.com/news/technology/abbott-stock-surges-after-spelling-out-bull-case-in-battle-with-weight-loss-drugs/", "time_published": "20230928T162200", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "Abbott Stock Surges After Spelling Our Bull Case In Battle With ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2019/10/stock-Abbott-05-shutter.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.980922"}], "overall_sentiment_score": 0.259839, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "EVR", "relevance_score": "0.082393", "ticker_sentiment_score": "0.067297", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.163909", "ticker_sentiment_score": "0.272253", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABT", "relevance_score": "0.163909", "ticker_sentiment_score": "0.052129", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.395012", "ticker_sentiment_score": "0.090731", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dynatronics Corporation  ( DYNT )  Reports Q4 Loss, Tops Revenue Estimates", "url": "https://www.zacks.com/stock/news/2157128/dynatronics-corporation-dynt-reports-q4-loss-tops-revenue-estimates", "time_published": "20230928T141502", "authors": ["Zacks Equity Research"], "summary": "Dynatronics Corporation (DYNT) delivered earnings and revenue surprises of -85.29% and 5.02%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default123.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999892"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.121452, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.141726", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DYNT", "relevance_score": "0.407844", "ticker_sentiment_score": "0.071885", "ticker_sentiment_label": "Neutral"}]}, {"title": "This Is What Whales Are Betting On DexCom - DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/markets/options/23/09/34977046/this-is-what-whales-are-betting-on-dexcom", "time_published": "20230928T140138", "authors": ["Benzinga Insights"], "summary": "Someone with a lot of money to spend has taken a bearish stance on DexCom DXCM. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.166772, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.78028", "ticker_sentiment_score": "0.19851", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "DexCom  ( DXCM )  Partners With RxFood for Automated Dietary Monitoring", "url": "https://www.zacks.com/stock/news/2156255/dexcom-dxcm-partners-with-rxfood-for-automated-dietary-monitoring", "time_published": "20230927T131600", "authors": ["Zacks Equity Research"], "summary": "DexCom's (DXCM) CGM systems will make dietary assessment through AI-enabled RxFood app, which automatically interprets food images for calorie count in Canada.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c0/2297.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}], "overall_sentiment_score": 0.313251, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.157141", "ticker_sentiment_score": "0.159438", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ALGN", "relevance_score": "0.157141", "ticker_sentiment_score": "0.120089", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCK", "relevance_score": "0.157141", "ticker_sentiment_score": "0.050559", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.645091", "ticker_sentiment_score": "0.429713", "ticker_sentiment_label": "Bullish"}]}, {"title": "Should Vanguard Mid-Cap Growth ETF  ( VOT )  Be on Your Investing Radar?", "url": "https://www.zacks.com/stock/news/2155920/should-vanguard-mid-cap-growth-etf-vot-be-on-your-investing-radar", "time_published": "20230927T102006", "authors": ["Zacks Equity Research"], "summary": "Style Box ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default301.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.305068, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "APH", "relevance_score": "0.115787", "ticker_sentiment_score": "0.066792", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.115787", "ticker_sentiment_score": "0.066792", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSI", "relevance_score": "0.115787", "ticker_sentiment_score": "0.066792", "ticker_sentiment_label": "Neutral"}]}, {"title": "Analysts Predict A 19% S&P 500 Surge Soon - Lifted By 10 Stocks", "url": "https://www.investors.com/etfs-and-funds/sectors/sp-500-analysts-predict-a-19-surge-soon-lifted-by-stocks/", "time_published": "20230925T120000", "authors": ["MATT KRANTZ", "Investor's Business Daily"], "summary": "It's been a rough half of the year for the S&P 500 - with it slipping nearly 3%. But that's not stopping analysts from calling for an amazing next 12 months.", "banner_image": "https://www.investors.com/wp-content/uploads/2021/04/Stock-flyingmoney-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}], "overall_sentiment_score": 0.328224, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "UAL", "relevance_score": "0.138066", "ticker_sentiment_score": "0.333697", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MGM", "relevance_score": "0.138066", "ticker_sentiment_score": "0.333697", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PODD", "relevance_score": "0.272029", "ticker_sentiment_score": "0.141792", "ticker_sentiment_label": "Neutral"}, {"ticker": "SEDG", "relevance_score": "0.33628", "ticker_sentiment_score": "0.174694", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.138066", "ticker_sentiment_score": "-0.078533", "ticker_sentiment_label": "Neutral"}]}, {"title": "Which High-Profile Stock-Split Stock Is the Cheapest? Get Ready to Be Shocked...", "url": "https://www.fool.com/investing/2023/09/25/which-high-profile-stock-split-stock-is-cheapest/", "time_published": "20230925T092100", "authors": ["Sean Williams"], "summary": "Among Nvidia, Amazon, DexCom, Shopify, Alphabet, Tesla, Palo Alto Networks, Monster Beverage, and Novo Nordisk, there's one clear-cut stock-split stock that's notably cheaper than the rest.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F748247%2Fstock-certificate-investment-retire-heirloom-donate-capital-gains-tax-getty.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.692272"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.744043"}], "overall_sentiment_score": 0.26852, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SHOP", "relevance_score": "0.074576", "ticker_sentiment_score": "0.130831", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.037329", "ticker_sentiment_score": "0.13785", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.074576", "ticker_sentiment_score": "0.130831", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.074576", "ticker_sentiment_score": "0.130831", "ticker_sentiment_label": "Neutral"}, {"ticker": "MNST", "relevance_score": "0.037329", "ticker_sentiment_score": "0.13785", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.037329", "ticker_sentiment_score": "0.065077", "ticker_sentiment_label": "Neutral"}, {"ticker": "USEG", "relevance_score": "0.037329", "ticker_sentiment_score": "0.13785", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.360229", "ticker_sentiment_score": "0.22883", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.037329", "ticker_sentiment_score": "0.13785", "ticker_sentiment_label": "Neutral"}, {"ticker": "PANW", "relevance_score": "0.074576", "ticker_sentiment_score": "0.130831", "ticker_sentiment_label": "Neutral"}]}, {"title": "Navigating The S&P 500 Landscape: Here Are The Stocks Analysts Believe Have The Highest Potential And Biggest Downside - Meta Platforms  ( NASDAQ:META ) , NVIDIA  ( NASDAQ:NVDA ) , SolarEdge Technologies  ( NASDAQ:SEDG ) , Expeditors Intl  ( NASDAQ:EXPD ) ", "url": "https://www.benzinga.com/markets/equities/23/09/34839781/navigating-the-s-p-500-landscape-here-are-the-stocks-analysts-believe-have-the-highest-potential", "time_published": "20230924T140118", "authors": ["Nabaparna Bhattacharya"], "summary": "In the middle of the AI revolution and the Federal Reserve's steadfast stance on interest rates, the stock market has seen unexpected twists and turns. Despite hopes of the U.S. sidestepping a potential recession, the stock market's trajectory remains unpredictable.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/24/spx.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.77141"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}], "overall_sentiment_score": 0.004746, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "META", "relevance_score": "0.121343", "ticker_sentiment_score": "0.054421", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.121343", "ticker_sentiment_score": "0.054421", "ticker_sentiment_label": "Neutral"}, {"ticker": "SEDG", "relevance_score": "0.121343", "ticker_sentiment_score": "-0.096623", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.060848", "ticker_sentiment_score": "-0.085002", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.239895", "ticker_sentiment_score": "0.007166", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXPD", "relevance_score": "0.121343", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PODD", "relevance_score": "0.121343", "ticker_sentiment_score": "-0.047596", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.121343", "ticker_sentiment_score": "-0.047596", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSN", "relevance_score": "0.121343", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ED", "relevance_score": "0.121343", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "DexCom Unusual Options Activity For September 22 - DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/markets/options/23/09/34828460/dexcom-unusual-options-activity-for-september-22", "time_published": "20230922T164558", "authors": ["Benzinga Insights"], "summary": "Someone with a lot of money to spend has taken a bullish stance on DexCom DXCM. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.163563, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.844916", "ticker_sentiment_score": "0.415258", "ticker_sentiment_label": "Bullish"}]}, {"title": "2 Healthcare Stocks That Could Make You Richer", "url": "https://www.fool.com/investing/2023/09/22/2-healthcare-stocks-that-could-make-you-richer/", "time_published": "20230922T140700", "authors": ["Prosper Junior Bakiny"], "summary": "They've beaten the market before.", "banner_image": "https://media.ycharts.com/charts/8f84b5c945a42d6a6356362e19522775.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.839681"}], "overall_sentiment_score": 0.229777, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.341699", "ticker_sentiment_score": "-0.00737", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.341699", "ticker_sentiment_score": "0.365333", "ticker_sentiment_label": "Bullish"}, {"ticker": "ABT", "relevance_score": "0.058759", "ticker_sentiment_score": "0.141", "ticker_sentiment_label": "Neutral"}]}, {"title": "Medtech Makers Are Real Losers From Obesity Drugs", "url": "https://www.barrons.com/articles/weight-loss-drugs-obesity-eli-lilly-novo-nordisk-bcd3dd6e", "time_published": "20230921T050000", "authors": ["Bill Alpert"], "summary": "Weight-Loss Drugs Are Bad News for Companies That Treat Obesity ... ...", "banner_image": "https://images.barrons.com/im-06751388?width=700&height=466", "source": "Barrons", "category_within_source": "n/a", "source_domain": "www.barrons.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.119443, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "INSP", "relevance_score": "0.414559", "ticker_sentiment_score": "0.161174", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TNDM", "relevance_score": "0.414559", "ticker_sentiment_score": "0.161174", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVO", "relevance_score": "0.414559", "ticker_sentiment_score": "0.428457", "ticker_sentiment_label": "Bullish"}, {"ticker": "LLY", "relevance_score": "0.414559", "ticker_sentiment_score": "0.428457", "ticker_sentiment_label": "Bullish"}, {"ticker": "MDGL", "relevance_score": "0.414559", "ticker_sentiment_score": "0.161174", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RMD", "relevance_score": "0.414559", "ticker_sentiment_score": "0.161174", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PODD", "relevance_score": "0.414559", "ticker_sentiment_score": "0.161174", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.586747", "ticker_sentiment_score": "0.049711", "ticker_sentiment_label": "Neutral"}]}, {"title": "Massive Insider Trade At DexCom - DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/news/23/09/34766167/massive-insider-trade-at-dexcom", "time_published": "20230920T150353", "authors": ["Benzinga Insights"], "summary": "Steven R Altman, Board Member at DexCom DXCM, reported a large insider sell on September 19, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Tuesday showed that Altman sold 1,000 shares of DexCom. The total transaction amounted to ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/insider_image_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.905476"}], "overall_sentiment_score": 0.127784, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.514619", "ticker_sentiment_score": "0.284661", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "3 Healthcare Stocks That Turned $100,000 Into $1 Million in 10 Years", "url": "https://www.fool.com/investing/2023/09/20/3-healthcare-stocks-that-turned-100000-into-1-mill/", "time_published": "20230920T093900", "authors": ["David Jagielski"], "summary": "Are these highly successful stocks still good buys today?", "banner_image": "https://media.ycharts.com/charts/baf7a2c02e6b9383f1853d6d4357574c.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.658903"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.995973"}], "overall_sentiment_score": 0.327785, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.280294", "ticker_sentiment_score": "0.164338", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WST", "relevance_score": "0.22595", "ticker_sentiment_score": "0.23179", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.22595", "ticker_sentiment_score": "0.206779", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "6 Healthcare Stocks Analysts Still Like", "url": "https://www.barrons.com/articles/healthcare-stocks-analysts-like-8b0f4dd2", "time_published": "20230920T070000", "authors": ["Josh Nathan-Kazis"], "summary": "This has been an epically bad year for the healthcare sector, but there are still a few stocks out there that Wall Street analysts like. Some of them are even more beaten down than the rest of the industry. The S&P 500 Health Care sector index is down 3% this year, vastly behind the S&P 500, ...", "banner_image": "https://images.barrons.com/im-81046107?width=639&height=426", "source": "Barrons", "category_within_source": "n/a", "source_domain": "www.barrons.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.918141"}, {"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.054264, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "TECH", "relevance_score": "0.240489", "ticker_sentiment_score": "0.079998", "ticker_sentiment_label": "Neutral"}, {"ticker": "BSX", "relevance_score": "0.16171", "ticker_sentiment_score": "0.059347", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.16171", "ticker_sentiment_score": "0.059347", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.16171", "ticker_sentiment_score": "0.059347", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZTS", "relevance_score": "0.459624", "ticker_sentiment_score": "0.130657", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIO", "relevance_score": "0.16171", "ticker_sentiment_score": "0.059347", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.16171", "ticker_sentiment_score": "0.059347", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.16171", "ticker_sentiment_score": "0.059347", "ticker_sentiment_label": "Neutral"}]}, {"title": "DexCom  ( DXCM )  Dips More Than Broader Markets: What You Should Know", "url": "https://www.zacks.com/stock/news/2152796/dexcom-dxcm-dips-more-than-broader-markets-what-you-should-know", "time_published": "20230919T220018", "authors": ["Zacks Equity Research"], "summary": "DexCom (DXCM) closed at $94.16 in the latest trading session, marking a -1.19% move from the prior day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default262.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972476"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.148675, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.610329", "ticker_sentiment_score": "0.225355", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "DexCom Unusual Options Activity - DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/markets/options/23/09/34739242/dexcom-unusual-options-activity", "time_published": "20230919T184558", "authors": ["Benzinga Insights"], "summary": "Someone with a lot of money to spend has taken a bullish stance on DexCom DXCM. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.", "banner_image": "https://www.benzinga.com/files/images/story/2023/1695149155_0.png", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.202802, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.815635", "ticker_sentiment_score": "0.369547", "ticker_sentiment_label": "Bullish"}]}, {"title": "Should Vanguard Mid-Cap ETF  ( VO )  Be on Your Investing Radar?", "url": "https://www.zacks.com/stock/news/2152267/should-vanguard-mid-cap-etf-vo-be-on-your-investing-radar", "time_published": "20230919T102005", "authors": ["Zacks Equity Research"], "summary": "Style Box ETF report for VO ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default67.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999999"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.241342, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "APH", "relevance_score": "0.130926", "ticker_sentiment_score": "0.070514", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.130926", "ticker_sentiment_score": "0.070514", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSI", "relevance_score": "0.130926", "ticker_sentiment_score": "0.070514", "ticker_sentiment_label": "Neutral"}]}, {"title": "Will DexCom Stock Recover To Its Pre-Inflation Shock Highs Of $160?", "url": "https://www.forbes.com/sites/greatspeculations/2023/09/18/will-dexcom-stock-recover-to-its-pre-inflation-shock-highs-of-160/", "time_published": "20230918T130000", "authors": ["Trefis Team"], "summary": "The notable increase in DexCom's revenues over recent quarters has also contributed to the stock recovery.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/6507c744660465a285935f6b/0x0.jpg?format=jpg&width=1200", "source": "Forbes", "category_within_source": "Markets", "source_domain": "www.forbes.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.9545"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.5855"}, {"topic": "Earnings", "relevance_score": "0.77141"}], "overall_sentiment_score": -0.082601, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.712997", "ticker_sentiment_score": "-0.104672", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.049939", "ticker_sentiment_score": "-0.136197", "ticker_sentiment_label": "Neutral"}]}, {"title": "DexCom  ( DXCM )  Launches Latest CGM Sensor ONE in France", "url": "https://www.zacks.com/stock/news/2151761/dexcom-dxcm-launches-latest-cgm-sensor-one-in-france", "time_published": "20230918T115900", "authors": ["Zacks Equity Research"], "summary": "DexCom's (DXCM) latest CGM sensor, DexCom ONE, secures reimbursement coverage in France, bringing the real-time CGM sensor to half a million diabetes patients in the country.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c8/39674.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Earnings", "relevance_score": "0.875462"}], "overall_sentiment_score": 0.317415, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HQY", "relevance_score": "0.148731", "ticker_sentiment_score": "0.04621", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALGN", "relevance_score": "0.148731", "ticker_sentiment_score": "0.104707", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCK", "relevance_score": "0.148731", "ticker_sentiment_score": "0.04621", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.76497", "ticker_sentiment_score": "0.578461", "ticker_sentiment_label": "Bullish"}]}, {"title": "Why DexCom Stock Dove by 5% Today", "url": "https://www.fool.com/investing/2023/09/15/why-dexcom-stock-dove-by-5-today/", "time_published": "20230915T221116", "authors": ["Eric Volkman"], "summary": "A note from an increasingly cautious pundit may have created a downdraft for this high-flying glucose monitor company.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.226084, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.760593", "ticker_sentiment_score": "0.363419", "ticker_sentiment_label": "Bullish"}]}, {"title": "Apple Taps Seasoned Executive To Head 'Secret' Team Developing Glucose Monitoring Device - Stocks To Watch - Apple  ( NASDAQ:AAPL ) ", "url": "https://www.benzinga.com/news/large-cap/23/09/34623127/apple-taps-seasoned-executive-to-head-secret-team-developing-glucose-monitoring-device-stocks-to-w", "time_published": "20230915T174653", "authors": ["Vandana Singh"], "summary": "Apple Inc AAPL has appointed Tim Millet, a seasoned executive with a background in iPhone and Mac chip technology, to oversee its secretive team dedicated to developing a noninvasive blood sugar monitor, signaling a significant move in the company's health technology endeavors.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/15/aapl-shutterstock_326987396.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.160861, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AAPL", "relevance_score": "0.531326", "ticker_sentiment_score": "0.379072", "ticker_sentiment_label": "Bullish"}, {"ticker": "PODD", "relevance_score": "0.33628", "ticker_sentiment_score": "0.261234", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABT", "relevance_score": "0.228073", "ticker_sentiment_score": "0.176207", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TNDM", "relevance_score": "0.33628", "ticker_sentiment_score": "0.261234", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.33628", "ticker_sentiment_score": "0.261234", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Stocks making the biggest moves midday: General Motors, Stellantis, Planet Fitness, Adobe and more", "url": "https://www.cnbc.com/2023/09/15/stocks-making-the-biggest-moves-midday-gm-stla-adbe-dash-and-more.html", "time_published": "20230915T170933", "authors": ["Alex Harring"], "summary": "These are the stocks posting the largest moves in midday trading.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107301565-1694790723029-gettyimages-1668230195-776023795wentzvilleuawstrike020.jpeg?v=1694798185&w=1920&h=1080", "source": "CNBC", "category_within_source": "Market Insider", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.692272"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.857896"}], "overall_sentiment_score": 0.074092, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMAT", "relevance_score": "0.052918", "ticker_sentiment_score": "-0.139003", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.105604", "ticker_sentiment_score": "0.020668", "ticker_sentiment_label": "Neutral"}, {"ticker": "GM", "relevance_score": "0.105604", "ticker_sentiment_score": "0.107059", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.052918", "ticker_sentiment_score": "0.071682", "ticker_sentiment_label": "Neutral"}, {"ticker": "PLNT", "relevance_score": "0.052918", "ticker_sentiment_score": "0.010995", "ticker_sentiment_label": "Neutral"}, {"ticker": "APLS", "relevance_score": "0.052918", "ticker_sentiment_score": "0.082034", "ticker_sentiment_label": "Neutral"}, {"ticker": "CWST", "relevance_score": "0.052918", "ticker_sentiment_score": "-0.112637", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.105604", "ticker_sentiment_score": "0.018545", "ticker_sentiment_label": "Neutral"}, {"ticker": "DASH", "relevance_score": "0.052918", "ticker_sentiment_score": "0.002001", "ticker_sentiment_label": "Neutral"}, {"ticker": "ASML", "relevance_score": "0.052918", "ticker_sentiment_score": "-0.139003", "ticker_sentiment_label": "Neutral"}, {"ticker": "PTCT", "relevance_score": "0.052918", "ticker_sentiment_score": "-0.011005", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.052918", "ticker_sentiment_score": "0.082034", "ticker_sentiment_label": "Neutral"}, {"ticker": "LRCX", "relevance_score": "0.052918", "ticker_sentiment_score": "-0.139003", "ticker_sentiment_label": "Neutral"}, {"ticker": "PODD", "relevance_score": "0.105604", "ticker_sentiment_score": "0.076543", "ticker_sentiment_label": "Neutral"}, {"ticker": "AXS", "relevance_score": "0.052918", "ticker_sentiment_score": "-0.074676", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.105604", "ticker_sentiment_score": "0.076543", "ticker_sentiment_label": "Neutral"}, {"ticker": "NUE", "relevance_score": "0.105604", "ticker_sentiment_score": "0.0588", "ticker_sentiment_label": "Neutral"}]}, {"title": "DexCom Unusual Options Activity - DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/markets/options/23/09/34619682/dexcom-unusual-options-activity", "time_published": "20230915T151658", "authors": ["Benzinga Insights"], "summary": "Someone with a lot of money to spend has taken a bearish stance on DexCom DXCM. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.17588, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.811755", "ticker_sentiment_score": "0.239598", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Beta Bionics Secures $100M To Advance Diabetic Care With iLet Artificial Pancreas System", "url": "https://www.benzinga.com/news/23/09/34597686/beta-bionics-secures-100m-to-advance-diabetic-care-with-ilet-artificial-pancreas-system", "time_published": "20230915T032340", "authors": ["Caleb Naysmith"], "summary": "Diabetes management technology pioneer Beta Bionics has achieved another milestone, successfully amassing $100 million in its latest Series D equity funding round. The recent accomplishment surpasses the company's previous Series C round in which it secured $57 million in early 2022.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/AI_Robot_Photo_by_Blue_Planet_Studio_on_Shutterstock_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.938793"}], "overall_sentiment_score": 0.26274, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.076602", "ticker_sentiment_score": "0.144613", "ticker_sentiment_label": "Neutral"}]}, {"title": "Apple Inc taps new leader for 'secret' team developing glucose tracker", "url": "https://www.business-standard.com/technology/tech-news/apple-inc-taps-new-leader-for-secret-team-developing-glucose-tracker-123091500147_1.html", "time_published": "20230915T031618", "authors": ["Bloomberg"], "summary": "Apple Inc. has named a new leader for its secret group working on a noninvasive blood sugar monitor, putting a veteran iPhone and Mac chip executive in charge of one of the company's most ambitious forays into health technology.", "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2023-09/15/full/1694747229-9875.jpg?im=FeatureCrop,size=(826,465)", "source": "Business Standard", "category_within_source": "GoogleRSS", "source_domain": "www.business-standard.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.132896, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AAPL", "relevance_score": "0.076847", "ticker_sentiment_score": "0.131685", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABT", "relevance_score": "0.076847", "ticker_sentiment_score": "-0.028784", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.152983", "ticker_sentiment_score": "-0.0377", "ticker_sentiment_label": "Neutral"}, {"ticker": "INTC", "relevance_score": "0.076847", "ticker_sentiment_score": "0.035358", "ticker_sentiment_label": "Neutral"}]}, {"title": "IoT Medical Devices Market Size is projected to reach USD 112 billion by 2031, growing at a CAGR of 27.6%: Straits Research", "url": "https://www.benzinga.com/pressreleases/23/09/g34583244/iot-medical-devices-market-size-is-projected-to-reach-usd-112-billion-by-2031-growing-at-a-cagr-of", "time_published": "20230914T141500", "authors": ["Globe Newswire"], "summary": "New York, United States, Sept. 14, 2023 ( GLOBE NEWSWIRE ) -- IoT medical devices manage mechanical ventilation systems and artificial airways, disperse aerosol-based medications, and identify and treat cardiopulmonary diseases.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.191031, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DGWPF", "relevance_score": "0.02671", "ticker_sentiment_score": "-0.025173", "ticker_sentiment_label": "Neutral"}, {"ticker": "GTLS", "relevance_score": "0.02671", "ticker_sentiment_score": "-0.025173", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.02671", "ticker_sentiment_score": "-0.025173", "ticker_sentiment_label": "Neutral"}, {"ticker": "RMD", "relevance_score": "0.05339", "ticker_sentiment_score": "0.044883", "ticker_sentiment_label": "Neutral"}, {"ticker": "MASI", "relevance_score": "0.02671", "ticker_sentiment_score": "-0.025173", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDT", "relevance_score": "0.02671", "ticker_sentiment_score": "-0.025173", "ticker_sentiment_label": "Neutral"}, {"ticker": "WLDS", "relevance_score": "0.02671", "ticker_sentiment_score": "0.089755", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.02671", "ticker_sentiment_score": "0.089755", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMIN", "relevance_score": "0.02671", "ticker_sentiment_score": "0.140861", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's Why You Should Retain DexCom  ( DXCM )  Stock for Now", "url": "https://www.zacks.com/stock/news/2148797/heres-why-you-should-retain-dexcom-dxcm-stock-for-now", "time_published": "20230914T115700", "authors": ["Zacks Equity Research"], "summary": "DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c0/2297.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}, {"topic": "Earnings", "relevance_score": "0.938238"}], "overall_sentiment_score": 0.266931, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HQY", "relevance_score": "0.122269", "ticker_sentiment_score": "0.04164", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALGN", "relevance_score": "0.122269", "ticker_sentiment_score": "0.094649", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCK", "relevance_score": "0.122269", "ticker_sentiment_score": "0.04164", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.427316", "ticker_sentiment_score": "0.415812", "ticker_sentiment_label": "Bullish"}]}, {"title": "DexCom  ( DXCM )  Outpaces Stock Market Gains: What You Should Know", "url": "https://www.zacks.com/stock/news/2148627/dexcom-dxcm-outpaces-stock-market-gains-what-you-should-know", "time_published": "20230913T220018", "authors": ["Zacks Equity Research"], "summary": "DexCom (DXCM) closed the most recent trading day at $105.22, moving +0.34% from the previous trading session.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default250.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.961735"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.177747, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.622414", "ticker_sentiment_score": "0.281948", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "DexCom  ( DXCM )  Rises 7% in One Week: What's Driving It?", "url": "https://www.zacks.com/stock/news/2147775/dexcom-dxcm-rises-7-in-one-week-whats-driving-it", "time_published": "20230912T124700", "authors": ["Zacks Equity Research"], "summary": "DexCom's (DXCM) shares have rallied nearly 7% over the past week, presumably on positive outlook for its CGM devices amid rising competition.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c8/39674.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.875462"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}], "overall_sentiment_score": 0.185275, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HQY", "relevance_score": "0.135602", "ticker_sentiment_score": "0.043832", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALGN", "relevance_score": "0.135602", "ticker_sentiment_score": "0.099456", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCK", "relevance_score": "0.135602", "ticker_sentiment_score": "0.043832", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.606834", "ticker_sentiment_score": "0.249896", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "$100 Invested In This Stock 15 Years Ago Would Be Worth $6,500 Today - DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/news/earnings/23/09/34452384/100-invested-in-this-stock-15-years-ago-would-be-worth-6-500-today", "time_published": "20230911T180030", "authors": ["Benzinga Insights"], "summary": "DexCom DXCM has outperformed the market over the past 15 years by 22.87% on an annualized basis producing an average annual return of 31.93%. Currently, DexCom has a market capitalization of $41.71 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.983605", "ticker_sentiment_score": "0.387251", "ticker_sentiment_label": "Bullish"}]}, {"title": "How Is The Market Feeling About DexCom? - DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/short-sellers/23/09/34367266/how-is-the-market-feeling-about-dexcom", "time_published": "20230908T171515", "authors": ["Benzinga Insights"], "summary": "DexCom's DXCM short percent of float has risen 11.87% since its last report. The company recently reported that it has 16.78 million shares sold short, which is 4.9% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.76 days to cover their ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.26961, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.224903", "ticker_sentiment_score": "0.158881", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "The Unexpected Reason Gilead Notched Its Biggest Single-Day Move In A Month", "url": "https://www.investors.com/news/technology/gild-stock-nabs-biggest-single-day-move-in-a-month-here-is-why/", "time_published": "20230908T164200", "authors": ["ALLISON GATLIN", "Investor's Business Daily"], "summary": "GILD Stock Nabs Biggest Single-Day Move In A Month. Here's Why Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2020/04/Stock-Gilead-07-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.996023"}], "overall_sentiment_score": 0.05558, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BAC", "relevance_score": "0.077094", "ticker_sentiment_score": "-0.039416", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.077094", "ticker_sentiment_score": "-0.186819", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "GILD", "relevance_score": "0.50186", "ticker_sentiment_score": "0.214434", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Why This Top Stock, With 172% Growth, Just Surged For A Second Day", "url": "https://www.investors.com/news/technology/cbay-stock-how-cymabay-with-huge-growth-this-year-is-taking-on-intercept-genfit/", "time_published": "20230908T155000", "authors": ["ALLISON GATLIN", "Investor's Business Daily"], "summary": "CBAY Stock: How CymaBay, With 172% Growth This Year, Is Taking ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2017/11/stock-drug-opioid-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.990999"}], "overall_sentiment_score": 0.087204, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CBAY", "relevance_score": "0.546745", "ticker_sentiment_score": "0.511169", "ticker_sentiment_label": "Bullish"}, {"ticker": "GNFT", "relevance_score": "0.252114", "ticker_sentiment_score": "0.085891", "ticker_sentiment_label": "Neutral"}, {"ticker": "ICPT", "relevance_score": "0.169676", "ticker_sentiment_score": "0.124904", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSSMY", "relevance_score": "0.169676", "ticker_sentiment_score": "0.182779", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.085324", "ticker_sentiment_score": "-0.190995", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "With 2x Potential Returns Is DexCom A Better Pick Over Intuitive Surgical?", "url": "https://www.forbes.com/sites/greatspeculations/2023/09/08/with-2x-potential-returns-is-dexcom-a-better-pick-over-intuitive-surgical/", "time_published": "20230908T100041", "authors": ["Trefis Team"], "summary": "We believe DexCom stock (NASDAQ: DXCM) is a better healthcare pick than Intuitive Surgical stock (NASDAQ: ISRG).", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/649a8cfb03be94c29c09d90c/0x0.jpg?format=jpg&width=1200", "source": "Forbes", "category_within_source": "Markets", "source_domain": "www.forbes.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.658903"}, {"topic": "Earnings", "relevance_score": "1.0"}], "overall_sentiment_score": 0.205194, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ISRG", "relevance_score": "0.755843", "ticker_sentiment_score": "0.330948", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.703596", "ticker_sentiment_score": "0.361349", "ticker_sentiment_label": "Bullish"}]}, {"title": "DexCom  ( DXCM )  Dips More Than Broader Markets: What You Should Know", "url": "https://www.zacks.com/stock/news/2146305/dexcom-dxcm-dips-more-than-broader-markets-what-you-should-know", "time_published": "20230907T220020", "authors": ["Zacks Equity Research"], "summary": "DexCom (DXCM) closed the most recent trading day at $104.91, moving -1.84% from the previous trading session.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default276.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.95493"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.162077, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.675573", "ticker_sentiment_score": "0.293406", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Strength Seen in DexCom  ( DXCM ) : Can Its 6.5% Jump Turn into More Strength?", "url": "https://www.zacks.com/stock/news/2145977/strength-seen-in-dexcom-dxcm-can-its-65-jump-turn-into-more-strength", "time_published": "20230907T134300", "authors": ["Zacks Equity Research"], "summary": "DexCom (DXCM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default236.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.972476"}], "overall_sentiment_score": 0.244162, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ITGR", "relevance_score": "0.522854", "ticker_sentiment_score": "-0.082906", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.68039", "ticker_sentiment_score": "0.380842", "ticker_sentiment_label": "Bullish"}]}, {"title": "Stock Market Eases Larger Losses; Drone Stock Rockets", "url": "https://www.investors.com/market-trend/stock-market-today/stock-market-trims-some-losses-drone-stock-rockets/", "time_published": "20230906T192200", "authors": ["KIMBERLEY KOENIG", "Investor's Business Daily"], "summary": "Stock Market Trims Some Losses. Drone Stock Rockets Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/06/Stock-drones-surveil-shutt.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.999996"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.744043"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.139119, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ASAN", "relevance_score": "0.127795", "ticker_sentiment_score": "-0.147154", "ticker_sentiment_label": "Neutral"}, {"ticker": "ROKU", "relevance_score": "0.190667", "ticker_sentiment_score": "0.138572", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVAV", "relevance_score": "0.127795", "ticker_sentiment_score": "0.010796", "ticker_sentiment_label": "Neutral"}, {"ticker": "NXGN", "relevance_score": "0.127795", "ticker_sentiment_score": "0.285491", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WFC", "relevance_score": "0.064104", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZS", "relevance_score": "0.127795", "ticker_sentiment_score": "0.055696", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.064104", "ticker_sentiment_score": "0.101176", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.127795", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "How Dexcom Allayed Concerns Of A Weight-Loss Bloodbath", "url": "https://www.investors.com/news/technology/dexcom-stock-leads-a-medtech-rally-how-it-allayed-concerns-of-a-weight-loss-bloodbath/", "time_published": "20230906T181300", "authors": ["ALLISON GATLIN", "Investor's Business Daily"], "summary": "Dexcom ( DXCM ) stock helped lead a medical surge Wednesday after the company allayed concerns that popular weight-loss drugs like Wegovy would tamp down usage of its diabetes devices. Instead, the inverse appears to be true, Dexcom said in a presentation Tuesday.", "banner_image": "https://www.investors.com/wp-content/uploads/2023/03/Stock-dexcom-one-04-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.990999"}], "overall_sentiment_score": 0.172265, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ZBH", "relevance_score": "0.259727", "ticker_sentiment_score": "0.383293", "ticker_sentiment_label": "Bullish"}, {"ticker": "DXCM", "relevance_score": "0.544246", "ticker_sentiment_score": "0.395399", "ticker_sentiment_label": "Bullish"}, {"ticker": "PODD", "relevance_score": "0.196344", "ticker_sentiment_score": "0.313165", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Stocks making the biggest moves midday: Roku, Tesla, AMC, AeroVironment and more", "url": "https://www.cnbc.com/2023/09/06/stocks-making-the-biggest-moves-midday.html", "time_published": "20230906T170123", "authors": ["Michelle Fox"], "summary": "These are the stocks posting the largest moves midday.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107287680-1692210746914-gettyimages-1602777575-AA_16082023_1310102.jpeg?v=1694020570&w=1920&h=1080", "source": "CNBC", "category_within_source": "Market Insider", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.990999"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.999996"}], "overall_sentiment_score": 0.123672, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ASAN", "relevance_score": "0.063258", "ticker_sentiment_score": "-0.170349", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "HOG", "relevance_score": "0.063258", "ticker_sentiment_score": "0.220339", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ROKU", "relevance_score": "0.126119", "ticker_sentiment_score": "0.199786", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GTLB", "relevance_score": "0.063258", "ticker_sentiment_score": "0.079284", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.063258", "ticker_sentiment_score": "-0.082211", "ticker_sentiment_label": "Neutral"}, {"ticker": "D", "relevance_score": "0.063258", "ticker_sentiment_score": "-0.01509", "ticker_sentiment_label": "Neutral"}, {"ticker": "LUV", "relevance_score": "0.126119", "ticker_sentiment_score": "-0.08474", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVAV", "relevance_score": "0.063258", "ticker_sentiment_score": "0.08904", "ticker_sentiment_label": "Neutral"}, {"ticker": "NXGN", "relevance_score": "0.063258", "ticker_sentiment_score": "0.12709", "ticker_sentiment_label": "Neutral"}, {"ticker": "APE", "relevance_score": "0.126119", "ticker_sentiment_score": "0.201251", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ENB", "relevance_score": "0.063258", "ticker_sentiment_score": "-0.01509", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZS", "relevance_score": "0.126119", "ticker_sentiment_score": "0.194361", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.126119", "ticker_sentiment_score": "0.043624", "ticker_sentiment_label": "Neutral"}]}, {"title": "AeroVironment, Daktronics, GitLab And Other Big Stocks Moving Higher On Wednesday - Bridger Aerospace Gr  ( NASDAQ:BAER ) , AeroVironment  ( NASDAQ:AVAV ) ", "url": "https://www.benzinga.com/news/23/09/34281971/aerovironment-daktronics-gitlab-and-other-big-stocks-moving-higher-on-wednesday", "time_published": "20230906T144321", "authors": ["Lisa Levin"], "summary": "U.S. stocks traded lower, with the Dow Jones falling around 100 points on Wednesday. Here are some big stocks recording gains in today's session. AeroVironment, Inc. AVAV shares surged 28.7% to $122.65 after the company reported better-than-expected results for its first quarter. Mitek Systems, ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/06/aerovironment_-_logo.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Real Estate & Construction", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}], "overall_sentiment_score": 0.352175, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "ROKU", "relevance_score": "0.288893", "ticker_sentiment_score": "-0.00652", "ticker_sentiment_label": "Neutral"}, {"ticker": "GTLB", "relevance_score": "0.288893", "ticker_sentiment_score": "0.770277", "ticker_sentiment_label": "Bullish"}, {"ticker": "WALD", "relevance_score": "0.288893", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SFWL", "relevance_score": "0.288893", "ticker_sentiment_score": "0.17288", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HKIT", "relevance_score": "0.288893", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOGO", "relevance_score": "0.421485", "ticker_sentiment_score": "0.385788", "ticker_sentiment_label": "Bullish"}, {"ticker": "BAER", "relevance_score": "0.288893", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVAV", "relevance_score": "0.288893", "ticker_sentiment_score": "0.557282", "ticker_sentiment_label": "Bullish"}, {"ticker": "NXGN", "relevance_score": "0.288893", "ticker_sentiment_score": "0.615482", "ticker_sentiment_label": "Bullish"}, {"ticker": "MITK", "relevance_score": "0.288893", "ticker_sentiment_score": "0.435147", "ticker_sentiment_label": "Bullish"}, {"ticker": "DAKT", "relevance_score": "0.288893", "ticker_sentiment_score": "0.518962", "ticker_sentiment_label": "Bullish"}, {"ticker": "CGC", "relevance_score": "0.288893", "ticker_sentiment_score": "0.563486", "ticker_sentiment_label": "Bullish"}, {"ticker": "DXCM", "relevance_score": "0.421485", "ticker_sentiment_score": "-0.192575", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CWCO", "relevance_score": "0.288893", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Jim Cramer's top 10 things to watch in the stock market Wednesday", "url": "https://www.cnbc.com/2023/09/06/jim-cramers-top-10-things-to-watch-in-the-stock-market-wednesday-.html", "time_published": "20230906T130822", "authors": ["Jim Cramer"], "summary": "Equities are lower in premarket trading Wednesday, while Arm Holdings' roadshow ahead of a planned initial public offering is impressive.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107290745-1692802098753-gettyimages-1619153799-ARM_IPO.jpeg?v=1694005702&w=1920&h=1080", "source": "CNBC", "category_within_source": "Top News", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "IPO", "relevance_score": "0.310843"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.997405"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.076538, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "TJX", "relevance_score": "0.136113", "ticker_sentiment_score": "0.161328", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "D", "relevance_score": "0.068306", "ticker_sentiment_score": "0.112032", "ticker_sentiment_label": "Neutral"}, {"ticker": "TTD", "relevance_score": "0.136113", "ticker_sentiment_score": "0.024715", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.136113", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SFTBF", "relevance_score": "0.068306", "ticker_sentiment_score": "0.078215", "ticker_sentiment_label": "Neutral"}, {"ticker": "STZ", "relevance_score": "0.136113", "ticker_sentiment_score": "0.17828", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CHTR", "relevance_score": "0.136113", "ticker_sentiment_score": "-0.3583", "ticker_sentiment_label": "Bearish"}, {"ticker": "AMGN", "relevance_score": "0.136113", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.136113", "ticker_sentiment_score": "0.028359", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.136113", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Down 10.3%, Is Abbott Laboratories Stock a Buy on the Dip?", "url": "https://www.fool.com/investing/2023/09/05/down-103-is-abbott-laboratories-stock-a-buy-on-the/", "time_published": "20230905T160041", "authors": ["Cory Renauer"], "summary": "Its latest pullback could be an opportunity to buy a legendary dividend stock before it begins a long upward climb.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F746425%2Fbiotech-laboratory-getty.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.967321"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.275783, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.127456", "ticker_sentiment_score": "0.103462", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABT", "relevance_score": "0.25168", "ticker_sentiment_score": "0.24504", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Why DexCom  ( DXCM )  is a Top Growth Stock for the Long-Term", "url": "https://www.zacks.com/stock/news/2144843/why-dexcom-dxcm-is-a-top-growth-stock-for-the-long-term", "time_published": "20230905T134507", "authors": ["Zacks Equity Research"], "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default185.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.838487"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}], "overall_sentiment_score": 0.390001, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.524949", "ticker_sentiment_score": "0.385734", "ticker_sentiment_label": "Bullish"}]}, {"title": "DexCom's  ( DXCM )  G6 CGM Connects With Omnipod 5 AID in Germany", "url": "https://www.zacks.com/stock/news/2144686/dexcoms-dxcm-g6-cgm-connects-with-omnipod-5-aid-in-germany", "time_published": "20230905T112900", "authors": ["Zacks Equity Research"], "summary": "DexCom's (DXCM) G6 CGM system and Omnipod 5 AID system can now simplify diabetes management and improve health outcomes in Germany.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c8/39674.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.875462"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}], "overall_sentiment_score": 0.268606, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HQY", "relevance_score": "0.157483", "ticker_sentiment_score": "0.047892", "ticker_sentiment_label": "Neutral"}, {"ticker": "PODD", "relevance_score": "0.208914", "ticker_sentiment_score": "0.04784", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALGN", "relevance_score": "0.157483", "ticker_sentiment_score": "0.108438", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCK", "relevance_score": "0.157483", "ticker_sentiment_score": "0.047892", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.835692", "ticker_sentiment_score": "0.512977", "ticker_sentiment_label": "Bullish"}]}, {"title": "DexCom  ( DXCM )  Outpaces Stock Market Gains: What You Should Know", "url": "https://www.zacks.com/stock/news/2143963/dexcom-dxcm-outpaces-stock-market-gains-what-you-should-know", "time_published": "20230901T215013", "authors": ["Zacks Equity Research"], "summary": "In the latest trading session, DexCom (DXCM) closed at $101.90, marking a +0.91% move from the previous day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default279.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972476"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.177233, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.677342", "ticker_sentiment_score": "0.315924", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "What's Next For DexCom Stock After A 17% Fall In A Month?", "url": "https://www.forbes.com/sites/greatspeculations/2023/09/01/whats-next-for-dexcom-stock-after-a-17-fall-in-a-month/", "time_published": "20230901T130042", "authors": ["Trefis Team"], "summary": "DexCom stock (NASDAQ: DXCM) has seen a 17% fall in a month, compared to a 2% fall for the broader S&P500 index.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/64f172bbc826a8a8881e8144/0x0.jpg?format=jpg&width=1200", "source": "Forbes", "category_within_source": "Markets", "source_domain": "www.forbes.com", "topics": [{"topic": "Earnings", "relevance_score": "0.98396"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.413559"}], "overall_sentiment_score": 0.17935, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.830107", "ticker_sentiment_score": "0.301318", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVO", "relevance_score": "0.078099", "ticker_sentiment_score": "-0.055025", "ticker_sentiment_label": "Neutral"}]}, {"title": "S&P 500 Hits 4500 As Odds Of Rate Pause Rise; Apple Offers Buy Point Ahead Of Key Event", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-pares-gains-from-rise-on-rate-pause-hopes-apple-offers-buy-point-ahead-of-key-event/", "time_published": "20230830T193800", "authors": ["Investor's Business Daily", "VIDYA RAMAKRISHNAN"], "summary": "S&P 500 Hits 4500 As Odds Of Rate Pause Rise. Apple Offers Buy ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2017/04/stock-wallstreet-shutter.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.998947"}, {"topic": "Earnings", "relevance_score": "0.576289"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.106856, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AAPL", "relevance_score": "0.128478", "ticker_sentiment_score": "-0.025095", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRWD", "relevance_score": "0.128478", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HPQ", "relevance_score": "0.128478", "ticker_sentiment_score": "-0.121955", "ticker_sentiment_label": "Neutral"}, {"ticker": "PODD", "relevance_score": "0.128478", "ticker_sentiment_score": "0.321296", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HPE", "relevance_score": "0.128478", "ticker_sentiment_score": "-0.133225", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADP", "relevance_score": "0.128478", "ticker_sentiment_score": "-0.027422", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.128478", "ticker_sentiment_score": "0.321296", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PANW", "relevance_score": "0.128478", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is Trending Stock DexCom, Inc.  ( DXCM )  a Buy Now?", "url": "https://www.zacks.com/stock/news/2142336/is-trending-stock-dexcom-inc-dxcm-a-buy-now", "time_published": "20230830T130005", "authors": ["Zacks Equity Research"], "summary": "Recently, Zacks.com users have been paying close attention to DexCom (DXCM). This makes it worthwhile to examine what the stock has in store.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default250.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999999"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.5855"}], "overall_sentiment_score": 0.230493, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.488469", "ticker_sentiment_score": "0.134862", "ticker_sentiment_label": "Neutral"}]}, {"title": "Insulet  ( PODD )  Launches Omnipod 5 AID System in Germany", "url": "https://www.zacks.com/stock/news/2142068/insulet-podd-launches-omnipod-5-aid-system-in-germany", "time_published": "20230829T153700", "authors": ["Zacks Equity Research"], "summary": "Insulet's (PODD) Omnipod 5 is available in the United States and the United Kingdom.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.890401"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.259565, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.464844", "ticker_sentiment_score": "0.400101", "ticker_sentiment_label": "Bullish"}, {"ticker": "HAE", "relevance_score": "0.243498", "ticker_sentiment_score": "0.101083", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.123209", "ticker_sentiment_score": "0.125524", "ticker_sentiment_label": "Neutral"}, {"ticker": "QTRX", "relevance_score": "0.123209", "ticker_sentiment_score": "0.059367", "ticker_sentiment_label": "Neutral"}]}, {"title": "1 Stock-Split Stock Billionaires Are Buying Hand Over Fist and 1 Unexpected Stock-Split Stock They're Selling", "url": "https://www.fool.com/investing/2023/08/28/1-stock-split-stock-billionaires-are-buying-hand-o/", "time_published": "20230828T105300", "authors": ["Cory Renauer"], "summary": "Some of the world's most successful investors are focusing on stocks.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F745579%2Findividual-investor-looking-at-stock-charts-getty.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.77141"}], "overall_sentiment_score": 0.244949, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NVDA", "relevance_score": "0.432701", "ticker_sentiment_score": "0.341449", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.151222", "ticker_sentiment_score": "0.071877", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABT", "relevance_score": "0.050679", "ticker_sentiment_score": "0.000998", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's Why You Should Retain Tandem Diabetes  ( TNDM )  Now", "url": "https://www.zacks.com/stock/news/2140703/heres-why-you-should-retain-tandem-diabetes-tndm-now", "time_published": "20230825T130400", "authors": ["Zacks Equity Research"], "summary": "Investors continue to be optimistic about Tandem Diabetes (TNDM) due to the t:slim X2 insulin pump and new product innovations.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2a/3899.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.997845"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.202184, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MDT", "relevance_score": "0.046907", "ticker_sentiment_score": "0.165505", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TNDM", "relevance_score": "0.231332", "ticker_sentiment_score": "0.209043", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HAE", "relevance_score": "0.231332", "ticker_sentiment_score": "0.07417", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.093653", "ticker_sentiment_score": "0.1527", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "QTRX", "relevance_score": "0.18602", "ticker_sentiment_score": "0.036012", "ticker_sentiment_label": "Neutral"}]}, {"title": "Should iShares Russell Mid-Cap Growth ETF  ( IWP )  Be on Your Investing Radar?", "url": "https://www.zacks.com/stock/news/2139351/should-ishares-russell-mid-cap-growth-etf-iwp-be-on-your-investing-radar", "time_published": "20230822T215905", "authors": ["Zacks Equity Research"], "summary": "Style Box ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default110.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.272958, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "APO", "relevance_score": "0.115787", "ticker_sentiment_score": "0.066792", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLK", "relevance_score": "0.058047", "ticker_sentiment_score": "0.128989", "ticker_sentiment_label": "Neutral"}, {"ticker": "IDXX", "relevance_score": "0.115787", "ticker_sentiment_score": "0.066792", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.115787", "ticker_sentiment_score": "0.066792", "ticker_sentiment_label": "Neutral"}]}, {"title": "Check Out What Whales Are Doing With DXCM - DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/markets/options/23/08/33992421/check-out-what-whales-are-doing-with-dxcm", "time_published": "20230822T191612", "authors": ["Benzinga Insights"], "summary": "Someone with a lot of money to spend has taken a bearish stance on DexCom DXCM. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.138862, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CCORF", "relevance_score": "0.095517", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.850133", "ticker_sentiment_score": "0.161812", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BCS", "relevance_score": "0.095517", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Revolutionary Stocks I'd Buy Right Now Without Hesitation", "url": "https://www.fool.com/investing/2023/08/22/3-revolutionary-stocks-id-buy-right-now-without/", "time_published": "20230822T140000", "authors": ["Prosper Junior Bakiny"], "summary": "Helping save and improve patients' lives in novel ways can be a lucrative activity.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F744850%2Fa-blue-tesla-car-driving-on-an-open-road.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.905476"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.268883, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.093289", "ticker_sentiment_score": "0.136447", "ticker_sentiment_label": "Neutral"}, {"ticker": "SRPT", "relevance_score": "0.274834", "ticker_sentiment_score": "0.245501", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.402045", "ticker_sentiment_score": "0.219254", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Jim Cramer's top 10 things to watch in the stock market Monday", "url": "https://www.cnbc.com/2023/08/21/jim-cramers-top-10-things-to-watch-in-the-stock-market-monday.html", "time_published": "20230821T130637", "authors": ["Jim Cramer"], "summary": "Stocks edge up in premarket trading Monday, following three-consecutive weeks of losses, as the market looks to Nvidia's (NVDA) quarterly report.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107247053-1685079163512-gettyimages-1177538069-MOBILE_WORLD_CONGRESS.jpeg?v=1692623197&w=1920&h=1080", "source": "CNBC", "category_within_source": "Top News", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.999822"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.576289"}], "overall_sentiment_score": 0.175159, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "EVR", "relevance_score": "0.058903", "ticker_sentiment_score": "0.067987", "ticker_sentiment_label": "Neutral"}, {"ticker": "DE", "relevance_score": "0.117486", "ticker_sentiment_score": "0.028623", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.175433", "ticker_sentiment_score": "-0.020198", "ticker_sentiment_label": "Neutral"}, {"ticker": "C", "relevance_score": "0.058903", "ticker_sentiment_score": "0.245053", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PTON", "relevance_score": "0.117486", "ticker_sentiment_score": "0.076178", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.117486", "ticker_sentiment_score": "0.174511", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.117486", "ticker_sentiment_score": "0.078557", "ticker_sentiment_label": "Neutral"}, {"ticker": "PANW", "relevance_score": "0.117486", "ticker_sentiment_score": "0.1932", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WMT", "relevance_score": "0.117486", "ticker_sentiment_score": "0.276597", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Insulin Patients Can Find Discounts With Amazon's New Automated Coupon System", "url": "https://www.kiplinger.com/personal-finance/health-insurance/insulin-patients-can-find-discounts-with-amazons-new-automated-coupon-system", "time_published": "20230816T213653", "authors": ["Joey Solitro"], "summary": "Amazon Pharmacy said it will now automatically apply manufacturer-sponsored coupons on more than 15 of the most prescribed insulin and diabetes care brand-name products to eligible customers for a price starting at $35 a month.", "banner_image": "https://cdn.mos.cms.futurecdn.net/9CpYF6JJBhujnHUTjGWPug-415-80.jpg", "source": "Kiplinger", "category_within_source": "n/a", "source_domain": "www.kiplinger.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.368353, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.079921", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.079921", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.079921", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.079921", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's Why You Should Invest in Edward Lifesciences  ( EW )  Now", "url": "https://www.zacks.com/stock/news/2136848/heres-why-you-should-invest-in-edward-lifesciences-ew-now", "time_published": "20230816T124100", "authors": ["Zacks Equity Research"], "summary": "Investors continue to be optimistic about Edward Lifesciences (EW) on the strength of a solid foundation for innovative therapies.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5d/2633.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.998287"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.257844, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "EW", "relevance_score": "0.245339", "ticker_sentiment_score": "0.234842", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BSX", "relevance_score": "0.049835", "ticker_sentiment_score": "-0.066389", "ticker_sentiment_label": "Neutral"}, {"ticker": "PEN", "relevance_score": "0.197413", "ticker_sentiment_score": "0.062318", "ticker_sentiment_label": "Neutral"}, {"ticker": "ICUI", "relevance_score": "0.049835", "ticker_sentiment_score": "0.1872", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MDT", "relevance_score": "0.099476", "ticker_sentiment_score": "0.12097", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.245339", "ticker_sentiment_score": "0.077788", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.148731", "ticker_sentiment_score": "0.030938", "ticker_sentiment_label": "Neutral"}]}, {"title": "Myriad Genetics  ( MYGN )  Adds ARR to Prolaris Biomarker Test", "url": "https://www.zacks.com/stock/news/2136842/myriad-genetics-mygn-adds-arr-to-prolaris-biomarker-test", "time_published": "20230816T123600", "authors": ["Zacks Equity Research"], "summary": "Myriad Genetics (MYGN) announces the integration of ARR into the Prolaris prostate cancer prognostic test.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/09/2677.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.904684"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.075103, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "HAE", "relevance_score": "0.113866", "ticker_sentiment_score": "0.057484", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.113866", "ticker_sentiment_score": "0.057484", "ticker_sentiment_label": "Neutral"}, {"ticker": "MYGN", "relevance_score": "0.383765", "ticker_sentiment_score": "-0.038731", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is Caribou Biosciences  ( CRBU )  Stock Outpacing Its Medical Peers This Year?", "url": "https://www.zacks.com/stock/news/2136629/is-caribou-biosciences-crbu-stock-outpacing-its-medical-peers-this-year", "time_published": "20230815T190802", "authors": ["Zacks Equity Research"], "summary": "Here is how Caribou Biosciences, Inc. (CRBU) and DexCom (DXCM) have performed compared to their sector so far this year.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default240.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.714479"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.224164, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CRBU", "relevance_score": "0.7414", "ticker_sentiment_score": "0.366955", "ticker_sentiment_label": "Bullish"}, {"ticker": "DXCM", "relevance_score": "0.384397", "ticker_sentiment_score": "0.200086", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Amazon's Boon for Diabetes Patients, Streamlining Pharmacy Discounts - Amazon.com  ( NASDAQ:AMZN ) ", "url": "https://www.benzinga.com/news/23/08/33857951/amazons-boon-for-diabetes-patients-streamlining-pharmacy-discounts", "time_published": "20230815T164143", "authors": ["Anusuya Lahiri"], "summary": "Amazon.Com Inc's AMZN online pharmacy launched a new initiative on Tuesday to streamline the process for diabetes patients seeking discounts on their medications. The program automatically applies manufacturer-sponsored coupons to over 15 insulin and diabetes drugs.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/08/15/amazon_pharmacy.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}], "overall_sentiment_score": 0.18233, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CVS", "relevance_score": "0.230235", "ticker_sentiment_score": "0.295601", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVO", "relevance_score": "0.230235", "ticker_sentiment_score": "-0.031595", "ticker_sentiment_label": "Neutral"}, {"ticker": "WBA", "relevance_score": "0.230235", "ticker_sentiment_score": "0.295601", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LLY", "relevance_score": "0.230235", "ticker_sentiment_score": "-0.031595", "ticker_sentiment_label": "Neutral"}, {"ticker": "PODD", "relevance_score": "0.116348", "ticker_sentiment_score": "0.087101", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.620083", "ticker_sentiment_score": "0.291297", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.116348", "ticker_sentiment_score": "0.087101", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.230235", "ticker_sentiment_score": "-0.031595", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amazon Pharmacy Announces Coupons For Insulin- Revolutionizing Medication Access, Yet Again", "url": "https://www.forbes.com/sites/saibala/2023/08/15/amazon-pharmacy-announces-coupons-for-insulin--revolutionizing-medication-access-yet-again/", "time_published": "20230815T110824", "authors": ["J.D.", "Sai Balasubramanian", "M.D."], "summary": "With a commitment to improving patient care and a tech-forward mindset, Amazon Pharmacy is powerful force of innovation.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/64db5c778cd8bf5f77635ee6/0x0.jpg?format=jpg&crop=555,312,x0,y58,safe&width=1200", "source": "Forbes", "category_within_source": "Business", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.372885, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.05387", "ticker_sentiment_score": "0.193812", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.05387", "ticker_sentiment_score": "0.193812", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVO", "relevance_score": "0.05387", "ticker_sentiment_score": "0.193812", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNY", "relevance_score": "0.05387", "ticker_sentiment_score": "0.193812", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Amazon Pharmacy automates discounts to help insulin patients get pledged prices", "url": "https://www.reuters.com/business/retail-consumer/amazon-pharmacy-automates-discounts-help-insulin-patients-get-pledged-prices-2023-08-15/", "time_published": "20230815T110500", "authors": ["Patrick Wingrove"], "summary": "Aug 15 ( Reuters ) - Amazon.com ( AMZN.O ) said on Tuesday its online pharmacy will automatically apply manufacturer-sponsored coupons to more than 15 insulin and diabetes medicines to help patients access discounts pledged by the drug industry.", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/5MJTPB6Y6RM5VABWXQGMXIYZ4M.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}], "overall_sentiment_score": 0.177439, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CVS", "relevance_score": "0.08687", "ticker_sentiment_score": "0.139198", "ticker_sentiment_label": "Neutral"}, {"ticker": "PODD", "relevance_score": "0.08687", "ticker_sentiment_score": "0.214015", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.08687", "ticker_sentiment_score": "0.214015", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVO", "relevance_score": "0.08687", "ticker_sentiment_score": "-0.052904", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.172713", "ticker_sentiment_score": "-0.073495", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amazon Pharmacy Launches $35 Insulin Coupons As Transparency Takes Hold", "url": "https://www.forbes.com/sites/brucejapsen/2023/08/15/amazon-pharmacy-launches-35-insulin-coupons-amid-transparency-debate/", "time_published": "20230815T110000", "authors": ["Bruce Japsen"], "summary": "Amazon Pharmacy is rolling out coupons that \"automatically\" reduce customer costs for insulin to as low as $35 a month on more than a dozen diabetes care brands.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/64da7ade3bc405da80635ebe/0x0.jpg?format=jpg&width=1200", "source": "Forbes", "category_within_source": "Business", "source_domain": "www.forbes.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.131092, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.089462", "ticker_sentiment_score": "0.165028", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.089462", "ticker_sentiment_score": "0.165028", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HCSG", "relevance_score": "0.089462", "ticker_sentiment_score": "0.107692", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.089462", "ticker_sentiment_score": "0.165028", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNY", "relevance_score": "0.089462", "ticker_sentiment_score": "0.165028", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Abbott  ( ABT )  EPD Arm Grows, Low Testing Sales Play Spoilsport", "url": "https://www.zacks.com/stock/news/2136258/abbott-abt-epd-arm-grows-low-testing-sales-play-spoilsport", "time_published": "20230814T154400", "authors": ["Zacks Equity Research"], "summary": "Banking on the successful execution of Abbott's (ABT) branded generic operating model, EPD is well positioned for sustained growth in many of the growing pharmaceutical markets.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3c/1479.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.995869"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.232948, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ABT", "relevance_score": "0.162073", "ticker_sentiment_score": "0.123826", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.214937", "ticker_sentiment_score": "0.083275", "ticker_sentiment_label": "Neutral"}, {"ticker": "ISRG", "relevance_score": "0.214937", "ticker_sentiment_score": "0.079526", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.214937", "ticker_sentiment_score": "0.119267", "ticker_sentiment_label": "Neutral"}]}, {"title": "Reasons to Retain Quest Diagnostics  ( DGX )  Stock for Now", "url": "https://www.zacks.com/stock/news/2136208/reasons-to-retain-quest-diagnostics-dgx-stock-for-now", "time_published": "20230814T141500", "authors": ["Zacks Equity Research"], "summary": "Investors are optimistic about Quest Diagnostics (DGX) on the strength of the base business performance and acquisitions.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7b/2387.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Earnings", "relevance_score": "0.997845"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.299751, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "III", "relevance_score": "0.098054", "ticker_sentiment_score": "-0.049371", "ticker_sentiment_label": "Neutral"}, {"ticker": "PEN", "relevance_score": "0.194632", "ticker_sentiment_score": "0.06165", "ticker_sentiment_label": "Neutral"}, {"ticker": "DGX", "relevance_score": "0.501986", "ticker_sentiment_score": "0.474596", "ticker_sentiment_label": "Bullish"}, {"ticker": "HAE", "relevance_score": "0.241924", "ticker_sentiment_score": "0.076912", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.146618", "ticker_sentiment_score": "0.031991", "ticker_sentiment_label": "Neutral"}]}, {"title": "Cigna  ( CI )  Unit Ties Up to Offer Digital Health Tool to Clients", "url": "https://www.zacks.com/stock/news/2135912/cigna-ci-unit-ties-up-to-offer-digital-health-tool-to-clients", "time_published": "20230811T160600", "authors": ["Zacks Equity Research"], "summary": "Cigna's (CI) division, Cigna Healthcare, teams up with Virgin Pulse to make an effective digital health solution available to its clients, who can now improve their well-being.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4b/2087.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.890401"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.313349, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMPH", "relevance_score": "0.312158", "ticker_sentiment_score": "0.20583", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CI", "relevance_score": "0.312158", "ticker_sentiment_score": "0.380466", "ticker_sentiment_label": "Bullish"}, {"ticker": "DXCM", "relevance_score": "0.211191", "ticker_sentiment_score": "0.131004", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCA", "relevance_score": "0.26224", "ticker_sentiment_score": "0.151959", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "How Is The Market Feeling About DexCom? - DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/short-sellers/23/08/33748794/how-is-the-market-feeling-about-dexcom", "time_published": "20230811T131516", "authors": ["Benzinga Insights"], "summary": "DexCom's DXCM short percent of float has risen 20.99% since its last report. The company recently reported that it has 15.00 million shares sold short, which is 4.38% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.31 days to cover their ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.26961, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.224903", "ticker_sentiment_score": "0.158881", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Syneos Health  ( SYNH )  to Go Private, Reports Q2 Performance", "url": "https://www.zacks.com/stock/news/2135568/syneos-health-synh-to-go-private-reports-q2-performance", "time_published": "20230811T125300", "authors": ["Zacks Equity Research"], "summary": "Syneos Health (SYNH) announces shareholders' approval for the impending merger and releases second-quarter 2023 financial results.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f6/47493.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.98396"}, {"topic": "Earnings", "relevance_score": "0.994953"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.258079, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HAE", "relevance_score": "0.176287", "ticker_sentiment_score": "0.063257", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.176287", "ticker_sentiment_score": "0.063257", "ticker_sentiment_label": "Neutral"}, {"ticker": "SYNH", "relevance_score": "0.396798", "ticker_sentiment_score": "0.411583", "ticker_sentiment_label": "Bullish"}]}, {"title": "Medtronic  ( MDT )  Rides on Strong Global Growth, New Launches", "url": "https://www.zacks.com/stock/news/2135176/medtronic-mdt-rides-on-strong-global-growth-new-launches", "time_published": "20230810T152700", "authors": ["Zacks Equity Research"], "summary": "Medtronic (MDT) is gaining from positive sales momentum with the rollout of its differentiated Hugo robotic system in many international markets.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5e/1093.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}, {"topic": "Earnings", "relevance_score": "0.99489"}], "overall_sentiment_score": 0.227757, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MDT", "relevance_score": "0.536645", "ticker_sentiment_score": "0.283489", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HAE", "relevance_score": "0.261117", "ticker_sentiment_score": "0.09744", "ticker_sentiment_label": "Neutral"}, {"ticker": "ISRG", "relevance_score": "0.158519", "ticker_sentiment_score": "0.060196", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.210274", "ticker_sentiment_score": "0.120453", "ticker_sentiment_label": "Neutral"}]}, {"title": "Accuray  ( ARAY )  Q4 Earnings and Revenues Lag Estimates", "url": "https://www.zacks.com/stock/news/2135175/accuray-aray-q4-earnings-and-revenues-lag-estimates", "time_published": "20230810T152600", "authors": ["Zacks Equity Research"], "summary": "Accuray (ARAY) reports a solid fiscal fourth quarter top line on the back of robust segmental performances.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/df/34747.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.996718"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": -0.043492, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ITGR", "relevance_score": "0.17879", "ticker_sentiment_score": "0.026061", "ticker_sentiment_label": "Neutral"}, {"ticker": "ISRG", "relevance_score": "0.17879", "ticker_sentiment_score": "-0.007307", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.17879", "ticker_sentiment_score": "0.057806", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARAY", "relevance_score": "0.465709", "ticker_sentiment_score": "0.164194", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Avanos  ( AVNS )  Q2 Earnings and Revenues Fall Shy of Estimates", "url": "https://www.zacks.com/stock/news/2135169/avanos-avns-q2-earnings-and-revenues-fall-shy-of-estimates", "time_published": "20230810T152200", "authors": ["Zacks Equity Research"], "summary": "Despite strength in Avanos' (AVNS) Digestive Health segment, its overall second-quarter results reflect soft performances.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/01/36484.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.99992"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": -0.004847, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AVNS", "relevance_score": "0.166455", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITGR", "relevance_score": "0.166455", "ticker_sentiment_score": "0.024788", "ticker_sentiment_label": "Neutral"}, {"ticker": "ISRG", "relevance_score": "0.166455", "ticker_sentiment_score": "-0.006949", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.166455", "ticker_sentiment_score": "0.054988", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is Abbott Laboratories Stock a Buy Now?", "url": "https://www.fool.com/investing/2023/08/10/is-abbott-laboratories-stock-a-buy-now/", "time_published": "20230810T140000", "authors": ["David Jagielski"], "summary": "The healthcare company recently boosted its guidance.", "banner_image": "https://media.ycharts.com/charts/4fd9131b7f4cc20aabd5921507aa6e3e.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.917436"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.413559"}], "overall_sentiment_score": 0.334497, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.057767", "ticker_sentiment_score": "0.123119", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABT", "relevance_score": "0.172097", "ticker_sentiment_score": "0.237394", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Here's Why You Should Retain National Vision  ( EYE )  Stock Now", "url": "https://www.zacks.com/stock/news/2134925/heres-why-you-should-retain-national-vision-eye-stock-now", "time_published": "20230810T130800", "authors": ["Zacks Equity Research"], "summary": "Investors are optimistic about National Vision's (EYE) stock, banking on comparable store sales growth and technological investments.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/b2/19786.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.929393"}, {"topic": "Earnings", "relevance_score": "0.998917"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.302517, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "EYE", "relevance_score": "0.512453", "ticker_sentiment_score": "0.508479", "ticker_sentiment_label": "Bullish"}, {"ticker": "WRBY", "relevance_score": "0.039548", "ticker_sentiment_score": "-0.023785", "ticker_sentiment_label": "Neutral"}, {"ticker": "TOPCF", "relevance_score": "0.039548", "ticker_sentiment_score": "0.229663", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HAE", "relevance_score": "0.195814", "ticker_sentiment_score": "0.063501", "ticker_sentiment_label": "Neutral"}, {"ticker": "ISRG", "relevance_score": "0.157227", "ticker_sentiment_score": "0.05304", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.118257", "ticker_sentiment_score": "0.028624", "ticker_sentiment_label": "Neutral"}]}, {"title": "QuidelOrtho  ( QDEL )  Q2 Earnings Top Estimates, FY23 View Revised", "url": "https://www.zacks.com/stock/news/2134452/quidelortho-qdel-q2-earnings-top-estimates-fy23-view-revised", "time_published": "20230809T165300", "authors": ["Zacks Equity Research"], "summary": "Despite solid performances by the Labs segment and Other region, QuidelOrtho (QDEL) reports soft overall top-line results in second-quarter 2023.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/df/34747.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.999955"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": -0.004769, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ITGR", "relevance_score": "0.140076", "ticker_sentiment_score": "0.021018", "ticker_sentiment_label": "Neutral"}, {"ticker": "ISRG", "relevance_score": "0.140076", "ticker_sentiment_score": "-0.006233", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.140076", "ticker_sentiment_score": "0.050651", "ticker_sentiment_label": "Neutral"}, {"ticker": "QDEL", "relevance_score": "0.40348", "ticker_sentiment_score": "0.084533", "ticker_sentiment_label": "Neutral"}]}, {"title": "Masimo  ( MASI )  Q2 Earnings Lag Estimates, Margins Rise", "url": "https://www.zacks.com/stock/news/2134451/masimo-masi-q2-earnings-lag-estimates-margins-rise", "time_published": "20230809T165100", "authors": ["Zacks Equity Research"], "summary": "Despite strength in Hearables category, Masimo's (MASI) overall second-quarter results reflect soft performances.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/01/36484.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.999975"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": -0.028439, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MASI", "relevance_score": "0.415802", "ticker_sentiment_score": "0.100787", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITGR", "relevance_score": "0.157741", "ticker_sentiment_score": "0.023919", "ticker_sentiment_label": "Neutral"}, {"ticker": "ISRG", "relevance_score": "0.157741", "ticker_sentiment_score": "-0.006705", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.157741", "ticker_sentiment_score": "0.053067", "ticker_sentiment_label": "Neutral"}]}, {"title": "This Is What Whales Are Betting On DexCom - DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/markets/options/23/08/33668720/this-is-what-whales-are-betting-on-dexcom", "time_published": "20230809T140224", "authors": ["Benzinga Insights"], "summary": "A whale with a lot of money to spend has taken a noticeably bearish stance on DexCom. Looking at options history for DexCom DXCM we detected 11 strange trades. If we consider the specifics of each trade, it is accurate to state that 18% of the investors opened trades with bullish expectations ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.125164, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BCS", "relevance_score": "0.109455", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "C", "relevance_score": "0.109455", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CCORF", "relevance_score": "0.109455", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.869914", "ticker_sentiment_score": "0.041231", "ticker_sentiment_label": "Neutral"}]}, {"title": "Investing $1,000 in These 2 Top Stocks Would Be a Brilliant Move", "url": "https://www.fool.com/investing/2023/08/09/investing-1000-in-these-2-top-stocks-would-be-a/", "time_published": "20230809T130000", "authors": ["Prosper Junior Bakiny"], "summary": "Even after crushing the market in the past year, these stocks are worth investing in.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.839681"}, {"topic": "Earnings", "relevance_score": "0.972756"}], "overall_sentiment_score": 0.204248, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ABT", "relevance_score": "0.048523", "ticker_sentiment_score": "0.080759", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.41608", "ticker_sentiment_score": "0.221131", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HCSG", "relevance_score": "0.048523", "ticker_sentiment_score": "0.047391", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCA", "relevance_score": "0.457157", "ticker_sentiment_score": "0.197175", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "PacBio  ( PACB )  Inks Research Collaboration for Genome Sequencing", "url": "https://www.zacks.com/stock/news/2134275/pacbio-pacb-inks-research-collaboration-for-genome-sequencing", "time_published": "20230809T121600", "authors": ["Zacks Equity Research"], "summary": "PacBio (PACB) and GeneDx sign a deal with the University of Washington to study long-read sequencing in rare diseases. The study will use PacBio's Revio system to explore novel variants.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7b/850.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.220373, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.120733", "ticker_sentiment_score": "0.095128", "ticker_sentiment_label": "Neutral"}, {"ticker": "WGS", "relevance_score": "0.552443", "ticker_sentiment_score": "0.240095", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PACB", "relevance_score": "0.295867", "ticker_sentiment_score": "0.210311", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.180236", "ticker_sentiment_score": "0.146051", "ticker_sentiment_label": "Neutral"}]}, {"title": "Inogen  ( INGN )  Q2 Earnings Beat Estimates, Revenues Down Y/Y", "url": "https://www.zacks.com/stock/news/2133763/inogen-ingn-q2-earnings-beat-estimates-revenues-down-yy", "time_published": "20230808T154000", "authors": ["Zacks Equity Research"], "summary": "Despite higher domestic business-to-business sales and rental revenues, Inogen's (INGN) overall second-quarter results reflect soft performances.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/01/36484.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.998663"}], "overall_sentiment_score": 0.035864, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ITGR", "relevance_score": "0.173645", "ticker_sentiment_score": "0.025524", "ticker_sentiment_label": "Neutral"}, {"ticker": "ISRG", "relevance_score": "0.173645", "ticker_sentiment_score": "-0.007157", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.173645", "ticker_sentiment_score": "0.056618", "ticker_sentiment_label": "Neutral"}, {"ticker": "INGN", "relevance_score": "0.524142", "ticker_sentiment_score": "0.043467", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's Why You Should Retain Insulet  ( PODD )  Stock for Now", "url": "https://www.zacks.com/stock/news/2133521/heres-why-you-should-retain-insulet-podd-stock-for-now", "time_published": "20230808T122000", "authors": ["Zacks Equity Research"], "summary": "Investors continue to be optimistic about Insulet (PODD) on the strength of the Omnipod 5 AID system.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c0/2563.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Earnings", "relevance_score": "0.999997"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.197681, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.535653", "ticker_sentiment_score": "0.270795", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MDT", "relevance_score": "0.038906", "ticker_sentiment_score": "0.182485", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TNDM", "relevance_score": "0.038906", "ticker_sentiment_score": "0.182485", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HAE", "relevance_score": "0.192694", "ticker_sentiment_score": "0.062734", "ticker_sentiment_label": "Neutral"}, {"ticker": "ISRG", "relevance_score": "0.154703", "ticker_sentiment_score": "0.131912", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.116348", "ticker_sentiment_score": "0.028426", "ticker_sentiment_label": "Neutral"}]}, {"title": "MannKind  ( MNKD )  Q2 2023 Earnings Call Transcript", "url": "https://www.fool.com/earnings/call-transcripts/2023/08/08/mannkind-mnkd-q2-2023-earnings-call-transcript/", "time_published": "20230808T040023", "authors": ["Motley Fool Transcribing"], "summary": "MNKD earnings call for the period ending June 30, 2023.", "banner_image": "https://g.foolcdn.com/misc-assets/fool-transcripts-logo.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.999612"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Real Estate & Construction", "relevance_score": "0.5"}], "overall_sentiment_score": 0.24904, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "APG", "relevance_score": "0.005073", "ticker_sentiment_score": "0.166676", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MDT", "relevance_score": "0.005073", "ticker_sentiment_score": "0.13282", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSSMY", "relevance_score": "0.005073", "ticker_sentiment_score": "0.159461", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.04057", "ticker_sentiment_score": "0.076577", "ticker_sentiment_label": "Neutral"}, {"ticker": "MNKD", "relevance_score": "0.055762", "ticker_sentiment_score": "0.081", "ticker_sentiment_label": "Neutral"}, {"ticker": "UTHR", "relevance_score": "0.035502", "ticker_sentiment_score": "0.147925", "ticker_sentiment_label": "Neutral"}]}, {"title": "OPKO Health  ( OPK )  Q2 Earnings and Revenues Top Estimates", "url": "https://www.zacks.com/stock/news/2133267/opko-health-opk-q2-earnings-and-revenues-top-estimates", "time_published": "20230807T172100", "authors": ["Zacks Equity Research"], "summary": "Despite OPKO Health's (OPK) robust RAYALDEE sales and strength in the Pharmaceuticals segment, its overall second-quarter results reflect soft performances.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/01/36484.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.938793"}], "overall_sentiment_score": 0.047882, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "OPK", "relevance_score": "0.532761", "ticker_sentiment_score": "0.006736", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITGR", "relevance_score": "0.153715", "ticker_sentiment_score": "0.022213", "ticker_sentiment_label": "Neutral"}, {"ticker": "ISRG", "relevance_score": "0.153715", "ticker_sentiment_score": "-0.00659", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.153715", "ticker_sentiment_score": "0.053522", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.077218", "ticker_sentiment_score": "0.184518", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Mobile health solutions market to grow at a CAGR of 27.09% from 2022 to 2027 | Increasing smartphone penetration will drive growth - Technavio", "url": "https://www.benzinga.com/pressreleases/23/08/n33534424/mobile-health-solutions-market-to-grow-at-a-cagr-of-27-09-from-2022-to-2027-increasing-smartphone-", "time_published": "20230802T211500", "authors": ["PRNewswire"], "summary": "NEW YORK, Aug. 2, 2023 /PRNewswire/ -- The mobile health solutions market size is estimated to grow by USD 256.69 billion from 2022 to 2027, at a CAGR of 27.09% according to Technavio. Download a Sample Report! Coverage: Parent market analysis. key drivers, major trends, and challenges.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.198256, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AAPL", "relevance_score": "0.028816", "ticker_sentiment_score": "0.089819", "ticker_sentiment_label": "Neutral"}, {"ticker": "CSCO", "relevance_score": "0.086297", "ticker_sentiment_score": "0.070871", "ticker_sentiment_label": "Neutral"}, {"ticker": "BSX", "relevance_score": "0.086297", "ticker_sentiment_score": "0.070871", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.01441", "ticker_sentiment_score": "0.091708", "ticker_sentiment_label": "Neutral"}, {"ticker": "MASI", "relevance_score": "0.028816", "ticker_sentiment_score": "0.233446", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ORCL", "relevance_score": "0.057594", "ticker_sentiment_score": "0.079957", "ticker_sentiment_label": "Neutral"}, {"ticker": "NOK", "relevance_score": "0.01441", "ticker_sentiment_score": "0.091708", "ticker_sentiment_label": "Neutral"}, {"ticker": "SSNLF", "relevance_score": "0.086297", "ticker_sentiment_score": "0.057487", "ticker_sentiment_label": "Neutral"}, {"ticker": "OMRNF", "relevance_score": "0.057594", "ticker_sentiment_score": "0.079957", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABT", "relevance_score": "0.01441", "ticker_sentiment_score": "0.091708", "ticker_sentiment_label": "Neutral"}, {"ticker": "QCOM", "relevance_score": "0.01441", "ticker_sentiment_score": "0.091708", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDRX", "relevance_score": "0.057594", "ticker_sentiment_score": "0.071956", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDT", "relevance_score": "0.057594", "ticker_sentiment_score": "0.079957", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.043212", "ticker_sentiment_score": "0.084081", "ticker_sentiment_label": "Neutral"}]}, {"title": "5 Top Stocks Likely to Beat Earnings Estimates", "url": "https://www.zacks.com/stock/news/2130906/5-top-stocks-likely-to-beat-earnings-estimates", "time_published": "20230802T105700", "authors": ["Sanghamitra Saha"], "summary": "These top-ranked stocks are likely to beat on the bottom line in their upcoming releases. Tap Coty (COTY), BJ's Restaurants (BJRI), DexCom (DXCM), Livent (LTHM) and D.R. Horton (DHI).", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/6d/30194.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.503496"}], "overall_sentiment_score": 0.329739, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.199037", "ticker_sentiment_score": "0.146295", "ticker_sentiment_label": "Neutral"}, {"ticker": "LTHM", "relevance_score": "0.199037", "ticker_sentiment_score": "0.121635", "ticker_sentiment_label": "Neutral"}]}, {"title": "DexCom  ( NASDAQ:DXCM )  Stock Rating Lowered by StockNews.com", "url": "https://www.defenseworld.net/2023/08/02/dexcom-nasdaqdxcm-stock-rating-lowered-by-stocknews-com.html", "time_published": "20230802T063244", "authors": ["Defense World Staff"], "summary": "DexCom ( NASDAQ:DXCM - Get Free Report ) was downgraded by StockNews.com from a \"buy\" rating to a \"hold\" rating in a research note issued to investors on Monday. A number of other research analysts also recently weighed in on the company.", "banner_image": "https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&Symbol=DXCM", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Real Estate & Construction", "relevance_score": "0.5"}], "overall_sentiment_score": 0.276503, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "APG", "relevance_score": "0.043658", "ticker_sentiment_score": "0.108273", "ticker_sentiment_label": "Neutral"}, {"ticker": "CCORF", "relevance_score": "0.043658", "ticker_sentiment_score": "0.054662", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.792014", "ticker_sentiment_score": "0.447152", "ticker_sentiment_label": "Bullish"}]}, {"title": "Dow Jones Closes Higher; Tesla Rival Surges On New EV Truck Deal", "url": "https://www.investors.com:443/market-trend/stock-market-today/dow-jones-holds-gains-apple-software-stocks-rise-as-ipo-stock-breaks-out-branch/", "time_published": "20230731T203034", "authors": ["Investor's Business Daily", "VIDYA RAMAKRISHNAN"], "summary": "Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2020/12/Stock-Nikola-TreElectric-company.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com:443", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "0.999999"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.983605"}, {"topic": "Real Estate & Construction", "relevance_score": "0.166667"}], "overall_sentiment_score": 0.139971, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AAPL", "relevance_score": "0.145583", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRWD", "relevance_score": "0.145583", "ticker_sentiment_score": "0.192444", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MS", "relevance_score": "0.073098", "ticker_sentiment_score": "0.110786", "ticker_sentiment_label": "Neutral"}, {"ticker": "DDOG", "relevance_score": "0.145583", "ticker_sentiment_score": "0.192444", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RMBS", "relevance_score": "0.21686", "ticker_sentiment_score": "0.021926", "ticker_sentiment_label": "Neutral"}, {"ticker": "URI", "relevance_score": "0.145583", "ticker_sentiment_score": "0.094643", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.21686", "ticker_sentiment_score": "0.232892", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DT", "relevance_score": "0.145583", "ticker_sentiment_score": "0.084634", "ticker_sentiment_label": "Neutral"}, {"ticker": "SHOP", "relevance_score": "0.21686", "ticker_sentiment_score": "0.111873", "ticker_sentiment_label": "Neutral"}, {"ticker": "SLRN", "relevance_score": "0.145583", "ticker_sentiment_score": "-0.18396", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "TSLA", "relevance_score": "0.145583", "ticker_sentiment_score": "0.070852", "ticker_sentiment_label": "Neutral"}, {"ticker": "SBUX", "relevance_score": "0.145583", "ticker_sentiment_score": "0.177394", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NKLA", "relevance_score": "0.145583", "ticker_sentiment_score": "0.070852", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADBE", "relevance_score": "0.21686", "ticker_sentiment_score": "0.20645", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMD", "relevance_score": "0.21686", "ticker_sentiment_score": "0.232892", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RSTGF", "relevance_score": "0.073098", "ticker_sentiment_score": "-0.145459", "ticker_sentiment_label": "Neutral"}, {"ticker": "GNRC", "relevance_score": "0.145583", "ticker_sentiment_score": "0.084634", "ticker_sentiment_label": "Neutral"}, {"ticker": "TEAM", "relevance_score": "0.28636", "ticker_sentiment_score": "0.298217", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HUBS", "relevance_score": "0.145583", "ticker_sentiment_score": "0.084634", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBER", "relevance_score": "0.145583", "ticker_sentiment_score": "0.177394", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.145583", "ticker_sentiment_score": "-0.130979", "ticker_sentiment_label": "Neutral"}, {"ticker": "ON", "relevance_score": "0.073098", "ticker_sentiment_score": "0.227339", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "S&P 500: Entertainment Giants, AI Play Lead Monday's Winners", "url": "https://www.investors.com/news/sp-500-entertainment-giants-ai-play-adobe-lead-monday-5-best-medtech-firms-sicken/", "time_published": "20230731T202600", "authors": ["ED CARSON", "Investor's Business Daily"], "summary": "S&P 500: Entertainment Giants, AI Play Lead Monday's 5 Best. Medtech Firms Sicken Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2016/10/BIZ08_Paramount_101016_company.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.999997"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.875462"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": -0.094629, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NFLX", "relevance_score": "0.144275", "ticker_sentiment_score": "-0.10412", "ticker_sentiment_label": "Neutral"}, {"ticker": "A", "relevance_score": "0.072435", "ticker_sentiment_score": "-0.188627", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PARA", "relevance_score": "0.350564", "ticker_sentiment_score": "-0.312457", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MS", "relevance_score": "0.072435", "ticker_sentiment_score": "0.238828", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.214937", "ticker_sentiment_score": "-0.338748", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ADBE", "relevance_score": "0.28387", "ticker_sentiment_score": "0.033288", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAX", "relevance_score": "0.28387", "ticker_sentiment_score": "-0.288383", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "HAS", "relevance_score": "0.144275", "ticker_sentiment_score": "-0.114448", "ticker_sentiment_label": "Neutral"}, {"ticker": "MTD", "relevance_score": "0.28387", "ticker_sentiment_score": "-0.36827", "ticker_sentiment_label": "Bearish"}, {"ticker": "URI", "relevance_score": "0.350564", "ticker_sentiment_score": "-0.332521", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "DXCM", "relevance_score": "0.350564", "ticker_sentiment_score": "-0.071612", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dow Jones Holds Gains: Apple, Software Stocks Rise As IPO Stock Breaks Out", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-holds-gains-apple-software-stocks-rise-as-ipo-stock-breaks-out/", "time_published": "20230731T180100", "authors": ["VIDYA RAMAKRISHNAN", "Investor's Business Daily"], "summary": "Major indexes traded sideways on Monday at 1:30 p.m. ET. The Dow Jones Industrial Average rose by less than 0.5%, holding a gain of over 3% for the month after June's hefty 4.6% gain. The S&P 500 declined less than 0.1%. The Nasdaq was also down less than 0.1% in early afternoon trading.", "banner_image": "https://www.investors.com/wp-content/uploads/2019/06/Stock-Software-39-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.999966"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.838487"}], "overall_sentiment_score": 0.172362, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AAPL", "relevance_score": "0.18046", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRWD", "relevance_score": "0.18046", "ticker_sentiment_score": "0.130383", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.090816", "ticker_sentiment_score": "0.123832", "ticker_sentiment_label": "Neutral"}, {"ticker": "DDOG", "relevance_score": "0.18046", "ticker_sentiment_score": "0.130383", "ticker_sentiment_label": "Neutral"}, {"ticker": "RMBS", "relevance_score": "0.267804", "ticker_sentiment_score": "0.167438", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "URI", "relevance_score": "0.18046", "ticker_sentiment_score": "0.177733", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.267804", "ticker_sentiment_score": "0.300056", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DT", "relevance_score": "0.18046", "ticker_sentiment_score": "0.1232", "ticker_sentiment_label": "Neutral"}, {"ticker": "SHOP", "relevance_score": "0.267804", "ticker_sentiment_score": "0.167438", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SLRN", "relevance_score": "0.18046", "ticker_sentiment_score": "-0.204907", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SBUX", "relevance_score": "0.18046", "ticker_sentiment_score": "0.223442", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ADBE", "relevance_score": "0.267804", "ticker_sentiment_score": "0.214051", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMD", "relevance_score": "0.267804", "ticker_sentiment_score": "0.300056", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RSTGF", "relevance_score": "0.090816", "ticker_sentiment_score": "-0.148783", "ticker_sentiment_label": "Neutral"}, {"ticker": "GNRC", "relevance_score": "0.18046", "ticker_sentiment_score": "0.1232", "ticker_sentiment_label": "Neutral"}, {"ticker": "TEAM", "relevance_score": "0.351807", "ticker_sentiment_score": "0.29744", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HUBS", "relevance_score": "0.18046", "ticker_sentiment_score": "0.1232", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBER", "relevance_score": "0.18046", "ticker_sentiment_score": "0.223442", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.18046", "ticker_sentiment_score": "-0.288489", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ON", "relevance_score": "0.090816", "ticker_sentiment_score": "0.288535", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Stock Market Rallies Amid Earnings Wave, Fed Hike: Weekly Review", "url": "https://www.investors.com/news/stock-market-rallies-amid-huge-earnings-fed-rate-hike-inflation-data-weekly-review/", "time_published": "20230728T180600", "authors": ["IBD STAFF", "Investor's Business Daily"], "summary": "The stock market rally advanced amid a massive wave of earnings reports, a new Fed rate hike and tame inflation data, though the Dow Jones ended a long winning streak. Microsoft ( MSFT ) guidance disappointed, hitting many related stocks.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/11/SSA_runners_111716_adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Economy - Monetary", "relevance_score": "0.998626"}, {"topic": "IPO", "relevance_score": "0.310843"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "0.999998"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Real Estate & Construction", "relevance_score": "0.166667"}], "overall_sentiment_score": 0.046839, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALK", "relevance_score": "0.028023", "ticker_sentiment_score": "0.085676", "ticker_sentiment_label": "Neutral"}, {"ticker": "MEDP", "relevance_score": "0.042024", "ticker_sentiment_score": "0.023927", "ticker_sentiment_label": "Neutral"}, {"ticker": "MXL", "relevance_score": "0.042024", "ticker_sentiment_score": "0.080984", "ticker_sentiment_label": "Neutral"}, {"ticker": "XPEV", "relevance_score": "0.056011", "ticker_sentiment_score": "0.075891", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDNDF", "relevance_score": "0.028023", "ticker_sentiment_score": "0.000969", "ticker_sentiment_label": "Neutral"}, {"ticker": "CROX", "relevance_score": "0.042024", "ticker_sentiment_score": "-0.03692", "ticker_sentiment_label": "Neutral"}, {"ticker": "STM", "relevance_score": "0.028023", "ticker_sentiment_score": "0.079327", "ticker_sentiment_label": "Neutral"}, {"ticker": "EADSF", "relevance_score": "0.028023", "ticker_sentiment_score": "0.022458", "ticker_sentiment_label": "Neutral"}, {"ticker": "TMHC", "relevance_score": "0.042024", "ticker_sentiment_score": "0.040814", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.042024", "ticker_sentiment_score": "0.067579", "ticker_sentiment_label": "Neutral"}, {"ticker": "MA", "relevance_score": "0.014014", "ticker_sentiment_score": "0.125985", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMG", "relevance_score": "0.056011", "ticker_sentiment_score": "0.001005", "ticker_sentiment_label": "Neutral"}, {"ticker": "NXT(EXP20091224)", "relevance_score": "0.028023", "ticker_sentiment_score": "0.045804", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.125606", "ticker_sentiment_score": "0.003689", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPOT", "relevance_score": "0.042024", "ticker_sentiment_score": "0.023684", "ticker_sentiment_label": "Neutral"}, {"ticker": "YELL", "relevance_score": "0.028023", "ticker_sentiment_score": "-0.183394", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "DMPZF", "relevance_score": "0.014014", "ticker_sentiment_score": "0.000903", "ticker_sentiment_label": "Neutral"}, {"ticker": "FSLR", "relevance_score": "0.028023", "ticker_sentiment_score": "0.082349", "ticker_sentiment_label": "Neutral"}, {"ticker": "NOW", "relevance_score": "0.028023", "ticker_sentiment_score": "-0.00188", "ticker_sentiment_label": "Neutral"}, {"ticker": "XOM", "relevance_score": "0.028023", "ticker_sentiment_score": "-0.045613", "ticker_sentiment_label": "Neutral"}, {"ticker": "RCL", "relevance_score": "0.042024", "ticker_sentiment_score": "0.088612", "ticker_sentiment_label": "Neutral"}, {"ticker": "BA", "relevance_score": "0.097854", "ticker_sentiment_score": "0.057951", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.028023", "ticker_sentiment_score": "0.19241", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ENPH", "relevance_score": "0.028023", "ticker_sentiment_score": "0.082349", "ticker_sentiment_label": "Neutral"}, {"ticker": "CVX", "relevance_score": "0.028023", "ticker_sentiment_score": "-0.045613", "ticker_sentiment_label": "Neutral"}, {"ticker": "RETA", "relevance_score": "0.042024", "ticker_sentiment_score": "0.20082", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SRGRF", "relevance_score": "0.014014", "ticker_sentiment_score": "0.077924", "ticker_sentiment_label": "Neutral"}, {"ticker": "TXN", "relevance_score": "0.028023", "ticker_sentiment_score": "0.079327", "ticker_sentiment_label": "Neutral"}, {"ticker": "TPH", "relevance_score": "0.042024", "ticker_sentiment_score": "0.040814", "ticker_sentiment_label": "Neutral"}, {"ticker": "URI", "relevance_score": "0.028023", "ticker_sentiment_score": "-0.1576", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ARCB", "relevance_score": "0.042024", "ticker_sentiment_score": "-0.188433", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "DPZ", "relevance_score": "0.028023", "ticker_sentiment_score": "0.000969", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.125606", "ticker_sentiment_score": "0.044225", "ticker_sentiment_label": "Neutral"}, {"ticker": "NCLH", "relevance_score": "0.042024", "ticker_sentiment_score": "0.088612", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNP", "relevance_score": "0.028023", "ticker_sentiment_score": "-0.183394", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "V", "relevance_score": "0.028023", "ticker_sentiment_score": "0.135277", "ticker_sentiment_label": "Neutral"}, {"ticker": "RTX", "relevance_score": "0.069982", "ticker_sentiment_score": "-0.057853", "ticker_sentiment_label": "Neutral"}, {"ticker": "LRCX", "relevance_score": "0.028023", "ticker_sentiment_score": "0.079327", "ticker_sentiment_label": "Neutral"}, {"ticker": "X", "relevance_score": "0.028023", "ticker_sentiment_score": "-0.037481", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.028023", "ticker_sentiment_score": "0.068047", "ticker_sentiment_label": "Neutral"}, {"ticker": "GE", "relevance_score": "0.069982", "ticker_sentiment_score": "0.163632", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NUE", "relevance_score": "0.042024", "ticker_sentiment_score": "-0.038835", "ticker_sentiment_label": "Neutral"}, {"ticker": "KLAC", "relevance_score": "0.028023", "ticker_sentiment_score": "0.079327", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.069982", "ticker_sentiment_score": "0.021478", "ticker_sentiment_label": "Neutral"}, {"ticker": "GM", "relevance_score": "0.083931", "ticker_sentiment_score": "0.056588", "ticker_sentiment_label": "Neutral"}, {"ticker": "NXPI", "relevance_score": "0.028023", "ticker_sentiment_score": "0.079327", "ticker_sentiment_label": "Neutral"}, {"ticker": "LUV", "relevance_score": "0.028023", "ticker_sentiment_score": "0.085676", "ticker_sentiment_label": "Neutral"}, {"ticker": "CCS", "relevance_score": "0.028023", "ticker_sentiment_score": "0.03937", "ticker_sentiment_label": "Neutral"}, {"ticker": "NIO", "relevance_score": "0.028023", "ticker_sentiment_score": "0.069735", "ticker_sentiment_label": "Neutral"}, {"ticker": "INTC", "relevance_score": "0.028023", "ticker_sentiment_score": "0.079327", "ticker_sentiment_label": "Neutral"}, {"ticker": "PI", "relevance_score": "0.028023", "ticker_sentiment_score": "0.079327", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIO", "relevance_score": "0.028023", "ticker_sentiment_score": "-0.037481", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLF", "relevance_score": "0.042024", "ticker_sentiment_score": "-0.038835", "ticker_sentiment_label": "Neutral"}, {"ticker": "LI", "relevance_score": "0.028023", "ticker_sentiment_score": "0.069735", "ticker_sentiment_label": "Neutral"}, {"ticker": "ODFL", "relevance_score": "0.042024", "ticker_sentiment_score": "-0.188433", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CRYPTO:NXT", "relevance_score": "0.028023", "ticker_sentiment_score": "0.045804", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dow Jones Rally Sparked By Surging Intel Stock; Nasdaq 100 Leaders Include Tesla, Dexcom, KLAC", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-rally-sparked-by-surging-intel-stock-nasdaq-100-leaders-tesla-tsla-dexcom-dxcm-klacs/", "time_published": "20230728T145000", "authors": ["Investor's Business Daily", "KEN SHREVE"], "summary": "Dow Jones Rally Sparked By Surging Intel Stock. Nasdaq 100 Leaders Include Tesla, Dexcom, KLAC Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2018/05/Stock-dow-04-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.998333"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.999986"}], "overall_sentiment_score": 0.32493, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "KLAC", "relevance_score": "0.156461", "ticker_sentiment_score": "0.336563", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ENPH", "relevance_score": "0.156461", "ticker_sentiment_score": "-0.164017", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CVX", "relevance_score": "0.104683", "ticker_sentiment_score": "-0.225203", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "RETA", "relevance_score": "0.104683", "ticker_sentiment_score": "0.15005", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HURN", "relevance_score": "0.104683", "ticker_sentiment_score": "0.248102", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IVZ", "relevance_score": "0.052455", "ticker_sentiment_score": "0.414996", "ticker_sentiment_label": "Bullish"}, {"ticker": "FUTU", "relevance_score": "0.156461", "ticker_sentiment_score": "0.152466", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FSLR", "relevance_score": "0.104683", "ticker_sentiment_score": "0.128486", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.104683", "ticker_sentiment_score": "0.300492", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "INTC", "relevance_score": "0.156461", "ticker_sentiment_score": "0.375556", "ticker_sentiment_label": "Bullish"}, {"ticker": "PG", "relevance_score": "0.104683", "ticker_sentiment_score": "0.267759", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "XOM", "relevance_score": "0.104683", "ticker_sentiment_score": "-0.225203", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "LI", "relevance_score": "0.104683", "ticker_sentiment_score": "0.126157", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.104683", "ticker_sentiment_score": "0.450224", "ticker_sentiment_label": "Bullish"}, {"ticker": "SAM", "relevance_score": "0.104683", "ticker_sentiment_score": "-0.099024", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.104683", "ticker_sentiment_score": "0.15005", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Why DexCom  ( DXCM )  Shares Are Trading Higher Today - DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/news/earnings/23/07/33438151/why-dexcom-shares-are-trading-higher-today", "time_published": "20230728T140136", "authors": ["Lekha Gupta"], "summary": "DexCom Inc DXCM shares are trading higher after the company reported better-than-expected Q2 FY23 results. It posted sales of $871.3 million, up 25% Y/Y ( +26% Y/Y organic basis ) , beating the consensus of $841.6 million.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/07/28/dxcm.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.650727"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.159355, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.837089", "ticker_sentiment_score": "0.170904", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "DexCom  ( DXCM )  Q2 Earnings Beat Estimates, Volumes Remain Strong", "url": "https://www.zacks.com/stock/news/2129448/dexcom-dxcm-q2-earnings-beat-estimates-volumes-remain-strong", "time_published": "20230728T125200", "authors": ["Zacks Equity Research"], "summary": "DexCom's (DXCM) second-quarter 2023 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/01/36484.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}], "overall_sentiment_score": 0.226145, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ABT", "relevance_score": "0.092748", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ISRG", "relevance_score": "0.184246", "ticker_sentiment_score": "0.0353", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.515466", "ticker_sentiment_score": "0.394568", "ticker_sentiment_label": "Bullish"}, {"ticker": "ELV", "relevance_score": "0.184246", "ticker_sentiment_score": "0.069667", "ticker_sentiment_label": "Neutral"}]}, {"title": "Market Rebounds With Inflation Data Due; 5 Earnings Winners", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-market-rally-rebounds-inflation-data-5-earnings-winners/", "time_published": "20230728T120900", "authors": ["ED CARSON", "Investor's Business Daily"], "summary": "Dow Jones Futures: Market Rally Set To Rebound With Inflation Data Due. 5 Earnings Winners Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2016/02/KPBLOG01-022916-shutterstock.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.769861"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.997902"}], "overall_sentiment_score": 0.174092, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "KLAC", "relevance_score": "0.17484", "ticker_sentiment_score": "0.356094", "ticker_sentiment_label": "Bullish"}, {"ticker": "GOOG", "relevance_score": "0.070414", "ticker_sentiment_score": "0.240804", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "META", "relevance_score": "0.17484", "ticker_sentiment_score": "0.182407", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVDA", "relevance_score": "0.14028", "ticker_sentiment_score": "0.181152", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ROKU", "relevance_score": "0.14028", "ticker_sentiment_score": "0.209496", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AAPL", "relevance_score": "0.17484", "ticker_sentiment_score": "0.029781", "ticker_sentiment_label": "Neutral"}, {"ticker": "CVX", "relevance_score": "0.17484", "ticker_sentiment_score": "0.271358", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RETA", "relevance_score": "0.105449", "ticker_sentiment_score": "0.053918", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.24289", "ticker_sentiment_score": "0.133391", "ticker_sentiment_label": "Neutral"}, {"ticker": "FSLR", "relevance_score": "0.14028", "ticker_sentiment_score": "0.264604", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TSLA", "relevance_score": "0.24289", "ticker_sentiment_score": "0.20334", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "INTC", "relevance_score": "0.17484", "ticker_sentiment_score": "0.394719", "ticker_sentiment_label": "Bullish"}, {"ticker": "NOW", "relevance_score": "0.035241", "ticker_sentiment_score": "0.142231", "ticker_sentiment_label": "Neutral"}, {"ticker": "XOM", "relevance_score": "0.14028", "ticker_sentiment_score": "0.184321", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LRCX", "relevance_score": "0.070414", "ticker_sentiment_score": "0.188193", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMZN", "relevance_score": "0.070414", "ticker_sentiment_score": "0.185183", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.105449", "ticker_sentiment_score": "0.26509", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.105449", "ticker_sentiment_score": "0.053918", "ticker_sentiment_label": "Neutral"}]}, {"title": "Align Technology Joins Rank Of Stocks With RS Ratings Over 90", "url": "https://www.investors.com/ibd-data-stories/align-technology-joins-rank-of-stocks-with-rs-ratings-over-90/", "time_published": "20230728T070000", "authors": ["INVESTOR'S BUSINESS DAILY", "Investor's Business Daily"], "summary": "Align Technology ( ALGN ) had its Relative Strength ( RS ) Rating upgraded from 85 to 95 Friday. X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.161647"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.351923, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "PDEX", "relevance_score": "0.323078", "ticker_sentiment_score": "0.131438", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALGN", "relevance_score": "0.323078", "ticker_sentiment_score": "0.693499", "ticker_sentiment_label": "Bullish"}, {"ticker": "LNTH", "relevance_score": "0.323078", "ticker_sentiment_score": "0.131438", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.323078", "ticker_sentiment_score": "0.131438", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stocks With Rising Composite Ratings: Lantheus Holdings", "url": "https://www.investors.com/ibd-data-stories/stocks-with-rising-composite-ratings-lantheus-holdings/", "time_published": "20230728T070000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "Lantheus Holdings ( LNTH ) saw its IBD SmartSelect Composite Rating jump to 96 Friday, up from 94 the day before. X The upgrade means the stock currently tops 96% of all other stocks in terms of key performance metrics and technical strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.744043"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.281529, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LNTH", "relevance_score": "0.595343", "ticker_sentiment_score": "-0.109784", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.323078", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PDEX", "relevance_score": "0.323078", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "DexCom  ( DXCM )  Q2 2023 Earnings Call Transcript", "url": "https://www.fool.com/earnings/call-transcripts/2023/07/28/dexcom-dxcm-q2-2023-earnings-call-transcript/", "time_published": "20230728T050057", "authors": ["Motley Fool Transcribing"], "summary": "DXCM earnings call for the period ending June 30, 2023.", "banner_image": "https://g.foolcdn.com/misc-assets/fool-transcripts-logo.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.976913"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.296189, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BCS", "relevance_score": "0.004803", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "C", "relevance_score": "0.004803", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.004803", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.004803", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.004803", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PODD", "relevance_score": "0.004803", "ticker_sentiment_score": "0.017524", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.157452", "ticker_sentiment_score": "0.161043", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "DexCom  ( DXCM )  Beats Q2 Earnings and Revenue Estimates", "url": "https://www.zacks.com/stock/news/2129057/dexcom-dxcm-beats-q2-earnings-and-revenue-estimates", "time_published": "20230727T214513", "authors": ["Zacks Equity Research"], "summary": "DexCom (DXCM) delivered earnings and revenue surprises of 54.55% and 4.10%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default335.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999992"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.184704, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.410059", "ticker_sentiment_score": "0.250965", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "EAR", "relevance_score": "0.212425", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Futures: Market Reverses, But Tesla Forges New Buy Point", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-snaps-win-streak-in-market-reversal-tesla-forges-new-buy-point-roku-intel-jump-late/", "time_published": "20230727T212500", "authors": ["Investor's Business Daily", "ED CARSON"], "summary": "Dow Jones Snaps Win Streak In Market Reversal. Tesla Forges New Buy Point. Roku, Intel Jump Late Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/06/Stock-teslafrontnose-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.938238"}], "overall_sentiment_score": 0.091153, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "KLAC", "relevance_score": "0.114409", "ticker_sentiment_score": "0.083246", "ticker_sentiment_label": "Neutral"}, {"ticker": "ENPH", "relevance_score": "0.085936", "ticker_sentiment_score": "-0.029243", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.142734", "ticker_sentiment_score": "0.100487", "ticker_sentiment_label": "Neutral"}, {"ticker": "ROKU", "relevance_score": "0.170878", "ticker_sentiment_score": "0.011398", "ticker_sentiment_label": "Neutral"}, {"ticker": "CVX", "relevance_score": "0.142734", "ticker_sentiment_score": "0.096966", "ticker_sentiment_label": "Neutral"}, {"ticker": "F", "relevance_score": "0.057352", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.142734", "ticker_sentiment_score": "-0.069127", "ticker_sentiment_label": "Neutral"}, {"ticker": "FSLR", "relevance_score": "0.114409", "ticker_sentiment_score": "-0.049459", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.198803", "ticker_sentiment_score": "0.046877", "ticker_sentiment_label": "Neutral"}, {"ticker": "INTC", "relevance_score": "0.198803", "ticker_sentiment_score": "0.099502", "ticker_sentiment_label": "Neutral"}, {"ticker": "NOW", "relevance_score": "0.085936", "ticker_sentiment_score": "-0.033535", "ticker_sentiment_label": "Neutral"}, {"ticker": "XOM", "relevance_score": "0.057352", "ticker_sentiment_score": "0.077009", "ticker_sentiment_label": "Neutral"}, {"ticker": "LRCX", "relevance_score": "0.085936", "ticker_sentiment_score": "-0.015784", "ticker_sentiment_label": "Neutral"}, {"ticker": "RCL", "relevance_score": "0.114409", "ticker_sentiment_score": "0.072049", "ticker_sentiment_label": "Neutral"}, {"ticker": "UPST", "relevance_score": "0.085936", "ticker_sentiment_score": "-0.085693", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.114409", "ticker_sentiment_score": "0.01722", "ticker_sentiment_label": "Neutral"}, {"ticker": "NXT(EXP20091224)", "relevance_score": "0.028695", "ticker_sentiment_score": "0.149095", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:USD", "relevance_score": "0.028695", "ticker_sentiment_score": "0.072803", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:NXT", "relevance_score": "0.057352", "ticker_sentiment_score": "0.158986", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Stocks making the biggest moves after hours: Intel, Ford, Roku, Enphase Energy and more", "url": "https://www.cnbc.com/2023/07/27/stocks-making-the-biggest-moves-after-hours-intc-f-roku-enph.html", "time_published": "20230727T211036", "authors": ["Alex Harring"], "summary": "These are the stocks posting the largest moves in extended trading.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107012803-1644358663637-AP195173321082.jpg?v=1690492236&w=1920&h=1080", "source": "CNBC", "category_within_source": "Market Insider", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.241566, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ENPH", "relevance_score": "0.082677", "ticker_sentiment_score": "-0.015642", "ticker_sentiment_label": "Neutral"}, {"ticker": "ROKU", "relevance_score": "0.082677", "ticker_sentiment_score": "0.107483", "ticker_sentiment_label": "Neutral"}, {"ticker": "FSLR", "relevance_score": "0.164468", "ticker_sentiment_score": "0.114878", "ticker_sentiment_label": "Neutral"}, {"ticker": "SG", "relevance_score": "0.082677", "ticker_sentiment_score": "-0.079607", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.164468", "ticker_sentiment_score": "0.20726", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SAM", "relevance_score": "0.164468", "ticker_sentiment_score": "0.35839", "ticker_sentiment_label": "Bullish"}]}, {"title": "Dexcom lifts revenue forecast on demand for glucose-monitoring devices", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/dexcom-lifts-revenue-forecast-demand-glucose-monitoring-devices-2023-07-27/", "time_published": "20230727T210200", "authors": ["Reuters"], "summary": "July 27 ( Reuters ) - Medical device maker Dexcom Inc ( DXCM.O ) on Thursday raised its annual revenue forecast after strong demand for its continuous glucose monitoring ( CGM ) systems boosted second-quarter results, lifting its shares up about 3% in aftermarket trading.", "banner_image": "https://www.reuters.com/pf/resources/images/reuters/reuters-default.webp?d=149", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Earnings", "relevance_score": "0.744043"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.242003, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.416844", "ticker_sentiment_score": "0.397644", "ticker_sentiment_label": "Bullish"}]}, {"title": "Dexcom Earnings Tops Estimates, Medical Device Maker Hikes Outlook", "url": "https://www.investors.com/news/technology/dexcom-stock-dexcom-earnings-dexcom-stock-q22023/", "time_published": "20230727T202400", "authors": ["Investor's Business Daily", "REINHARDT KRAUSE"], "summary": "Dexcom ( DXCM ) reported June-quarter earnings and revenue that topped Wall Street targets. Shares of Dexcom stock rose as the company raised its outlook for the year. Dexcom said second-quarter profit doubled to 34 cents a share. Revenue climbed 25% to $871.3 million.", "banner_image": "https://www.investors.com/wp-content/uploads/2020/02/stock-Dexcom-01-company.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.992549"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.989041"}], "overall_sentiment_score": 0.18609, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MDT", "relevance_score": "0.28387", "ticker_sentiment_score": "0.161261", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.930964", "ticker_sentiment_score": "0.3944", "ticker_sentiment_label": "Bullish"}, {"ticker": "ABT", "relevance_score": "0.28387", "ticker_sentiment_score": "0.161261", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "The Zacks Analyst Blog Highlights Toyota, Deere, Starbucks, AbbVie and DexCom", "url": "https://www.zacks.com/stock/news/2127481/the-zacks-analyst-blog-highlights-toyota-deere-starbucks-abbvie-and-dexcom", "time_published": "20230726T090000", "authors": ["Zacks Equity Research"], "summary": "Toyota, Deere, Starbucks, AbbVie and DexCom are included in this Analyst Blog.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/df/565.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.614606"}], "overall_sentiment_score": 0.365722, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "DE", "relevance_score": "0.362858", "ticker_sentiment_score": "0.254993", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TM", "relevance_score": "0.222838", "ticker_sentiment_score": "0.052037", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.149656", "ticker_sentiment_score": "0.039096", "ticker_sentiment_label": "Neutral"}, {"ticker": "SBUX", "relevance_score": "0.294093", "ticker_sentiment_score": "0.21138", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.149656", "ticker_sentiment_score": "0.039096", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:JPY", "relevance_score": "0.075161", "ticker_sentiment_score": "0.301441", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "2 Top Dividend Stocks to Buy and Hold Forever", "url": "https://www.fool.com/investing/2023/07/25/2-top-dividend-stocks-to-buy-and-hold-forever/", "time_published": "20230725T140700", "authors": ["Prosper Junior Bakiny"], "summary": "They have been paying dividends for a long time.", "banner_image": "https://media.ycharts.com/charts/339861dbe124a08b08a31c7417e8caba.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.684621"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.261867, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.053992", "ticker_sentiment_score": "0.025", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABT", "relevance_score": "0.364529", "ticker_sentiment_score": "0.322342", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.315493", "ticker_sentiment_score": "0.148128", "ticker_sentiment_label": "Neutral"}]}, {"title": "Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick", "url": "https://www.zacks.com/stock/news/2126895/are-you-a-growth-investor-this-1-stock-could-be-the-perfect-pick", "time_published": "20230725T134503", "authors": ["Zacks Equity Research"], "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default302.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.682689"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}], "overall_sentiment_score": 0.412518, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.417304", "ticker_sentiment_score": "0.336981", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Are Medical Stocks Lagging Boston Scientific  ( BSX )  This Year?", "url": "https://www.zacks.com/stock/news/2126079/are-medical-stocks-lagging-boston-scientific-bsx-this-year", "time_published": "20230724T134011", "authors": ["Zacks Equity Research"], "summary": "Here is how Boston Scientific (BSX) and DexCom (DXCM) have performed compared to their sector so far this year.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default133.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.614606"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.248141, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BSX", "relevance_score": "0.745397", "ticker_sentiment_score": "0.45367", "ticker_sentiment_label": "Bullish"}, {"ticker": "DXCM", "relevance_score": "0.473208", "ticker_sentiment_score": "0.218216", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "DexCom  ( DXCM )  to Report Q2 Earnings: What's in the Cards?", "url": "https://www.zacks.com/stock/news/2126187/dexcom-dxcm-to-report-q2-earnings-whats-in-the-cards", "time_published": "20230724T131500", "authors": ["Zacks Equity Research"], "summary": "DexCom's (DXCM) second-quarter 2023 results are likely to reflect rising volumes across all channels.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c0/2297.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Earnings", "relevance_score": "1.0"}], "overall_sentiment_score": 0.248635, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AVNS", "relevance_score": "0.153797", "ticker_sentiment_score": "-0.062044", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCK", "relevance_score": "0.102888", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.102888", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.349153", "ticker_sentiment_score": "0.21529", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "DexCom  ( DXCM )  Stock Sinks As Market Gains: What You Should Know", "url": "https://www.zacks.com/stock/news/2125711/dexcom-dxcm-stock-sinks-as-market-gains-what-you-should-know", "time_published": "20230721T220018", "authors": ["Zacks Equity Research"], "summary": "DexCom (DXCM) closed the most recent trading day at $130.60, moving -0.04% from the previous trading session.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default279.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.95493"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.266421, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.705799", "ticker_sentiment_score": "0.414487", "ticker_sentiment_label": "Bullish"}]}, {"title": "3 Highly-Ranked Large Cap Stocks to Buy Before Earnings for Big Upside", "url": "https://www.zacks.com/stock/news/2125639/3-highly-ranked-large-cap-stocks-to-buy-before-earnings-for-big-upside", "time_published": "20230721T202000", "authors": ["Benjamin Rains"], "summary": "Exploring three highly-ranked large-cap stocks--Honeywell, DexCom, and NextEra Energy--that investors might want to buy before their upcoming earnings releases for both near-term and long-term upside.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/b1/44137.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.999365"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.996675"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.144093, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NFLX", "relevance_score": "0.080188", "ticker_sentiment_score": "-0.04417", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.080188", "ticker_sentiment_score": "-0.04417", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.275423", "ticker_sentiment_score": "-0.022612", "ticker_sentiment_label": "Neutral"}, {"ticker": "HON", "relevance_score": "0.237358", "ticker_sentiment_score": "0.106091", "ticker_sentiment_label": "Neutral"}, {"ticker": "NEE", "relevance_score": "0.31282", "ticker_sentiment_score": "0.047615", "ticker_sentiment_label": "Neutral"}]}, {"title": "Select Medical  ( SEM )  Expects Q2 Adjusted EBITDA to Jump 21% Y/Y", "url": "https://www.zacks.com/stock/news/2125530/select-medical-sem-expects-q2-adjusted-ebitda-to-jump-21-yy", "time_published": "20230721T155200", "authors": ["Zacks Equity Research"], "summary": "Select Medical's (SEM) strong second-quarter 2023 guidance highlights improving performance in all four segments.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c0/2563.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.993781"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.289546, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALC", "relevance_score": "0.249744", "ticker_sentiment_score": "0.152818", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SEM", "relevance_score": "0.573826", "ticker_sentiment_score": "0.465496", "ticker_sentiment_label": "Bullish"}, {"ticker": "DXCM", "relevance_score": "0.249744", "ticker_sentiment_score": "0.152818", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HCA", "relevance_score": "0.30928", "ticker_sentiment_score": "0.195853", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "DexCom  ( NASDAQ:DXCM )  Upgraded to Buy by StockNews.com", "url": "https://www.defenseworld.net/2023/07/21/dexcom-nasdaqdxcm-upgraded-to-buy-by-stocknews-com.html", "time_published": "20230721T052845", "authors": ["Defense World Staff"], "summary": "DexCom ( NASDAQ:DXCM - Get Free Report ) was upgraded by research analysts at StockNews.com from a \"hold\" rating to a \"buy\" rating in a report released on Friday.", "banner_image": "https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&Symbol=DXCM", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.846708"}, {"topic": "Real Estate & Construction", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.256682, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "APG", "relevance_score": "0.043264", "ticker_sentiment_score": "0.110132", "ticker_sentiment_label": "Neutral"}, {"ticker": "FHB", "relevance_score": "0.0864", "ticker_sentiment_score": "0.198205", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "C", "relevance_score": "0.043264", "ticker_sentiment_score": "0.056737", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.841604", "ticker_sentiment_score": "0.426364", "ticker_sentiment_label": "Bullish"}, {"ticker": "MS", "relevance_score": "0.043264", "ticker_sentiment_score": "0.056737", "ticker_sentiment_label": "Neutral"}]}, {"title": "Looking At DexCom's Recent Unusual Options Activity - DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/markets/options/23/07/33288408/looking-at-dexcoms-recent-unusual-options-activity", "time_published": "20230719T160112", "authors": ["Benzinga Insights"], "summary": "Benzinga's options scanner just detected over 14 options trades for DexCom DXCM summing a total amount of $530,082. At the same time, our algo caught 12 for a total amount of 533,882.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.181811, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.799626", "ticker_sentiment_score": "0.195295", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "C", "relevance_score": "0.145145", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "NextGen  ( NXGN )  Settles Misrepresentation Allegations for $31M", "url": "https://www.zacks.com/stock/news/2123885/nextgen-nxgn-settles-misrepresentation-allegations-for-31m", "time_published": "20230719T141800", "authors": ["Zacks Investment Research"], "summary": "NextGen (NXGN) settles accusations of software fraud and anti-kickback violations for $31M. However, the company denies any wrongdoing.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e7/2307.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.682689"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.197553, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALC", "relevance_score": "0.185781", "ticker_sentiment_score": "0.130209", "ticker_sentiment_label": "Neutral"}, {"ticker": "HOLX", "relevance_score": "0.185781", "ticker_sentiment_score": "0.12581", "ticker_sentiment_label": "Neutral"}, {"ticker": "NXGN", "relevance_score": "0.245959", "ticker_sentiment_score": "0.104098", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.185781", "ticker_sentiment_score": "0.122877", "ticker_sentiment_label": "Neutral"}]}, {"title": "Reasons to Add West Pharmaceutical  ( WST )  to Your Portfolio Now", "url": "https://www.zacks.com/stock/news/2123042/reasons-to-add-west-pharmaceutical-wst-to-your-portfolio-now", "time_published": "20230718T141400", "authors": ["Zacks Investment Research"], "summary": "West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.976671"}], "overall_sentiment_score": 0.296343, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALC", "relevance_score": "0.213517", "ticker_sentiment_score": "0.08284", "ticker_sentiment_label": "Neutral"}, {"ticker": "CURN", "relevance_score": "0.053992", "ticker_sentiment_score": "-0.162", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "WST", "relevance_score": "0.315493", "ticker_sentiment_score": "0.161452", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HOLX", "relevance_score": "0.213517", "ticker_sentiment_score": "0.079585", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.213517", "ticker_sentiment_score": "0.077957", "ticker_sentiment_label": "Neutral"}]}, {"title": "If You Invested $1000 in DexCom a Decade Ago, This is How Much It'd Be Worth Now", "url": "https://www.zacks.com/stock/news/2121941/if-you-invested-1000-in-dexcom-a-decade-ago-this-is-how-much-itd-be-worth-now", "time_published": "20230717T123006", "authors": ["Zacks Investment Research"], "summary": "Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default133.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.744043"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.929393"}], "overall_sentiment_score": 0.309086, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.553082", "ticker_sentiment_score": "0.444535", "ticker_sentiment_label": "Bullish"}]}, {"title": "Here is Why Growth Investors Should Buy DexCom  ( DXCM )  Now", "url": "https://www.zacks.com/stock/news/2121547/here-is-why-growth-investors-should-buy-dexcom-dxcm-now", "time_published": "20230714T164506", "authors": ["Zacks Investment Research"], "summary": "DexCom (DXCM) could produce exceptional returns because of its solid growth attributes.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default321.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.983783"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.455487, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.513173", "ticker_sentiment_score": "0.379263", "ticker_sentiment_label": "Bullish"}]}, {"title": "Select Medical  ( SEM )  Up 21% Year to Date: More Room to Run?", "url": "https://www.zacks.com/stock/news/2121554/select-medical-sem-up-21-year-to-date-more-room-to-run", "time_published": "20230714T155900", "authors": ["Zacks Investment Research"], "summary": "Select Medical (SEM) is well-poised for growth on the back of improved patient volumes, an expanding healthcare portfolio and solid cash-generating abilities.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7b/2387.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.990678"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.353071, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "ALC", "relevance_score": "0.215415", "ticker_sentiment_score": "0.135844", "ticker_sentiment_label": "Neutral"}, {"ticker": "SEM", "relevance_score": "0.461468", "ticker_sentiment_score": "0.535012", "ticker_sentiment_label": "Bullish"}, {"ticker": "DXCM", "relevance_score": "0.215415", "ticker_sentiment_score": "0.135844", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCA", "relevance_score": "0.267413", "ticker_sentiment_score": "0.174621", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "DexCom  ( DXCM )  Stock Hits 52-Week High: More Room to Grow?", "url": "https://www.zacks.com/stock/news/2121295/dexcom-dxcm-stock-hits-52-week-high-more-room-to-grow", "time_published": "20230714T123600", "authors": ["Zacks Investment Research"], "summary": "DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c0/2297.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.986413"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.302912, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALC", "relevance_score": "0.127231", "ticker_sentiment_score": "0.103376", "ticker_sentiment_label": "Neutral"}, {"ticker": "HOLX", "relevance_score": "0.127231", "ticker_sentiment_score": "0.099872", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.369076", "ticker_sentiment_score": "0.36738", "ticker_sentiment_label": "Bullish"}, {"ticker": "PRGO", "relevance_score": "0.085022", "ticker_sentiment_score": "0.053242", "ticker_sentiment_label": "Neutral"}]}, {"title": "DexCom  ( NASDAQ:DXCM )  Downgraded by StockNews.com to Hold", "url": "https://www.defenseworld.net/2023/07/14/dexcom-nasdaqdxcm-downgraded-by-stocknews-com-to-hold.html", "time_published": "20230714T091847", "authors": ["Defense World Staff"], "summary": "StockNews.com downgraded shares of DexCom ( NASDAQ:DXCM - Free Report ) from a buy rating to a hold rating in a research note released on Thursday morning. Several other equities research analysts also recently weighed in on the stock.", "banner_image": "https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&Symbol=DXCM", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.82617"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.273008, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "APG", "relevance_score": "0.043818", "ticker_sentiment_score": "0.114279", "ticker_sentiment_label": "Neutral"}, {"ticker": "FHB", "relevance_score": "0.087503", "ticker_sentiment_score": "0.160588", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PEP", "relevance_score": "0.043818", "ticker_sentiment_score": "0.114279", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCS", "relevance_score": "0.043818", "ticker_sentiment_score": "0.142674", "ticker_sentiment_label": "Neutral"}, {"ticker": "C", "relevance_score": "0.043818", "ticker_sentiment_score": "0.142674", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.773257", "ticker_sentiment_score": "0.455757", "ticker_sentiment_label": "Bullish"}]}, {"title": "DexCom  ( DXCM )  Gains But Lags Market: What You Should Know", "url": "https://www.zacks.com/stock/news/2120950/dexcom-dxcm-gains-but-lags-market-what-you-should-know", "time_published": "20230713T220022", "authors": ["Zacks Investment Research"], "summary": "In the latest trading session, DexCom (DXCM) closed at $133.98, marking a +0.23% move from the previous day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default61.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.976913"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.207758, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.627711", "ticker_sentiment_score": "0.308288", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "AngioDynamics  ( ANGO )  Q4 Earnings Lag Estimates, Revenues Top", "url": "https://www.zacks.com/stock/news/2120780/angiodynamics-ango-q4-earnings-lag-estimates-revenues-top", "time_published": "20230713T155900", "authors": ["Zacks Investment Research"], "summary": "AngioDynamics (ANGO) registers strong revenue growth in the Med Tech and Med Device businesses in fourth-quarter fiscal 2023.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/01/36484.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.929393"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.047598, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BSX", "relevance_score": "0.141102", "ticker_sentiment_score": "0.053697", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.141102", "ticker_sentiment_score": "0.073474", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDX", "relevance_score": "0.07083", "ticker_sentiment_score": "0.065291", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Reasons to Add Intuitive Surgical  ( ISRG )  to Your Portfolio", "url": "https://www.zacks.com/stock/news/2120724/3-reasons-to-add-intuitive-surgical-isrg-to-your-portfolio", "time_published": "20230713T140100", "authors": ["Zacks Investment Research"], "summary": "Intuitive Surgical (ISRG) continues to raise optimism among investors, owing to its strength in robotics.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7b/2387.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.890401"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.384259, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "ALC", "relevance_score": "0.159218", "ticker_sentiment_score": "0.117127", "ticker_sentiment_label": "Neutral"}, {"ticker": "HOLX", "relevance_score": "0.159218", "ticker_sentiment_score": "0.113162", "ticker_sentiment_label": "Neutral"}, {"ticker": "ISRG", "relevance_score": "0.453277", "ticker_sentiment_score": "0.457739", "ticker_sentiment_label": "Bullish"}, {"ticker": "DXCM", "relevance_score": "0.159218", "ticker_sentiment_score": "0.110518", "ticker_sentiment_label": "Neutral"}]}, {"title": "Who Should Be Tracking Their Glucose?", "url": "https://www.nytimes.com/2023/07/12/well/eat/glucose-blood-sugar-monitors.html", "time_published": "20230712T150024", "authors": [], "summary": "Do You Need a Glucose Monitor? The New York Times ...", "banner_image": "https://static01.nyt.com/images/2023/07/12/well/12WELL-CGMs3/12WELL-CGMs3-articleLarge.jpg?quality=75&auto=webp&disable=upscale", "source": "New York Times", "category_within_source": "GoogleRSS", "source_domain": "www.nytimes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.054959, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.063848", "ticker_sentiment_score": "0.054022", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's Why You Should Retain CONMED  ( CNMD )  Stock for Now", "url": "https://www.zacks.com/stock/news/2120006/heres-why-you-should-retain-conmed-cnmd-stock-for-now", "time_published": "20230712T135700", "authors": ["Zacks Investment Research"], "summary": "CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c0/2297.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.904684"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.182091, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALC", "relevance_score": "0.143987", "ticker_sentiment_score": "0.141377", "ticker_sentiment_label": "Neutral"}, {"ticker": "HOLX", "relevance_score": "0.143987", "ticker_sentiment_score": "0.136391", "ticker_sentiment_label": "Neutral"}, {"ticker": "CNMD", "relevance_score": "0.413803", "ticker_sentiment_score": "0.164679", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.143987", "ticker_sentiment_score": "0.133898", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stryker  ( SYK )  Launches Q Guidance System for Cranial Surgeries", "url": "https://www.zacks.com/stock/news/2119937/stryker-syk-launches-q-guidance-system-for-cranial-surgeries", "time_published": "20230712T130100", "authors": ["Zacks Investment Research"], "summary": "Stryker (SYK) launches its Q Guidance system with Cranial Guidance software, offering surgeons a comprehensive planning and guidance solution for complex cranial procedures.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7b/2387.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.682689"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.402451, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "ALC", "relevance_score": "0.170878", "ticker_sentiment_score": "0.122738", "ticker_sentiment_label": "Neutral"}, {"ticker": "HOLX", "relevance_score": "0.170878", "ticker_sentiment_score": "0.118586", "ticker_sentiment_label": "Neutral"}, {"ticker": "SYK", "relevance_score": "0.435074", "ticker_sentiment_score": "0.597263", "ticker_sentiment_label": "Bullish"}, {"ticker": "DXCM", "relevance_score": "0.170878", "ticker_sentiment_score": "0.115818", "ticker_sentiment_label": "Neutral"}]}, {"title": "Integra's  ( IART )  Codman EVD Catheter Study Data Favorable", "url": "https://www.zacks.com/stock/news/2119337/integras-iart-codman-evd-catheter-study-data-favorable", "time_published": "20230711T145000", "authors": ["Zacks Investment Research"], "summary": "Integra's (IART) Codman Bactiseal EVD lowers financial burdens and guarantees a safe clinical outcome in patients with aSAH-related hydrocephalus.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.795202"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.252156, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALC", "relevance_score": "0.157827", "ticker_sentiment_score": "0.12042", "ticker_sentiment_label": "Neutral"}, {"ticker": "IART", "relevance_score": "0.105604", "ticker_sentiment_score": "0.051281", "ticker_sentiment_label": "Neutral"}, {"ticker": "HOLX", "relevance_score": "0.157827", "ticker_sentiment_score": "0.121735", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.157827", "ticker_sentiment_score": "0.11779", "ticker_sentiment_label": "Neutral"}]}, {"title": "Cigna  ( CI )  to Add Three Biosimilars to NPF, Enable Cost Savings", "url": "https://www.zacks.com/stock/news/2119335/cigna-ci-to-add-three-biosimilars-to-npf-enable-cost-savings", "time_published": "20230711T144600", "authors": ["Zacks Investment Research"], "summary": "Cigna (CI) plans to integrate three cost-effective biosimilars within NPF in a bid to offer varied treatment options for Americans and solidify its pharmacy business.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5d/2633.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.682689"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.247645, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "EHC", "relevance_score": "0.256989", "ticker_sentiment_score": "0.247222", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CI", "relevance_score": "0.318074", "ticker_sentiment_score": "0.326866", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.318074", "ticker_sentiment_score": "0.267716", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Here's Why You Should Add McKesson  ( MCK )  to Your Portfolio", "url": "https://www.zacks.com/stock/news/2119040/heres-why-you-should-add-mckesson-mck-to-your-portfolio", "time_published": "20230711T120300", "authors": ["Zacks Investment Research"], "summary": "McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}, {"topic": "Earnings", "relevance_score": "0.9545"}], "overall_sentiment_score": 0.317748, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HOLX", "relevance_score": "0.167709", "ticker_sentiment_score": "0.118456", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCK", "relevance_score": "0.603038", "ticker_sentiment_score": "0.474543", "ticker_sentiment_label": "Bullish"}, {"ticker": "HCA", "relevance_score": "0.112269", "ticker_sentiment_score": "0.155891", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WBA", "relevance_score": "0.056275", "ticker_sentiment_score": "0.086904", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALC", "relevance_score": "0.167709", "ticker_sentiment_score": "0.122557", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSGR", "relevance_score": "0.112269", "ticker_sentiment_score": "0.12099", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.167709", "ticker_sentiment_score": "0.115722", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCSG", "relevance_score": "0.056275", "ticker_sentiment_score": "0.099908", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stocks To Watch: 10x Genomics Sees Relative Strength Rating Rise To 93", "url": "https://www.investors.com/ibd-data-stories/stocks-to-watch-10x-genomics-sees-relative-strength-rating-rise-to-93/", "time_published": "20230711T070000", "authors": ["INVESTOR'S BUSINESS DAILY", "Investor's Business Daily"], "summary": "On Tuesday, 10x Genomics ( TXG ) reached an important technical milestone, with its Relative Strength ( RS ) Rating moving into the 90-plus percentile with an improvement to 93, a rise from 90 the day before. X When looking for the best stocks to buy and watch, one factor to watch closely is ...", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.538269"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.300308, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PEN", "relevance_score": "0.320974", "ticker_sentiment_score": "0.135251", "ticker_sentiment_label": "Neutral"}, {"ticker": "TXG", "relevance_score": "0.465196", "ticker_sentiment_score": "0.468336", "ticker_sentiment_label": "Bullish"}, {"ticker": "LNTH", "relevance_score": "0.320974", "ticker_sentiment_score": "0.135251", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.320974", "ticker_sentiment_score": "0.135251", "ticker_sentiment_label": "Neutral"}]}, {"title": "Mega Caps Like Tesla, Apple Sag -- And That's Good for the Market", "url": "https://realmoney.thestreet.com/investing/stocks/mega-caps-like-tesla-apple-sag-and-that-s-good-for-the-market-16128345", "time_published": "20230710T155205", "authors": ["James \"Rev Shark\" DePorre"], "summary": "The leading big-cap technology stocks are lagging Monday, but the broad market is strong. Tesla ( TESLA ) , Amazon ( AMZN ) , Nvidia ( NVDA ) , Apple ( AAPL ) , and Alphabet ( GOOGL ) are all in negative territory, but Nasdaq 100/Invesco fund stocks' ( QQQ ) breadth is extremely strong, with just ...", "banner_image": "http://s.thestreet.com/files/tsc/v2008/photos/contrib/uploads/313e14c9-4c09-11ea-b239-b7afe5cfe71e.png", "source": "The Street", "category_within_source": "GoogleRSS", "source_domain": "realmoney.thestreet.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}], "overall_sentiment_score": 0.227667, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NVDA", "relevance_score": "0.221819", "ticker_sentiment_score": "0.269915", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SPHR", "relevance_score": "0.221819", "ticker_sentiment_score": "0.24023", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AAPL", "relevance_score": "0.221819", "ticker_sentiment_score": "0.269915", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "C", "relevance_score": "0.112008", "ticker_sentiment_score": "0.07266", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.112008", "ticker_sentiment_score": "0.177614", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DDOG", "relevance_score": "0.221819", "ticker_sentiment_score": "0.111361", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.112008", "ticker_sentiment_score": "0.177614", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMZN", "relevance_score": "0.221819", "ticker_sentiment_score": "0.269915", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.221819", "ticker_sentiment_score": "0.111361", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stryker  ( SYK )  Launches Autonomous Guidance System for Surgeries", "url": "https://www.zacks.com/stock/news/2118541/stryker-syk-launches-autonomous-guidance-system-for-surgeries", "time_published": "20230710T102400", "authors": ["Zacks Investment Research"], "summary": "Stryker's (SYK) fully autonomous Ortho Q Guidance system offers smart and streamlined workflow, leading to enhanced procedural speed and efficiency.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c0/2297.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.682689"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.427056, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "ALC", "relevance_score": "0.172507", "ticker_sentiment_score": "0.12354", "ticker_sentiment_label": "Neutral"}, {"ticker": "HOLX", "relevance_score": "0.172507", "ticker_sentiment_score": "0.119361", "ticker_sentiment_label": "Neutral"}, {"ticker": "SYK", "relevance_score": "0.337044", "ticker_sentiment_score": "0.421674", "ticker_sentiment_label": "Bullish"}, {"ticker": "DXCM", "relevance_score": "0.172507", "ticker_sentiment_score": "0.116575", "ticker_sentiment_label": "Neutral"}]}, {"title": "Nvidia And This AI Stock Lead 5 Names Near Buy Points", "url": "https://www.investors.com/news/nvidia-and-this-ai-stock-lead-5-names-near-buy-points/", "time_published": "20230708T131700", "authors": ["Investor's Business Daily", "JED GRAHAM"], "summary": "Artificial intelligence stocks Nvidia ( NVDA ) and Arista Networks ( ANET ) lead this weekend's watch list of five stocks near buy points. In addition to NVDA stock and ANET, the group includes Datadog ( DDOG ) , whose computer-network monitoring software business should get a boost from AI ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/05/Stock-nvidia-hq-04-company.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.169728, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.079261", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.118647", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.449503", "ticker_sentiment_score": "0.246667", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ANET", "relevance_score": "0.272354", "ticker_sentiment_score": "0.143576", "ticker_sentiment_label": "Neutral"}, {"ticker": "MA", "relevance_score": "0.118647", "ticker_sentiment_score": "0.186699", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JPM", "relevance_score": "0.039679", "ticker_sentiment_score": "0.115556", "ticker_sentiment_label": "Neutral"}, {"ticker": "V", "relevance_score": "0.079261", "ticker_sentiment_score": "0.17655", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DDOG", "relevance_score": "0.309377", "ticker_sentiment_score": "0.143483", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.079261", "ticker_sentiment_score": "-0.067977", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.196451", "ticker_sentiment_score": "0.084633", "ticker_sentiment_label": "Neutral"}]}, {"title": "Investing Action Plan: Amazon Prime Day, JPMorgan, Delta Launch Q2", "url": "https://www.investors.com/research/investing-action-plan/stock-market-action-plan-july-10-14-amazon-prime-day-jpmorgan-unitedhealth-delta-launch-q2/", "time_published": "20230707T212000", "authors": ["IBD STAFF", "Investor's Business Daily"], "summary": "A soft first week of July was no surprise after the stock market clocked a record setting first half advance. Heading into mid-month, Amazon.com's ( AMZN ) Prime Day shopping event will garner attention early in the week.", "banner_image": "https://www.investors.com/wp-content/uploads/2020/05/Stock-AmazonPrimeday-02-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Economy - Monetary", "relevance_score": "0.890401"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "0.999921"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "1.0"}], "overall_sentiment_score": 0.156295, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.08183", "ticker_sentiment_score": "-0.014681", "ticker_sentiment_label": "Neutral"}, {"ticker": "TGT", "relevance_score": "0.054607", "ticker_sentiment_score": "0.019983", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.054607", "ticker_sentiment_score": "0.134813", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANET", "relevance_score": "0.054607", "ticker_sentiment_score": "0.134813", "ticker_sentiment_label": "Neutral"}, {"ticker": "C", "relevance_score": "0.08183", "ticker_sentiment_score": "0.052562", "ticker_sentiment_label": "Neutral"}, {"ticker": "VZ", "relevance_score": "0.054607", "ticker_sentiment_score": "0.1138", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.135959", "ticker_sentiment_score": "0.069977", "ticker_sentiment_label": "Neutral"}, {"ticker": "DDOG", "relevance_score": "0.027319", "ticker_sentiment_score": "0.125143", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAG", "relevance_score": "0.054607", "ticker_sentiment_score": "0.066231", "ticker_sentiment_label": "Neutral"}, {"ticker": "KSS", "relevance_score": "0.054607", "ticker_sentiment_score": "0.019983", "ticker_sentiment_label": "Neutral"}, {"ticker": "M", "relevance_score": "0.027319", "ticker_sentiment_score": "0.018389", "ticker_sentiment_label": "Neutral"}, {"ticker": "DAL", "relevance_score": "0.08183", "ticker_sentiment_score": "0.069558", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.08183", "ticker_sentiment_score": "0.053823", "ticker_sentiment_label": "Neutral"}, {"ticker": "STT", "relevance_score": "0.08183", "ticker_sentiment_score": "-0.014681", "ticker_sentiment_label": "Neutral"}, {"ticker": "MA", "relevance_score": "0.027319", "ticker_sentiment_score": "0.125143", "ticker_sentiment_label": "Neutral"}, {"ticker": "SBUX", "relevance_score": "0.027319", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.108958", "ticker_sentiment_score": "0.056767", "ticker_sentiment_label": "Neutral"}, {"ticker": "HELE", "relevance_score": "0.054607", "ticker_sentiment_score": "0.029", "ticker_sentiment_label": "Neutral"}, {"ticker": "BBY", "relevance_score": "0.054607", "ticker_sentiment_score": "0.019983", "ticker_sentiment_label": "Neutral"}, {"ticker": "PEP", "relevance_score": "0.054607", "ticker_sentiment_score": "0.142819", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTAS", "relevance_score": "0.08183", "ticker_sentiment_score": "0.11223", "ticker_sentiment_label": "Neutral"}, {"ticker": "FAST", "relevance_score": "0.054607", "ticker_sentiment_score": "0.220183", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMZN", "relevance_score": "0.135959", "ticker_sentiment_score": "0.040115", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.054607", "ticker_sentiment_score": "0.134813", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's How Much You Would Have Made Owning DexCom Stock In The Last 5 Years - DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/news/earnings/23/07/33153244/heres-how-much-you-would-have-made-owning-dexcom-stock-in-the-last-5-years", "time_published": "20230707T203028", "authors": ["Benzinga Insights"], "summary": "DexCom DXCM has outperformed the market over the past 5 years by 28.87% on an annualized basis producing an average annual return of 38.35%. Currently, DexCom has a market capitalization of $49.12 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.983605", "ticker_sentiment_score": "0.387251", "ticker_sentiment_label": "Bullish"}]}, {"title": "2 Growth Stocks That Could Double in 5 Years", "url": "https://www.fool.com/investing/2023/07/07/2-growth-stocks-that-could-double-in-5-years/", "time_published": "20230707T141500", "authors": ["Prosper Junior Bakiny"], "summary": "They could deliver excellent returns well beyond that.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F738581%2Fgrowth-5.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.214378"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.226409, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "EBAY", "relevance_score": "0.049629", "ticker_sentiment_score": "0.094674", "ticker_sentiment_label": "Neutral"}, {"ticker": "ETSY", "relevance_score": "0.424634", "ticker_sentiment_score": "0.301104", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.544869", "ticker_sentiment_score": "0.31868", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Futures: Jobs Data Looms; 7 Resilient Stocks", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-jobs-report-on-tap-meta-leads-resilient-stocks-as-threads-signups-soar/", "time_published": "20230707T120100", "authors": ["Investor's Business Daily", "ED CARSON"], "summary": "Dow Jones Futures: Jobs Report Looms Large As Yields Soar. Meta Leads 7 Resilient Stocks | Investor's Business Daily Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/07/Stock-threadsmeta-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.03149, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "META", "relevance_score": "0.093289", "ticker_sentiment_score": "0.017315", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.162489", "ticker_sentiment_score": "0.012497", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.023372", "ticker_sentiment_score": "0.025513", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.023372", "ticker_sentiment_score": "0.088997", "ticker_sentiment_label": "Neutral"}, {"ticker": "AIU", "relevance_score": "0.023372", "ticker_sentiment_score": "0.047218", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.139534", "ticker_sentiment_score": "-0.065431", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.070036", "ticker_sentiment_score": "0.013407", "ticker_sentiment_label": "Neutral"}, {"ticker": "MA", "relevance_score": "0.046724", "ticker_sentiment_score": "0.042268", "ticker_sentiment_label": "Neutral"}, {"ticker": "V", "relevance_score": "0.116461", "ticker_sentiment_score": "0.079599", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADBE", "relevance_score": "0.046724", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.070036", "ticker_sentiment_score": "0.062235", "ticker_sentiment_label": "Neutral"}, {"ticker": "HUBS", "relevance_score": "0.185306", "ticker_sentiment_score": "0.11497", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.093289", "ticker_sentiment_score": "0.102104", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.023372", "ticker_sentiment_score": "0.352308", "ticker_sentiment_label": "Bullish"}, {"ticker": "BIIB", "relevance_score": "0.070036", "ticker_sentiment_score": "0.229579", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Reasons to Retain ShockWave Medical  ( SWAV )  in Your Portfolio", "url": "https://www.zacks.com/stock/news/2117958/reasons-to-retain-shockwave-medical-swav-in-your-portfolio", "time_published": "20230707T114000", "authors": ["Zacks Investment Research"], "summary": "ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c0/2297.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.9545"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.373632, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "ALC", "relevance_score": "0.172507", "ticker_sentiment_score": "0.122147", "ticker_sentiment_label": "Neutral"}, {"ticker": "HOLX", "relevance_score": "0.172507", "ticker_sentiment_score": "0.117968", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.172507", "ticker_sentiment_score": "0.115182", "ticker_sentiment_label": "Neutral"}, {"ticker": "SWAV", "relevance_score": "0.486729", "ticker_sentiment_score": "0.505378", "ticker_sentiment_label": "Bullish"}]}, {"title": "Futures: Jobs Data Due; Elon Musk Rips 'Cheating' Threads", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-falls-with-jobs-report-due-meta-threads-has-record-launch-elon-musk-decries-cheating/", "time_published": "20230706T211600", "authors": ["ED CARSON", "Investor's Business Daily"], "summary": "Dow Jones Falls With Jobs Report Due. Meta's Threads Has Record Launch As Elon Musk Decries 'Cheating ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/07/Stock-threadsmeta-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.033961, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "META", "relevance_score": "0.099683", "ticker_sentiment_score": "0.01996", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.173511", "ticker_sentiment_score": "0.013077", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.024982", "ticker_sentiment_score": "0.025792", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.024982", "ticker_sentiment_score": "0.089839", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.149038", "ticker_sentiment_score": "-0.067984", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.074848", "ticker_sentiment_score": "0.014671", "ticker_sentiment_label": "Neutral"}, {"ticker": "MA", "relevance_score": "0.049939", "ticker_sentiment_score": "0.042561", "ticker_sentiment_label": "Neutral"}, {"ticker": "V", "relevance_score": "0.124421", "ticker_sentiment_score": "0.081884", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADBE", "relevance_score": "0.049939", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.049939", "ticker_sentiment_score": "0.077345", "ticker_sentiment_label": "Neutral"}, {"ticker": "HUBS", "relevance_score": "0.197816", "ticker_sentiment_score": "0.120699", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.099683", "ticker_sentiment_score": "0.104064", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.024982", "ticker_sentiment_score": "0.35403", "ticker_sentiment_label": "Bullish"}, {"ticker": "BIIB", "relevance_score": "0.074848", "ticker_sentiment_score": "0.254359", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "France $3.39 Bn Diabetes Markets to 2028: Insulin Pump, CGM, Self-Monitoring Blood Device and Company Analysis", "url": "https://www.prnewswire.com/news-releases/france-3-39-bn-diabetes-markets-to-2028-insulin-pump-cgm-self-monitoring-blood-device-and-company-analysis-301870998.html", "time_published": "20230706T153000", "authors": ["Research and Markets"], "summary": "DUBLIN, July 6, 2023 /PRNewswire/ -- The \"France Diabetes Market, Size, Forecast 2023-2028, By Insulin Pump, CGM, Self-Monitoring Blood Device and Company Analysis\" report has been added to ResearchAndMarkets.com's offering.", "banner_image": "https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.086326, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ABT", "relevance_score": "0.038969", "ticker_sentiment_score": "-0.078115", "ticker_sentiment_label": "Neutral"}, {"ticker": "DRIO", "relevance_score": "0.038969", "ticker_sentiment_score": "-0.078115", "ticker_sentiment_label": "Neutral"}, {"ticker": "TNDM", "relevance_score": "0.038969", "ticker_sentiment_score": "-0.078115", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.116536", "ticker_sentiment_score": "-0.003388", "ticker_sentiment_label": "Neutral"}, {"ticker": "TRUMF", "relevance_score": "0.038969", "ticker_sentiment_score": "-0.078115", "ticker_sentiment_label": "Neutral"}, {"ticker": "PODD", "relevance_score": "0.038969", "ticker_sentiment_score": "-0.078115", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDT", "relevance_score": "0.038969", "ticker_sentiment_score": "-0.078115", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.038969", "ticker_sentiment_score": "-0.078115", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's Why You Should Add Stryker  ( SYK )  Stock to Your Portfolio", "url": "https://www.zacks.com/stock/news/2117461/heres-why-you-should-add-stryker-syk-stock-to-your-portfolio", "time_published": "20230706T122200", "authors": ["Zacks Investment Research"], "summary": "Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio. However, pricing pressure weighs on the stock.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c0/2297.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.9545"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.320117, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALC", "relevance_score": "0.158173", "ticker_sentiment_score": "0.117954", "ticker_sentiment_label": "Neutral"}, {"ticker": "HOLX", "relevance_score": "0.158173", "ticker_sentiment_score": "0.114004", "ticker_sentiment_label": "Neutral"}, {"ticker": "SYK", "relevance_score": "0.49407", "ticker_sentiment_score": "0.480975", "ticker_sentiment_label": "Bullish"}, {"ticker": "DXCM", "relevance_score": "0.158173", "ticker_sentiment_score": "0.111371", "ticker_sentiment_label": "Neutral"}]}, {"title": "A Look Into DexCom Inc's Price Over Earnings - DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/news/23/07/33121269/a-look-into-dexcom-incs-price-over-earnings", "time_published": "20230705T185157", "authors": ["Benzinga Insights"], "summary": "In the current session, the stock is trading at $127.65, after a 0.50% increase. Over the past month, DexCom Inc. DXCM stock increased by 6.75%, and in the past year, by 55.82%.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.459462"}], "overall_sentiment_score": 0.082678, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.541149", "ticker_sentiment_score": "0.444232", "ticker_sentiment_label": "Bullish"}]}, {"title": "The 5 Best Stocks To Buy And Watch Right Now", "url": "https://www.investors.com/research/best-stocks-to-buy-now/", "time_published": "20230705T182300", "authors": ["MICHAEL LARKIN", "Investor's Business Daily"], "summary": "Buying a stock is easy, but buying the right stock without a time-tested strategy is incredibly hard. So what are the best stocks to buy now or put on a watchlist? Chipotle Mexican Grill ( CMG ) , Shopify ( SHOP ) , MongoDB ( MDB ) , DexCom ( DXCM ) and HubSpot ( HUBS ) are prime candidates.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/12/BESTof_trophy_123016_adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "1.0"}], "overall_sentiment_score": 0.280621, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SHOP", "relevance_score": "0.189941", "ticker_sentiment_score": "0.161751", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GOOG", "relevance_score": "0.017432", "ticker_sentiment_score": "0.006198", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.017432", "ticker_sentiment_score": "0.145081", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDB", "relevance_score": "0.138763", "ticker_sentiment_score": "0.16783", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CMG", "relevance_score": "0.069646", "ticker_sentiment_score": "0.048702", "ticker_sentiment_label": "Neutral"}, {"ticker": "HUBS", "relevance_score": "0.121562", "ticker_sentiment_score": "0.270397", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.17296", "ticker_sentiment_score": "0.164049", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "DexCom's  ( DXCM )  G7 CGM System Gets Nod From Health Canada", "url": "https://www.zacks.com/stock/news/2117001/dexcoms-dxcm-g7-cgm-system-gets-nod-from-health-canada", "time_published": "20230705T140100", "authors": ["Zacks Investment Research"], "summary": "DexCom's (DXCM) G7 CGM System's latest approval by Health Canada is expected to combine simplicity and power, thereby providing a better way to manage diabetes.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2a/3899.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.576289"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.292197, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HQY", "relevance_score": "0.21258", "ticker_sentiment_score": "0.040452", "ticker_sentiment_label": "Neutral"}, {"ticker": "HOLX", "relevance_score": "0.21258", "ticker_sentiment_score": "0.136065", "ticker_sentiment_label": "Neutral"}, {"ticker": "BSX", "relevance_score": "0.21258", "ticker_sentiment_score": "0.040391", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.822443", "ticker_sentiment_score": "0.519815", "ticker_sentiment_label": "Bullish"}]}, {"title": "Reasons to Retain AmerisourceBergen  ( ABC )  in Your Portfolio", "url": "https://www.zacks.com/stock/news/2116933/reasons-to-retain-amerisourcebergen-abc-in-your-portfolio", "time_published": "20230705T124300", "authors": ["Zacks Investment Research"], "summary": "AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.986413"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.38995, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "ALC", "relevance_score": "0.148121", "ticker_sentiment_score": "0.108248", "ticker_sentiment_label": "Neutral"}, {"ticker": "HOLX", "relevance_score": "0.148121", "ticker_sentiment_score": "0.105718", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.148121", "ticker_sentiment_score": "0.103188", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCSG", "relevance_score": "0.049629", "ticker_sentiment_score": "0.115172", "ticker_sentiment_label": "Neutral"}]}, {"title": "8 S&P 500 Stocks Make The Cut In Goldman's 'Rule Of 10' Screens", "url": "https://www.investors.com/news/sp-500-stocks-8-make-the-cut-in-goldmans-rule-of-10-screens/", "time_published": "20230705T114500", "authors": ["Investor's Business Daily", "ED CARSON"], "summary": "Looking for steady long-term earnings and sales growth? ServiceNow ( NOW ) , Chipotle Mexican Grill ( CMG ) , Fortinet ( FTNT ) , Cadence Design Systems ( CDNS ) , Intuit ( INTU ) , Paycom Software ( PAYC ) , Insulet ( PODD ) and Aptiv ( APTV ) appear in Goldman Sachs' \"Rule of 10\" stock screens ...", "banner_image": "https://www.investors.com/wp-content/uploads/2020/10/Stock-fastgrowing-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "0.999922"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.495866"}], "overall_sentiment_score": 0.256045, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ENPH", "relevance_score": "0.224903", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.113597", "ticker_sentiment_score": "0.144278", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANET", "relevance_score": "0.224903", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "INTU", "relevance_score": "0.432291", "ticker_sentiment_score": "0.156038", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MNST", "relevance_score": "0.224903", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AXON", "relevance_score": "0.224903", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.113597", "ticker_sentiment_score": "0.241692", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SEDG", "relevance_score": "0.224903", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.524949", "ticker_sentiment_score": "0.057568", "ticker_sentiment_label": "Neutral"}, {"ticker": "SBUX", "relevance_score": "0.224903", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "FTNT", "relevance_score": "0.524949", "ticker_sentiment_score": "0.308614", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NOW", "relevance_score": "0.331765", "ticker_sentiment_score": "0.109928", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADBE", "relevance_score": "0.224903", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CDNS", "relevance_score": "0.331765", "ticker_sentiment_score": "0.54445", "ticker_sentiment_label": "Bullish"}, {"ticker": "PODD", "relevance_score": "0.331765", "ticker_sentiment_score": "0.247528", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CMG", "relevance_score": "0.682689", "ticker_sentiment_score": "0.132854", "ticker_sentiment_label": "Neutral"}, {"ticker": "BKNG", "relevance_score": "0.113597", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.224903", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PAYC", "relevance_score": "0.224903", "ticker_sentiment_score": "0.361013", "ticker_sentiment_label": "Bullish"}, {"ticker": "PANW", "relevance_score": "0.432291", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dexcom G7 Continuous Glucose Monitoring System Gets Regulatory Nod From Health Canada - DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/markets/equities/23/07/33112307/dexcom-g7-continuous-glucose-monitoring-system-gets-regulatory-nod-from-health-canada", "time_published": "20230705T111637", "authors": ["Nabaparna Bhattacharya"], "summary": "DexCom, Inc.'s DXCM next-generation Dexcom G7 Continuous Glucose Monitoring System has been approved by Health Canada. This department operates under the Government of Canada and is responsible for national health policy.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/07/05/dxcm.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.211179, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.939207", "ticker_sentiment_score": "0.260351", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Wearable Bioelectronics Skin Patches Market to reach USD 14.8 billion in 2031, expanding at a CAGR of 11.5%: TMR Report", "url": "https://www.benzinga.com/pressreleases/23/07/g33106889/wearable-bioelectronics-skin-patches-market-to-reach-usd-14-8-billion-in-2031-expanding-at-a-cagr-", "time_published": "20230704T143000", "authors": ["Globe Newswire"], "summary": "Wilmington, Delaware, United States, July 04, 2023 ( GLOBE NEWSWIRE ) -- The global wearable bioelectronics skin patches market is projected to flourish at a CAGR of 11.5% from 2023 to 2031. As per the report published by TMR, a valuation of US$ 14.8 billion is anticipated for the market in 2031.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.265629, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "IRTC", "relevance_score": "0.041682", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PODD", "relevance_score": "0.041682", "ticker_sentiment_score": "0.076844", "ticker_sentiment_label": "Neutral"}, {"ticker": "WLDS", "relevance_score": "0.041682", "ticker_sentiment_score": "0.064788", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.124593", "ticker_sentiment_score": "0.180097", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Reasons to Add Inari Medical  ( NARI )  Stock to Your Portfolio", "url": "https://www.zacks.com/stock/news/2116395/reasons-to-add-inari-medical-nari-stock-to-your-portfolio", "time_published": "20230704T111900", "authors": ["Zacks Investment Research"], "summary": "Inari Medical (NARI) continues to benefit from its commitment to understand the venous system. However, its dependency on adoption of products is a concern.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/09/2677.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.890401"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.265562, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALC", "relevance_score": "0.135347", "ticker_sentiment_score": "0.065707", "ticker_sentiment_label": "Neutral"}, {"ticker": "HOLX", "relevance_score": "0.135347", "ticker_sentiment_score": "0.064508", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.135347", "ticker_sentiment_score": "0.062109", "ticker_sentiment_label": "Neutral"}, {"ticker": "NARI", "relevance_score": "0.430088", "ticker_sentiment_score": "0.356417", "ticker_sentiment_label": "Bullish"}]}, {"title": "These stocks could be the next Magnificent Seven market leaders, says Goldman Sachs.", "url": "https://www.marketwatch.com/story/these-stocks-could-be-the-next-magnificent-seven-market-leaders-says-goldman-sachs-5ea8a4e6", "time_published": "20230703T113600", "authors": ["Barbara Kollmeyer"], "summary": "Our call of the day, from a team at Goldman Sachs led by chief U.S. equity strategist David Kostin has some fresh ideas on how to find big market outperformers.", "banner_image": "https://images.mktw.net/im-810844?width=700&height=464", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "0.996023"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.682689"}], "overall_sentiment_score": 0.199537, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "XPEV", "relevance_score": "0.075043", "ticker_sentiment_score": "0.341262", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ENPH", "relevance_score": "0.075043", "ticker_sentiment_score": "0.030438", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.075043", "ticker_sentiment_score": "0.135423", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.112357", "ticker_sentiment_score": "-0.127586", "ticker_sentiment_label": "Neutral"}, {"ticker": "BKR", "relevance_score": "0.075043", "ticker_sentiment_score": "0.12427", "ticker_sentiment_label": "Neutral"}, {"ticker": "III", "relevance_score": "0.037563", "ticker_sentiment_score": "0.225607", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SLB", "relevance_score": "0.037563", "ticker_sentiment_score": "0.118693", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.037563", "ticker_sentiment_score": "0.059324", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.075043", "ticker_sentiment_score": "0.135423", "ticker_sentiment_label": "Neutral"}, {"ticker": "FIS", "relevance_score": "0.075043", "ticker_sentiment_score": "0.234039", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HAL", "relevance_score": "0.075043", "ticker_sentiment_score": "0.12427", "ticker_sentiment_label": "Neutral"}, {"ticker": "SEDG", "relevance_score": "0.075043", "ticker_sentiment_score": "0.030438", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.328333", "ticker_sentiment_score": "0.233697", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FTNT", "relevance_score": "0.112357", "ticker_sentiment_score": "0.025609", "ticker_sentiment_label": "Neutral"}, {"ticker": "NIO", "relevance_score": "0.075043", "ticker_sentiment_score": "0.341262", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NOW", "relevance_score": "0.075043", "ticker_sentiment_score": "0.076942", "ticker_sentiment_label": "Neutral"}, {"ticker": "CDNS", "relevance_score": "0.075043", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PODD", "relevance_score": "0.149424", "ticker_sentiment_score": "0.085564", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMG", "relevance_score": "0.075043", "ticker_sentiment_score": "0.12427", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.075043", "ticker_sentiment_score": "0.135423", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.075043", "ticker_sentiment_score": "0.030438", "ticker_sentiment_label": "Neutral"}, {"ticker": "PAYC", "relevance_score": "0.075043", "ticker_sentiment_score": "0.030438", "ticker_sentiment_label": "Neutral"}, {"ticker": "PANW", "relevance_score": "0.075043", "ticker_sentiment_score": "0.030438", "ticker_sentiment_label": "Neutral"}]}, {"title": "Friday's ETF Winners And Losers: Large-Cap Fund Flows - VOO and SPY Add More Than $1.5 Billion Each - Apple  ( NASDAQ:AAPL ) , Berkshire Hathaway Inc. New Common Stock  ( NYSE:BRK/B ) ", "url": "https://www.benzinga.com/news/large-cap/23/06/33081969/fridays-etf-winners-and-losers-large-cap-fund-flows-voo-and-spy-add-more-than-1-5-billion-each", "time_published": "20230630T175133", "authors": ["Johnny Rice"], "summary": "We performed a screening of large-cap ETFs - defined as having Assets Under Management ( AUM ) over $10 billion - to determine what funds had the largest change in net assets on the week, according to data from etfdb.com. Only non-leveraged funds were considered.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/06/30/hans-eiskonen-wn57csq7vzi-unsplash_1.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.995015"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}], "overall_sentiment_score": 0.131066, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.294977", "ticker_sentiment_score": "0.246691", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AAPL", "relevance_score": "0.294977", "ticker_sentiment_score": "0.246691", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.150122", "ticker_sentiment_score": "0.149949", "ticker_sentiment_label": "Neutral"}, {"ticker": "BRK-A", "relevance_score": "0.075397", "ticker_sentiment_score": "-0.013354", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRVL", "relevance_score": "0.150122", "ticker_sentiment_score": "0.149949", "ticker_sentiment_label": "Neutral"}, {"ticker": "XOM", "relevance_score": "0.150122", "ticker_sentiment_score": "-0.017391", "ticker_sentiment_label": "Neutral"}]}, {"title": "Peering Into DexCom's Recent Short Interest - DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/short-sellers/23/06/33066100/peering-into-dexcoms-recent-short-interest", "time_published": "20230629T191534", "authors": ["Benzinga Insights"], "summary": "DexCom's DXCM short percent of float has fallen 12.09% since its last report. The company recently reported that it has 12.71 million shares sold short, which is 3.71% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.3 days to cover their ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.24389, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.224903", "ticker_sentiment_score": "0.085754", "ticker_sentiment_label": "Neutral"}]}, {"title": "DexCom  ( DXCM )  Just Flashed Golden Cross Signal: Do You Buy?", "url": "https://www.zacks.com/stock/news/2114760/dexcom-dxcm-just-flashed-golden-cross-signal-do-you-buy", "time_published": "20230629T133504", "authors": ["Zacks Investment Research"], "summary": "Should investors be excited or worried when a stock crosses above the 20-day simple moving average?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default65.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.359119, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.804667", "ticker_sentiment_score": "0.626806", "ticker_sentiment_label": "Bullish"}]}, {"title": "Looking for a Growth Stock? 3 Reasons Why DexCom  ( DXCM )  is a Solid Choice", "url": "https://www.zacks.com/stock/news/2114389/looking-for-a-growth-stock-3-reasons-why-dexcom-dxcm-is-a-solid-choice", "time_published": "20230628T164507", "authors": ["Zacks Investment Research"], "summary": "DexCom (DXCM) could produce exceptional returns because of its solid growth attributes.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default229.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.983783"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.445181, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.504646", "ticker_sentiment_score": "0.37857", "ticker_sentiment_label": "Bullish"}]}, {"title": "Here's How Much a $1000 Investment in DexCom Made 10 Years Ago Would Be Worth Today", "url": "https://www.zacks.com/stock/news/2114061/heres-how-much-a-1000-investment-in-dexcom-made-10-years-ago-would-be-worth-today", "time_published": "20230628T123005", "authors": ["Zacks Investment Research"], "summary": "Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default249.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.744043"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.929393"}], "overall_sentiment_score": 0.313513, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.549265", "ticker_sentiment_score": "0.45399", "ticker_sentiment_label": "Bullish"}]}, {"title": "Dexcom  ( DXCM )  to Launch New Product in 2024, Ups Long-Term View", "url": "https://www.zacks.com/stock/news/2113582/dexcom-dxcm-to-launch-new-product-in-2024-ups-long-term-view", "time_published": "20230627T123500", "authors": ["Zacks Investment Research"], "summary": "Dexcom (DXCM) announces encouraging developments in 2024, including faster coverage for its products by private payers and new product launch for diabetic patients not on insulin.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/09/2677.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.576289"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.228903, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALC", "relevance_score": "0.175859", "ticker_sentiment_score": "0.116735", "ticker_sentiment_label": "Neutral"}, {"ticker": "HOLX", "relevance_score": "0.175859", "ticker_sentiment_score": "0.119558", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.664434", "ticker_sentiment_score": "0.355466", "ticker_sentiment_label": "Bullish"}, {"ticker": "PRGO", "relevance_score": "0.117774", "ticker_sentiment_score": "0.057121", "ticker_sentiment_label": "Neutral"}]}, {"title": "DexCom Unusual Options Activity For June 26 - DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/markets/options/23/06/33010891/dexcom-unusual-options-activity-for-june-26", "time_published": "20230626T170133", "authors": ["Benzinga Insights"], "summary": "A whale with a lot of money to spend has taken a noticeably bearish stance on DexCom. Looking at options history for DexCom DXCM we detected 13 strange trades. If we consider the specifics of each trade, it is accurate to state that 30% of the investors opened trades with bullish expectations ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.134722, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.759278", "ticker_sentiment_score": "0.047062", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.1331", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stock Market Starts Slow; Cruise Stock Sinks", "url": "https://www.investors.com/market-trend/stock-market-today/stock-market-slow-to-start-last-week-of-quarter-cruise-line-stock-sinks-after-earnings/", "time_published": "20230626T145700", "authors": ["Investor's Business Daily", "KIMBERLEY KOENIG"], "summary": "Stock Market Slow To Start Last Week Of Quarter. Cruise Line Stock ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/06/Stock-carnvialship-03-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.796627"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.071776, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.063594", "ticker_sentiment_score": "-0.074034", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.189175", "ticker_sentiment_score": "-0.021249", "ticker_sentiment_label": "Neutral"}, {"ticker": "MLTX", "relevance_score": "0.126784", "ticker_sentiment_score": "0.233049", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GS", "relevance_score": "0.063594", "ticker_sentiment_score": "-0.08104", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.063594", "ticker_sentiment_score": "0.258554", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.126784", "ticker_sentiment_score": "0.010745", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.189175", "ticker_sentiment_score": "0.020733", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.063594", "ticker_sentiment_score": "-0.003011", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.063594", "ticker_sentiment_score": "-0.275646", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "DexCom Revises 2025 Outlook, Announces New Product For Diabetics - DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/markets/equities/23/06/33001382/dexcom-revises-2025-outlook-announces-new-product-for-diabetics", "time_published": "20230626T120715", "authors": ["Lekha Gupta"], "summary": "DexCom Inc DXCM disclosed the 2025 financial targets revision at its investor day last week. The company raised the outlook for revenue to $4.6 billion - $5.1 billion ( from $4.0 billion - $4.5 billion ) , adjusted operating profit margin to 21% ( from 20% ) , and adjusted EBITDA margin to 31% ( ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/06/26/dxcm.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.538269"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.235473, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.692465", "ticker_sentiment_score": "0.658857", "ticker_sentiment_label": "Bullish"}]}, {"title": "Futures: Time To Buy These 5 Stocks Amid Orderly Pullback?", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-time-to-buy-these-5-stocks-amid-market-pullback/", "time_published": "20230625T173100", "authors": ["Investor's Business Daily", "ED CARSON"], "summary": "Dow Jones futures will open Sunday evening, along with S&P 500 futures and Nasdaq futures. The stock market rally retreated last week, with a long-awaited pullback taking hold. The selling has been orderly for the Nasdaq and S&P 500.", "banner_image": "https://www.investors.com/wp-content/uploads/2022/09/Stock-applestoreentrance-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.0699, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.076602", "ticker_sentiment_score": "0.023577", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.076602", "ticker_sentiment_score": "0.072421", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.133629", "ticker_sentiment_score": "0.032449", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.114682", "ticker_sentiment_score": "0.159199", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SMCI", "relevance_score": "0.038345", "ticker_sentiment_score": "0.099343", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDB", "relevance_score": "0.208546", "ticker_sentiment_score": "0.116475", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.019178", "ticker_sentiment_score": "-0.194128", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ROK", "relevance_score": "0.038345", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.227007", "ticker_sentiment_score": "0.083343", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMD", "relevance_score": "0.095669", "ticker_sentiment_score": "-0.018431", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMG", "relevance_score": "0.171282", "ticker_sentiment_score": "0.099374", "ticker_sentiment_label": "Neutral"}, {"ticker": "HUBS", "relevance_score": "0.208546", "ticker_sentiment_score": "0.062444", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.152499", "ticker_sentiment_score": "0.138392", "ticker_sentiment_label": "Neutral"}, {"ticker": "SWAV", "relevance_score": "0.076602", "ticker_sentiment_score": "0.092238", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:USD", "relevance_score": "0.019178", "ticker_sentiment_score": "-0.1609", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "These Fund Yields Up To 13% And Leave ETFs In The Dust", "url": "https://www.forbes.com/sites/brettowens/2023/06/25/these-fund-yields-up-to-13-and-leave-etfs-in-the-dust/", "time_published": "20230625T131400", "authors": ["Brett Owens"], "summary": "AI bubble? Bear market rally? I don't care because I see five dividends between 10.1% and 13.5%.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/64944cf3d90997e8347b67fd/0x0.jpg?format=jpg&crop=2860,1608,x320,y15,safe&height=900&width=1600&fit=bounds", "source": "Forbes", "category_within_source": "Markets", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.999997"}, {"topic": "Manufacturing", "relevance_score": "0.25"}], "overall_sentiment_score": 0.110738, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.050096", "ticker_sentiment_score": "0.087325", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.050096", "ticker_sentiment_score": "0.087325", "ticker_sentiment_label": "Neutral"}, {"ticker": "SYK", "relevance_score": "0.050096", "ticker_sentiment_score": "0.087325", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADI", "relevance_score": "0.050096", "ticker_sentiment_score": "0.087325", "ticker_sentiment_label": "Neutral"}, {"ticker": "AXON", "relevance_score": "0.050096", "ticker_sentiment_score": "0.087325", "ticker_sentiment_label": "Neutral"}, {"ticker": "RMD", "relevance_score": "0.050096", "ticker_sentiment_score": "0.087325", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.050096", "ticker_sentiment_score": "0.087325", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.02506", "ticker_sentiment_score": "-0.006659", "ticker_sentiment_label": "Neutral"}, {"ticker": "HESG", "relevance_score": "0.02506", "ticker_sentiment_score": "0.079655", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.050096", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PEN", "relevance_score": "0.050096", "ticker_sentiment_score": "0.087325", "ticker_sentiment_label": "Neutral"}, {"ticker": "APH", "relevance_score": "0.050096", "ticker_sentiment_score": "0.087325", "ticker_sentiment_label": "Neutral"}, {"ticker": "ENTG", "relevance_score": "0.050096", "ticker_sentiment_score": "0.087325", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.050096", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.050096", "ticker_sentiment_score": "0.087325", "ticker_sentiment_label": "Neutral"}]}, {"title": "Top 2% Dexcom Bolsters 2025 Outlook On 'Rapidly' Expanding Market", "url": "https://www.investors.com/news/technology/dexcom-stock-the-bullish-2025-call-that-could-send-shares-soaring/", "time_published": "20230624T001500", "authors": ["ALLISON GATLIN", "Investor's Business Daily"], "summary": "Dexcom Stock: The Bullish 2025 Call That Could Send Shares ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2020/02/stock-Dexcom-02-shutter.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.977154"}], "overall_sentiment_score": 0.196814, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MDT", "relevance_score": "0.120733", "ticker_sentiment_score": "0.150139", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.596532", "ticker_sentiment_score": "0.273204", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABT", "relevance_score": "0.120733", "ticker_sentiment_score": "0.150139", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Market Pullback Healthy So Far; What To Do Now", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-market-pullback-healthy-as-apple-hits-record-high-what-to-do/", "time_published": "20230623T220300", "authors": ["ED CARSON", "Investor's Business Daily"], "summary": "Pullback Healthy So Far, Apple Hits High. What To Do Now Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2022/09/Stock-applestoreentrance-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}], "overall_sentiment_score": 0.048428, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.07238", "ticker_sentiment_score": "0.020365", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.07238", "ticker_sentiment_score": "0.038615", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.144167", "ticker_sentiment_score": "0.014305", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.108385", "ticker_sentiment_score": "0.124979", "ticker_sentiment_label": "Neutral"}, {"ticker": "SMCI", "relevance_score": "0.036228", "ticker_sentiment_score": "0.098817", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDB", "relevance_score": "0.197266", "ticker_sentiment_score": "0.111621", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.018118", "ticker_sentiment_score": "-0.193032", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ROK", "relevance_score": "0.036228", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.214778", "ticker_sentiment_score": "0.061385", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMD", "relevance_score": "0.108385", "ticker_sentiment_score": "-0.011244", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMG", "relevance_score": "0.161952", "ticker_sentiment_score": "0.095711", "ticker_sentiment_label": "Neutral"}, {"ticker": "HUBS", "relevance_score": "0.197266", "ticker_sentiment_score": "0.059822", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.108385", "ticker_sentiment_score": "0.1042", "ticker_sentiment_label": "Neutral"}, {"ticker": "SWAV", "relevance_score": "0.07238", "ticker_sentiment_score": "0.091735", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:USD", "relevance_score": "0.018118", "ticker_sentiment_score": "-0.160144", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "DexCom Unusual Options Activity - DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/markets/options/23/06/32986186/dexcom-unusual-options-activity", "time_published": "20230623T150517", "authors": ["Benzinga Insights"], "summary": "Someone with a lot of money to spend has taken a bullish stance on DexCom DXCM. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.159134, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.779232", "ticker_sentiment_score": "0.433478", "ticker_sentiment_label": "Bullish"}, {"ticker": "MS", "relevance_score": "0.12165", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stocks Lower After Jobless Claims; Powell Speech Later", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-jobless-claims-powell-speech-tesla-stock-downgraded/", "time_published": "20230622T140800", "authors": ["Investor's Business Daily", "SCOTT LEHTONEN"], "summary": "Dow Jones Falls On Rising Jobless Claims. Powell Speech Now ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2022/06/Stock-jeromepowell2022-03-gov.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Economy - Monetary", "relevance_score": "0.769861"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Real Estate & Construction", "relevance_score": "0.166667"}], "overall_sentiment_score": 0.100944, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ROKU", "relevance_score": "0.150404", "ticker_sentiment_score": "0.089733", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.120582", "ticker_sentiment_score": "-0.035317", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.120582", "ticker_sentiment_score": "0.081982", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.060464", "ticker_sentiment_score": "-0.116491", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.030254", "ticker_sentiment_score": "0.105731", "ticker_sentiment_label": "Neutral"}, {"ticker": "KBH", "relevance_score": "0.090588", "ticker_sentiment_score": "-0.027591", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.150404", "ticker_sentiment_score": "0.101561", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCS", "relevance_score": "0.030254", "ticker_sentiment_score": "-0.110443", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.180012", "ticker_sentiment_score": "-0.133064", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCK", "relevance_score": "0.150404", "ticker_sentiment_score": "0.210954", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SPR", "relevance_score": "0.060464", "ticker_sentiment_score": "0.049061", "ticker_sentiment_label": "Neutral"}, {"ticker": "DRI", "relevance_score": "0.060464", "ticker_sentiment_score": "-0.026084", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMG", "relevance_score": "0.180012", "ticker_sentiment_score": "0.238329", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.150404", "ticker_sentiment_score": "0.151224", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BA", "relevance_score": "0.120582", "ticker_sentiment_score": "0.120811", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Reasons to Hold DexCom  ( DXCM )  Stock in Your Portfolio", "url": "https://www.zacks.com/stock/news/2111595/3-reasons-to-hold-dexcom-dxcm-stock-in-your-portfolio", "time_published": "20230622T093000", "authors": ["Zacks Investment Research"], "summary": "DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e7/2307.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.96136"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.303155, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALC", "relevance_score": "0.141171", "ticker_sentiment_score": "0.101627", "ticker_sentiment_label": "Neutral"}, {"ticker": "MMSI", "relevance_score": "0.141171", "ticker_sentiment_score": "0.106552", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.36472", "ticker_sentiment_score": "0.30255", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PRGO", "relevance_score": "0.09439", "ticker_sentiment_score": "0.05328", "ticker_sentiment_label": "Neutral"}]}, {"title": "If You Invested $1000 In This Stock 15 Years Ago, You Would Have $74,000 Today - DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/news/earnings/23/06/32955073/if-you-invested-1000-in-this-stock-15-years-ago-you-would-have-74-000-today", "time_published": "20230621T193028", "authors": ["Benzinga Insights"], "summary": "DexCom DXCM has outperformed the market over the past 15 years by 25.01% on an annualized basis producing an average annual return of 33.52%. Currently, DexCom has a market capitalization of $49.57 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_3.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.983605", "ticker_sentiment_score": "0.387251", "ticker_sentiment_label": "Bullish"}]}, {"title": "Insulet  ( PODD )  Launches the Omnipod 5 AID System in the UK", "url": "https://www.zacks.com/stock/news/2111213/insulet-podd-launches-the-omnipod-5-aid-system-in-the-uk", "time_published": "20230621T134800", "authors": ["Zacks Investment Research"], "summary": "Insulet (PODD) commercializes its revolutionary Omnipod 5 AID System in the United Kingdom.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/eb/4111.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.983783"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.277104, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PEN", "relevance_score": "0.181591", "ticker_sentiment_score": "0.061732", "ticker_sentiment_label": "Neutral"}, {"ticker": "PODD", "relevance_score": "0.353898", "ticker_sentiment_score": "0.334741", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HAE", "relevance_score": "0.298023", "ticker_sentiment_score": "0.165625", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LNTH", "relevance_score": "0.240489", "ticker_sentiment_score": "0.08921", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.12165", "ticker_sentiment_score": "0.115503", "ticker_sentiment_label": "Neutral"}]}, {"title": "Futures Lower As Powell Expects More Rate Hikes", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-powell-speech-tesla-stock-downgraded/", "time_published": "20230621T123900", "authors": ["SCOTT LEHTONEN", "Investor's Business Daily"], "summary": "Dow Jones Futures Fall Ahead Of Powell Speech. Tesla Stock ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2018/10/stock-Jerome-Powell-02-fed.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Economy - Monetary", "relevance_score": "0.682689"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.576289"}], "overall_sentiment_score": 0.153848, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.155451", "ticker_sentiment_score": "0.027394", "ticker_sentiment_label": "Neutral"}, {"ticker": "ROKU", "relevance_score": "0.155451", "ticker_sentiment_score": "0.169019", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AAPL", "relevance_score": "0.124647", "ticker_sentiment_score": "0.007083", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCS", "relevance_score": "0.062515", "ticker_sentiment_score": "0.029076", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.18602", "ticker_sentiment_score": "0.022615", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCK", "relevance_score": "0.124647", "ticker_sentiment_score": "0.249852", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JPM", "relevance_score": "0.124647", "ticker_sentiment_score": "0.083241", "ticker_sentiment_label": "Neutral"}, {"ticker": "FDX", "relevance_score": "0.093653", "ticker_sentiment_score": "-0.087286", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMG", "relevance_score": "0.155451", "ticker_sentiment_score": "0.277727", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IVZ", "relevance_score": "0.031282", "ticker_sentiment_score": "0.106228", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.155451", "ticker_sentiment_score": "0.187022", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BA", "relevance_score": "0.155451", "ticker_sentiment_score": "0.033274", "ticker_sentiment_label": "Neutral"}]}, {"title": "Futures Fall Ahead Of Key Housing Data", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-alibaba-slides-as-ceo-steps-down/", "time_published": "20230620T120900", "authors": ["SCOTT LEHTONEN", "Investor's Business Daily"], "summary": "Dow Jones futures dropped Tuesday morning ahead of key housing data, with the release of housing starts and permits from the Commerce Department. Chinese e-commerce giant Alibaba ( BABA ) fell sharply after CEO Daniel Zhang stepped down in a management shake-up. Housing data is due out at 8:30 ...", "banner_image": "https://www.investors.com/wp-content/uploads/2017/02/stock-wallStreet-1-shutter.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.160409, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BABA", "relevance_score": "0.102741", "ticker_sentiment_score": "-0.09889", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.170395", "ticker_sentiment_score": "0.117043", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.136693", "ticker_sentiment_score": "-0.121669", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.136693", "ticker_sentiment_score": "0.081186", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.136693", "ticker_sentiment_score": "0.078671", "ticker_sentiment_label": "Neutral"}, {"ticker": "NKE", "relevance_score": "0.0686", "ticker_sentiment_score": "0.058094", "ticker_sentiment_label": "Neutral"}, {"ticker": "FDX", "relevance_score": "0.102741", "ticker_sentiment_score": "-0.075924", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMG", "relevance_score": "0.170395", "ticker_sentiment_score": "0.251177", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IVZ", "relevance_score": "0.034332", "ticker_sentiment_score": "0.107606", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.170395", "ticker_sentiment_score": "0.18737", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BA", "relevance_score": "0.170395", "ticker_sentiment_score": "0.085216", "ticker_sentiment_label": "Neutral"}, {"ticker": "KNSL", "relevance_score": "0.136693", "ticker_sentiment_score": "0.108346", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dow Jones Holds Firm Above 34K; Adobe Surges On Bullish Earnings, AI Potential", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-holds-firm-above-34k-adobe-surges-bullish-earnings-ai-potential/", "time_published": "20230616T143800", "authors": ["Investor's Business Daily", "KEN SHREVE"], "summary": "Dow Jones Holds Firm Above 34K. Adobe Surges On Bullish ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2017/04/Wall-St-Shutterstock-1-SMT0300-4.27.17.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.999819"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.976913"}], "overall_sentiment_score": 0.217108, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DKNG", "relevance_score": "0.12165", "ticker_sentiment_score": "0.06814", "ticker_sentiment_label": "Neutral"}, {"ticker": "TGTX", "relevance_score": "0.12165", "ticker_sentiment_score": "0.179363", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVDA", "relevance_score": "0.12165", "ticker_sentiment_score": "0.07487", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.12165", "ticker_sentiment_score": "0.07487", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.061003", "ticker_sentiment_score": "0.064146", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADBE", "relevance_score": "0.240489", "ticker_sentiment_score": "0.301713", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IRBT", "relevance_score": "0.12165", "ticker_sentiment_score": "-0.029243", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPCE", "relevance_score": "0.12165", "ticker_sentiment_score": "0.064739", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.12165", "ticker_sentiment_score": "0.07487", "ticker_sentiment_label": "Neutral"}, {"ticker": "BA", "relevance_score": "0.12165", "ticker_sentiment_score": "0.109324", "ticker_sentiment_label": "Neutral"}, {"ticker": "PANW", "relevance_score": "0.181591", "ticker_sentiment_score": "0.089121", "ticker_sentiment_label": "Neutral"}]}, {"title": "Tech Futures Rise Ahead Of Inflation Survey", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-inflation-survey-virgin-galactic-rockets-on-planned-spaceflight/", "time_published": "20230616T121700", "authors": ["Investor's Business Daily", "SCOTT LEHTONEN"], "summary": "Dow Jones Futures Paused Ahead Of Inflation Survey. Virgin ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2017/03/stock-wallstreet-031317-shutter.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.19586, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.161062", "ticker_sentiment_score": "0.123325", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.129168", "ticker_sentiment_score": "-0.039614", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.129168", "ticker_sentiment_score": "0.020299", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.129168", "ticker_sentiment_score": "0.120603", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADBE", "relevance_score": "0.097062", "ticker_sentiment_score": "0.130915", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPCE", "relevance_score": "0.097062", "ticker_sentiment_score": "-0.026628", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMG", "relevance_score": "0.161062", "ticker_sentiment_score": "0.270609", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IVZ", "relevance_score": "0.064797", "ticker_sentiment_score": "0.072167", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.161062", "ticker_sentiment_score": "0.159284", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BA", "relevance_score": "0.161062", "ticker_sentiment_score": "0.063047", "ticker_sentiment_label": "Neutral"}, {"ticker": "KNSL", "relevance_score": "0.129168", "ticker_sentiment_score": "0.105297", "ticker_sentiment_label": "Neutral"}]}, {"title": "Inspire Medical Grows Like Gangbusters With Innovative Sleep Apnea Treatment", "url": "https://www.investors.com/research/inspire-medical-grows-like-gangbusters-innovative-sleep-apnea-treatment/", "time_published": "20230615T183900", "authors": ["Investor's Business Daily", "KEN SHREVE"], "summary": "Inspire Medical Grows Like Gangbusters With Innovative Sleep ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/06/Stock-inspiremedicalsystems-01-comany.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.905476"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.929393"}], "overall_sentiment_score": 0.340804, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "INSP", "relevance_score": "0.277433", "ticker_sentiment_score": "0.570858", "ticker_sentiment_label": "Bullish"}, {"ticker": "PEN", "relevance_score": "0.140896", "ticker_sentiment_score": "0.075721", "ticker_sentiment_label": "Neutral"}, {"ticker": "MMSI", "relevance_score": "0.140896", "ticker_sentiment_score": "0.075721", "ticker_sentiment_label": "Neutral"}, {"ticker": "SYK", "relevance_score": "0.140896", "ticker_sentiment_score": "0.075721", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.140896", "ticker_sentiment_score": "0.075721", "ticker_sentiment_label": "Neutral"}]}, {"title": "Spotlight Shines On Super Bowl, Chip Stocks And Nick Jonas", "url": "https://www.investors.com/research/ibd-stock-analysis/dexcom-stock-shines-pokes-at-buy-zone-with-spotlight-on-super-bowl-chip-stocks-and-nick-jonas/", "time_published": "20230615T153600", "authors": ["Investor's Business Daily", "MATTHEW GALGANI"], "summary": "What do semiconductor stocks, the Super Bowl and Nick Jonas have in common? They all have ties to Dexcom ( DXCM ) , a pioneer in treating people with diabetes. That has DXCM stock on the IBD Stock Spotlight screen as it pumps up a buy zone.", "banner_image": "https://www.investors.com/wp-content/uploads/2023/06/ISA-dexcom-061423-ap.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Earnings", "relevance_score": "0.744043"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.211459, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.06623", "ticker_sentiment_score": "0.153374", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PEN", "relevance_score": "0.132004", "ticker_sentiment_score": "0.149295", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.842269", "ticker_sentiment_score": "0.322663", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Stocks Fall After Jobless Claims, Retail Sales", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-jobless-claims-tesla-stock-extends-losses/", "time_published": "20230615T142400", "authors": ["Investor's Business Daily", "SCOTT LEHTONEN"], "summary": "Dow Jones Rallies 225 Points On Surprise Rise In Jobless Claims ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2017/04/stock-wallstreet-shutter.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Real Estate & Construction", "relevance_score": "0.166667"}], "overall_sentiment_score": 0.146579, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AAPL", "relevance_score": "0.124164", "ticker_sentiment_score": "0.030211", "ticker_sentiment_label": "Neutral"}, {"ticker": "CSCO", "relevance_score": "0.124164", "ticker_sentiment_score": "0.112626", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.124164", "ticker_sentiment_score": "0.074921", "ticker_sentiment_label": "Neutral"}, {"ticker": "KR", "relevance_score": "0.093289", "ticker_sentiment_score": "-0.050006", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.031159", "ticker_sentiment_score": "0.110013", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.062271", "ticker_sentiment_score": "-0.092021", "ticker_sentiment_label": "Neutral"}, {"ticker": "ASML", "relevance_score": "0.062271", "ticker_sentiment_score": "0.015036", "ticker_sentiment_label": "Neutral"}, {"ticker": "CHDN", "relevance_score": "0.154852", "ticker_sentiment_score": "0.16492", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MSFT", "relevance_score": "0.154852", "ticker_sentiment_score": "0.151492", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TSLA", "relevance_score": "0.185306", "ticker_sentiment_score": "0.060771", "ticker_sentiment_label": "Neutral"}, {"ticker": "LEN", "relevance_score": "0.124164", "ticker_sentiment_score": "0.227781", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JBL", "relevance_score": "0.093289", "ticker_sentiment_score": "-0.050006", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADBE", "relevance_score": "0.062271", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.154852", "ticker_sentiment_score": "0.163192", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "KNSL", "relevance_score": "0.124164", "ticker_sentiment_score": "0.053926", "ticker_sentiment_label": "Neutral"}]}, {"title": "Market Resilient; Big Warning Fuels This Group", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-market-rally-resilient-after-fed-surprise-tesla-ends-record-run/", "time_published": "20230615T101900", "authors": ["Investor's Business Daily", "ED CARSON"], "summary": "Dow Jones Futures Fall: Market Rally Resilient After Fed Surprise ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2018/04/stock-Federal-Reserve-06-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.769861"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}], "overall_sentiment_score": 0.009652, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVDA", "relevance_score": "0.151812", "ticker_sentiment_score": "-0.027103", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZBH", "relevance_score": "0.130335", "ticker_sentiment_score": "0.095057", "ticker_sentiment_label": "Neutral"}, {"ticker": "SYK", "relevance_score": "0.108761", "ticker_sentiment_score": "0.040158", "ticker_sentiment_label": "Neutral"}, {"ticker": "BSX", "relevance_score": "0.108761", "ticker_sentiment_score": "0.088149", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.021817", "ticker_sentiment_score": "-0.039883", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.108761", "ticker_sentiment_score": "-0.057256", "ticker_sentiment_label": "Neutral"}, {"ticker": "EW", "relevance_score": "0.108761", "ticker_sentiment_score": "0.058224", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNN", "relevance_score": "0.087106", "ticker_sentiment_score": "0.062734", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.21551", "ticker_sentiment_score": "0.01224", "ticker_sentiment_label": "Neutral"}, {"ticker": "LEN", "relevance_score": "0.065387", "ticker_sentiment_score": "0.080655", "ticker_sentiment_label": "Neutral"}, {"ticker": "BACHY", "relevance_score": "0.021817", "ticker_sentiment_score": "-0.082657", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSSMY", "relevance_score": "0.043618", "ticker_sentiment_score": "0.059564", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.108761", "ticker_sentiment_score": "0.038959", "ticker_sentiment_label": "Neutral"}, {"ticker": "INMD", "relevance_score": "0.087106", "ticker_sentiment_score": "0.086045", "ticker_sentiment_label": "Neutral"}, {"ticker": "SWAV", "relevance_score": "0.130335", "ticker_sentiment_score": "0.023847", "ticker_sentiment_label": "Neutral"}]}, {"title": "Market Resilient; Big Warning Fuels This Group", "url": "https://www.investors.com/market-trend/stock-market-today/market-rally-resilient-after-fed-surprise-tesla-ends-record-run-big-warning-fuels-this-group/", "time_published": "20230615T022700", "authors": ["Investor's Business Daily", "ED CARSON"], "summary": "Market Rally Resilient After Fed Surprise. Tesla Ends Record Run ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2018/04/stock-Federal-Reserve-06-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.769861"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}], "overall_sentiment_score": 0.024086, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVDA", "relevance_score": "0.135602", "ticker_sentiment_score": "0.010069", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZBH", "relevance_score": "0.135602", "ticker_sentiment_score": "0.097017", "ticker_sentiment_label": "Neutral"}, {"ticker": "SYK", "relevance_score": "0.113169", "ticker_sentiment_score": "0.040788", "ticker_sentiment_label": "Neutral"}, {"ticker": "BSX", "relevance_score": "0.113169", "ticker_sentiment_score": "0.089467", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.022707", "ticker_sentiment_score": "-0.040038", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.113169", "ticker_sentiment_score": "-0.058172", "ticker_sentiment_label": "Neutral"}, {"ticker": "EW", "relevance_score": "0.113169", "ticker_sentiment_score": "0.059087", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNN", "relevance_score": "0.090645", "ticker_sentiment_score": "0.063206", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.180124", "ticker_sentiment_score": "0.067175", "ticker_sentiment_label": "Neutral"}, {"ticker": "LEN", "relevance_score": "0.068048", "ticker_sentiment_score": "0.080928", "ticker_sentiment_label": "Neutral"}, {"ticker": "BACHY", "relevance_score": "0.022707", "ticker_sentiment_score": "-0.12307", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSSMY", "relevance_score": "0.045396", "ticker_sentiment_score": "0.05985", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.113169", "ticker_sentiment_score": "0.039566", "ticker_sentiment_label": "Neutral"}, {"ticker": "INMD", "relevance_score": "0.090645", "ticker_sentiment_score": "0.086766", "ticker_sentiment_label": "Neutral"}, {"ticker": "SWAV", "relevance_score": "0.135602", "ticker_sentiment_score": "0.024345", "ticker_sentiment_label": "Neutral"}]}, {"title": "Futures Mixed Ahead Of Inflation Data; Fed Decision, Powell Next", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-fall-ahead-of-key-inflation-data-fed-decision-powell-comments-loom/", "time_published": "20230614T121700", "authors": ["Investor's Business Daily", "SCOTT LEHTONEN"], "summary": "Futures Mixed Ahead Of Inflation Data. Fed Decision, Powell Next Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2022/06/Stock-jeromepowell2022-03-gov.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.769861"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.2"}], "overall_sentiment_score": 0.155656, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AAPL", "relevance_score": "0.12028", "ticker_sentiment_score": "0.02933", "ticker_sentiment_label": "Neutral"}, {"ticker": "CSCO", "relevance_score": "0.12028", "ticker_sentiment_score": "0.07355", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.12028", "ticker_sentiment_score": "0.220867", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GS", "relevance_score": "0.030178", "ticker_sentiment_score": "-0.003946", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.060312", "ticker_sentiment_score": "0.038038", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.060312", "ticker_sentiment_score": "-0.004061", "ticker_sentiment_label": "Neutral"}, {"ticker": "CHDN", "relevance_score": "0.150029", "ticker_sentiment_score": "0.181791", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MSFT", "relevance_score": "0.150029", "ticker_sentiment_score": "0.111622", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.179565", "ticker_sentiment_score": "0.021835", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMD", "relevance_score": "0.060312", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.060312", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.150029", "ticker_sentiment_score": "0.114538", "ticker_sentiment_label": "Neutral"}, {"ticker": "KNSL", "relevance_score": "0.12028", "ticker_sentiment_score": "0.0974", "ticker_sentiment_label": "Neutral"}]}, {"title": "LSI USA Emerging Medtech Summit Returns to Dana Point March 18, 2024", "url": "https://www.prnewswire.com/news-releases/lsi-usa-emerging-medtech-summit-returns-to-dana-point-march-18-2024-301849891.html", "time_published": "20230613T175700", "authors": ["Life Science Intelligence"], "summary": "HUNTINGTON BEACH, Calif., June 13, 2023 /PRNewswire/ -- LSI, the company behind LSI Emerging Medtech Summits, the partnering events for global leaders building breakthrough healthcare businesses, today announced it will host its next USA Emerging Medtech Summit, LSI USA '24, on March 18 through ...", "banner_image": "https://mma.prnewswire.com/media/1994504/Life_Science_Intelligence_Logov1.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.261649, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.074001", "ticker_sentiment_score": "0.053388", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZBH", "relevance_score": "0.074001", "ticker_sentiment_score": "0.053388", "ticker_sentiment_label": "Neutral"}, {"ticker": "BSX", "relevance_score": "0.074001", "ticker_sentiment_score": "0.053388", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.074001", "ticker_sentiment_score": "0.053388", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.074001", "ticker_sentiment_score": "0.053388", "ticker_sentiment_label": "Neutral"}, {"ticker": "TFX", "relevance_score": "0.074001", "ticker_sentiment_score": "0.053388", "ticker_sentiment_label": "Neutral"}, {"ticker": "EW", "relevance_score": "0.074001", "ticker_sentiment_score": "0.053388", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.074001", "ticker_sentiment_score": "0.053388", "ticker_sentiment_label": "Neutral"}, {"ticker": "TMO", "relevance_score": "0.074001", "ticker_sentiment_score": "0.053388", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSBHF", "relevance_score": "0.074001", "ticker_sentiment_score": "0.053388", "ticker_sentiment_label": "Neutral"}, {"ticker": "FUJIF", "relevance_score": "0.074001", "ticker_sentiment_score": "0.053388", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDT", "relevance_score": "0.147366", "ticker_sentiment_score": "0.110447", "ticker_sentiment_label": "Neutral"}, {"ticker": "CNMD", "relevance_score": "0.074001", "ticker_sentiment_score": "0.053388", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.074001", "ticker_sentiment_score": "0.053388", "ticker_sentiment_label": "Neutral"}]}, {"title": "Futures Pause Ahead Of Inflation Data", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-cpi-inflation-data-cathie-wood-tesla-stock/", "time_published": "20230613T122200", "authors": ["Investor's Business Daily", "SCOTT LEHTONEN"], "summary": "Dow Jones Futures Waver Ahead Of Inflation Data. Cathie Wood ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2019/10/stock-wall-street-flags-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.990678"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.185173, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NVDA", "relevance_score": "0.091509", "ticker_sentiment_score": "0.100877", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.121804", "ticker_sentiment_score": "0.058479", "ticker_sentiment_label": "Neutral"}, {"ticker": "CSCO", "relevance_score": "0.121804", "ticker_sentiment_score": "0.057046", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.121804", "ticker_sentiment_score": "0.186366", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ORCL", "relevance_score": "0.091509", "ticker_sentiment_score": "0.132257", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.030563", "ticker_sentiment_score": "0.109717", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.151922", "ticker_sentiment_score": "0.122746", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.181819", "ticker_sentiment_score": "0.14005", "ticker_sentiment_label": "Neutral"}, {"ticker": "FTNT", "relevance_score": "0.151922", "ticker_sentiment_score": "0.154879", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "INTC", "relevance_score": "0.091509", "ticker_sentiment_score": "0.051881", "ticker_sentiment_label": "Neutral"}, {"ticker": "SFTBF", "relevance_score": "0.030563", "ticker_sentiment_score": "0.046224", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.151922", "ticker_sentiment_score": "0.110855", "ticker_sentiment_label": "Neutral"}, {"ticker": "KNSL", "relevance_score": "0.121804", "ticker_sentiment_score": "0.07904", "ticker_sentiment_label": "Neutral"}]}, {"title": "Futures: Fed Meeting, Inflation Data Loom", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-nasdaq-hits-2023-high-inflation-data-fed-meeting-loom-tesla-stock-extends-win-streak/", "time_published": "20230612T204300", "authors": ["Investor's Business Daily", "SCOTT LEHTONEN"], "summary": "Dow Jones Futures: Nasdaq Hits New 2023 High As Inflation Data ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/06/SMT-jeromepowell-0612-news.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.9545"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.197111, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.145804", "ticker_sentiment_score": "0.137369", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.109622", "ticker_sentiment_score": "0.096374", "ticker_sentiment_label": "Neutral"}, {"ticker": "CSCO", "relevance_score": "0.145804", "ticker_sentiment_score": "0.113528", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.145804", "ticker_sentiment_score": "0.08596", "ticker_sentiment_label": "Neutral"}, {"ticker": "FTNT", "relevance_score": "0.145804", "ticker_sentiment_score": "0.162481", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JPM", "relevance_score": "0.145804", "ticker_sentiment_score": "0.203899", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ORCL", "relevance_score": "0.109622", "ticker_sentiment_score": "0.142425", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.145804", "ticker_sentiment_score": "0.117255", "ticker_sentiment_label": "Neutral"}, {"ticker": "KNSL", "relevance_score": "0.109622", "ticker_sentiment_score": "0.130297", "ticker_sentiment_label": "Neutral"}]}, {"title": "Tech Futures Lead Ahead Of Inflation Data, Fed Meeting", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-inflation-data-fed-meeting-amd-amazon-rally/", "time_published": "20230612T121600", "authors": ["Investor's Business Daily", "SCOTT LEHTONEN"], "summary": "Dow Jones Futures Rise Ahead Of Inflation Data, Fed Meeting. AMD ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2017/03/stock-wallstreet2-031317-shutter.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.990678"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.153506, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AAPL", "relevance_score": "0.130394", "ticker_sentiment_score": "0.047462", "ticker_sentiment_label": "Neutral"}, {"ticker": "CSCO", "relevance_score": "0.130394", "ticker_sentiment_score": "0.112875", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.130394", "ticker_sentiment_score": "0.192268", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ORCL", "relevance_score": "0.065416", "ticker_sentiment_score": "0.169363", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GS", "relevance_score": "0.032736", "ticker_sentiment_score": "-0.172171", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "IVZ", "relevance_score": "0.032736", "ticker_sentiment_score": "0.110766", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.162583", "ticker_sentiment_score": "0.10658", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.130394", "ticker_sentiment_score": "0.111693", "ticker_sentiment_label": "Neutral"}, {"ticker": "FTNT", "relevance_score": "0.130394", "ticker_sentiment_score": "0.156696", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMD", "relevance_score": "0.097987", "ticker_sentiment_score": "-0.044742", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.097987", "ticker_sentiment_score": "-0.044742", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.162583", "ticker_sentiment_score": "0.236383", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "KNSL", "relevance_score": "0.130394", "ticker_sentiment_score": "0.11051", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Is Steris  ( STE )  Down 0.9% Since Last Earnings Report?", "url": "https://www.zacks.com/stock/news/2106514/why-is-steris-ste-down-09-since-last-earnings-report", "time_published": "20230609T153030", "authors": ["Zacks Investment Research"], "summary": "Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default148.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.962106"}, {"topic": "Earnings", "relevance_score": "0.999994"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.075445, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "STE", "relevance_score": "0.384397", "ticker_sentiment_score": "0.063932", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.198221", "ticker_sentiment_score": "0.023264", "ticker_sentiment_label": "Neutral"}]}, {"title": "Futures Mixed As Tesla Surges On GM Deal", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-tesla-stock-gm-deal-target-downgrade/", "time_published": "20230609T125800", "authors": ["SCOTT LEHTONEN", "Investor's Business Daily"], "summary": "Dow Jones Futures Fall As Tesla Stock Surges On GM Deal. Target ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2017/09/Stock-Tesla-mall02-IBD.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.576289"}], "overall_sentiment_score": 0.182461, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "TGT", "relevance_score": "0.095138", "ticker_sentiment_score": "0.013817", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.063509", "ticker_sentiment_score": "-0.042101", "ticker_sentiment_label": "Neutral"}, {"ticker": "C", "relevance_score": "0.063509", "ticker_sentiment_score": "0.013036", "ticker_sentiment_label": "Neutral"}, {"ticker": "CSCO", "relevance_score": "0.126617", "ticker_sentiment_score": "0.057487", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDNDF", "relevance_score": "0.095138", "ticker_sentiment_score": "0.035085", "ticker_sentiment_label": "Neutral"}, {"ticker": "GM", "relevance_score": "0.126617", "ticker_sentiment_score": "0.058944", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.03178", "ticker_sentiment_score": "0.110314", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.095138", "ticker_sentiment_score": "0.124424", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.219667", "ticker_sentiment_score": "0.116342", "ticker_sentiment_label": "Neutral"}, {"ticker": "FTNT", "relevance_score": "0.126617", "ticker_sentiment_score": "0.184935", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NIO", "relevance_score": "0.095138", "ticker_sentiment_score": "-0.042538", "ticker_sentiment_label": "Neutral"}, {"ticker": "DOCU", "relevance_score": "0.063509", "ticker_sentiment_score": "0.234427", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.157896", "ticker_sentiment_score": "0.232106", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "KNSL", "relevance_score": "0.126617", "ticker_sentiment_score": "0.10664", "ticker_sentiment_label": "Neutral"}]}, {"title": "Futures Hover Ahead Of Jobless Claims", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-jobless-claims-gme-stock-crashes/", "time_published": "20230608T122800", "authors": ["Investor's Business Daily", "SCOTT LEHTONEN"], "summary": "Dow Jones Futures Fall Ahead Of Jobless Claims. GME Stock ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2017/02/stock-wallStreet-1-shutter.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}], "overall_sentiment_score": 0.130935, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.165712", "ticker_sentiment_score": "0.074233", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.132916", "ticker_sentiment_score": "-0.061226", "ticker_sentiment_label": "Neutral"}, {"ticker": "CSCO", "relevance_score": "0.132916", "ticker_sentiment_score": "0.058897", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.132916", "ticker_sentiment_score": "0.057249", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDNDF", "relevance_score": "0.09989", "ticker_sentiment_score": "0.073189", "ticker_sentiment_label": "Neutral"}, {"ticker": "FTNT", "relevance_score": "0.132916", "ticker_sentiment_score": "0.128987", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.033375", "ticker_sentiment_score": "0.11106", "ticker_sentiment_label": "Neutral"}, {"ticker": "SMAR", "relevance_score": "0.066691", "ticker_sentiment_score": "-0.131156", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.165712", "ticker_sentiment_score": "0.212326", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GME", "relevance_score": "0.132916", "ticker_sentiment_score": "-0.171899", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "KNSL", "relevance_score": "0.132916", "ticker_sentiment_score": "0.109179", "ticker_sentiment_label": "Neutral"}]}, {"title": "Qualcomm Sponsoring EvoNexus Incubator Demo Day June 26th, 2023", "url": "https://www.prnewswire.com/news-releases/qualcomm-sponsoring-evonexus-incubator-demo-day-june-26th-2023-301845503.html", "time_published": "20230607T213700", "authors": ["EvoNexus"], "summary": "Qualcomm Sponsoring EvoNexus Incubator Demo Day June 26th ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1214429/EvoNexus_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.246204, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CRUS", "relevance_score": "0.092927", "ticker_sentiment_score": "0.141115", "ticker_sentiment_label": "Neutral"}, {"ticker": "QCOM", "relevance_score": "0.70655", "ticker_sentiment_score": "0.302623", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RMD", "relevance_score": "0.092927", "ticker_sentiment_score": "0.141115", "ticker_sentiment_label": "Neutral"}, {"ticker": "VSAT", "relevance_score": "0.092927", "ticker_sentiment_score": "0.141115", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAESF", "relevance_score": "0.092927", "ticker_sentiment_score": "0.141115", "ticker_sentiment_label": "Neutral"}, {"ticker": "RBCPF", "relevance_score": "0.092927", "ticker_sentiment_score": "0.141115", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.092927", "ticker_sentiment_score": "0.141115", "ticker_sentiment_label": "Neutral"}]}, {"title": "Futures Edge Higher With Tesla Set To Hit 2023 High.", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-fall-tesla-stock-set-to-hit-new-2023-high-netflix-stock-jumps/", "time_published": "20230607T121500", "authors": ["Investor's Business Daily", "SCOTT LEHTONEN"], "summary": "Dow Jones Futures Fall With Tesla Set To Hit New 2023 High ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2019/03/stock-Tesla-sign-02-shutter.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}], "overall_sentiment_score": 0.245914, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.135921", "ticker_sentiment_score": "0.159209", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NFLX", "relevance_score": "0.135921", "ticker_sentiment_score": "0.065931", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.135921", "ticker_sentiment_score": "-0.094985", "ticker_sentiment_label": "Neutral"}, {"ticker": "CSCO", "relevance_score": "0.135921", "ticker_sentiment_score": "0.101991", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.202648", "ticker_sentiment_score": "0.100786", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDNDF", "relevance_score": "0.102158", "ticker_sentiment_score": "0.068063", "ticker_sentiment_label": "Neutral"}, {"ticker": "SFIX", "relevance_score": "0.034136", "ticker_sentiment_score": "0.343867", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FTNT", "relevance_score": "0.169437", "ticker_sentiment_score": "0.190629", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WFC", "relevance_score": "0.034136", "ticker_sentiment_score": "0.058475", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.034136", "ticker_sentiment_score": "0.058475", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.034136", "ticker_sentiment_score": "0.111401", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.169437", "ticker_sentiment_score": "0.276715", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Building Better Breakouts: These Growth Stocks Are Getting Pumped", "url": "https://www.investors.com/research/breakout-stocks-technical-analysis/growth-stocks-to-watch-asml-tsm-stock-among-top-names-pumping-up-breakouts/", "time_published": "20230607T120000", "authors": ["Investor's Business Daily", "MATTHEW GALGANI"], "summary": "The latest IBD/TIPP survey shows the U.S. economy remains stuck in a rut, and President Joe Biden's job approval rating just slid to its worst level of 2023.", "banner_image": "https://www.investors.com/wp-content/uploads/2023/06/Stock-muscles-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "0.990893"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.192588, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "KLAC", "relevance_score": "0.15697", "ticker_sentiment_score": "0.027894", "ticker_sentiment_label": "Neutral"}, {"ticker": "CELH", "relevance_score": "0.233556", "ticker_sentiment_score": "0.118798", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANET", "relevance_score": "0.233556", "ticker_sentiment_score": "0.092758", "ticker_sentiment_label": "Neutral"}, {"ticker": "CSCO", "relevance_score": "0.233556", "ticker_sentiment_score": "-0.106464", "ticker_sentiment_label": "Neutral"}, {"ticker": "WING", "relevance_score": "0.15697", "ticker_sentiment_score": "0.16064", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JPM", "relevance_score": "0.15697", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RMBS", "relevance_score": "0.233556", "ticker_sentiment_score": "0.106679", "ticker_sentiment_label": "Neutral"}, {"ticker": "AEHR", "relevance_score": "0.307924", "ticker_sentiment_score": "0.115111", "ticker_sentiment_label": "Neutral"}, {"ticker": "SHOP", "relevance_score": "0.307924", "ticker_sentiment_score": "0.284106", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "EXTR", "relevance_score": "0.15697", "ticker_sentiment_score": "-0.137046", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADBE", "relevance_score": "0.15697", "ticker_sentiment_score": "0.16064", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LRCX", "relevance_score": "0.15697", "ticker_sentiment_score": "0.027894", "ticker_sentiment_label": "Neutral"}, {"ticker": "RCL", "relevance_score": "0.15697", "ticker_sentiment_score": "0.206463", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DBX", "relevance_score": "0.15697", "ticker_sentiment_score": "-0.137046", "ticker_sentiment_label": "Neutral"}, {"ticker": "ISRG", "relevance_score": "0.15697", "ticker_sentiment_score": "0.206463", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.15697", "ticker_sentiment_score": "0.16064", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRVL", "relevance_score": "0.15697", "ticker_sentiment_score": "0.027894", "ticker_sentiment_label": "Neutral"}, {"ticker": "ON", "relevance_score": "0.07887", "ticker_sentiment_score": "0.020823", "ticker_sentiment_label": "Neutral"}]}, {"title": "Novocure Stock Gets Relative Strength Rating Upgrade, Then Drops 30%", "url": "https://www.investors.com/research/novocure-gets-relative-strength-rating-upgrade/", "time_published": "20230606T144100", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY", "GLENN LARKIN"], "summary": "Novocure Stock Gets Relative Strength Rating Upgrade, Then Drops ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2017/05/IRU1.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.231944, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PEN", "relevance_score": "0.254307", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.254307", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVCR", "relevance_score": "0.373378", "ticker_sentiment_score": "0.181647", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Indexes Retreat, But Not Much; Two Big Movers Late", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-market-rally-retreats-on-apple-5-stocks-in-buy-areas/", "time_published": "20230606T103300", "authors": ["Investor's Business Daily", "ED CARSON"], "summary": "Dow Jones Futures Fall: Market Rally Retreats On Apple. 5 Stocks In ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/06/Stock-Apple-visionproglasses-02-company.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Blockchain", "relevance_score": "0.158519"}, {"topic": "IPO", "relevance_score": "0.310843"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.538269"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Real Estate & Construction", "relevance_score": "0.166667"}], "overall_sentiment_score": 0.048431, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MARA", "relevance_score": "0.02607", "ticker_sentiment_score": "-0.220932", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SHOP", "relevance_score": "0.129795", "ticker_sentiment_score": "0.155798", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AAPL", "relevance_score": "0.206245", "ticker_sentiment_score": "0.07424", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.180943", "ticker_sentiment_score": "0.123288", "ticker_sentiment_label": "Neutral"}, {"ticker": "WING", "relevance_score": "0.180943", "ticker_sentiment_score": "0.07244", "ticker_sentiment_label": "Neutral"}, {"ticker": "FTNT", "relevance_score": "0.256179", "ticker_sentiment_score": "-0.021236", "ticker_sentiment_label": "Neutral"}, {"ticker": "INTC", "relevance_score": "0.052112", "ticker_sentiment_score": "-0.057", "ticker_sentiment_label": "Neutral"}, {"ticker": "FLNC", "relevance_score": "0.052112", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.02607", "ticker_sentiment_score": "-0.00462", "ticker_sentiment_label": "Neutral"}, {"ticker": "COIN", "relevance_score": "0.104002", "ticker_sentiment_score": "-0.050066", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.129795", "ticker_sentiment_score": "0.083334", "ticker_sentiment_label": "Neutral"}, {"ticker": "IOT", "relevance_score": "0.052112", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.052112", "ticker_sentiment_score": "-0.228181", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Have $1,500? 2 Top Growth Stocks to Buy and Hold for the Long Haul", "url": "https://www.fool.com/investing/2023/06/06/have-1500-2-top-growth-stocks-to-buy-and-hold-for/", "time_published": "20230606T093000", "authors": ["Rachel Warren"], "summary": "Fears of a bear market shouldn't deter long-term investors from quality businesses.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F734194%2Fhospital-er-and-main-entrance-signs.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972756"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}], "overall_sentiment_score": 0.232991, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "FVRR", "relevance_score": "0.354459", "ticker_sentiment_score": "0.156081", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.121856", "ticker_sentiment_score": "0.035164", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.04076", "ticker_sentiment_score": "0.280389", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Market Holds Bulk Of Recent Gains; 5 Stocks In Buy Areas", "url": "https://www.investors.com/market-trend/stock-market-today/market-rally-holds-bulk-of-recent-gains-despite-apple-reversal-5-stocks-in-buy-areas/", "time_published": "20230605T210700", "authors": ["ED CARSON", "Investor's Business Daily"], "summary": "Market Rally Holds Bulk Of Recent Gains Despite Apple Reversal. 5 ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/06/Stock-Apple-visionproglasses-02-company.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Blockchain", "relevance_score": "0.158519"}, {"topic": "IPO", "relevance_score": "0.310843"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.538269"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Real Estate & Construction", "relevance_score": "0.166667"}], "overall_sentiment_score": 0.067466, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MARA", "relevance_score": "0.026591", "ticker_sentiment_score": "-0.221268", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SHOP", "relevance_score": "0.132368", "ticker_sentiment_score": "0.157358", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AAPL", "relevance_score": "0.210274", "ticker_sentiment_score": "0.077123", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.184497", "ticker_sentiment_score": "0.125031", "ticker_sentiment_label": "Neutral"}, {"ticker": "WING", "relevance_score": "0.184497", "ticker_sentiment_score": "0.073473", "ticker_sentiment_label": "Neutral"}, {"ticker": "FTNT", "relevance_score": "0.261117", "ticker_sentiment_score": "-0.021567", "ticker_sentiment_label": "Neutral"}, {"ticker": "INTC", "relevance_score": "0.053153", "ticker_sentiment_score": "-0.057005", "ticker_sentiment_label": "Neutral"}, {"ticker": "FLNC", "relevance_score": "0.053153", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.026591", "ticker_sentiment_score": "-0.004633", "ticker_sentiment_label": "Neutral"}, {"ticker": "COIN", "relevance_score": "0.10607", "ticker_sentiment_score": "-0.050456", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.132368", "ticker_sentiment_score": "0.084169", "ticker_sentiment_label": "Neutral"}, {"ticker": "IOT", "relevance_score": "0.053153", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.053153", "ticker_sentiment_score": "-0.22828", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "If You Invested $100 In This Stock 15 Years Ago, You Would Have $6,800 Today - DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/news/earnings/23/06/32725586/if-you-invested-100-in-this-stock-15-years-ago-you-would-have-6-800-today", "time_published": "20230605T203022", "authors": ["Benzinga Insights"], "summary": "DexCom DXCM has outperformed the market over the past 15 years by 24.83% on an annualized basis producing an average annual return of 32.76%. Currently, DexCom has a market capitalization of $48.32 billion.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.983605", "ticker_sentiment_score": "0.387251", "ticker_sentiment_label": "Bullish"}]}, {"title": "Dow Jones Falls As Apple Unveils These Products; This Stock Soars After Cathie Wood Sells It", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-falls-even-as-apple-unveils-ios-17-vr-headset-vision-pro-this-stock-soars-after-cathie-wood-sells-it/", "time_published": "20230605T191500", "authors": ["MICHAEL LARKIN", "Investor's Business Daily"], "summary": "Dow Jones Falls As Apple Unveils These Products. This Stock Soars ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/06/SMT-cathiewood-0605-news.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.650727"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.222938, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AAPL", "relevance_score": "0.197413", "ticker_sentiment_score": "0.003186", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.049835", "ticker_sentiment_score": "0.117203", "ticker_sentiment_label": "Neutral"}, {"ticker": "FTNT", "relevance_score": "0.148731", "ticker_sentiment_score": "0.160553", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "INTC", "relevance_score": "0.099476", "ticker_sentiment_score": "-0.078554", "ticker_sentiment_label": "Neutral"}, {"ticker": "EPAM", "relevance_score": "0.099476", "ticker_sentiment_score": "-0.137989", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZS", "relevance_score": "0.099476", "ticker_sentiment_score": "0.452585", "ticker_sentiment_label": "Bullish"}, {"ticker": "DISH", "relevance_score": "0.099476", "ticker_sentiment_score": "0.058326", "ticker_sentiment_label": "Neutral"}, {"ticker": "SDGR", "relevance_score": "0.245339", "ticker_sentiment_score": "0.058344", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.099476", "ticker_sentiment_score": "-0.078554", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.245339", "ticker_sentiment_score": "0.220675", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "KNSL", "relevance_score": "0.148731", "ticker_sentiment_score": "0.240416", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PANW", "relevance_score": "0.245339", "ticker_sentiment_score": "0.256946", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "New Wiz Runtime Sensor Pioneers a Unified Approach to Cloud Security", "url": "https://www.benzinga.com/pressreleases/23/06/g32717176/new-wiz-runtime-sensor-pioneers-a-unified-approach-to-cloud-security", "time_published": "20230605T143348", "authors": ["Globe Newswire"], "summary": "NEW YORK, June 05, 2023 ( GLOBE NEWSWIRE ) -- Wiz, the leading cloud security platform, today announced the public preview for the Wiz Runtime Sensor, which helps organizations further protect cloud workloads by detecting and responding to potential threats in real-time.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Real Estate & Construction", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}], "overall_sentiment_score": 0.150893, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DV", "relevance_score": "0.056808", "ticker_sentiment_score": "0.094206", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVY", "relevance_score": "0.056808", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DOCU", "relevance_score": "0.056808", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BX", "relevance_score": "0.056808", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CWK", "relevance_score": "0.056808", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.113329", "ticker_sentiment_score": "0.14657", "ticker_sentiment_label": "Neutral"}]}, {"title": "Futures: Character Change For Market; Here's What To Do", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-market-rally-shows-character-change-tesla-apple-in-focus/", "time_published": "20230604T185800", "authors": ["ED CARSON", "Investor's Business Daily"], "summary": "Dow Jones Futures: Market Rally Shows Character Change. Tesla ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2018/07/stock-bull-charge-02-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Real Estate & Construction", "relevance_score": "0.166667"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.155959, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "META", "relevance_score": "0.080796", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.20019", "ticker_sentiment_score": "-0.014138", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.239109", "ticker_sentiment_score": "0.120195", "ticker_sentiment_label": "Neutral"}, {"ticker": "LEN", "relevance_score": "0.180535", "ticker_sentiment_score": "0.054716", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.140896", "ticker_sentiment_score": "0.10828", "ticker_sentiment_label": "Neutral"}, {"ticker": "RCL", "relevance_score": "0.04045", "ticker_sentiment_score": "0.011726", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.020232", "ticker_sentiment_score": "0.096166", "ticker_sentiment_label": "Neutral"}, {"ticker": "ISRG", "relevance_score": "0.04045", "ticker_sentiment_score": "0.087318", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.140896", "ticker_sentiment_score": "0.11029", "ticker_sentiment_label": "Neutral"}, {"ticker": "SWAV", "relevance_score": "0.04045", "ticker_sentiment_score": "0.087318", "ticker_sentiment_label": "Neutral"}, {"ticker": "MAR", "relevance_score": "0.120936", "ticker_sentiment_score": "0.011597", "ticker_sentiment_label": "Neutral"}, {"ticker": "PANW", "relevance_score": "0.120936", "ticker_sentiment_score": "0.003485", "ticker_sentiment_label": "Neutral"}]}, {"title": "Tesla Leads 5 Stocks Near Buy Points As Market Revs Up", "url": "https://www.investors.com/news/sp-500-giant-tesla-leads-five-stocks-near-buy-points-as-market-revs-up/", "time_published": "20230603T120000", "authors": ["KIT NORTON", "Investor's Business Daily"], "summary": "S&P 500 stocks Tesla ( TSLA ) and DexCom ( DXCM ) , along with Fluence Energy ( FLNC ) , Wingstop ( WING ) and Extreme Networks ( EXTR ) are in focus this week. The market rally picked up steam late in the week.", "banner_image": "https://www.investors.com/wp-content/uploads/2021/01/Stock-Tesla-modelY-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.999996"}], "overall_sentiment_score": 0.163552, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "EXTR", "relevance_score": "0.292023", "ticker_sentiment_score": "0.021105", "ticker_sentiment_label": "Neutral"}, {"ticker": "FLNC", "relevance_score": "0.414133", "ticker_sentiment_score": "0.244497", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TSLA", "relevance_score": "0.317186", "ticker_sentiment_score": "0.242652", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WING", "relevance_score": "0.390497", "ticker_sentiment_score": "0.214003", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.266537", "ticker_sentiment_score": "0.079513", "ticker_sentiment_label": "Neutral"}]}, {"title": "Want $1 Million in Retirement? Invest $250,000 in These 3 Stocks and Wait a Decade", "url": "https://www.fool.com/investing/2023/06/03/want-1-million-in-retirement-invest-250000-in-thes/", "time_published": "20230603T114500", "authors": ["Prosper Junior Bakiny"], "summary": "All three trounced the market over the past 10 years.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F734327%2Fbear-market-stocks-plunge-crash-invest-correction-getty.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}, {"topic": "Earnings", "relevance_score": "0.650727"}], "overall_sentiment_score": 0.209682, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.316168", "ticker_sentiment_score": "0.230526", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMZN", "relevance_score": "0.365294", "ticker_sentiment_score": "0.209484", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.365294", "ticker_sentiment_score": "0.14085", "ticker_sentiment_label": "Neutral"}]}, {"title": "Market Rally Shows Strength, Breadth; Here's What To Do", "url": "https://www.investors.com/market-trend/stock-market-today/stock-market-rally-shows-strength-breadth-tesla-apple-in-focus-what-to-do-now/", "time_published": "20230602T211400", "authors": ["ED CARSON", "Investor's Business Daily"], "summary": "Market Rally Shows Strength, Breadth. Here's What To Do Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2018/07/stock-bull-charge-02-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Real Estate & Construction", "relevance_score": "0.166667"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.181031, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "META", "relevance_score": "0.092569", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.206392", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.206392", "ticker_sentiment_score": "0.137986", "ticker_sentiment_label": "Neutral"}, {"ticker": "LEN", "relevance_score": "0.206392", "ticker_sentiment_score": "0.065575", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.161247", "ticker_sentiment_score": "0.117567", "ticker_sentiment_label": "Neutral"}, {"ticker": "RCL", "relevance_score": "0.046363", "ticker_sentiment_score": "0.011892", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.023191", "ticker_sentiment_score": "0.097665", "ticker_sentiment_label": "Neutral"}, {"ticker": "ISRG", "relevance_score": "0.046363", "ticker_sentiment_score": "0.0887", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.161247", "ticker_sentiment_score": "0.11971", "ticker_sentiment_label": "Neutral"}, {"ticker": "SWAV", "relevance_score": "0.046363", "ticker_sentiment_score": "0.0887", "ticker_sentiment_label": "Neutral"}, {"ticker": "MAR", "relevance_score": "0.138464", "ticker_sentiment_score": "0.012421", "ticker_sentiment_label": "Neutral"}]}, {"title": "Investing Action Plan: Tesla Among Stocks Near Buy Points", "url": "https://www.investors.com/research/investing-action-plan/tesla-among-stocks-to-watch-with-earnings-season-slowing/", "time_published": "20230602T101900", "authors": ["ED CARSON", "Investor's Business Daily"], "summary": "Investing Action Plan: Tesla Among Stocks To Watch With Earnings ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2021/11/Stock-Tesla-charging-company.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.998962"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.999994"}, {"topic": "Technology", "relevance_score": "0.25"}], "overall_sentiment_score": 0.139297, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CIEN", "relevance_score": "0.097854", "ticker_sentiment_score": "0.051634", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXTR", "relevance_score": "0.146321", "ticker_sentiment_score": "0.088645", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.194242", "ticker_sentiment_score": "0.13456", "ticker_sentiment_label": "Neutral"}, {"ticker": "WING", "relevance_score": "0.146321", "ticker_sentiment_score": "0.088645", "ticker_sentiment_label": "Neutral"}, {"ticker": "NIO", "relevance_score": "0.097854", "ticker_sentiment_score": "0.233711", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "THO", "relevance_score": "0.097854", "ticker_sentiment_score": "0.034843", "ticker_sentiment_label": "Neutral"}, {"ticker": "AWON", "relevance_score": "0.049019", "ticker_sentiment_score": "0.023884", "ticker_sentiment_label": "Neutral"}, {"ticker": "FLNC", "relevance_score": "0.146321", "ticker_sentiment_score": "0.088645", "ticker_sentiment_label": "Neutral"}, {"ticker": "DOCU", "relevance_score": "0.097854", "ticker_sentiment_score": "0.025633", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.146321", "ticker_sentiment_score": "0.088645", "ticker_sentiment_label": "Neutral"}, {"ticker": "OLLI", "relevance_score": "0.097854", "ticker_sentiment_score": "0.116297", "ticker_sentiment_label": "Neutral"}]}, {"title": "Action Plan: Tesla In Buy Zone, Apple To Show Off Headset", "url": "https://www.investors.com/research/investing-action-plan/tesla-among-stocks-to-watch-with-earnings-season-slowing/", "time_published": "20230602T101900", "authors": ["Investor's Business Daily", "ED CARSON"], "summary": "Investing Action Plan: Tesla Among Stocks To Watch With Earnings ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2021/11/Stock-Tesla-charging-company.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.998962"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.999994"}, {"topic": "Technology", "relevance_score": "0.25"}], "overall_sentiment_score": 0.125043, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "META", "relevance_score": "0.08687", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.297404", "ticker_sentiment_score": "0.030175", "ticker_sentiment_label": "Neutral"}, {"ticker": "WING", "relevance_score": "0.129983", "ticker_sentiment_score": "0.083214", "ticker_sentiment_label": "Neutral"}, {"ticker": "AWON", "relevance_score": "0.043499", "ticker_sentiment_score": "0.023646", "ticker_sentiment_label": "Neutral"}, {"ticker": "CIEN", "relevance_score": "0.08687", "ticker_sentiment_score": "0.050343", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXTR", "relevance_score": "0.129983", "ticker_sentiment_score": "0.083214", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.172713", "ticker_sentiment_score": "0.123641", "ticker_sentiment_label": "Neutral"}, {"ticker": "NIO", "relevance_score": "0.08687", "ticker_sentiment_score": "0.227557", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "THO", "relevance_score": "0.08687", "ticker_sentiment_score": "0.033727", "ticker_sentiment_label": "Neutral"}, {"ticker": "FLNC", "relevance_score": "0.129983", "ticker_sentiment_score": "0.083214", "ticker_sentiment_label": "Neutral"}, {"ticker": "DOCU", "relevance_score": "0.08687", "ticker_sentiment_score": "0.02491", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.129983", "ticker_sentiment_score": "0.083214", "ticker_sentiment_label": "Neutral"}, {"ticker": "OLLI", "relevance_score": "0.08687", "ticker_sentiment_score": "0.110203", "ticker_sentiment_label": "Neutral"}]}, {"title": "ResMed Joins Elite List Of Stocks With 95-Plus Composite Rating", "url": "https://www.investors.com/ibd-data-stories/resmed-joins-elite-list-of-stocks-with-95-plus-composite-rating/", "time_published": "20230602T070000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "ResMed ( RMD ) saw its IBD SmartSelect Composite Rating jump to 96 Friday, up from 94 the day before. X The new score tells you the company is now outperforming 96% of all stocks in terms of the most important fundamental and technical stock-picking criteria.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.986564"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.340819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PEN", "relevance_score": "0.280615", "ticker_sentiment_score": "0.125551", "ticker_sentiment_label": "Neutral"}, {"ticker": "RMD", "relevance_score": "0.52759", "ticker_sentiment_score": "-0.00324", "ticker_sentiment_label": "Neutral"}, {"ticker": "LNTH", "relevance_score": "0.280615", "ticker_sentiment_score": "0.125551", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.280615", "ticker_sentiment_score": "0.125551", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Incredible Growth Stocks to Buy Before the Next Bull Market", "url": "https://www.fool.com/investing/2023/05/31/2-incredible-growth-stocks-to-buy-before-the-next/", "time_published": "20230531T133700", "authors": ["Rachel Warren"], "summary": "These companies have what it takes to keep growing and enriching investors in the years ahead.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F734276%2Froth-ira-road-sign-gettyimages-514516902.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.650727"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}], "overall_sentiment_score": 0.226569, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ETSY", "relevance_score": "0.390227", "ticker_sentiment_score": "0.039985", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.223248", "ticker_sentiment_score": "0.133669", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Stock-Split Stocks Billionaires Can't Stop Buying", "url": "https://www.fool.com/investing/2023/05/31/3-stock-split-stocks-billionaires-cant-stop-buying/", "time_published": "20230531T090600", "authors": ["Sean Williams"], "summary": "Based on the latest round of 13F filings, a number of prominent billionaire investors piled into three fast-growing stock-split stocks.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F734219%2Fpaper-certificate-shares-invest-stock-split-market-reverse-getty.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.108179"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.261891, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.315224", "ticker_sentiment_score": "0.178188", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.285156", "ticker_sentiment_score": "0.303303", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PANW", "relevance_score": "0.096932", "ticker_sentiment_score": "0.096524", "ticker_sentiment_label": "Neutral"}]}, {"title": "Blood Glucose Monitoring Devices Market to grow by USD 7,488.81 million during 2023-2027; The rising global burden of diabetes to drive the market growth - Technavio", "url": "https://www.prnewswire.com/news-releases/blood-glucose-monitoring-devices-market-to-grow-by-usd-7-488-81-million-during-2023-2027-the-rising-global-burden-of-diabetes-to-drive-the-market-growth---technavio-301835790.html", "time_published": "20230529T164500", "authors": ["Technavio"], "summary": "Blood Glucose Monitoring Devices Market to grow by USD 7,488.81 ... PR ...", "banner_image": "https://mma.prnewswire.com/media/2086694/Technavio_Logo_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.149961, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.036926", "ticker_sentiment_score": "0.047631", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABT", "relevance_score": "0.036926", "ticker_sentiment_score": "0.047631", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's Why You Should Retain Tandem Diabetes  ( TNDM )  Now", "url": "https://www.zacks.com/stock/news/2100780/heres-why-you-should-retain-tandem-diabetes-tndm-now", "time_published": "20230529T121800", "authors": ["Zacks Investment Research"], "summary": "Investors continue to be optimistic about Tandem Diabetes (TNDM) based on the strong performance of the t:slim X2 insulin pump.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ca/2357.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.9545"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.203901, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PEN", "relevance_score": "0.200273", "ticker_sentiment_score": "0.116011", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZBH", "relevance_score": "0.200273", "ticker_sentiment_score": "0.096212", "ticker_sentiment_label": "Neutral"}, {"ticker": "HOLX", "relevance_score": "0.200273", "ticker_sentiment_score": "0.004713", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDT", "relevance_score": "0.050572", "ticker_sentiment_score": "0.166315", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TNDM", "relevance_score": "0.342939", "ticker_sentiment_score": "0.261244", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.050572", "ticker_sentiment_score": "0.10634", "ticker_sentiment_label": "Neutral"}]}, {"title": "How Dexcom and Abbott are moving beyond diabetes with blood sugar monitoring", "url": "https://www.cnbc.com/2023/05/26/how-dexcom-and-abbott-are-moving-beyond-diabetes.html", "time_published": "20230526T120001", "authors": ["Erin Black"], "summary": "CNBC spoke with both Abbott and Dexcom about the technology inside continuous glucose monitors and how they see the technology expanding.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107033926-210318_TechDiabetesCure_finecut00_01_58_17Still006.jpg?v=1647869227&w=750&h=422&vtcrop=y", "source": "CNBC", "category_within_source": "Top News", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.091258, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.509589", "ticker_sentiment_score": "0.349111", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "DexCom Unusual Options Activity - DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/markets/options/23/05/32583071/dexcom-unusual-options-activity", "time_published": "20230525T193334", "authors": ["Benzinga Insights"], "summary": "Someone with a lot of money to spend has taken a bullish stance on DexCom DXCM. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.179589, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CCORF", "relevance_score": "0.095899", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.851762", "ticker_sentiment_score": "0.269016", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BCS", "relevance_score": "0.095899", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Reasons to Hold DexCom  ( DXCM )  Stock in Your Portfolio", "url": "https://www.zacks.com/stock/news/2099724/3-reasons-to-hold-dexcom-dxcm-stock-in-your-portfolio", "time_published": "20230525T141400", "authors": ["Zacks Investment Research"], "summary": "Investors continue to be optimistic about DexCom (DXCM), owing to its strong product portfolio.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ca/2357.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.96136"}], "overall_sentiment_score": 0.292606, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "WST", "relevance_score": "0.140348", "ticker_sentiment_score": "0.072967", "ticker_sentiment_label": "Neutral"}, {"ticker": "MMSI", "relevance_score": "0.140348", "ticker_sentiment_score": "0.107437", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.362725", "ticker_sentiment_score": "0.317468", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PRGO", "relevance_score": "0.093836", "ticker_sentiment_score": "0.053209", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Best Stocks to Invest $500 in Right Now", "url": "https://www.fool.com/investing/2023/05/25/the-best-stocks-to-invest-500-in-right-now/", "time_published": "20230525T140700", "authors": ["Rachel Warren"], "summary": "The market is still volatile, but great companies are thriving.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F733395%2Fa-digital-render-of-a-self-driving-car-stopped-at-a-cross-walk-surrounded-by-people.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.986564"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.095116, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.171282", "ticker_sentiment_score": "0.057523", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABNB", "relevance_score": "0.436009", "ticker_sentiment_score": "0.070353", "ticker_sentiment_label": "Neutral"}]}, {"title": "4 Growth Stocks to Buy and Hold Forever", "url": "https://www.fool.com/investing/2023/05/24/4-growth-stocks-to-buy-and-hold-forever/", "time_published": "20230524T130000", "authors": ["James Brumley"], "summary": "Some products and services are bigger than any economic, cultural, technological, or societal cycle.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F733395%2Fa-digital-render-of-a-self-driving-car-stopped-at-a-cross-walk-surrounded-by-people.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.94762"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}], "overall_sentiment_score": 0.194585, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BROS", "relevance_score": "0.156715", "ticker_sentiment_score": "0.137969", "ticker_sentiment_label": "Neutral"}, {"ticker": "SBUX", "relevance_score": "0.156715", "ticker_sentiment_score": "0.107029", "ticker_sentiment_label": "Neutral"}, {"ticker": "BKNG", "relevance_score": "0.07874", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.11787", "ticker_sentiment_score": "0.207678", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Investing $1,000 in These 2 Top Growth Stocks Would Be a Brilliant Move", "url": "https://www.fool.com/investing/2023/05/23/investing-top-growth-stocks-brilliant-move-tdoc/", "time_published": "20230523T135521", "authors": ["Prosper Junior Bakiny"], "summary": "This move might not pay off immediately, but it eventually will.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F733349%2Fa-blue-tesla-car-driving-on-an-open-road.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.875462"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.650727"}], "overall_sentiment_score": 0.146519, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.341587", "ticker_sentiment_score": "0.320398", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TDOC", "relevance_score": "0.100518", "ticker_sentiment_score": "0.11095", "ticker_sentiment_label": "Neutral"}]}, {"title": "These stock pickers led the health-fund category over the past 5 years. Here's where they're investing now.", "url": "https://www.marketwatch.com/story/these-stock-pickers-led-the-health-fund-category-over-the-past-5-years-heres-where-theyre-investing-now-655dc99d", "time_published": "20230523T124500", "authors": ["Eleanor Laise"], "summary": "Baron Health Care fund managers find growth potential in Medicare Advantage plans, obesity treatments and advances in cancer screening.", "banner_image": "https://images.mktw.net/im-786249/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "IPO", "relevance_score": "0.310843"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.200508, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HUM", "relevance_score": "0.072108", "ticker_sentiment_score": "0.229606", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "EXAS", "relevance_score": "0.072108", "ticker_sentiment_score": "-0.19362", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "LLY", "relevance_score": "0.072108", "ticker_sentiment_score": "0.104118", "ticker_sentiment_label": "Neutral"}, {"ticker": "MORN", "relevance_score": "0.036091", "ticker_sentiment_score": "0.111257", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.072108", "ticker_sentiment_score": "0.05228", "ticker_sentiment_label": "Neutral"}, {"ticker": "ELV", "relevance_score": "0.072108", "ticker_sentiment_score": "0.229606", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "UNH", "relevance_score": "0.072108", "ticker_sentiment_score": "0.229606", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "How Much $10,000 Invested In Meta's IPO 11 Years Ago Is Worth Now", "url": "https://www.investors.com/etfs-and-funds/sectors/sp500-how-much-10000-invested-in-metas-ipo-11-years-ago-is-worth-now/", "time_published": "20230522T120000", "authors": ["Investor's Business Daily", "MATT KRANTZ"], "summary": "How Much $10000 Invested In Meta's IPO 11 Years Ago Is Worth Now Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2022/01/Stock-meta-facebook-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "IPO", "relevance_score": "0.682689"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.431657, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "META", "relevance_score": "0.3007", "ticker_sentiment_score": "0.3458", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVDA", "relevance_score": "0.203215", "ticker_sentiment_score": "0.224847", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SPGI", "relevance_score": "0.102449", "ticker_sentiment_score": "0.211808", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TSLA", "relevance_score": "0.3007", "ticker_sentiment_score": "0.349033", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.203215", "ticker_sentiment_score": "0.371271", "ticker_sentiment_label": "Bullish"}]}, {"title": "Here's How Much You Would Have Made Owning DexCom Stock In The Last 5 Years - DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/news/earnings/23/05/32495175/heres-how-much-you-would-have-made-owning-dexcom-stock-in-the-last-5-years", "time_published": "20230519T210022", "authors": ["Benzinga Insights"], "summary": "DexCom DXCM has outperformed the market over the past 5 years by 31.31% on an annualized basis producing an average annual return of 40.27%. Currently, DexCom has a market capitalization of $45.40 billion.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.983605", "ticker_sentiment_score": "0.387251", "ticker_sentiment_label": "Bullish"}]}, {"title": "Establishment Labs Hldgs Reaches 80-Plus Relative Strength Rating Benchmark", "url": "https://www.investors.com/ibd-data-stories/establishment-labs-hldgs-reaches-80-plus-relative-strength-rating-benchmark/", "time_published": "20230519T070000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "Establishment Labs Hldgs Reaches 80-Plus Relative Strength ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.384558, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "PEN", "relevance_score": "0.327366", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AWON", "relevance_score": "0.167322", "ticker_sentiment_score": "0.239425", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ESTA", "relevance_score": "0.601928", "ticker_sentiment_score": "0.231946", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.327366", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "What Recession? These Companies Expect 20% Sales Growth This Year.", "url": "https://www.fool.com/investing/2023/05/17/these-companies-are-expecting-20-sales-growth/", "time_published": "20230517T124500", "authors": ["David Jagielski"], "summary": "Recession or not, don't expect these businesses to run out of growth opportunities anytime soon.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F732038%2Fgrowth-3.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972476"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.270932, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DKNG", "relevance_score": "0.514619", "ticker_sentiment_score": "0.336734", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.399204", "ticker_sentiment_score": "0.56347", "ticker_sentiment_label": "Bullish"}]}, {"title": "Medical Second Opinion Market Size Report - 16.8% CAGR to Reach $10.73Bn, Globally, by 2027 | Growth Analysis by The Insight Partners", "url": "https://www.benzinga.com/pressreleases/23/05/g32422527/medical-second-opinion-market-size-report-16-8-cagr-to-reach-10-73bn-globally-by-2027-growth-analy", "time_published": "20230516T133059", "authors": ["Globe Newswire"], "summary": "Pune, India., May 16, 2023 ( GLOBE NEWSWIRE ) -- The Insight Partners published latest research report on \"Medical Second Opinion Market Size Report, Share, Trends, Growth & Forecast to 2027 - COVID-19 Impact and Global Analysis By Disorder. Service Providers.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.288794, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.044551", "ticker_sentiment_score": "0.256892", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TDOC", "relevance_score": "0.044551", "ticker_sentiment_score": "0.256892", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Zacks Investment Ideas feature highlights: Dexcom, Rambus, Advanced Micro Devices, Nvidia and Vipshops", "url": "https://www.zacks.com/stock/news/2095696/zacks-investment-ideas-feature-highlights-dexcom-rambus-advanced-micro-devices-nvidia-and-vipshops", "time_published": "20230516T115400", "authors": ["Zacks Investment Research"], "summary": "Dexcom, Rambus, Advanced Micro Devices, Nvidia and Vipshops are part of the Zacks Investment Ideas article.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/aa/2306.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.980922"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.955357"}], "overall_sentiment_score": 0.239024, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMD", "relevance_score": "0.176717", "ticker_sentiment_score": "0.18785", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVDA", "relevance_score": "0.176717", "ticker_sentiment_score": "0.18785", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RMBS", "relevance_score": "0.397697", "ticker_sentiment_score": "0.392787", "ticker_sentiment_label": "Bullish"}, {"ticker": "DXCM", "relevance_score": "0.448513", "ticker_sentiment_score": "0.196972", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "3 Stocks on the Verge of Breaking Out", "url": "https://www.zacks.com/commentary/2095141/3-stocks-on-the-verge-of-breaking-out", "time_published": "20230515T125000", "authors": ["Zacks Investment Research"], "summary": "Andrew Rocco combines fundamentals and technicals to bring you 3 top stocks on the verge of breaking out.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4d/14613.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.962106"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.955357"}], "overall_sentiment_score": 0.24138, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMD", "relevance_score": "0.123209", "ticker_sentiment_score": "0.237027", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVDA", "relevance_score": "0.123209", "ticker_sentiment_score": "0.237027", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RMBS", "relevance_score": "0.358152", "ticker_sentiment_score": "0.420212", "ticker_sentiment_label": "Bullish"}, {"ticker": "DXCM", "relevance_score": "0.412619", "ticker_sentiment_score": "0.221489", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "8 Stocks' Monster Profit Growth Can't Be Contained", "url": "https://www.investors.com/etfs-and-funds/sectors/sp500-stocks-monster-profit-growth-cant-be-contained/", "time_published": "20230515T120000", "authors": ["Investor's Business Daily", "MATT KRANTZ"], "summary": "Profits are down at S&P 500 companies at large. But a few are putting up monster profit gains that seem to have no bounds.", "banner_image": "https://www.investors.com/wp-content/uploads/2023/05/Stock-monstercagetrap-01-shutt.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.999989"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.36216, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "SPGI", "relevance_score": "0.07913", "ticker_sentiment_score": "0.260156", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CMG", "relevance_score": "0.234307", "ticker_sentiment_score": "0.274247", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FTNT", "relevance_score": "0.234307", "ticker_sentiment_score": "0.533859", "ticker_sentiment_label": "Bullish"}, {"ticker": "DXCM", "relevance_score": "0.234307", "ticker_sentiment_score": "0.413163", "ticker_sentiment_label": "Bullish"}]}, {"title": "S&P 500 Medtech Dexcom Leads 5 Stocks Near Buy Points", "url": "https://www.investors.com/news/sp-500-medtech-play-dexcom-leads-five-stocks-near-buy-points/", "time_published": "20230513T120000", "authors": ["KIT NORTON", "Investor's Business Daily"], "summary": "S&P 500 Medtech Play DexCom Leads Five Stocks Near Buy Points ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/03/Stock-dexcom-one-04-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.125004, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "TSLA", "relevance_score": "0.058759", "ticker_sentiment_score": "0.098992", "ticker_sentiment_label": "Neutral"}, {"ticker": "FLYW", "relevance_score": "0.287537", "ticker_sentiment_score": "0.138674", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.368144", "ticker_sentiment_score": "0.164691", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NEWR", "relevance_score": "0.341699", "ticker_sentiment_score": "0.04656", "ticker_sentiment_label": "Neutral"}, {"ticker": "KNSL", "relevance_score": "0.31482", "ticker_sentiment_score": "0.123457", "ticker_sentiment_label": "Neutral"}]}, {"title": "Action Plan: Walmart, Home Depot, On Holding On Tap", "url": "https://www.investors.com/research/investing-action-plan/stock-market-action-plan-may-15-19-walmart-target-deere/", "time_published": "20230512T213700", "authors": ["Investor's Business Daily", "ALAN R. ELLIOTT"], "summary": "Stock Market Action Plan, May 15-19: Walmart, Target, Deere Earnings Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2021/04/Stock-marketBoard-29-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.999896"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "1.0"}], "overall_sentiment_score": 0.127997, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "TGT", "relevance_score": "0.073849", "ticker_sentiment_score": "0.088999", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMAT", "relevance_score": "0.049271", "ticker_sentiment_score": "0.052423", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.049271", "ticker_sentiment_score": "-0.047006", "ticker_sentiment_label": "Neutral"}, {"ticker": "CSCO", "relevance_score": "0.098355", "ticker_sentiment_score": "0.126644", "ticker_sentiment_label": "Neutral"}, {"ticker": "CVX", "relevance_score": "0.049271", "ticker_sentiment_score": "-0.047006", "ticker_sentiment_label": "Neutral"}, {"ticker": "FLYW", "relevance_score": "0.049271", "ticker_sentiment_score": "0.003989", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDNDF", "relevance_score": "0.024648", "ticker_sentiment_score": "-0.044807", "ticker_sentiment_label": "Neutral"}, {"ticker": "FL", "relevance_score": "0.098355", "ticker_sentiment_score": "0.016173", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIDU", "relevance_score": "0.073849", "ticker_sentiment_score": "0.11934", "ticker_sentiment_label": "Neutral"}, {"ticker": "CSIQ", "relevance_score": "0.073849", "ticker_sentiment_score": "0.203167", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TCTZF", "relevance_score": "0.024648", "ticker_sentiment_score": "0.086884", "ticker_sentiment_label": "Neutral"}, {"ticker": "ASML", "relevance_score": "0.049271", "ticker_sentiment_score": "0.003989", "ticker_sentiment_label": "Neutral"}, {"ticker": "DT", "relevance_score": "0.049271", "ticker_sentiment_score": "0.033591", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.049271", "ticker_sentiment_score": "-0.047006", "ticker_sentiment_label": "Neutral"}, {"ticker": "RYAOF", "relevance_score": "0.024648", "ticker_sentiment_score": "0.020296", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.073849", "ticker_sentiment_score": "0.004062", "ticker_sentiment_label": "Neutral"}, {"ticker": "VIPS", "relevance_score": "0.049271", "ticker_sentiment_score": "0.093701", "ticker_sentiment_label": "Neutral"}, {"ticker": "BABA", "relevance_score": "0.073849", "ticker_sentiment_score": "0.11934", "ticker_sentiment_label": "Neutral"}, {"ticker": "TJX", "relevance_score": "0.049271", "ticker_sentiment_score": "0.183983", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "INTC", "relevance_score": "0.049271", "ticker_sentiment_score": "-0.047006", "ticker_sentiment_label": "Neutral"}, {"ticker": "NEWR", "relevance_score": "0.049271", "ticker_sentiment_score": "0.003989", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAT", "relevance_score": "0.049271", "ticker_sentiment_score": "-0.047006", "ticker_sentiment_label": "Neutral"}, {"ticker": "ROST", "relevance_score": "0.049271", "ticker_sentiment_score": "0.057", "ticker_sentiment_label": "Neutral"}, {"ticker": "HD", "relevance_score": "0.073849", "ticker_sentiment_score": "0.064901", "ticker_sentiment_label": "Neutral"}, {"ticker": "WMT", "relevance_score": "0.098355", "ticker_sentiment_score": "0.120122", "ticker_sentiment_label": "Neutral"}]}, {"title": "Action Plan: Walmart, Home Depot, On Holding On Tap", "url": "https://www.investors.com/research/investing-action-plan/stock-market-action-plan-may-15-19-walmart-target-deere/", "time_published": "20230512T213700", "authors": ["Investor's Business Daily", "ALAN R. ELLIOTT"], "summary": "Stock Market Action Plan, May 15-19: Walmart, Target, Deere Earnings Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2021/04/Stock-marketBoard-29-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.999896"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "1.0"}], "overall_sentiment_score": 0.121061, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "TGT", "relevance_score": "0.073622", "ticker_sentiment_score": "0.088972", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMAT", "relevance_score": "0.04912", "ticker_sentiment_score": "0.052407", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.04912", "ticker_sentiment_score": "-0.047005", "ticker_sentiment_label": "Neutral"}, {"ticker": "CSCO", "relevance_score": "0.098054", "ticker_sentiment_score": "0.126538", "ticker_sentiment_label": "Neutral"}, {"ticker": "CVX", "relevance_score": "0.04912", "ticker_sentiment_score": "-0.047005", "ticker_sentiment_label": "Neutral"}, {"ticker": "FLYW", "relevance_score": "0.04912", "ticker_sentiment_score": "0.003988", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDNDF", "relevance_score": "0.024572", "ticker_sentiment_score": "-0.044792", "ticker_sentiment_label": "Neutral"}, {"ticker": "FL", "relevance_score": "0.098054", "ticker_sentiment_score": "0.016158", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIDU", "relevance_score": "0.073622", "ticker_sentiment_score": "0.119304", "ticker_sentiment_label": "Neutral"}, {"ticker": "CSIQ", "relevance_score": "0.073622", "ticker_sentiment_score": "0.203108", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TCTZF", "relevance_score": "0.024572", "ticker_sentiment_score": "0.08685", "ticker_sentiment_label": "Neutral"}, {"ticker": "ASML", "relevance_score": "0.04912", "ticker_sentiment_score": "0.003988", "ticker_sentiment_label": "Neutral"}, {"ticker": "DT", "relevance_score": "0.04912", "ticker_sentiment_score": "0.033581", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.04912", "ticker_sentiment_score": "-0.047005", "ticker_sentiment_label": "Neutral"}, {"ticker": "RYAOF", "relevance_score": "0.024572", "ticker_sentiment_score": "0.020288", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.073622", "ticker_sentiment_score": "0.00406", "ticker_sentiment_label": "Neutral"}, {"ticker": "VIPS", "relevance_score": "0.04912", "ticker_sentiment_score": "0.093687", "ticker_sentiment_label": "Neutral"}, {"ticker": "BABA", "relevance_score": "0.073622", "ticker_sentiment_score": "0.119304", "ticker_sentiment_label": "Neutral"}, {"ticker": "TJX", "relevance_score": "0.04912", "ticker_sentiment_score": "0.183979", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "INTC", "relevance_score": "0.04912", "ticker_sentiment_score": "-0.047005", "ticker_sentiment_label": "Neutral"}, {"ticker": "NEWR", "relevance_score": "0.04912", "ticker_sentiment_score": "0.003988", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAT", "relevance_score": "0.04912", "ticker_sentiment_score": "-0.047005", "ticker_sentiment_label": "Neutral"}, {"ticker": "ROST", "relevance_score": "0.04912", "ticker_sentiment_score": "0.057", "ticker_sentiment_label": "Neutral"}, {"ticker": "HD", "relevance_score": "0.073622", "ticker_sentiment_score": "0.064879", "ticker_sentiment_label": "Neutral"}, {"ticker": "WMT", "relevance_score": "0.098054", "ticker_sentiment_score": "0.120021", "ticker_sentiment_label": "Neutral"}]}, {"title": "How Is The Market Feeling About DexCom? - DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/short-sellers/23/05/32365466/how-is-the-market-feeling-about-dexcom", "time_published": "20230512T141529", "authors": ["Benzinga Insights"], "summary": "DexCom's DXCM short percent of float has fallen 6.37% since its last report. The company recently reported that it has 12.08 million shares sold short, which is 3.53% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.3 days to cover their ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.24389, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.224903", "ticker_sentiment_score": "0.085754", "ticker_sentiment_label": "Neutral"}]}, {"title": "Check Out What Whales Are Doing With DXCM - DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/markets/options/23/05/32348175/check-out-what-whales-are-doing-with-dxcm", "time_published": "20230511T173216", "authors": ["Benzinga Insights"], "summary": "Someone with a lot of money to spend has taken a bullish stance on DexCom DXCM. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.1727, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.856646", "ticker_sentiment_score": "0.269539", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BCS", "relevance_score": "0.097062", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dexcom Holds Firm As Glucose Monitor Gets Bulls Interested", "url": "https://www.investors.com/stock-lists/stock-spotlight/dexcom-shows-strength-as-glucose-monitor-attracts-buyers/", "time_published": "20230511T172500", "authors": ["KIMBERLEY KOENIG", "Investor's Business Daily"], "summary": "Dexcom Shows Strength As Glucose Monitor Attracts Buyers ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/04/Stock-Dexcom-03-company.jpeg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.96136"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.858979"}], "overall_sentiment_score": 0.368873, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.556298", "ticker_sentiment_score": "0.388362", "ticker_sentiment_label": "Bullish"}]}, {"title": "DarioHealth Reports First Quarter Financial and Operating Results", "url": "https://www.prnewswire.com/il/news-releases/dariohealth-reports-first-quarter-financial-and-operating-results-301821918.html", "time_published": "20230511T103000", "authors": ["DarioHealth Corp."], "summary": "\u2022 Sequential quarterly growth in revenue to \u2022 Gross profit margin improving to 44.8% sequentially in the first quarter of 2023, up from 40.1% of revenues in the fourth quarter of 2022 \u2022 Non-GAAP gross margin was 60.1% of revenues for the first quarter of 2023, up from 58.1% of revenues in the ...", "banner_image": "https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.998962"}, {"topic": "Earnings", "relevance_score": "1.0"}], "overall_sentiment_score": 0.182545, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CVS", "relevance_score": "0.014401", "ticker_sentiment_score": "0.147826", "ticker_sentiment_label": "Neutral"}, {"ticker": "DRIO", "relevance_score": "0.071914", "ticker_sentiment_score": "0.101237", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.014401", "ticker_sentiment_score": "0.080789", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMWL", "relevance_score": "0.014401", "ticker_sentiment_score": "0.147826", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.057559", "ticker_sentiment_score": "0.102003", "ticker_sentiment_label": "Neutral"}]}, {"title": "GoodRx  ( GDRX )  Q1 2023 Earnings Call Transcript", "url": "https://www.fool.com/earnings/call-transcripts/2023/05/10/goodrx-gdrx-q1-2023-earnings-call-transcript/", "time_published": "20230510T203039", "authors": ["Motley Fool Transcribing"], "summary": "GDRX earnings call for the period ending March 31, 2023.", "banner_image": "https://g.foolcdn.com/misc-assets/fool-transcripts-logo.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.999975"}, {"topic": "Earnings", "relevance_score": "1.0"}], "overall_sentiment_score": 0.29046, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "EVR", "relevance_score": "0.003125", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GDRX", "relevance_score": "0.155251", "ticker_sentiment_score": "0.229796", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BCS", "relevance_score": "0.003125", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "C", "relevance_score": "0.003125", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GDDY", "relevance_score": "0.00625", "ticker_sentiment_score": "0.086514", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.003125", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.003125", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.003125", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.00625", "ticker_sentiment_score": "0.086702", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:XCP", "relevance_score": "0.003125", "ticker_sentiment_score": "0.011684", "ticker_sentiment_label": "Neutral"}]}, {"title": "MannKind  ( MNKD )  Q1 2023 Earnings Call Transcript", "url": "https://www.fool.com/earnings/call-transcripts/2023/05/09/mannkind-mnkd-q1-2023-earnings-call-transcript/", "time_published": "20230510T033034", "authors": ["Motley Fool Transcribing"], "summary": "MNKD earnings call for the period ending March 31, 2023.", "banner_image": "https://g.foolcdn.com/misc-assets/fool-transcripts-logo.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.999921"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Real Estate & Construction", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.249332, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GDRX", "relevance_score": "0.005683", "ticker_sentiment_score": "0.083061", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSSMY", "relevance_score": "0.011365", "ticker_sentiment_score": "0.144805", "ticker_sentiment_label": "Neutral"}, {"ticker": "APG", "relevance_score": "0.005683", "ticker_sentiment_score": "0.07212", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.034087", "ticker_sentiment_score": "0.043245", "ticker_sentiment_label": "Neutral"}, {"ticker": "MNKD", "relevance_score": "0.107647", "ticker_sentiment_score": "0.125298", "ticker_sentiment_label": "Neutral"}, {"ticker": "UTHR", "relevance_score": "0.011365", "ticker_sentiment_score": "0.093949", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.005683", "ticker_sentiment_score": "0.015216", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dow Jones Rises As Regional Banks Rebound. COIN Rises With Warren Buffett's Berkshire Earnings Due.", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-rises-as-regional-banks-rebound-coin-rises-with-warren-buffetts-berkshire-earnings-due/", "time_published": "20230505T175200", "authors": ["Investor's Business Daily", "VIDYA RAMAKRISHNAN"], "summary": "Dow Jones Rises As Regional Banks Rebound. COIN Rises With ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2016/02/SMT0300-021616-shutterstock.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.999993"}, {"topic": "Earnings", "relevance_score": "0.999326"}, {"topic": "Real Estate & Construction", "relevance_score": "0.2"}], "overall_sentiment_score": 0.043512, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DKNG", "relevance_score": "0.114682", "ticker_sentiment_score": "0.005756", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACW", "relevance_score": "0.114682", "ticker_sentiment_score": "-0.008187", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.171282", "ticker_sentiment_score": "0.230767", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WAL", "relevance_score": "0.114682", "ticker_sentiment_score": "-0.008187", "ticker_sentiment_label": "Neutral"}, {"ticker": "BRK-A", "relevance_score": "0.05749", "ticker_sentiment_score": "0.011012", "ticker_sentiment_label": "Neutral"}, {"ticker": "WYNN", "relevance_score": "0.114682", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "COIN", "relevance_score": "0.114682", "ticker_sentiment_score": "0.200953", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DT", "relevance_score": "0.114682", "ticker_sentiment_score": "-0.015743", "ticker_sentiment_label": "Neutral"}, {"ticker": "SBUX", "relevance_score": "0.114682", "ticker_sentiment_score": "0.042078", "ticker_sentiment_label": "Neutral"}, {"ticker": "CVNA", "relevance_score": "0.114682", "ticker_sentiment_score": "-0.022533", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.114682", "ticker_sentiment_score": "-0.012833", "ticker_sentiment_label": "Neutral"}, {"ticker": "SQ", "relevance_score": "0.114682", "ticker_sentiment_score": "-0.001282", "ticker_sentiment_label": "Neutral"}, {"ticker": "SWAV", "relevance_score": "0.114682", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Parks Associates: Smart Watch Adoption Jumps from 30% in 2022 to 35% in 2023", "url": "https://www.prnewswire.com/news-releases/parks-associates-smart-watch-adoption-jumps-from-30-in-2022-to-35-in-2023-301817085.html", "time_published": "20230505T120900", "authors": ["Parks Associates"], "summary": "Parks Associates: Smart Watch Adoption Jumps from 30% in 2022 to ... PR ...", "banner_image": "https://mma.prnewswire.com/media/2070581/Parks_Associates_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.343079, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CALX", "relevance_score": "0.080728", "ticker_sentiment_score": "0.088529", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.080728", "ticker_sentiment_score": "-0.006144", "ticker_sentiment_label": "Neutral"}, {"ticker": "CCZ", "relevance_score": "0.080728", "ticker_sentiment_score": "-0.006144", "ticker_sentiment_label": "Neutral"}]}, {"title": "Top Funds Back Up The Truck To Bet Billions On These 10 Stocks", "url": "https://www.investors.com/etfs-and-funds/mutual-funds/best-mutual-funds-bet-bet-billions-on-these-10-stocks-including-microsoft-salesforce-broadcom/", "time_published": "20230505T104500", "authors": ["MATTHEW GALGANI", "Investor's Business Daily"], "summary": "The Best Mutual Funds Bet Billions On 10 Stocks, Including ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/05/Stock-HundredDollarBill-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "IPO", "relevance_score": "0.310843"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.838487"}, {"topic": "Real Estate & Construction", "relevance_score": "0.2"}], "overall_sentiment_score": 0.311279, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MTH", "relevance_score": "0.102888", "ticker_sentiment_score": "-0.103927", "ticker_sentiment_label": "Neutral"}, {"ticker": "PCAR", "relevance_score": "0.153797", "ticker_sentiment_score": "0.111488", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVGO", "relevance_score": "0.204072", "ticker_sentiment_score": "0.205748", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVO", "relevance_score": "0.102888", "ticker_sentiment_score": "0.215333", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BLDR", "relevance_score": "0.102888", "ticker_sentiment_score": "-0.160072", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "TSCO", "relevance_score": "0.102888", "ticker_sentiment_score": "0.144933", "ticker_sentiment_label": "Neutral"}, {"ticker": "TPH", "relevance_score": "0.102888", "ticker_sentiment_score": "-0.103927", "ticker_sentiment_label": "Neutral"}, {"ticker": "FICO", "relevance_score": "0.253514", "ticker_sentiment_score": "0.390154", "ticker_sentiment_label": "Bullish"}, {"ticker": "MSFT", "relevance_score": "0.349153", "ticker_sentiment_score": "0.474346", "ticker_sentiment_label": "Bullish"}, {"ticker": "GNLX", "relevance_score": "0.204072", "ticker_sentiment_score": "0.233639", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PHM", "relevance_score": "0.102888", "ticker_sentiment_score": "0.335814", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IBP", "relevance_score": "0.102888", "ticker_sentiment_score": "-0.160072", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "LRCX", "relevance_score": "0.153797", "ticker_sentiment_score": "0.167688", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "YUMC", "relevance_score": "0.102888", "ticker_sentiment_score": "0.227269", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CMG", "relevance_score": "0.153797", "ticker_sentiment_score": "0.125918", "ticker_sentiment_label": "Neutral"}, {"ticker": "TXRH", "relevance_score": "0.204072", "ticker_sentiment_score": "0.153604", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.102888", "ticker_sentiment_score": "0.215333", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "INMD", "relevance_score": "0.102888", "ticker_sentiment_score": "0.215333", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PANW", "relevance_score": "0.102888", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "KLAC", "relevance_score": "0.102888", "ticker_sentiment_score": "0.136289", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.051551", "ticker_sentiment_score": "0.225581", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WING", "relevance_score": "0.153797", "ticker_sentiment_score": "0.125918", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.153797", "ticker_sentiment_score": "0.192363", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ORCL", "relevance_score": "0.102888", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CPRX", "relevance_score": "0.102888", "ticker_sentiment_score": "0.332562", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WDAY", "relevance_score": "0.153797", "ticker_sentiment_score": "0.198735", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LEN", "relevance_score": "0.102888", "ticker_sentiment_score": "0.335814", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FTNT", "relevance_score": "0.153797", "ticker_sentiment_score": "0.232294", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNPS", "relevance_score": "0.102888", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CDNS", "relevance_score": "0.153797", "ticker_sentiment_score": "0.232294", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BLD", "relevance_score": "0.102888", "ticker_sentiment_score": "-0.160072", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "HUBS", "relevance_score": "0.153797", "ticker_sentiment_score": "0.198735", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SWAV", "relevance_score": "0.102888", "ticker_sentiment_score": "-0.047569", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dexcom to build its first European factory in Ireland", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/dexcom-build-its-first-european-factory-ireland-2023-05-05/", "time_published": "20230505T083705", "authors": ["Reuters"], "summary": "DUBLIN, May 5 ( Reuters ) - U.S. medical device company Dexcom ( DXCM.O ) plans to invest 300 million euros ( $330.8 million ) over the next five years to build a manufacturing site in Ireland, creating up to 1,000 jobs, it said on Friday.", "banner_image": "https://www.reuters.com/pf/resources/images/reuters/reuters-default.webp?d=139", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.128139, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.366061", "ticker_sentiment_score": "0.07997", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.188193", "ticker_sentiment_score": "0.19051", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABT", "relevance_score": "0.188193", "ticker_sentiment_score": "0.006301", "ticker_sentiment_label": "Neutral"}]}, {"title": "DexCom  ( NASDAQ:DXCM )  Upgraded by StockNews.com to \"Buy\"", "url": "https://www.defenseworld.net/2023/05/02/dexcom-nasdaqdxcm-upgraded-by-stocknews-com-to-buy.html", "time_published": "20230502T091853", "authors": ["Defense World Staff"], "summary": "StockNews.com upgraded shares of DexCom ( NASDAQ:DXCM - Get Rating ) from a hold rating to a buy rating in a research report released on Monday.", "banner_image": "https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&Symbol=DXCM", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.24326, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.841282", "ticker_sentiment_score": "0.378181", "ticker_sentiment_label": "Bullish"}, {"ticker": "BCS", "relevance_score": "0.053509", "ticker_sentiment_score": "0.1127", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is Dexcom a Good Stock to Buy Now?", "url": "https://www.fool.com/investing/2023/05/02/is-dexcom-still-a-good-stock-to-buy/", "time_published": "20230502T091400", "authors": ["Cory Renauer"], "summary": "A poorly received first-quarter earnings report has investors wondering if this stock's best days are behind it.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F729843%2Fresearcher-works-at-lab-bench.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.990999"}], "overall_sentiment_score": 0.314039, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.534445", "ticker_sentiment_score": "0.474986", "ticker_sentiment_label": "Bullish"}, {"ticker": "ABT", "relevance_score": "0.128822", "ticker_sentiment_score": "0.218277", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "1 Stock-Split Stock That's a Surefire May Buy and 1 to Avoid", "url": "https://www.fool.com/investing/2023/05/02/1-stock-split-stock-surefire-buy-in-may-1-to-avoid/", "time_published": "20230502T090600", "authors": ["Sean Williams"], "summary": "A half-dozen, high-profile companies split their stock last year. One stands out as an exceptional value in May, while another is seeing its competitive advantages erode.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F730203%2Fpaper-certificate-shares-invest-stock-split-market-reverse-getty.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.928769"}, {"topic": "Technology", "relevance_score": "0.25"}], "overall_sentiment_score": 0.048857, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SHOP", "relevance_score": "0.057352", "ticker_sentiment_score": "0.04795", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.307661", "ticker_sentiment_score": "0.047784", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.435074", "ticker_sentiment_score": "0.085623", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.057352", "ticker_sentiment_score": "0.04795", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.057352", "ticker_sentiment_score": "0.04795", "ticker_sentiment_label": "Neutral"}, {"ticker": "PANW", "relevance_score": "0.057352", "ticker_sentiment_score": "0.04795", "ticker_sentiment_label": "Neutral"}]}, {"title": "Rally Eyes 2023 Highs After Shakeout, But Big News On Tap", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-market-rally-eyes-2023-highs-first-republic-bank/", "time_published": "20230430T150100", "authors": ["ED CARSON", "Investor's Business Daily"], "summary": "Dow Jones Futures: Market Rally Eyes 2023 Highs. First Republic ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2019/08/stock-bounce-back-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.976671"}], "overall_sentiment_score": 0.033837, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "XPEV", "relevance_score": "0.08204", "ticker_sentiment_score": "0.04729", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.08204", "ticker_sentiment_score": "0.061908", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.061578", "ticker_sentiment_score": "-0.026", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANET", "relevance_score": "0.14305", "ticker_sentiment_score": "0.041087", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.041075", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PNC", "relevance_score": "0.061578", "ticker_sentiment_score": "0.049176", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.08204", "ticker_sentiment_score": "0.04444", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.020544", "ticker_sentiment_score": "-0.034692", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.12279", "ticker_sentiment_score": "0.004812", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.163216", "ticker_sentiment_score": "0.096747", "ticker_sentiment_label": "Neutral"}, {"ticker": "NIO", "relevance_score": "0.08204", "ticker_sentiment_score": "0.04729", "ticker_sentiment_label": "Neutral"}, {"ticker": "FRC", "relevance_score": "0.163216", "ticker_sentiment_score": "-0.055776", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMD", "relevance_score": "0.14305", "ticker_sentiment_score": "-0.064905", "ticker_sentiment_label": "Neutral"}, {"ticker": "LRCX", "relevance_score": "0.041075", "ticker_sentiment_score": "-0.170281", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "LI", "relevance_score": "0.08204", "ticker_sentiment_score": "0.04729", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.08204", "ticker_sentiment_score": "0.019549", "ticker_sentiment_label": "Neutral"}, {"ticker": "INMD", "relevance_score": "0.08204", "ticker_sentiment_score": "-0.01024", "ticker_sentiment_label": "Neutral"}, {"ticker": "ON", "relevance_score": "0.020544", "ticker_sentiment_score": "-0.201299", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Amazon Leads 5 S&P 500 Stocks Near Buy Points After Earnings", "url": "https://www.investors.com/news/amazon-amzn-leads-5-sp-500-stocks-near-buy-points-after-earnings/", "time_published": "20230429T125800", "authors": ["Investor's Business Daily", "JED GRAHAM"], "summary": "Amazon stock leads this weekend's watch list of five S&P 500 stocks holding near buy points after delivering better-than-expected earnings. Amazon ( AMZN ) is joined by JPMorgan Chase ( JPM ) , Visa ( V ) , Exxon Mobil ( XOM ) , and Dexcom ( DXCM ) .", "banner_image": "https://www.investors.com/wp-content/uploads/2022/05/Stock-amazonwebservices-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.752319"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.115074, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMZN", "relevance_score": "0.33628", "ticker_sentiment_score": "0.224553", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.33628", "ticker_sentiment_score": "0.104092", "ticker_sentiment_label": "Neutral"}, {"ticker": "FRC", "relevance_score": "0.076971", "ticker_sentiment_score": "-0.159881", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JPM", "relevance_score": "0.264761", "ticker_sentiment_score": "0.068381", "ticker_sentiment_label": "Neutral"}, {"ticker": "V", "relevance_score": "0.264761", "ticker_sentiment_score": "0.286429", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "XOM", "relevance_score": "0.153226", "ticker_sentiment_score": "0.075748", "ticker_sentiment_label": "Neutral"}]}, {"title": "Market Shakeout May Be Bullish Sign; FDIC Set To Take Over FRC", "url": "https://www.investors.com/market-trend/stock-market-today/market-rally-shakeout-may-be-bullish-signal-fdic-takes-over-first-republic-amd-tesla-rivals-in-focus/", "time_published": "20230428T213700", "authors": ["ED CARSON", "Investor's Business Daily"], "summary": "Market Shakeout May Be Bullish Sign. FDIC Set To Take Over FRC Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2019/08/stock-bounce-back-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.976671"}], "overall_sentiment_score": 0.033937, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "XPEV", "relevance_score": "0.090389", "ticker_sentiment_score": "0.055667", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.090389", "ticker_sentiment_score": "0.063157", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.067855", "ticker_sentiment_score": "-0.026046", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANET", "relevance_score": "0.157483", "ticker_sentiment_score": "0.043559", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.022643", "ticker_sentiment_score": "-0.035041", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.135221", "ticker_sentiment_score": "0.005063", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.11285", "ticker_sentiment_score": "0.082644", "ticker_sentiment_label": "Neutral"}, {"ticker": "NIO", "relevance_score": "0.090389", "ticker_sentiment_score": "0.055667", "ticker_sentiment_label": "Neutral"}, {"ticker": "FRC", "relevance_score": "0.179621", "ticker_sentiment_score": "-0.044484", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMD", "relevance_score": "0.157483", "ticker_sentiment_score": "-0.068877", "ticker_sentiment_label": "Neutral"}, {"ticker": "LRCX", "relevance_score": "0.045267", "ticker_sentiment_score": "-0.170852", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "LI", "relevance_score": "0.090389", "ticker_sentiment_score": "0.055667", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.090389", "ticker_sentiment_score": "0.01993", "ticker_sentiment_label": "Neutral"}, {"ticker": "INMD", "relevance_score": "0.090389", "ticker_sentiment_score": "-0.010425", "ticker_sentiment_label": "Neutral"}, {"ticker": "ON", "relevance_score": "0.022643", "ticker_sentiment_score": "-0.203354", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "DexCom  ( DXCM )  Q1 2023 Earnings Call Transcript", "url": "https://www.fool.com/earnings/call-transcripts/2023/04/28/dexcom-dxcm-q1-2023-earnings-call-transcript/", "time_published": "20230428T193338", "authors": ["Motley Fool Transcribing"], "summary": "DXCM earnings call for the period ending March 31, 2023.", "banner_image": "https://g.foolcdn.com/misc-assets/fool-transcripts-logo.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.77141"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.29001, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GDRX", "relevance_score": "0.005143", "ticker_sentiment_score": "0.035868", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCS", "relevance_score": "0.005143", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.005143", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.005143", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.005143", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TRUMF", "relevance_score": "0.005143", "ticker_sentiment_score": "0.147917", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.148289", "ticker_sentiment_score": "0.185732", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FOREX:USD", "relevance_score": "0.005143", "ticker_sentiment_score": "0.132895", "ticker_sentiment_label": "Neutral"}]}, {"title": "Check Out What Whales Are Doing With DXCM - DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/markets/options/23/04/32092161/check-out-what-whales-are-doing-with-dxcm", "time_published": "20230428T191825", "authors": ["Benzinga Insights"], "summary": "A whale with a lot of money to spend has taken a noticeably bullish stance on DexCom. Looking at options history for DexCom DXCM we detected 11 strange trades. If we consider the specifics of each trade, it is accurate to state that 72% of the investors opened trades with bullish expectations ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.170452, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.889109", "ticker_sentiment_score": "0.33024", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Market Rally Volatile And Tight Amid Big Earnings Moves", "url": "https://www.investors.com/news/market-rally-wobbles-amid-big-earnings-moves-from-microsoft-meta-crocs-cloudflare/", "time_published": "20230428T163600", "authors": ["Investor's Business Daily", "IBD STAFF"], "summary": "Market Rally Wobbles Amid Big Earnings Moves From Microsoft ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2016/04/SSA-040816-shutterstock.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Economy - Monetary", "relevance_score": "0.838487"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "0.999999"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "1.0"}], "overall_sentiment_score": -0.102594, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MEDP", "relevance_score": "0.054773", "ticker_sentiment_score": "-0.11609", "ticker_sentiment_label": "Neutral"}, {"ticker": "MXL", "relevance_score": "0.036532", "ticker_sentiment_score": "-0.090238", "ticker_sentiment_label": "Neutral"}, {"ticker": "TER", "relevance_score": "0.036532", "ticker_sentiment_score": "-0.090238", "ticker_sentiment_label": "Neutral"}, {"ticker": "ROKU", "relevance_score": "0.036532", "ticker_sentiment_score": "0.069232", "ticker_sentiment_label": "Neutral"}, {"ticker": "CVX", "relevance_score": "0.054773", "ticker_sentiment_score": "-0.079945", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDNDF", "relevance_score": "0.036532", "ticker_sentiment_score": "-0.005866", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.036532", "ticker_sentiment_score": "-0.136848", "ticker_sentiment_label": "Neutral"}, {"ticker": "CROX", "relevance_score": "0.072987", "ticker_sentiment_score": "-0.030714", "ticker_sentiment_label": "Neutral"}, {"ticker": "TXN", "relevance_score": "0.036532", "ticker_sentiment_score": "-0.090238", "ticker_sentiment_label": "Neutral"}, {"ticker": "STM", "relevance_score": "0.054773", "ticker_sentiment_score": "-0.092033", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.091162", "ticker_sentiment_score": "-0.00108", "ticker_sentiment_label": "Neutral"}, {"ticker": "MA", "relevance_score": "0.036532", "ticker_sentiment_score": "0.141804", "ticker_sentiment_label": "Neutral"}, {"ticker": "V", "relevance_score": "0.072987", "ticker_sentiment_score": "0.148237", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.054773", "ticker_sentiment_score": "-0.068368", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMG", "relevance_score": "0.072987", "ticker_sentiment_score": "-0.006113", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.054773", "ticker_sentiment_score": "-0.11609", "ticker_sentiment_label": "Neutral"}, {"ticker": "GE", "relevance_score": "0.072987", "ticker_sentiment_score": "0.029672", "ticker_sentiment_label": "Neutral"}, {"ticker": "AYX", "relevance_score": "0.036532", "ticker_sentiment_score": "-0.1106", "ticker_sentiment_label": "Neutral"}, {"ticker": "KLAC", "relevance_score": "0.036532", "ticker_sentiment_score": "-0.090238", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.036532", "ticker_sentiment_score": "-0.041307", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.145364", "ticker_sentiment_score": "-0.098456", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPOT", "relevance_score": "0.036532", "ticker_sentiment_score": "-0.066788", "ticker_sentiment_label": "Neutral"}, {"ticker": "BSX", "relevance_score": "0.054773", "ticker_sentiment_score": "-0.11609", "ticker_sentiment_label": "Neutral"}, {"ticker": "GM", "relevance_score": "0.072987", "ticker_sentiment_score": "-0.017451", "ticker_sentiment_label": "Neutral"}, {"ticker": "ILMN", "relevance_score": "0.054773", "ticker_sentiment_score": "-0.11609", "ticker_sentiment_label": "Neutral"}, {"ticker": "SMCI", "relevance_score": "0.036532", "ticker_sentiment_score": "-0.108377", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.072987", "ticker_sentiment_score": "-0.111796", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.036532", "ticker_sentiment_score": "-0.067681", "ticker_sentiment_label": "Neutral"}, {"ticker": "CHDN", "relevance_score": "0.036532", "ticker_sentiment_score": "0.169405", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "EW", "relevance_score": "0.054773", "ticker_sentiment_score": "-0.11609", "ticker_sentiment_label": "Neutral"}, {"ticker": "FRC", "relevance_score": "0.091162", "ticker_sentiment_score": "-0.109548", "ticker_sentiment_label": "Neutral"}, {"ticker": "INTC", "relevance_score": "0.072987", "ticker_sentiment_score": "-0.093739", "ticker_sentiment_label": "Neutral"}, {"ticker": "NOW", "relevance_score": "0.036532", "ticker_sentiment_score": "-0.1106", "ticker_sentiment_label": "Neutral"}, {"ticker": "XOM", "relevance_score": "0.036532", "ticker_sentiment_score": "-0.077119", "ticker_sentiment_label": "Neutral"}, {"ticker": "CDNS", "relevance_score": "0.036532", "ticker_sentiment_score": "-0.042982", "ticker_sentiment_label": "Neutral"}, {"ticker": "PI", "relevance_score": "0.036532", "ticker_sentiment_score": "-0.090238", "ticker_sentiment_label": "Neutral"}, {"ticker": "WOLF", "relevance_score": "0.036532", "ticker_sentiment_score": "-0.090238", "ticker_sentiment_label": "Neutral"}, {"ticker": "NET", "relevance_score": "0.091162", "ticker_sentiment_score": "-0.095446", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.091162", "ticker_sentiment_score": "-0.037536", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.036532", "ticker_sentiment_score": "-0.06261", "ticker_sentiment_label": "Neutral"}]}, {"title": "DexCom  ( DXCM )  Q1 Earnings Beat Estimates, Volumes Remain Strong", "url": "https://www.zacks.com/stock/news/2086982/dexcom-dxcm-q1-earnings-beat-estimates-volumes-remain-strong", "time_published": "20230428T152400", "authors": ["Zacks Investment Research"], "summary": "DexCom's (DXCM) first-quarter 2023 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e7/4322.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999997"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.163347, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CHE", "relevance_score": "0.192694", "ticker_sentiment_score": "0.097619", "ticker_sentiment_label": "Neutral"}, {"ticker": "EW", "relevance_score": "0.192694", "ticker_sentiment_score": "0.089641", "ticker_sentiment_label": "Neutral"}, {"ticker": "ISRG", "relevance_score": "0.192694", "ticker_sentiment_score": "0.089641", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.457977", "ticker_sentiment_score": "0.26976", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Dexcom, A Top 2% Stock, Just Beat And Raised", "url": "https://www.investors.com/stock-lists/stock-spotlight/dexcom-stock-dexcom-earnings-q1-2023/", "time_published": "20230428T132800", "authors": ["ALLISON GATLIN", "Investor's Business Daily"], "summary": "Dexcom Stock, A Top 2% Stock, Skids As Sales Growth Slows ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2020/02/stock-Dexcom-02-shutter.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.980922"}], "overall_sentiment_score": 0.273566, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.853391", "ticker_sentiment_score": "0.329954", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Roblox And 3 Other Stocks Insiders Are Selling - Roblox  ( NYSE:RBLX ) , DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/news/23/04/32082570/roblox-and-3-other-stocks-insiders-are-selling", "time_published": "20230428T130032", "authors": ["Lisa Levin"], "summary": "The Nasdaq Composite closed sharply higher on Thursday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it indicates their concern in the company's prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to go ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/04/28/roblox_-_logo.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.203972, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "RBLX", "relevance_score": "0.436009", "ticker_sentiment_score": "0.380371", "ticker_sentiment_label": "Bullish"}, {"ticker": "SSD", "relevance_score": "0.436009", "ticker_sentiment_score": "0.304243", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.511256", "ticker_sentiment_score": "0.340339", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SLP", "relevance_score": "0.436009", "ticker_sentiment_score": "0.19394", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Mastercard To Rally Over 18%? Here Are 10 Other Analyst Forecasts For Friday - BJ's Restaurants  ( NASDAQ:BJRI ) , Amazon.com  ( NASDAQ:AMZN ) ", "url": "https://www.benzinga.com/news/23/04/32081984/mastercard-to-rally-over-18-here-are-10-other-analyst-forecasts-for-friday", "time_published": "20230428T124040", "authors": ["Lisa Levin"], "summary": "Wells Fargo raised the price target for Molina Healthcare, Inc. MOH from $282 to $290. Wells Fargo analyst Stephen Baxter maintained an Underweight rating. Molina Healthcare shares gained 7.8% to close at $296.92 on Thursday. Credit Suisse boosted the price target for Eli Lilly and Company LLY ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/04/28/mastercard_-_logo.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.999186"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}], "overall_sentiment_score": 0.222023, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "META", "relevance_score": "0.195025", "ticker_sentiment_score": "0.239115", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MCRB", "relevance_score": "0.288893", "ticker_sentiment_score": "0.006465", "ticker_sentiment_label": "Neutral"}, {"ticker": "C", "relevance_score": "0.195025", "ticker_sentiment_score": "0.080597", "ticker_sentiment_label": "Neutral"}, {"ticker": "MOH", "relevance_score": "0.288893", "ticker_sentiment_score": "0.298253", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CCORF", "relevance_score": "0.195025", "ticker_sentiment_score": "-0.041374", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.378572", "ticker_sentiment_score": "0.21", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MA", "relevance_score": "0.195025", "ticker_sentiment_score": "0.080597", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.195025", "ticker_sentiment_score": "0.221127", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LLY", "relevance_score": "0.288893", "ticker_sentiment_score": "0.571166", "ticker_sentiment_label": "Bullish"}, {"ticker": "WOLF", "relevance_score": "0.288893", "ticker_sentiment_score": "0.0065", "ticker_sentiment_label": "Neutral"}, {"ticker": "PINS", "relevance_score": "0.288893", "ticker_sentiment_score": "-0.060888", "ticker_sentiment_label": "Neutral"}, {"ticker": "ICPT", "relevance_score": "0.288893", "ticker_sentiment_score": "0.327388", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMZN", "relevance_score": "0.195025", "ticker_sentiment_score": "0.00863", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.288893", "ticker_sentiment_score": "-0.056454", "ticker_sentiment_label": "Neutral"}]}, {"title": "DexCom Q1 Earnings Beat Sets Stage For Upcoming Catalysts During 2023, Analyst Says - DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/news/earnings/23/04/32077625/dexcom-q1-earnings-beat-sets-stage-for-upcoming-catalysts-during-2023-analyst-says", "time_published": "20230428T115625", "authors": ["Vandana Singh"], "summary": "DexCom Inc DXCM raised its 2023 financial guidance following strong Q1 FY23 financial results. It posted Q1 sales of $741.50 million, up 18% Y/Y ( 19% organic basis ) , beating the consensus of $720.74 million.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/04/28/dxcm.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.684621"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.367959, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.911721", "ticker_sentiment_score": "0.479211", "ticker_sentiment_label": "Bullish"}]}, {"title": "Futures: Amazon Erases Gains On Cloud Fears; These Techs Dive", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-amazon-continues-earnings-surge-for-tech-titans-but-cloudflare-snap-plunge/", "time_published": "20230427T213200", "authors": ["ED CARSON", "Investor's Business Daily"], "summary": "Futures: Amazon Jumps On Earnings, But These Techs Plunge Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2018/07/stock-bull-charge-02-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "1.0"}], "overall_sentiment_score": 0.096773, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AYX", "relevance_score": "0.046184", "ticker_sentiment_score": "-0.156323", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ENPH", "relevance_score": "0.046184", "ticker_sentiment_score": "0.067013", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.023102", "ticker_sentiment_score": "0.217449", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "META", "relevance_score": "0.092213", "ticker_sentiment_score": "0.039533", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.069227", "ticker_sentiment_score": "0.198088", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CVX", "relevance_score": "0.069227", "ticker_sentiment_score": "0.079631", "ticker_sentiment_label": "Neutral"}, {"ticker": "CROX", "relevance_score": "0.115121", "ticker_sentiment_score": "0.019396", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.023102", "ticker_sentiment_score": "0.042606", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.046184", "ticker_sentiment_score": "-0.156323", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MSFT", "relevance_score": "0.137934", "ticker_sentiment_score": "0.186854", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FSLR", "relevance_score": "0.137934", "ticker_sentiment_score": "0.003946", "ticker_sentiment_label": "Neutral"}, {"ticker": "INTC", "relevance_score": "0.046184", "ticker_sentiment_score": "-0.156323", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PI", "relevance_score": "0.046184", "ticker_sentiment_score": "-0.102237", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.046184", "ticker_sentiment_score": "-0.156323", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PINS", "relevance_score": "0.046184", "ticker_sentiment_score": "-0.156323", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "NET", "relevance_score": "0.137934", "ticker_sentiment_score": "-0.109802", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.227859", "ticker_sentiment_score": "0.093466", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.183198", "ticker_sentiment_score": "-0.001522", "ticker_sentiment_label": "Neutral"}]}, {"title": "DexCom  ( DXCM )  Q1 Earnings and Revenues Beat Estimates", "url": "https://www.zacks.com/stock/news/2086409/dexcom-dxcm-q1-earnings-and-revenues-beat-estimates", "time_published": "20230427T212515", "authors": ["Zacks Investment Research"], "summary": "DexCom (DXCM) delivered earnings and revenue surprises of 13.33% and 3.01%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default62.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999992"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.182782, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.40348", "ticker_sentiment_score": "0.278955", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Dexcom, A Top 2% Stock, Just Beat And Raised", "url": "https://www.investors.com/news/technology/dexcom-stock-dexcom-earnings-q1-2023/", "time_published": "20230427T202700", "authors": ["ALLISON GATLIN", "Investor's Business Daily"], "summary": "Dexcom Stock, Top 2% Stock, Beats Expectations, Raises Outlook ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2020/02/stock-Dexcom-02-shutter.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.576289"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.929393"}], "overall_sentiment_score": 0.290071, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.966495", "ticker_sentiment_score": "0.430515", "ticker_sentiment_label": "Bullish"}]}, {"title": "2 Growth Stocks That Could Double in 5 Years", "url": "https://www.fool.com/investing/2023/04/27/2-growth-stocks-that-could-double-in-5-years/", "time_published": "20230427T142300", "authors": ["Prosper Junior Bakiny"], "summary": "Both of these companies did more than that in the past five years.", "banner_image": "https://media.ycharts.com/charts/aad705648228686a363b4d6cf11ead45.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.858979"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.245317, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.261678", "ticker_sentiment_score": "0.224657", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.360005", "ticker_sentiment_score": "0.289935", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "2 Growth Stocks That Could Double in 5 Years", "url": "https://moneymorning.com/investing/2-growth-stocks-that-could-double-in-5-years/", "time_published": "20230427T142300", "authors": ["Fool.com", "fool.com"], "summary": "As a group, growth stocks had a year to forget in 2022. And even with the market recovery we are experiencing this year, many remain in the red over the past 12 months. But there are always outliers. Some growth stocks have performed just fine recently compared to the broader market.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fmedia.ycharts.com%2Fcharts%2Faad705648228686a363b4d6cf11ead45.png&w=700", "source": "Money Morning", "category_within_source": "RSS", "source_domain": "moneymorning.com", "topics": [{"topic": "Earnings", "relevance_score": "0.538269"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.18202, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.385286", "ticker_sentiment_score": "0.301318", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.237358", "ticker_sentiment_score": "0.159628", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Medical Device Stocks' Q1 Earnings on Apr 27: WST, DXCM, BAX", "url": "https://www.zacks.com/stock/news/2085159/medical-device-stocks-q1-earnings-on-apr-27-wst-dxcm-bax", "time_published": "20230426T145200", "authors": ["Zacks Investment Research"], "summary": "Medical Device companies' Q1 results are likely to reflect strength in customer demand. Let's see how WST, DXCM and BAX are placed ahead of their earnings releases.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/45/26891.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "1.0"}], "overall_sentiment_score": 0.1262, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BAX", "relevance_score": "0.244635", "ticker_sentiment_score": "0.127136", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.035502", "ticker_sentiment_score": "0.262347", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WST", "relevance_score": "0.210579", "ticker_sentiment_score": "0.145932", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDT", "relevance_score": "0.106227", "ticker_sentiment_score": "0.293109", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.210579", "ticker_sentiment_score": "0.163969", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Healthcare: An Essential Sector  ( 3 Stocks to Buy Ahead of Earnings ) ", "url": "https://www.zacks.com/commentary/2084719/healthcare-an-essential-sector-3-stocks-to-buy-ahead-of-earnings", "time_published": "20230426T115800", "authors": ["Zacks Investment Research"], "summary": "Healthcare stocks are an excellent place to park your money in the current market environment. Due to it's necessity, the sector tends to due well in any economy.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default313.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Financial Markets", "relevance_score": "0.818451"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.928769"}], "overall_sentiment_score": 0.060193, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.149966", "ticker_sentiment_score": "0.032", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.149966", "ticker_sentiment_score": "0.081033", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.149966", "ticker_sentiment_score": "0.032", "ticker_sentiment_label": "Neutral"}, {"ticker": "SYK", "relevance_score": "0.100308", "ticker_sentiment_score": "0.138506", "ticker_sentiment_label": "Neutral"}, {"ticker": "FRC", "relevance_score": "0.100308", "ticker_sentiment_score": "-0.111408", "ticker_sentiment_label": "Neutral"}, {"ticker": "ISRG", "relevance_score": "0.100308", "ticker_sentiment_score": "0.138506", "ticker_sentiment_label": "Neutral"}, {"ticker": "BFC", "relevance_score": "0.050254", "ticker_sentiment_score": "-0.102848", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.199037", "ticker_sentiment_score": "0.190085", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HCSG", "relevance_score": "0.050254", "ticker_sentiment_score": "0.031059", "ticker_sentiment_label": "Neutral"}, {"ticker": "SWAV", "relevance_score": "0.199037", "ticker_sentiment_score": "0.213786", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Medical Sensors Market Size to Hit USD 32.15 Bn by 2028 Owing to Rising Health Awareness and Prevalence of Chronic Diseases across the Globe", "url": "https://www.benzinga.com/pressreleases/23/04/g31999245/medical-sensors-market-size-to-hit-usd-32-15-bn-by-2028-owing-to-rising-health-awareness-and-preva", "time_published": "20230425T203000", "authors": ["Globe Newswire"], "summary": "Wilmington, Delaware, United States, April 26, 2023 ( GLOBE NEWSWIRE ) -- According to the recent study by Transparency Market Research, the global medical sensors market stood at USD 15.23 Bn in 2020 and is projected to reach USD 32.15 Bn by 2028 with CAGR of 9.9% from 2021 to 2028.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.282639, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HON", "relevance_score": "0.037387", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MOOIF", "relevance_score": "0.037387", "ticker_sentiment_score": "0.199618", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TEL", "relevance_score": "0.037387", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDT", "relevance_score": "0.037387", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "WLDS", "relevance_score": "0.037387", "ticker_sentiment_score": "0.105024", "ticker_sentiment_label": "Neutral"}, {"ticker": "SMGKF", "relevance_score": "0.037387", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.037387", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DHR", "relevance_score": "0.037387", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "P/E Ratio Insights for DexCom - DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/news/23/04/31992484/pe-ratio-insights-for-dexcom", "time_published": "20230425T153044", "authors": ["Benzinga Insights"], "summary": "In the current session, the stock is trading at $124.65, after a 0.66% increase. Over the past month, DexCom Inc. DXCM stock increased by 9.38%, and in the past year, by 20.72%.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.503496"}], "overall_sentiment_score": 0.004766, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.431065", "ticker_sentiment_score": "0.199379", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "2 Monster Stocks to Buy Without Any Hesitation", "url": "https://www.fool.com/investing/2023/04/25/2-monster-stocks-to-buy-without-any-hesitation/", "time_published": "20230425T142000", "authors": ["Jim Halley"], "summary": "These stocks have grown revenue, earnings and share price over the past five years.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F729189%2Fnio-et5.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999993"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.247204, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.244846", "ticker_sentiment_score": "0.243995", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.382193", "ticker_sentiment_score": "0.273202", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABBV", "relevance_score": "0.049732", "ticker_sentiment_score": "0.166157", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "This Company's Non-Invasive Tech Looks To Be Unique In the Market And Can Help People Take Ownership Over Monitoring Their Health - Abbott Laboratories  ( NYSE:ABT ) , DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/general/healthcare/23/04/31985359/this-companys-non-invasive-tech-looks-to-be-unique-in-the-market-and-can-help-people", "time_published": "20230425T114843", "authors": ["David Willey"], "summary": "The need for noninvasive healthcare technology that allows people to take ownership and gather more insight into their health became acute when COVID revealed the fragility of the hospital system. This health-driven interest is reflected in the burgeoning healthtech market, currently valued at ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/04/25/screenshot_2023-04-25_at_5.18.16_pm.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.152974, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.269033", "ticker_sentiment_score": "0.189327", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABT", "relevance_score": "0.136499", "ticker_sentiment_score": "0.116736", "ticker_sentiment_label": "Neutral"}, {"ticker": "YEWTF", "relevance_score": "0.068502", "ticker_sentiment_score": "-0.033256", "ticker_sentiment_label": "Neutral"}]}, {"title": "Mercury Systems Hosts U.S. Senator Kyrsten Sinema at its Phoenix Facility", "url": "https://www.globenewswire.com/news-release/2023/04/25/2653705/18849/en/Mercury-Systems-Hosts-U-S-Senator-Kyrsten-Sinema-at-its-Phoenix-Facility.html", "time_published": "20230425T110000", "authors": ["Mercury Systems Inc"], "summary": "ANDOVER, Mass., April 25, 2023 ( GLOBE NEWSWIRE ) -- Mercury Systems, Inc. ( NASDAQ: MRCY, www.mrcy.com ) , a technology company that delivers processing power for the most demanding aerospace and defense missions, on Friday hosted U.S. Sen.", "banner_image": "https://ml.globenewswire.com/Resource/Download/03b7814b-0e2f-47e9-8ec7-4ccc80c5750b", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.122913, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.042196", "ticker_sentiment_score": "0.111273", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRCY", "relevance_score": "0.208644", "ticker_sentiment_score": "0.228718", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Mercury Systems Hosts U.S. Senator Kyrsten Sinema at its Phoenix Facility - Mercury Sys  ( NASDAQ:MRCY ) ", "url": "https://www.benzinga.com/pressreleases/23/04/g31984054/mercury-systems-hosts-u-s-senator-kyrsten-sinema-at-its-phoenix-facility", "time_published": "20230425T110000", "authors": ["Globe Newswire"], "summary": "ANDOVER, Mass., April 25, 2023 ( GLOBE NEWSWIRE ) -- Mercury Systems, Inc. MRCY www.mrcy.com ) ) ) , a technology company that delivers processing power for the most demanding aerospace and defense missions, on Friday hosted U.S. Sen.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.117988, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.041039", "ticker_sentiment_score": "0.110977", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRCY", "relevance_score": "0.163078", "ticker_sentiment_score": "0.179974", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Zacks Investment Ideas feature highlights: Nasdaq 100 ETF, Dexcom, Merck, Intuitive Surgical and SPDR S&P Regional Bank ETF", "url": "https://www.zacks.com/stock/news/2083812/zacks-investment-ideas-feature-highlights-nasdaq-100-etf-dexcom-merck-intuitive-surgical-and-spdr-sp-regional-bank-etf", "time_published": "20230425T090000", "authors": ["Zacks Investment Research"], "summary": "Nasdaq 100 ETF, Dexcom, Merck, Intuitive Surgical and SPDR S&P Regional Bank ETF have been highlighted in this Investment Ideas article.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/cd/2084.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.714479"}], "overall_sentiment_score": -0.054778, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "WBD", "relevance_score": "0.102888", "ticker_sentiment_score": "-0.108835", "ticker_sentiment_label": "Neutral"}, {"ticker": "ISRG", "relevance_score": "0.301933", "ticker_sentiment_score": "0.091551", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.301933", "ticker_sentiment_score": "0.091551", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.301933", "ticker_sentiment_score": "-0.310968", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Sell the News? 5 Reasons Tech May Pullback", "url": "https://www.zacks.com/commentary/2083614/sell-the-news-5-reasons-tech-may-pullback", "time_published": "20230424T172300", "authors": ["Zacks Investment Research"], "summary": "Though the medium-term trend remains intact for tech, some subtle signs of weakness are appearing beneath the surface. Andrew Rocco breaks it down.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default270.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": -0.071554, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "WBD", "relevance_score": "0.112532", "ticker_sentiment_score": "-0.181122", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ISRG", "relevance_score": "0.222838", "ticker_sentiment_score": "0.110189", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.222838", "ticker_sentiment_score": "0.110189", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.328819", "ticker_sentiment_score": "-0.330473", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Big Tech Earnings & Economic Numbers: 3 Ways to Survive the Week Ahead", "url": "https://www.zacks.com/commentary/2083214/big-tech-earnings-economic-numbers-3-ways-to-survive-the-week-ahead", "time_published": "20230424T112700", "authors": ["Zacks Investment Research"], "summary": "Many of the FANG stocks are slated to report earnings this week. Today, we will lay out how investors can best navigate the action packed week ahead.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e0/427.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.858979"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.990678"}], "overall_sentiment_score": 0.058616, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.155451", "ticker_sentiment_score": "0.001308", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.155451", "ticker_sentiment_score": "0.001308", "ticker_sentiment_label": "Neutral"}, {"ticker": "FSLR", "relevance_score": "0.155451", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "WBD", "relevance_score": "0.078099", "ticker_sentiment_score": "-0.085183", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.155451", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PINS", "relevance_score": "0.155451", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.155451", "ticker_sentiment_score": "0.001308", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.155451", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "DexCom  ( DXCM )  to Report Q1 Earnings: What's in the Cards?", "url": "https://www.zacks.com/stock/news/2083218/dexcom-dxcm-to-report-q1-earnings-whats-in-the-cards", "time_published": "20230424T103500", "authors": ["Zacks Investment Research"], "summary": "DexCom's (DXCM) first-quarter results likely to reflect rising volumes across all channels.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/dc/1107.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Earnings", "relevance_score": "0.999985"}], "overall_sentiment_score": 0.233122, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HSIC", "relevance_score": "0.157483", "ticker_sentiment_score": "0.091382", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCK", "relevance_score": "0.157483", "ticker_sentiment_score": "0.115002", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.610722", "ticker_sentiment_score": "0.494949", "ticker_sentiment_label": "Bullish"}]}, {"title": "Futures: Four Titans Lead Earnings Wave; What To Do Now", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-microsoft-meta-google-lead-earnings-wave/", "time_published": "20230423T140600", "authors": ["ED CARSON", "Investor's Business Daily"], "summary": "Futures: Four Titans Lead Earnings Wave. What To Do Now Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2020/04/Stock-BigWavePipe-08-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.904684"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.041172, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.159993", "ticker_sentiment_score": "0.153581", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "META", "relevance_score": "0.096412", "ticker_sentiment_score": "0.036404", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANET", "relevance_score": "0.096412", "ticker_sentiment_score": "0.139177", "ticker_sentiment_label": "Neutral"}, {"ticker": "BSX", "relevance_score": "0.096412", "ticker_sentiment_score": "0.103155", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.096412", "ticker_sentiment_score": "0.089411", "ticker_sentiment_label": "Neutral"}, {"ticker": "BBBY", "relevance_score": "0.096412", "ticker_sentiment_score": "-0.398167", "ticker_sentiment_label": "Bearish"}, {"ticker": "ALGN", "relevance_score": "0.064362", "ticker_sentiment_score": "0.067043", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.032207", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.222546", "ticker_sentiment_score": "0.165179", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FSLR", "relevance_score": "0.064362", "ticker_sentiment_score": "0.067043", "ticker_sentiment_label": "Neutral"}, {"ticker": "V", "relevance_score": "0.064362", "ticker_sentiment_score": "0.067043", "ticker_sentiment_label": "Neutral"}, {"ticker": "NOW", "relevance_score": "0.032207", "ticker_sentiment_score": "0.062685", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMG", "relevance_score": "0.064362", "ticker_sentiment_score": "0.067043", "ticker_sentiment_label": "Neutral"}, {"ticker": "NET", "relevance_score": "0.064362", "ticker_sentiment_score": "0.067043", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.064362", "ticker_sentiment_score": "0.067043", "ticker_sentiment_label": "Neutral"}, {"ticker": "SWAV", "relevance_score": "0.128306", "ticker_sentiment_score": "0.114348", "ticker_sentiment_label": "Neutral"}, {"ticker": "BA", "relevance_score": "0.064362", "ticker_sentiment_score": "0.067043", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stocks Quiet Ahead Of Earnings Flood; What To Do Now", "url": "https://www.investors.com/market-trend/stock-market-today/market-rally-awaits-earnings-flood-microsoft-meta-amazon-google/", "time_published": "20230421T205800", "authors": ["Investor's Business Daily", "ED CARSON"], "summary": "Market Rally Awaits Earnings Wave Led By Microsoft, Meta, Amazon ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2020/04/Stock-BigWavePipe-08-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.904684"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.081768, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.165712", "ticker_sentiment_score": "0.157161", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "META", "relevance_score": "0.09989", "ticker_sentiment_score": "0.036789", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANET", "relevance_score": "0.09989", "ticker_sentiment_score": "0.140487", "ticker_sentiment_label": "Neutral"}, {"ticker": "BSX", "relevance_score": "0.09989", "ticker_sentiment_score": "0.101983", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.09989", "ticker_sentiment_score": "0.090243", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALGN", "relevance_score": "0.066691", "ticker_sentiment_score": "0.06711", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.033375", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.230391", "ticker_sentiment_score": "0.169719", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FSLR", "relevance_score": "0.066691", "ticker_sentiment_score": "0.06711", "ticker_sentiment_label": "Neutral"}, {"ticker": "V", "relevance_score": "0.066691", "ticker_sentiment_score": "0.06711", "ticker_sentiment_label": "Neutral"}, {"ticker": "NOW", "relevance_score": "0.033375", "ticker_sentiment_score": "0.06303", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMG", "relevance_score": "0.066691", "ticker_sentiment_score": "0.06711", "ticker_sentiment_label": "Neutral"}, {"ticker": "NET", "relevance_score": "0.066691", "ticker_sentiment_score": "0.06711", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.066691", "ticker_sentiment_score": "0.06711", "ticker_sentiment_label": "Neutral"}, {"ticker": "SWAV", "relevance_score": "0.132916", "ticker_sentiment_score": "0.113954", "ticker_sentiment_label": "Neutral"}, {"ticker": "BA", "relevance_score": "0.066691", "ticker_sentiment_score": "0.06711", "ticker_sentiment_label": "Neutral"}]}, {"title": "Market Rally Drifts Lower; Tesla Dives On Margins: Weekly Review", "url": "https://www.investors.com/news/stock-market-rally-drifts-lower-tesla-dives-on-margins-isrg-dhi-lvs-are-winners/", "time_published": "20230421T151600", "authors": ["IBD STAFF", "Investor's Business Daily"], "summary": "Market Rally Drifts Lower. Tesla Dives On Margins: Weekly Review Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2021/01/Stock-Tesla-modelY-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "0.99977"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": -0.09001, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "XPEV", "relevance_score": "0.062271", "ticker_sentiment_score": "-0.003015", "ticker_sentiment_label": "Neutral"}, {"ticker": "WAL", "relevance_score": "0.041538", "ticker_sentiment_score": "0.008941", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.062271", "ticker_sentiment_score": "-0.0486", "ticker_sentiment_label": "Neutral"}, {"ticker": "LVS", "relevance_score": "0.124164", "ticker_sentiment_score": "-0.02055", "ticker_sentiment_label": "Neutral"}, {"ticker": "SLB", "relevance_score": "0.062271", "ticker_sentiment_score": "0.051316", "ticker_sentiment_label": "Neutral"}, {"ticker": "BK", "relevance_score": "0.041538", "ticker_sentiment_score": "0.008941", "ticker_sentiment_label": "Neutral"}, {"ticker": "STT", "relevance_score": "0.062271", "ticker_sentiment_score": "0.009061", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABT", "relevance_score": "0.041538", "ticker_sentiment_score": "-0.047931", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.185306", "ticker_sentiment_score": "-0.079295", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNP", "relevance_score": "0.062271", "ticker_sentiment_score": "-0.087197", "ticker_sentiment_label": "Neutral"}, {"ticker": "LRCX", "relevance_score": "0.103598", "ticker_sentiment_score": "-0.112153", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPGI", "relevance_score": "0.020776", "ticker_sentiment_score": "-0.013591", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.041538", "ticker_sentiment_score": "-0.060168", "ticker_sentiment_label": "Neutral"}, {"ticker": "NFLX", "relevance_score": "0.062271", "ticker_sentiment_score": "-0.087018", "ticker_sentiment_label": "Neutral"}, {"ticker": "IBKR", "relevance_score": "0.062271", "ticker_sentiment_score": "0.003046", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.041538", "ticker_sentiment_score": "0.008941", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.041538", "ticker_sentiment_score": "0.008941", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCA", "relevance_score": "0.041538", "ticker_sentiment_score": "0.08633", "ticker_sentiment_label": "Neutral"}, {"ticker": "BKR", "relevance_score": "0.062271", "ticker_sentiment_score": "0.051316", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.041538", "ticker_sentiment_score": "0.008941", "ticker_sentiment_label": "Neutral"}, {"ticker": "AN", "relevance_score": "0.020776", "ticker_sentiment_score": "-0.109884", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCB", "relevance_score": "0.041538", "ticker_sentiment_score": "0.008941", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSM", "relevance_score": "0.082963", "ticker_sentiment_score": "-0.105451", "ticker_sentiment_label": "Neutral"}, {"ticker": "LMT", "relevance_score": "0.041538", "ticker_sentiment_score": "0.050024", "ticker_sentiment_label": "Neutral"}, {"ticker": "NIO", "relevance_score": "0.062271", "ticker_sentiment_score": "-0.003015", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALB", "relevance_score": "0.062271", "ticker_sentiment_score": "-0.179135", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PG", "relevance_score": "0.062271", "ticker_sentiment_score": "-0.056259", "ticker_sentiment_label": "Neutral"}, {"ticker": "AXP", "relevance_score": "0.041538", "ticker_sentiment_score": "-0.056996", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIO", "relevance_score": "0.041538", "ticker_sentiment_score": "-0.175689", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SCHW", "relevance_score": "0.062271", "ticker_sentiment_score": "0.003046", "ticker_sentiment_label": "Neutral"}, {"ticker": "FCX", "relevance_score": "0.041538", "ticker_sentiment_score": "-0.024978", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.062271", "ticker_sentiment_score": "-0.043466", "ticker_sentiment_label": "Neutral"}, {"ticker": "ISRG", "relevance_score": "0.144646", "ticker_sentiment_score": "0.007934", "ticker_sentiment_label": "Neutral"}, {"ticker": "LI", "relevance_score": "0.062271", "ticker_sentiment_score": "-0.003015", "ticker_sentiment_label": "Neutral"}, {"ticker": "KEY", "relevance_score": "0.041538", "ticker_sentiment_score": "0.008941", "ticker_sentiment_label": "Neutral"}]}, {"title": "NOW Stock Climbs Off Lows Ahead Q1 Results; Microsoft, META Headline Big Week Of Tech Earnings", "url": "https://www.investors.com/research/earnings-preview/now-stock-off-lows-q1-earnings-microsoft-meta-headline-big-week-tech-earnings/", "time_published": "20230421T142800", "authors": ["KEN SHREVE", "Investor's Business Daily"], "summary": "NOW Stock Climbs Off Lows Ahead Q1 Results. Microsoft, META ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/04/EARNwatchT042423.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}], "overall_sentiment_score": 0.137102, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.106384", "ticker_sentiment_score": "0.185824", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MTH", "relevance_score": "0.07104", "ticker_sentiment_score": "0.245023", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GOOG", "relevance_score": "0.035555", "ticker_sentiment_score": "0.16494", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "META", "relevance_score": "0.106384", "ticker_sentiment_score": "0.185824", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "INTC", "relevance_score": "0.07104", "ticker_sentiment_score": "0.250091", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CROX", "relevance_score": "0.07104", "ticker_sentiment_score": "0.05223", "ticker_sentiment_label": "Neutral"}, {"ticker": "NOW", "relevance_score": "0.176373", "ticker_sentiment_score": "0.14735", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.07104", "ticker_sentiment_score": "0.113634", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALGN", "relevance_score": "0.07104", "ticker_sentiment_score": "0.113634", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.035555", "ticker_sentiment_score": "0.108117", "ticker_sentiment_label": "Neutral"}]}, {"title": "Option Trading: Insulet Butterfly Taps Into Stock's Leadership, Potential Rally", "url": "https://www.investors.com/research/options/option-trading-insulet-butterfly-taps-into-stocks-leadership-potential-rally/", "time_published": "20230421T141300", "authors": ["Investor's Business Daily", "ANNE-MARIE BAIYND"], "summary": "Option Trading: Insulet Butterfly Taps Into Stock's Leadership ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2020/02/stock-Insulet-OmniPod-01-shutter.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999976"}], "overall_sentiment_score": 0.189713, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LNTH", "relevance_score": "0.105372", "ticker_sentiment_score": "0.163437", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.105372", "ticker_sentiment_score": "0.163437", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PODD", "relevance_score": "0.208914", "ticker_sentiment_score": "0.266522", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Zacks Investment Ideas feature highlights: Nvidia, First Solar, Intuitive Surgical, Dexcom and Asure Software", "url": "https://www.zacks.com/stock/news/2082605/zacks-investment-ideas-feature-highlights-nvidia-first-solar-intuitive-surgical-dexcom-and-asure-software", "time_published": "20230421T110500", "authors": ["Zacks Investment Research"], "summary": "Nvidia, First Solar, Intuitive Surgical, Dexcom and Asure Software are part of the Zacks Investment Ideas article.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/58/1952.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.955357"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.038217, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ASUR", "relevance_score": "0.238133", "ticker_sentiment_score": "-0.043734", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.238133", "ticker_sentiment_score": "-0.164732", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "FSLR", "relevance_score": "0.313817", "ticker_sentiment_score": "0.257299", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ISRG", "relevance_score": "0.238133", "ticker_sentiment_score": "0.145322", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.160099", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Riding the Wave: These 3 Industry Groups are Making a Splash with Expected Money Inflows", "url": "https://www.zacks.com/commentary/2081867/riding-the-wave-these-3-industry-groups-are-making-a-splash-with-expected-money-inflows", "time_published": "20230420T130500", "authors": ["Zacks Investment Research"], "summary": "Markets have been known to have periods of \"nasty\" industry group rotation. Get ahead of the curve with these 3 under-the-radar groups.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default295.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.996718"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.08296, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ASUR", "relevance_score": "0.132368", "ticker_sentiment_score": "0.063911", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.132368", "ticker_sentiment_score": "-0.097047", "ticker_sentiment_label": "Neutral"}, {"ticker": "FSLR", "relevance_score": "0.197413", "ticker_sentiment_score": "0.244176", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FSLY", "relevance_score": "0.132368", "ticker_sentiment_score": "0.063911", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.066414", "ticker_sentiment_score": "0.157058", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ISRG", "relevance_score": "0.132368", "ticker_sentiment_score": "0.087047", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.197413", "ticker_sentiment_score": "0.112757", "ticker_sentiment_label": "Neutral"}, {"ticker": "IOT", "relevance_score": "0.132368", "ticker_sentiment_score": "0.063911", "ticker_sentiment_label": "Neutral"}]}, {"title": "Futures: Tesla Margins Dive; Musk Willing To Push Profit To Zero", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-tesla-falls-as-gross-margins-free-cash-flow-dive/", "time_published": "20230420T015200", "authors": ["Investor's Business Daily", "ED CARSON"], "summary": "Dow Jones Futures: Tesla Falls As Margins Dive. Why Elon Musk Is ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2019/12/stock-Tesla-Model3-10-shutter.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.998645"}, {"topic": "Real Estate & Construction", "relevance_score": "0.2"}], "overall_sentiment_score": -0.075083, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NFLX", "relevance_score": "0.045612", "ticker_sentiment_score": "-0.134003", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.045612", "ticker_sentiment_score": "-0.008929", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.091075", "ticker_sentiment_score": "-0.008393", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.045612", "ticker_sentiment_score": "-0.224164", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "AAPL", "relevance_score": "0.091075", "ticker_sentiment_score": "-0.009476", "ticker_sentiment_label": "Neutral"}, {"ticker": "LVS", "relevance_score": "0.136242", "ticker_sentiment_score": "0.035889", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.113705", "ticker_sentiment_score": "-0.028359", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXTR", "relevance_score": "0.045612", "ticker_sentiment_score": "-0.23402", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "EW", "relevance_score": "0.045612", "ticker_sentiment_score": "-0.099583", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.39329", "ticker_sentiment_score": "-0.055393", "ticker_sentiment_label": "Neutral"}, {"ticker": "LRCX", "relevance_score": "0.180967", "ticker_sentiment_score": "-0.035547", "ticker_sentiment_label": "Neutral"}, {"ticker": "ISRG", "relevance_score": "0.045612", "ticker_sentiment_score": "-0.099583", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.045612", "ticker_sentiment_score": "-0.008929", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.045612", "ticker_sentiment_score": "-0.099583", "ticker_sentiment_label": "Neutral"}]}, {"title": "Are Medical Stocks Lagging DexCom  ( DXCM )  This Year?", "url": "https://www.zacks.com/stock/news/2081002/are-medical-stocks-lagging-dexcom-dxcm-this-year", "time_published": "20230419T134012", "authors": ["Zacks Investment Research"], "summary": "Here is how DexCom (DXCM) and Lantheus Holdings (LNTH) have performed compared to their sector so far this year.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default276.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.614606"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.241592, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LNTH", "relevance_score": "0.491255", "ticker_sentiment_score": "0.282026", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.765728", "ticker_sentiment_score": "0.406798", "ticker_sentiment_label": "Bullish"}]}, {"title": "Insulet Readies Breakout And Primes 56% Growth Ahead", "url": "https://www.investors.com/research/breakout-stocks-technical-analysis/insulet-joins-sp-500-as-podd-stock-gets-ready-to-spring-higher-with-q1-earnings-due/", "time_published": "20230419T120100", "authors": ["Investor's Business Daily", "MATTHEW GALGANI"], "summary": "Insulet Joins S&P 500 And Gets Ready To Pump Up New Breakout ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/04/Stock-omnipod-01-company.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.977154"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.917436"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.221839, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.061003", "ticker_sentiment_score": "0.400887", "ticker_sentiment_label": "Bullish"}, {"ticker": "PODD", "relevance_score": "0.806749", "ticker_sentiment_score": "0.334839", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TSLA", "relevance_score": "0.061003", "ticker_sentiment_score": "0.400887", "ticker_sentiment_label": "Bullish"}, {"ticker": "LNTH", "relevance_score": "0.12165", "ticker_sentiment_score": "0.171314", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.12165", "ticker_sentiment_score": "0.171314", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Physician Checks And Latest Script Data Support DexCom Growth Opportunity: Bullish Analyst Upgrades Stock - DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/analyst-ratings/analyst-color/23/04/31834827/physician-checks-and-latest-script-data-support-dexcom-growth-opportunity-bullish-a", "time_published": "20230417T175139", "authors": ["Lekha Gupta"], "summary": "Raymond James analyst Jayson Bedford upgraded DexCom Inc DXCM to Strong Buy from Outperform and increased the price target to $138 from $127. The analyst expects an acceleration in revenue growth from Q2 2023, which is not believed to be fully factored into current sentiment.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/04/17/dxcm.png?optimize=medium&dpr=2&auto=webp&width=3840", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.264777, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.395012", "ticker_sentiment_score": "0.664644", "ticker_sentiment_label": "Bullish"}]}, {"title": "$100 Invested In DexCom 5 Years Ago Would Be Worth This Much Today - DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/news/earnings/23/04/31838095/100-invested-in-dexcom-5-years-ago-would-be-worth-this-much-today", "time_published": "20230417T173025", "authors": ["Benzinga Insights"], "summary": "DexCom DXCM has outperformed the market over the past 5 years by 36.49% on an annualized basis producing an average annual return of 45.58%. Currently, DexCom has a market capitalization of $45.92 billion.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.983605", "ticker_sentiment_score": "0.387251", "ticker_sentiment_label": "Bullish"}]}, {"title": "The Medicare News That Propelled Dexcom Close To A Breakout", "url": "https://www.investors.com/news/technology/dexcom-stock-nears-breakout-propoelled-by-medicare-decision/", "time_published": "20230417T162300", "authors": ["ALLISON GATLIN", "Investor's Business Daily"], "summary": "Dexcom Stock Nears Breakout, Propelled By Medicare Decision ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/03/Stock-dexcom-one-04-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.989041"}], "overall_sentiment_score": 0.221435, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.595343", "ticker_sentiment_score": "0.110967", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio", "url": "https://www.zacks.com/stock/news/2079642/why-this-1-growth-stock-could-be-a-great-addition-to-your-portfolio", "time_published": "20230417T134506", "authors": ["Zacks Investment Research"], "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default113.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.890401"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.929393"}], "overall_sentiment_score": 0.406123, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.442082", "ticker_sentiment_score": "0.34683", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Visa To Rally 15%? Here Are 10 Other Analyst Forecasts For Monday - BlackRock  ( NYSE:BLK ) , American Express  ( NYSE:AXP ) ", "url": "https://www.benzinga.com/news/23/04/31828284/visa-to-rally-15-here-are-10-other-analyst-forecasts-for-monday", "time_published": "20230417T121938", "authors": ["Lisa Levin"], "summary": "Raymond James boosted the price target for DexCom, Inc. DXCM from $127 to $138. Raymond James analyst Jayson Bedford upgraded the stock from Outperform to Strong Buy. DexCom shares rose 1.8% to $117.75 in pre-market trading. Stifel increased the price target for Deckers Outdoor Corporation DECK ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/04/17/visa_-_logo.jpg?optimize=medium&dpr=2&auto=webp&width=3840", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.54554"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.27079, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.294682", "ticker_sentiment_score": "0.536968", "ticker_sentiment_label": "Bullish"}, {"ticker": "NFLX", "relevance_score": "0.294682", "ticker_sentiment_score": "0.143158", "ticker_sentiment_label": "Neutral"}, {"ticker": "C", "relevance_score": "0.47147", "ticker_sentiment_score": "0.328261", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "INTU", "relevance_score": "0.294682", "ticker_sentiment_score": "0.318394", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JPM", "relevance_score": "0.38588", "ticker_sentiment_score": "0.102825", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCS", "relevance_score": "0.199037", "ticker_sentiment_score": "-0.117762", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.294682", "ticker_sentiment_score": "-0.160059", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "FTNT", "relevance_score": "0.294682", "ticker_sentiment_score": "0.153614", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DECK", "relevance_score": "0.294682", "ticker_sentiment_score": "0.276812", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "V", "relevance_score": "0.294682", "ticker_sentiment_score": "0.316573", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AXP", "relevance_score": "0.294682", "ticker_sentiment_score": "0.006603", "ticker_sentiment_label": "Neutral"}, {"ticker": "PEP", "relevance_score": "0.294682", "ticker_sentiment_score": "0.156941", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.294682", "ticker_sentiment_score": "0.607905", "ticker_sentiment_label": "Bullish"}]}, {"title": "DexCom Stock Sets Up; Can It Catch Up To Company's Torrid Growth?", "url": "https://www.investors.com/stock-lists/ibd-big-cap-20/dexcom-stock-sets-up-can-it-catch-up-to-companys-torrid-growth/", "time_published": "20230413T202800", "authors": ["Investor's Business Daily", "JUAN CARLOS ARANCIBIA"], "summary": "DexCom Stock Sets Up. Can It Catch Up To Company's Torrid ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/04/Stock-Dexcom-03-company.jpeg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Earnings", "relevance_score": "0.983783"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.245357, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AAPL", "relevance_score": "0.272029", "ticker_sentiment_score": "0.093008", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.566143", "ticker_sentiment_score": "0.21971", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABT", "relevance_score": "0.138066", "ticker_sentiment_score": "0.036016", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Stocks That Turned $40,000 Into $1 Million in 10 Years", "url": "https://www.fool.com/investing/2023/04/13/2-stocks-turned-40000-into-1-million-in-10-years/", "time_published": "20230413T134500", "authors": ["David Jagielski"], "summary": "Are these stocks still good buys today?", "banner_image": "https://media.ycharts.com/charts/783d4362835bf023be846ce037e9b61e.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999186"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.77141"}], "overall_sentiment_score": 0.256843, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.47672", "ticker_sentiment_score": "0.469337", "ticker_sentiment_label": "Bullish"}, {"ticker": "TSLA", "relevance_score": "0.31006", "ticker_sentiment_score": "0.295674", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "3 Reasons to Hold DexCom  ( DXCM )  Stock in Your Portfolio", "url": "https://www.zacks.com/stock/news/2078042/3-reasons-to-hold-dexcom-dxcm-stock-in-your-portfolio", "time_published": "20230413T112500", "authors": ["Zacks Investment Research"], "summary": "Investors continue to be optimistic about DexCom (DXCM) owing to its strong product portfolio.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/dc/1107.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}, {"topic": "Earnings", "relevance_score": "0.96136"}], "overall_sentiment_score": 0.294705, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "COO", "relevance_score": "0.139804", "ticker_sentiment_score": "-0.021483", "ticker_sentiment_label": "Neutral"}, {"ticker": "HSIC", "relevance_score": "0.139804", "ticker_sentiment_score": "0.046123", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.27535", "ticker_sentiment_score": "0.285836", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BDX", "relevance_score": "0.139804", "ticker_sentiment_score": "0.10966", "ticker_sentiment_label": "Neutral"}]}, {"title": "Smith & Nephew ADR Clears Technical Benchmark, Hitting 80-Plus RS Rating", "url": "https://www.investors.com/ibd-data-stories/smith-nephew-adr-clears-technical-benchmark-hitting-80-plus-rs-rating/", "time_published": "20230413T070000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "Smith & Nephew ADR Clears Technical Benchmark, Hitting 80-Plus ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.345455, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MMSI", "relevance_score": "0.305058", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNN", "relevance_score": "0.567144", "ticker_sentiment_score": "0.383971", "ticker_sentiment_label": "Bullish"}, {"ticker": "DSSMY", "relevance_score": "0.443626", "ticker_sentiment_score": "0.334531", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.305058", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is SPDR S&P Health Care Equipment ETF  ( XHE )  a Strong ETF Right Now?", "url": "https://www.zacks.com/stock/news/2077297/is-spdr-sp-health-care-equipment-etf-xhe-a-strong-etf-right-now", "time_published": "20230412T102007", "authors": ["Zacks Investment Research"], "summary": "Smart Beta ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default199.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999892"}], "overall_sentiment_score": 0.285119, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SEM", "relevance_score": "0.059194", "ticker_sentiment_score": "0.084028", "ticker_sentiment_label": "Neutral"}, {"ticker": "STT", "relevance_score": "0.059194", "ticker_sentiment_score": "0.118", "ticker_sentiment_label": "Neutral"}, {"ticker": "ISRG", "relevance_score": "0.118064", "ticker_sentiment_score": "0.063933", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.118064", "ticker_sentiment_score": "0.063933", "ticker_sentiment_label": "Neutral"}]}, {"title": "Global Tubeless Insulin Pump Market Predicted to Garner a Revenue of $2,837.6 Million and Rise at a CAGR of 23.4% over the Analysis Timeframe 2019-2026 [95-Pages] | Explained by Research Dive", "url": "https://www.benzinga.com/pressreleases/23/04/g31725410/global-tubeless-insulin-pump-market-predicted-to-garner-a-revenue-of-2-837-6-million-and-rise-at-a", "time_published": "20230410T130200", "authors": ["Globe Newswire"], "summary": "New York, USA, April 10, 2023 ( GLOBE NEWSWIRE ) -- According to a report published by Research dive, the global tubeless insulin pump market is envisioned to generate a revenue of $2,837.6 million, growing at a striking CAGR of 23.4% throughout the forecast timeframe from 2019 to 2026.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.108179"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.256951, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.069697", "ticker_sentiment_score": "0.116816", "ticker_sentiment_label": "Neutral"}, {"ticker": "PODD", "relevance_score": "0.069697", "ticker_sentiment_score": "0.116816", "ticker_sentiment_label": "Neutral"}]}, {"title": "Teleflex Shows Improved Relative Price Performance; Still Shy Of Benchmark", "url": "https://www.investors.com/ibd-data-stories/teleflex-shows-improved-relative-price-performance-still-shy-of-benchmark/", "time_published": "20230410T070000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "Teleflex Shows Improved Relative Price Performance. Still Shy Of ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.371861, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.31482", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PODD", "relevance_score": "0.31482", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TFX", "relevance_score": "0.776097", "ticker_sentiment_score": "0.551425", "ticker_sentiment_label": "Bullish"}]}, {"title": "Zimmer Biomet Holdings Scores Relative Strength Rating Upgrade; Hits Key Threshold", "url": "https://www.investors.com/ibd-data-stories/zimmer-biomet-holdings-scores-relative-strength-rating-upgrade-hits-key-threshold/", "time_published": "20230410T070000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "Zimmer Biomet Holdings Scores Relative Strength Rating Upgrade ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.650727"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.289428, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ZBH", "relevance_score": "0.570165", "ticker_sentiment_score": "0.347058", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PODD", "relevance_score": "0.306963", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AWON", "relevance_score": "0.156461", "ticker_sentiment_score": "0.075273", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.306963", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "A Nasdaq Bull Market Is Coming: 2 Fantastic Stocks to Buy and Hold", "url": "https://www.fool.com/investing/2023/04/08/a-nasdaq-bull-market-is-coming-2-fantastic-stocks/", "time_published": "20230408T134500", "authors": ["Rachel Warren"], "summary": "Investing is a long-term game, and both of these companies are thinking that way.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F727101%2Fbuffett17-tmf.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.684621"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}], "overall_sentiment_score": 0.258073, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.293741", "ticker_sentiment_score": "0.254093", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABNB", "relevance_score": "0.236972", "ticker_sentiment_score": "0.230522", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "P/E Ratio Insights for DexCom - DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/news/23/04/31713130/pe-ratio-insights-for-dexcom", "time_published": "20230407T153037", "authors": ["Benzinga Insights"], "summary": "In the current market session, DexCom Inc. DXCM share price is at $112.47, after a 0.31% decrease. Over the past month, the stock spiked by 4.36%, but over the past year, it actually fell by 8.65%.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.614606"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.150023, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.33628", "ticker_sentiment_score": "-0.039254", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 No-Brainer Medical Device Stocks to Buy Right Now", "url": "https://www.fool.com/investing/2023/04/06/3-no-brainer-medical-device-stocks-to-buy-now/", "time_published": "20230406T114500", "authors": ["Jim Halley"], "summary": "These companies have consistently delivered revenue and EPS gains.", "banner_image": "https://media.ycharts.com/charts/6f4e27de9fc6770b3ab9bf698c3ef54c.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999999"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.231696, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.208464", "ticker_sentiment_score": "0.113257", "ticker_sentiment_label": "Neutral"}, {"ticker": "EW", "relevance_score": "0.157141", "ticker_sentiment_score": "0.261044", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABT", "relevance_score": "0.157141", "ticker_sentiment_score": "0.108558", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Explosive Growth Stocks to Buy in April", "url": "https://www.fool.com/investing/2023/04/05/2-explosive-growth-stocks-to-buy-in-april/", "time_published": "20230405T130800", "authors": ["Rachel Warren"], "summary": "These businesses look to be on solid footing even in a difficult operating environment.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F726993%2Finvestor-55.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}, {"topic": "Earnings", "relevance_score": "0.972756"}], "overall_sentiment_score": 0.273479, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CHWY", "relevance_score": "0.300088", "ticker_sentiment_score": "0.256144", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.20279", "ticker_sentiment_score": "0.279652", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Should iShares Russell Mid-Cap Growth ETF  ( IWP )  Be on Your Investing Radar?", "url": "https://www.zacks.com/stock/news/2074659/should-ishares-russell-mid-cap-growth-etf-iwp-be-on-your-investing-radar", "time_published": "20230405T102007", "authors": ["Zacks Investment Research"], "summary": "Style Box ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default296.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.348276, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.058188", "ticker_sentiment_score": "0.128992", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNPS", "relevance_score": "0.116067", "ticker_sentiment_score": "0.066855", "ticker_sentiment_label": "Neutral"}, {"ticker": "CDNS", "relevance_score": "0.116067", "ticker_sentiment_score": "0.066855", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.116067", "ticker_sentiment_score": "0.066855", "ticker_sentiment_label": "Neutral"}]}, {"title": "Tandem Diabetes  ( TNDM )  Gains on Pump Sales, Margin Woe Stays", "url": "https://www.zacks.com/stock/news/2073790/tandem-diabetes-tndm-gains-on-pump-sales-margin-woe-stays", "time_published": "20230403T151300", "authors": ["Zacks Investment Research"], "summary": "Tandem Diabetes (TNDM) is now increasing its renewal numbers both in volume and rates.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e7/288.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}, {"topic": "Earnings", "relevance_score": "0.744043"}], "overall_sentiment_score": 0.137003, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "HOLX", "relevance_score": "0.211191", "ticker_sentiment_score": "0.17076", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AVNS", "relevance_score": "0.159218", "ticker_sentiment_score": "0.055099", "ticker_sentiment_label": "Neutral"}, {"ticker": "HSIC", "relevance_score": "0.211191", "ticker_sentiment_score": "-0.05092", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDT", "relevance_score": "0.05339", "ticker_sentiment_score": "0.17897", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TNDM", "relevance_score": "0.159218", "ticker_sentiment_score": "0.11293", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.05339", "ticker_sentiment_score": "0.028891", "ticker_sentiment_label": "Neutral"}]}, {"title": "DexCom  ( DXCM )  Outpaces Stock Market Gains: What You Should Know", "url": "https://www.zacks.com/stock/news/2073401/dexcom-dxcm-outpaces-stock-market-gains-what-you-should-know", "time_published": "20230331T221523", "authors": ["Zacks Investment Research"], "summary": "DexCom (DXCM) closed the most recent trading day at $116.18, moving +1.56% from the previous trading session.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default3.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.961735"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.210474, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.686288", "ticker_sentiment_score": "0.326971", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Here's How Much You Would Have Made Owning DexCom Stock In The Last 5 Years - DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/news/earnings/23/03/31613271/heres-how-much-you-would-have-made-owning-dexcom-stock-in-the-last-5-years", "time_published": "20230331T170028", "authors": ["Benzinga Insights"], "summary": "DexCom DXCM has outperformed the market over the past 5 years by 34.74% on an annualized basis producing an average annual return of 44.07%. Currently, DexCom has a market capitalization of $44.79 billion.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.983605", "ticker_sentiment_score": "0.387251", "ticker_sentiment_label": "Bullish"}]}, {"title": "2 All-Weather Stocks to Buy Without Hesitation Right Now", "url": "https://www.fool.com/investing/2023/03/31/2-all-weather-stocks-to-buy-without-hesitation/", "time_published": "20230331T124500", "authors": ["Rachel Warren"], "summary": "Despite near-term economic clouds, long-term investors can still find compelling buying opportunities.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F726079%2Fbuffett19-tmf.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.87644"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.284475, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ISRG", "relevance_score": "0.363768", "ticker_sentiment_score": "0.237935", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.363768", "ticker_sentiment_score": "0.346107", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "AngioDynamics  ( ANGO )  Reports Q3 Loss, Lags Revenue Estimates", "url": "https://www.zacks.com/stock/news/2072298/angiodynamics-ango-reports-q3-loss-lags-revenue-estimates", "time_published": "20230330T121503", "authors": ["Zacks Investment Research"], "summary": "AngioDynamics (ANGO) delivered earnings and revenue surprises of -200% and 2.28%, respectively, for the quarter ended February 2023. Do the numbers hold clues to what lies ahead for the stock?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default21.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999981"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.130463, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.142989", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Where Will DexCom Be in 1 Year?", "url": "https://www.fool.com/investing/2023/03/29/where-will-dexcom-be-in-1-year/", "time_published": "20230329T114500", "authors": ["Prosper Junior Bakiny"], "summary": "The company may only be scratching the surface of its target market.", "banner_image": "https://media.ycharts.com/charts/0b08de4c32e4fd364c5df71815ba5fce.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.918141"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.294175, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.718321", "ticker_sentiment_score": "0.482584", "ticker_sentiment_label": "Bullish"}]}, {"title": "Dow Jones Gains As Bank Crisis Eases; These 3 Warren Buffett Stocks Eye Entries", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-gains-as-bank-crisis-eases-these-3-warren-buffett-stocks-eye-entries-bitcoin-dives-coinbase-stock-binance-changpeng-zhao-tesla-stock-apple-stock/", "time_published": "20230327T192000", "authors": ["Investor's Business Daily", "MICHAEL LARKIN"], "summary": "Dow Jones Gains As Bank Crisis Eases. These 3 Warren Buffett ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2019/05/stock-Buffett-Warren-02-shutter.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "Blockchain", "relevance_score": "0.682689"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.614606"}], "overall_sentiment_score": 0.185599, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MDLZ", "relevance_score": "0.076602", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.076602", "ticker_sentiment_score": "-0.023111", "ticker_sentiment_label": "Neutral"}, {"ticker": "C", "relevance_score": "0.038345", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.076602", "ticker_sentiment_score": "0.224354", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BRK-A", "relevance_score": "0.038345", "ticker_sentiment_score": "0.162384", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BRKR", "relevance_score": "0.114682", "ticker_sentiment_score": "0.233763", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "COIN", "relevance_score": "0.152499", "ticker_sentiment_score": "-0.234736", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MSFT", "relevance_score": "0.076602", "ticker_sentiment_score": "0.191513", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BCS", "relevance_score": "0.038345", "ticker_sentiment_score": "0.006907", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.227007", "ticker_sentiment_score": "0.044218", "ticker_sentiment_label": "Neutral"}, {"ticker": "MA", "relevance_score": "0.076602", "ticker_sentiment_score": "-0.068732", "ticker_sentiment_label": "Neutral"}, {"ticker": "FRC", "relevance_score": "0.076602", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CZBS", "relevance_score": "0.038345", "ticker_sentiment_score": "0.186186", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FIZN", "relevance_score": "0.038345", "ticker_sentiment_score": "0.186186", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PINS", "relevance_score": "0.114682", "ticker_sentiment_score": "0.353603", "ticker_sentiment_label": "Bullish"}, {"ticker": "DXCM", "relevance_score": "0.076602", "ticker_sentiment_score": "-0.080079", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.114682", "ticker_sentiment_score": "-0.174569", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Dow Jones Holds Gains While Tech Fades; Elon Musk Twitter Woes Increase", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-holds-gain-elon-musk-slashes-twitter-value-to-half-before-twitter-source-code-leak/", "time_published": "20230327T161700", "authors": ["VIDYA RAMAKRISHNAN", "Investor's Business Daily"], "summary": "Dow Jones Holds Gains While Tech Fades. Elon Musk Twitter Woes ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2022/10/Stock-moneytesla-01-shutt.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Economy - Fiscal", "relevance_score": "0.310843"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.98396"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.069772, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "META", "relevance_score": "0.197951", "ticker_sentiment_score": "0.007854", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.132733", "ticker_sentiment_score": "0.116262", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.132733", "ticker_sentiment_score": "0.216672", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVO", "relevance_score": "0.066598", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.132733", "ticker_sentiment_score": "0.216672", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "UNH", "relevance_score": "0.132733", "ticker_sentiment_score": "0.216672", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LULU", "relevance_score": "0.132733", "ticker_sentiment_score": "-0.223843", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "TSLA", "relevance_score": "0.197951", "ticker_sentiment_score": "0.087146", "ticker_sentiment_label": "Neutral"}, {"ticker": "IBM", "relevance_score": "0.132733", "ticker_sentiment_score": "0.216672", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WFC", "relevance_score": "0.132733", "ticker_sentiment_score": "0.116262", "ticker_sentiment_label": "Neutral"}, {"ticker": "WBA", "relevance_score": "0.132733", "ticker_sentiment_score": "-0.223843", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "DXCM", "relevance_score": "0.132733", "ticker_sentiment_score": "0.116262", "ticker_sentiment_label": "Neutral"}, {"ticker": "BA", "relevance_score": "0.132733", "ticker_sentiment_score": "0.216672", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PANW", "relevance_score": "0.132733", "ticker_sentiment_score": "0.006037", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dow Jones Rises; Elon Musk's Twitter Source Code Leaks Online, Cancer Drug Stock Jumps On Breakthrough", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-rises-elon-musks-twitter-source-code-leaks-online/", "time_published": "20230327T144900", "authors": ["Investor's Business Daily", "VIDYA RAMAKRISHNAN"], "summary": "Dow Jones Rises. Elon Musk's Twitter Source Code Leaks Online ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2022/10/Stock-musktwitter-01-shutt.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.938793"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.026588, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LULU", "relevance_score": "0.18046", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.267804", "ticker_sentiment_score": "0.010018", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.431554", "ticker_sentiment_score": "-0.254682", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BAC", "relevance_score": "0.18046", "ticker_sentiment_score": "-0.087285", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.18046", "ticker_sentiment_score": "-0.087285", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.18046", "ticker_sentiment_score": "0.114579", "ticker_sentiment_label": "Neutral"}, {"ticker": "WBA", "relevance_score": "0.18046", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.18046", "ticker_sentiment_score": "0.114579", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.18046", "ticker_sentiment_score": "-0.087285", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.18046", "ticker_sentiment_score": "0.114579", "ticker_sentiment_label": "Neutral"}, {"ticker": "BA", "relevance_score": "0.18046", "ticker_sentiment_score": "0.114579", "ticker_sentiment_label": "Neutral"}, {"ticker": "PANW", "relevance_score": "0.18046", "ticker_sentiment_score": "0.007344", "ticker_sentiment_label": "Neutral"}]}, {"title": "Nasdaq Bear Market: 2 Growth Stocks to Buy That Keep Bucking the Trend", "url": "https://www.fool.com/investing/2023/03/25/nasdaq-bear-market-2-growth-stocks-to-buy-that-kee/", "time_published": "20230325T094100", "authors": ["Cory Renauer"], "summary": "These red-hot stocks keep climbing despite the bear market.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F725141%2Fwarren-buffett-brka-brkb-berkshire-hathaway-motley-fool2.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.795202"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.098294, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.184834", "ticker_sentiment_score": "-0.156373", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ABT", "relevance_score": "0.06211", "ticker_sentiment_score": "0.219221", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.06211", "ticker_sentiment_score": "0.089017", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.303175", "ticker_sentiment_score": "-0.072436", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dexcom Stock Option Trade Could Return $465 While Risking Just $35", "url": "https://www.investors.com/research/options/dexcom-stock-option-trade-could-return-465-while-risking-just-35/", "time_published": "20230324T161008", "authors": ["ANNE-MARIE BAIYND", "Investor's Business Daily"], "summary": "Dexcom Stock Option Trade Could Return $465 While Risking Just ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2018/11/Stock-Dexcom-01-company.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.54554"}], "overall_sentiment_score": 0.114069, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.446742", "ticker_sentiment_score": "0.248052", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Dexcom  ( DXCM )  Launches G6 Glucose Monitoring System in Canada", "url": "https://www.zacks.com/stock/news/2070276/dexcom-dxcm-launches-g6-glucose-monitoring-system-in-canada", "time_published": "20230324T155900", "authors": ["Zacks Investment Research"], "summary": "Dexcom (DXCM) announces the availability of standard of care in diabetes management - G6 CGM system - for type 1 and 2 patients with basal and bolus insulin or using an insulin pump in Canada.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/09/2677.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.904684"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}], "overall_sentiment_score": 0.247742, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "COO", "relevance_score": "0.171688", "ticker_sentiment_score": "-0.023009", "ticker_sentiment_label": "Neutral"}, {"ticker": "HSIC", "relevance_score": "0.171688", "ticker_sentiment_score": "0.093985", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.436947", "ticker_sentiment_score": "0.309781", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BDX", "relevance_score": "0.171688", "ticker_sentiment_score": "0.125913", "ticker_sentiment_label": "Neutral"}]}, {"title": "Price Over Earnings Overview: DexCom - DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/news/23/03/31479780/price-over-earnings-overview-dexcom", "time_published": "20230323T173040", "authors": ["Benzinga Insights"], "summary": "Looking into the current session, DexCom Inc. DXCM shares are trading at $115.35, after a 0.30% increase. Moreover, over the past month, the stock went up by 3.04%, but in the past year, decreased by 4.13%.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.413559"}], "overall_sentiment_score": 0.15646, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.40348", "ticker_sentiment_score": "0.198626", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Have $1,000? 2 Stock-Split Companies to Add to Your Buy Basket Right Now.", "url": "https://www.fool.com/investing/2023/03/23/have-1000-2-stock-split-stocks-to-add-to-your-buy/", "time_published": "20230323T135300", "authors": ["Rachel Warren"], "summary": "Don't overlook these names in the current market.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F725187%2Fstack-of-one-hundred-dollar-bills-cash-money-stimulus-invest-retire-getty.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.980922"}, {"topic": "Earnings", "relevance_score": "0.839681"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.213241, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.290607", "ticker_sentiment_score": "0.158636", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "META", "relevance_score": "0.049526", "ticker_sentiment_score": "0.053993", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.243864", "ticker_sentiment_score": "0.258029", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Should You Invest in the SPDR S&P Health Care Equipment ETF  ( XHE ) ?", "url": "https://www.zacks.com/stock/news/2068832/should-you-invest-in-the-spdr-sp-health-care-equipment-etf-xhe", "time_published": "20230322T102010", "authors": ["Zacks Investment Research"], "summary": "Sector ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default131.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}], "overall_sentiment_score": 0.262031, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SEM", "relevance_score": "0.064276", "ticker_sentiment_score": "0.084223", "ticker_sentiment_label": "Neutral"}, {"ticker": "STT", "relevance_score": "0.064276", "ticker_sentiment_score": "0.082059", "ticker_sentiment_label": "Neutral"}, {"ticker": "ISRG", "relevance_score": "0.128135", "ticker_sentiment_score": "0.080304", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.128135", "ticker_sentiment_score": "0.080304", "ticker_sentiment_label": "Neutral"}]}, {"title": "Should Vanguard Mid-Cap Growth ETF  ( VOT )  Be on Your Investing Radar?", "url": "https://www.zacks.com/stock/news/2068842/should-vanguard-mid-cap-growth-etf-vot-be-on-your-investing-radar", "time_published": "20230322T102006", "authors": ["Zacks Investment Research"], "summary": "Style Box ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default196.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.314647, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "APH", "relevance_score": "0.117486", "ticker_sentiment_score": "0.067179", "ticker_sentiment_label": "Neutral"}, {"ticker": "CDNS", "relevance_score": "0.117486", "ticker_sentiment_score": "0.067179", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.117486", "ticker_sentiment_score": "0.067179", "ticker_sentiment_label": "Neutral"}]}, {"title": "DexCom  ( DXCM )  Outpaces Stock Market Gains: What You Should Know", "url": "https://www.zacks.com/stock/news/2068769/dexcom-dxcm-outpaces-stock-market-gains-what-you-should-know", "time_published": "20230321T221524", "authors": ["Zacks Investment Research"], "summary": "DexCom (DXCM) closed the most recent trading day at $118.98, moving +1.51% from the previous trading session.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default256.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.976913"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.212799, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.693563", "ticker_sentiment_score": "0.384415", "ticker_sentiment_label": "Bullish"}]}, {"title": "Want $1 Million in Retirement? Invest $100,000 in These 3 Stocks and Wait 10 Years", "url": "https://www.fool.com/investing/2023/03/21/want-1-million-in-retirement-invest-100000-in-thes/", "time_published": "20230321T091600", "authors": ["Cory Renauer"], "summary": "Patient investors who would like to see their investments rise 10x have some interesting options right now.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F725079%2Fglobal-bull-vs-bear-market.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.918141"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.118947, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "META", "relevance_score": "0.142565", "ticker_sentiment_score": "-0.055879", "ticker_sentiment_label": "Neutral"}, {"ticker": "TMDX", "relevance_score": "0.280615", "ticker_sentiment_score": "0.267496", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AVGO", "relevance_score": "0.047749", "ticker_sentiment_score": "0.006972", "ticker_sentiment_label": "Neutral"}, {"ticker": "DOCS", "relevance_score": "0.189298", "ticker_sentiment_score": "0.057704", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.047749", "ticker_sentiment_score": "0.006972", "ticker_sentiment_label": "Neutral"}, {"ticker": "SWAV", "relevance_score": "0.095327", "ticker_sentiment_score": "-0.064265", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dow Jones Rises Ahead Of Fed Meeting; Warren Buffett Talks To Regulators On The Bank Crisis", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-rises-ahead-of-fed-meeting-warren-buffett-talks-to-regulators-on-the-bank-crisis/", "time_published": "20230320T145127", "authors": ["Investor's Business Daily", "VIDYA RAMAKRISHNAN"], "summary": "Dow Jones Rises Ahead Of Fed Meeting. Warren Buffett Talks To ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2017/11/Stock-WarrenBuffett-01-shutt.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.999955"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.094362, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ENPH", "relevance_score": "0.128478", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.128478", "ticker_sentiment_score": "-0.048842", "ticker_sentiment_label": "Neutral"}, {"ticker": "LSCC", "relevance_score": "0.128478", "ticker_sentiment_score": "0.23213", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SIVB", "relevance_score": "0.064449", "ticker_sentiment_score": "0.095882", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.128478", "ticker_sentiment_score": "0.156758", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SMCI", "relevance_score": "0.128478", "ticker_sentiment_score": "0.23213", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NKE", "relevance_score": "0.128478", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.253646", "ticker_sentiment_score": "0.081793", "ticker_sentiment_label": "Neutral"}, {"ticker": "COIN", "relevance_score": "0.128478", "ticker_sentiment_score": "0.229776", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NYCB", "relevance_score": "0.064449", "ticker_sentiment_score": "0.095882", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALGM", "relevance_score": "0.128478", "ticker_sentiment_score": "0.23213", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MSFT", "relevance_score": "0.128478", "ticker_sentiment_score": "-0.135577", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPGI", "relevance_score": "0.064449", "ticker_sentiment_score": "-0.063438", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.128478", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.128478", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GME", "relevance_score": "0.128478", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.064449", "ticker_sentiment_score": "0.39275", "ticker_sentiment_label": "Bullish"}]}, {"title": "How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings", "url": "https://www.zacks.com/stock/news/2067859/how-to-boost-your-portfolio-with-top-medical-stocks-set-to-beat-earnings", "time_published": "20230320T125008", "authors": ["Zacks Investment Research"], "summary": "Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default68.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999855"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.402446, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.259727", "ticker_sentiment_score": "0.267644", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "THC", "relevance_score": "0.321393", "ticker_sentiment_score": "0.349822", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "10 stocks that are gaining market share for their disruptive innovations like AI, according to a portfolio manager", "url": "https://www.businessinsider.com/stocks-gaining-rapid-market-share-ai-disruptive-technology-2023-3", "time_published": "20230318T123339", "authors": ["Laila Maidan"], "summary": "10 Stocks Gaining Rapid Market Share in AI and Disruptive ... - Business Insider ...", "banner_image": null, "source": "Business Insider", "category_within_source": "GoogleRSS", "source_domain": "www.businessinsider.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.938238"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.171784, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.036983", "ticker_sentiment_score": "0.04151", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.110632", "ticker_sentiment_score": "0.130718", "ticker_sentiment_label": "Neutral"}, {"ticker": "EW", "relevance_score": "0.073886", "ticker_sentiment_score": "0.208811", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "INTU", "relevance_score": "0.073886", "ticker_sentiment_score": "0.142317", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADI", "relevance_score": "0.073886", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMD", "relevance_score": "0.073886", "ticker_sentiment_score": "0.249953", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IDXX", "relevance_score": "0.073886", "ticker_sentiment_score": "-0.087697", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.110632", "ticker_sentiment_score": "0.015498", "ticker_sentiment_label": "Neutral"}, {"ticker": "ASML", "relevance_score": "0.110632", "ticker_sentiment_score": "0.057308", "ticker_sentiment_label": "Neutral"}, {"ticker": "DHR", "relevance_score": "0.073886", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Tandem Diabetes  ( TNDM )  Releases Favorable Data on t:slim X2", "url": "https://www.zacks.com/stock/news/2067549/tandem-diabetes-tndm-releases-favorable-data-on-tslim-x2", "time_published": "20230317T190300", "authors": ["Zacks Investment Research"], "summary": "Tandem Diabetes (TNDM) demonstrated positive results from the clinical trial of advancing its Control-IQ technology to younger age group patients.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/d9/3163.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Earnings", "relevance_score": "0.890401"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.147154, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "TNDM", "relevance_score": "0.248343", "ticker_sentiment_score": "-0.030014", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.248343", "ticker_sentiment_score": "0.161245", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "KERN", "relevance_score": "0.248343", "ticker_sentiment_score": "-0.042156", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.050465", "ticker_sentiment_score": "0.078407", "ticker_sentiment_label": "Neutral"}]}, {"title": "DexCom Stock Gets A Composite Rating Upgrade After 4 Up Days", "url": "https://www.investors.com/research/dexcom-gets-a-composite-rating-upgrade/", "time_published": "20230316T151400", "authors": ["GLENN LARKIN", "Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "The IBD SmartSelect Composite Rating for DexCom ( DXCM ) rose from 94 to 97 Thursday. The new score means the company is now outperforming 97% of all stocks in terms of the most important fundamental and technical stock-picking criteria.", "banner_image": "https://www.investors.com/wp-content/uploads/2017/03/IDS2.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.891286"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.364183, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "LNTH", "relevance_score": "0.247838", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.472338", "ticker_sentiment_score": "0.156841", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "DexCom  ( DXCM )  Gains As Market Dips: What You Should Know", "url": "https://www.zacks.com/stock/news/2066451/dexcom-dxcm-gains-as-market-dips-what-you-should-know", "time_published": "20230315T221519", "authors": ["Zacks Investment Research"], "summary": "DexCom (DXCM) closed the most recent trading day at $113.72, moving +0.49% from the previous trading session.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default319.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.95493"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.143436, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.6809", "ticker_sentiment_score": "0.263563", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "$1000 Invested In This Stock 5 Years Ago Would Be Worth $6,900 Today - DexCom  ( NASDAQ:DXCM ) ", "url": "https://www.benzinga.com/news/earnings/23/03/31365475/1000-invested-in-this-stock-5-years-ago-would-be-worth-6-900-today", "time_published": "20230315T163029", "authors": ["Benzinga Insights"], "summary": "DexCom DXCM has outperformed the market over the past 5 years by 39.53% on an annualized basis producing an average annual return of 46.8%. Currently, DexCom has a market capitalization of $43.20 billion.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.983605", "ticker_sentiment_score": "0.387251", "ticker_sentiment_label": "Bullish"}]}, {"title": "Heska Shows Rising Relative Strength; Still Shy Of Key Threshold", "url": "https://www.investors.com/ibd-data-stories/heska-shows-rising-relative-strength-still-shy-of-key-threshold/", "time_published": "20230315T080000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "Heska Shows Rising Relative Strength. Still Shy Of Key Threshold Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.368694, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "HSKA", "relevance_score": "0.636698", "ticker_sentiment_score": "0.478908", "ticker_sentiment_label": "Bullish"}, {"ticker": "PODD", "relevance_score": "0.350564", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AWON", "relevance_score": "0.179788", "ticker_sentiment_score": "0.082791", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.350564", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stocks To Watch: Integer Holdings Sees RS Rating Rise To 82", "url": "https://www.investors.com/ibd-data-stories/stocks-to-watch-integer-holdings-sees-rs-rating-rise-to-82/", "time_published": "20230315T080000", "authors": ["INVESTOR'S BUSINESS DAILY", "Investor's Business Daily"], "summary": "Integer Holdings ( ITGR ) had its Relative Strength ( RS ) Rating upgraded from 74 to 82 Wednesday. X As you try to find the best stocks to buy and watch, be sure to pay attention to relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.386058, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.327366", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AWON", "relevance_score": "0.167322", "ticker_sentiment_score": "0.244834", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ITGR", "relevance_score": "0.601928", "ticker_sentiment_score": "0.395675", "ticker_sentiment_label": "Bullish"}, {"ticker": "DXCM", "relevance_score": "0.327366", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "GLUCOTRACK PROVIDES SHAREHOLDER UPDATE", "url": "https://www.globenewswire.com/news-release/2023/03/14/2626845/0/en/GLUCOTRACK-PROVIDES-SHAREHOLDER-UPDATE.html", "time_published": "20230314T140000", "authors": ["GlucoTrack", "Inc."], "summary": "Rutherford, NJ, March 14, 2023 ( GLOBE NEWSWIRE ) -- GlucoTrack, Inc. ( Nasdaq: GCTK ) ( \"GlucoTrack\" or the \"Company\" ) , a medical device and digital health platform company focused on diabetes and prediabetes, announced today that Paul V.", "banner_image": "https://ml.globenewswire.com/Resource/Download/b8950d4f-96bd-4c9a-936d-f586de9157da", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.240441, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SSNLF", "relevance_score": "0.03642", "ticker_sentiment_score": "0.110414", "ticker_sentiment_label": "Neutral"}, {"ticker": "GCTK", "relevance_score": "0.28511", "ticker_sentiment_score": "0.150664", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PODD", "relevance_score": "0.03642", "ticker_sentiment_score": "0.110414", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDT", "relevance_score": "0.03642", "ticker_sentiment_score": "0.110414", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.03642", "ticker_sentiment_score": "0.110414", "ticker_sentiment_label": "Neutral"}]}, {"title": "Silicon Valley Bank signed exclusive banking deals with some clients, leaving them unable to diversify", "url": "https://www.cnbc.com/2023/03/12/silicon-valley-bank-signed-exclusive-banking-deals-with-some-clients.html", "time_published": "20230313T002112", "authors": ["Rohan Goswami"], "summary": "Silicon Valley Bank required some clients to agree to exclusivity clauses, disabling them from diversifying where they held their money, SEC records show.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107207176-1678641674741-gettyimages-1248053989-PGONCHAR_6220.jpeg?v=1678647197", "source": "CNBC", "category_within_source": "Top News", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "IPO", "relevance_score": "0.310843"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.080682, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "EGIO", "relevance_score": "0.122269", "ticker_sentiment_score": "0.070598", "ticker_sentiment_label": "Neutral"}, {"ticker": "UPST", "relevance_score": "0.061315", "ticker_sentiment_score": "0.086006", "ticker_sentiment_label": "Neutral"}, {"ticker": "DOCU", "relevance_score": "0.241684", "ticker_sentiment_score": "0.165775", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WFC", "relevance_score": "0.061315", "ticker_sentiment_score": "0.114169", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.122269", "ticker_sentiment_score": "0.066024", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stocks Tumble Amid SVB Collapse, 'Faster' Powell: Weekly Review", "url": "https://www.investors.com/news/stock-market-tumbles-amid-svb-financial-collapse-faster-powell/", "time_published": "20230310T173800", "authors": ["Investor's Business Daily", "IBD STAFF"], "summary": "Stock Market Tumbles Amid SVB Financial Collapse, 'Faster' Powell ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2018/04/stock-bank-10-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "0.999186"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "1.0"}], "overall_sentiment_score": -0.162917, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "CRWD", "relevance_score": "0.063848", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ULTA", "relevance_score": "0.063848", "ticker_sentiment_score": "0.139085", "ticker_sentiment_label": "Neutral"}, {"ticker": "SIVB", "relevance_score": "0.189918", "ticker_sentiment_score": "-0.288661", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BJ", "relevance_score": "0.095644", "ticker_sentiment_score": "0.188748", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MDB", "relevance_score": "0.063848", "ticker_sentiment_score": "-0.081526", "ticker_sentiment_label": "Neutral"}, {"ticker": "DKS", "relevance_score": "0.095644", "ticker_sentiment_score": "-0.026233", "ticker_sentiment_label": "Neutral"}, {"ticker": "CIEN", "relevance_score": "0.095644", "ticker_sentiment_score": "-0.083906", "ticker_sentiment_label": "Neutral"}, {"ticker": "SI-P-A", "relevance_score": "0.063848", "ticker_sentiment_score": "-0.18862", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ABT", "relevance_score": "0.031949", "ticker_sentiment_score": "-0.137858", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.158728", "ticker_sentiment_score": "-0.17428", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SAVE", "relevance_score": "0.063848", "ticker_sentiment_score": "-0.017514", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.063848", "ticker_sentiment_score": "-0.142902", "ticker_sentiment_label": "Neutral"}, {"ticker": "GE", "relevance_score": "0.095644", "ticker_sentiment_score": "0.1707", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FOREX:USD", "relevance_score": "0.031949", "ticker_sentiment_score": "-0.314816", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Intercept Tumbles On A New Obstacle For Its Experimental NASH Drug", "url": "https://www.investors.com/news/technology/icpt-stock-tumbles-on-new-obstacle-for-its-nash-drug/", "time_published": "20230310T164900", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "Intercept Tumbles On A New Obstacle For Its Experimental NASH ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/01/Stock-interceptpharmaceuticals-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.989041"}], "overall_sentiment_score": 0.112839, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MDGL", "relevance_score": "0.140076", "ticker_sentiment_score": "0.331301", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABT", "relevance_score": "0.07031", "ticker_sentiment_score": "-0.167999", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ICPT", "relevance_score": "0.463192", "ticker_sentiment_score": "0.113725", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSSMY", "relevance_score": "0.208764", "ticker_sentiment_score": "0.099466", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.07031", "ticker_sentiment_score": "-0.167999", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Oracle  ( ORCL )  Q3 2023 Earnings Call Transcript", "url": "https://www.fool.com/earnings/call-transcripts/2023/03/09/oracle-orcl-q3-2023-earnings-call-transcript/", "time_published": "20230310T013038", "authors": ["Motley Fool Transcribing"], "summary": "ORCL earnings call for the period ending December 31, 2022.", "banner_image": "https://g.foolcdn.com/misc-assets/fool-transcripts-logo.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.962106"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.217684, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BHG", "relevance_score": "0.006353", "ticker_sentiment_score": "0.056115", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.006353", "ticker_sentiment_score": "0.150208", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HUM", "relevance_score": "0.006353", "ticker_sentiment_score": "0.056115", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.031755", "ticker_sentiment_score": "0.062216", "ticker_sentiment_label": "Neutral"}, {"ticker": "VZ", "relevance_score": "0.006353", "ticker_sentiment_score": "0.095134", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAYZF", "relevance_score": "0.006353", "ticker_sentiment_score": "0.137731", "ticker_sentiment_label": "Neutral"}, {"ticker": "ORCL", "relevance_score": "0.219496", "ticker_sentiment_score": "0.16349", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VOD", "relevance_score": "0.025406", "ticker_sentiment_score": "0.078826", "ticker_sentiment_label": "Neutral"}, {"ticker": "ICUI", "relevance_score": "0.006353", "ticker_sentiment_score": "0.137731", "ticker_sentiment_label": "Neutral"}, {"ticker": "TIIAY", "relevance_score": "0.006353", "ticker_sentiment_score": "0.095134", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.006353", "ticker_sentiment_score": "0.150208", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CURN", "relevance_score": "0.006353", "ticker_sentiment_score": "-0.030017", "ticker_sentiment_label": "Neutral"}, {"ticker": "SCI", "relevance_score": "0.006353", "ticker_sentiment_score": "0.056115", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBER", "relevance_score": "0.012705", "ticker_sentiment_score": "0.167806", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.006353", "ticker_sentiment_score": "0.219324", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "DexCom  ( DXCM )  Stock Moves -0.59%: What You Should Know", "url": "https://www.zacks.com/stock/news/2063863/dexcom-dxcm-stock-moves--059-what-you-should-know", "time_published": "20230309T231512", "authors": ["Zacks Investment Research"], "summary": "In the latest trading session, DexCom (DXCM) closed at $112.08, marking a -0.59% move from the previous day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default294.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972476"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.166407, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.549988", "ticker_sentiment_score": "0.266264", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "2 Top Stocks to Buy in March and Hold Forever", "url": "https://www.fool.com/investing/2023/03/09/2-top-stocks-to-buy-in-march-and-hold-forever/", "time_published": "20230309T145300", "authors": ["Rachel Warren"], "summary": "Don't let a turbulent market keep you on the sidelines this month.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F723734%2Fperson-looking-closely-at-computer-getty.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.650727"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.302854, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.107255", "ticker_sentiment_score": "0.129334", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.263942", "ticker_sentiment_score": "0.24308", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Eli Lilly's Decade-Long Effort In Alzheimer's Disease Just Failed", "url": "https://www.investors.com/news/technology/eli-lilly-stock-decade-long-effort-in-alzheimers-treatment-fails/", "time_published": "20230309T143700", "authors": ["ALLISON GATLIN", "Investor's Business Daily"], "summary": "Eli Lilly Stock: Decade-Long Effort In Alzheimer's Treatment Fails ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2018/05/Stock-Lilly-01-Shutterstock.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999897"}], "overall_sentiment_score": 0.099989, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "TRMNF", "relevance_score": "0.07446", "ticker_sentiment_score": "-0.010311", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABT", "relevance_score": "0.07446", "ticker_sentiment_score": "-0.16879", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "AZN", "relevance_score": "0.07446", "ticker_sentiment_score": "-0.144445", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.696068", "ticker_sentiment_score": "0.209471", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.07446", "ticker_sentiment_score": "-0.16879", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PFE", "relevance_score": "0.07446", "ticker_sentiment_score": "-0.144445", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.59972", "ticker_sentiment_score": "0.190453", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNY", "relevance_score": "0.07446", "ticker_sentiment_score": "-0.144445", "ticker_sentiment_label": "Neutral"}]}, {"title": "Want to Get Richer? 2 Top Stocks to Buy Now and Hold Forever", "url": "https://www.fool.com/investing/2023/03/09/want-to-get-richer-2-top-stocks-to-buy-and-hold/", "time_published": "20230309T130000", "authors": ["Rachel Warren"], "summary": "A bull market could supercharge these two top stocks.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F723519%2F2022-rivian-r1t-22.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.858979"}, {"topic": "Earnings", "relevance_score": "0.976913"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.278881, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CHWY", "relevance_score": "0.31282", "ticker_sentiment_score": "0.261787", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.31282", "ticker_sentiment_score": "0.148956", "ticker_sentiment_label": "Neutral"}, {"ticker": "TRUP", "relevance_score": "0.053509", "ticker_sentiment_score": "0.132706", "ticker_sentiment_label": "Neutral"}]}, {"title": "DarioHealth Reports Fourth Quarter and Record Revenue in Full-Year 2022 Financial and Operating Results", "url": "https://www.prnewswire.com/news-releases/dariohealth-reports-fourth-quarter-and-record-revenue-in-full-year-2022-financial-and-operating-results-301767874.html", "time_published": "20230309T114700", "authors": ["DarioHealth Corp."], "summary": "DarioHealth Reports Fourth Quarter and Record Revenue in Full ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.955357"}], "overall_sentiment_score": 0.148038, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DRIO", "relevance_score": "0.084324", "ticker_sentiment_score": "0.119797", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.01408", "ticker_sentiment_score": "0.134432", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.01408", "ticker_sentiment_score": "0.134432", "ticker_sentiment_label": "Neutral"}]}, {"title": "DarioHealth Reports Fourth Quarter and Record Revenue in Full-Year 2022 Financial and Operating Results", "url": "https://www.prnewswire.com/il/news-releases/dariohealth-reports-fourth-quarter-and-record-revenue-in-full-year-2022-financial-and-operating-results-301767874.html", "time_published": "20230309T114700", "authors": ["DarioHealth Corp."], "summary": "DarioHealth Reports Fourth Quarter and Record Revenue in Full ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.955357"}], "overall_sentiment_score": 0.148038, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DRIO", "relevance_score": "0.084324", "ticker_sentiment_score": "0.119797", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.01408", "ticker_sentiment_score": "0.134432", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.01408", "ticker_sentiment_score": "0.134432", "ticker_sentiment_label": "Neutral"}]}, {"title": "DarioHealth Reports Fourth Quarter and Record Revenue in Full-Year 2022 Financial and Operating Results", "url": "https://www.prnewswire.com/news-releases/dariohealth-reports-fourth-quarter-and-record-revenue-in-full-year-2022-financial-and-operating-results-301767770.html", "time_published": "20230309T113000", "authors": ["DarioHealth Corp."], "summary": "DarioHealth Reports Fourth Quarter and Record Revenue in Full ... PR ...", "banner_image": "https://content.prnewswire.com/images/prn_facebook_sharing_logo.jpg", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.955357"}], "overall_sentiment_score": 0.148038, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DRIO", "relevance_score": "0.084324", "ticker_sentiment_score": "0.119797", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.01408", "ticker_sentiment_score": "0.134432", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.01408", "ticker_sentiment_score": "0.134432", "ticker_sentiment_label": "Neutral"}]}, {"title": "DarioHealth Reports Fourth Quarter and Record Revenue in Full-Year 2022 Financial and Operating Results", "url": "https://www.prnewswire.com/il/news-releases/dariohealth-reports-fourth-quarter-and-record-revenue-in-full-year-2022-financial-and-operating-results-301767770.html", "time_published": "20230309T113000", "authors": ["DarioHealth Corp."], "summary": "DarioHealth Reports Fourth Quarter and Record Revenue in Full ... PR ...", "banner_image": "https://content.prnewswire.com/images/prn_facebook_sharing_logo.jpg", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.955357"}], "overall_sentiment_score": 0.148038, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DRIO", "relevance_score": "0.084324", "ticker_sentiment_score": "0.119797", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.01408", "ticker_sentiment_score": "0.134432", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.01408", "ticker_sentiment_score": "0.134432", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Top Healthcare Stocks Defying the Bear Market", "url": "https://www.fool.com/investing/2023/03/07/2-top-healthcare-stocks-defying-the-bear-market/", "time_published": "20230307T211500", "authors": ["George Budwell"], "summary": "These two healthcare stocks have been swimming against the current.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F723685%2Fhappy-investor.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.5855"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.254635, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GEHC", "relevance_score": "0.113597", "ticker_sentiment_score": "0.150562", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.056943", "ticker_sentiment_score": "0.156017", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GE", "relevance_score": "0.479683", "ticker_sentiment_score": "0.489848", "ticker_sentiment_label": "Bullish"}, {"ticker": "RETA", "relevance_score": "0.279015", "ticker_sentiment_score": "0.177441", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Merck Nears Breakout On A New $10 Billion Sales Potential", "url": "https://www.investors.com/news/technology/merck-stock-keytruda-who-analysts-eye-two-heart-drugs/", "time_published": "20230307T151400", "authors": ["ALLISON GATLIN", "Investor's Business Daily"], "summary": "Merck Stock: Keytruda Who? Analysts Eye $10 Billion From Two ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2017/10/stock-merck-01-company.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999499"}], "overall_sentiment_score": 0.181548, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "0.06179", "ticker_sentiment_score": "-0.167086", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ABT", "relevance_score": "0.06179", "ticker_sentiment_score": "-0.167086", "ticker_sentiment_label": "Somewhat-Bearish"}]}]}